Research Publications

Our researchers, scientists and clinical partners are active members of the scientific community and have published their work in well-respected, peer-reviewed journals.

NOTE: The links provided below redirect to third-party websites that may require a subscription to access publications.

2023 Publications

Phthalazinone-based lactams and cyclic ureas as ROCK2 selective inhibitors.

Hu Z, Sitkoff D, Glunz PW, Zou Y, Wang C, Muckelbauer JK, Adam LP, Wexler RR, Quan ML.
Bioorg Med Chem Lett. 2023 Apr 28;88:129304. doi: 10.1016/j.bmcl.2023.129304. Online ahead of print.

PMID: 37119973

Applications of single-cell RNA sequencing in drug discovery and development.

Van de Sande B, Lee JS, Mutasa-Gottgens E, Naughton B, Bacon W, Manning J, Wang Y, Pollard J, Mendez M, Hill J, Kumar N, Cao X, Chen X, Khaladkar M, Wen J, Leach A, Ferran E.

Nat Rev Drug Discov. 2023 Apr 28:1-25. doi: 10.1038/s41573-023-00688-4. Online ahead of print.

PMID: 37117846

An adaptive modeling approach using spiking-augmentation method to improve chemometric model performance in bioprocess monitoring.

Zhao Y, Tang Y, Wasalathanthri D, Xu J, Ding J.

Biotechnol Prog. 2023 Apr 27:e3349. doi: 10.1002/btpr.3349. Online ahead of print.

PMID: 37102507

Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.

Gorovits B, Azadeh M, Buchlis G, Fiscella M, Harrison T, Havert M, Janetzki S, Jawa V, Long B, Mahnke YD, McDermott A, Milton M, Nelson R, Vettermann C, Wu B.

AAPS J. 2023 Apr 26;25(3):47. doi: 10.1208/s12248-023-00814-5.

PMID: 37101079

Development of tandem-column liquid chromatographic methods for pharmaceutical compounds using simulations based on hydrophobic subtraction model parameters.

Liu Z, Zhou Y, Wang Q, Foley JP, Stoll DR, Shackman JG.

J Chromatogr A. 2023 Apr 26;1695:463925. doi: 10.1016/j.chroma.2023.463925. Epub 2023 Mar 12.

PMID: 36965284

Evaluation of oncology infusion pharmacy practices: A nationwide survey.

Boyd AM, Sue C, Khandoobhai A, Vinson B, Shaikh H, Sorenson S, Patel V, Snyder B, Bondarenk C, Koukounas Y, Earl M, Jenkins M.

J Oncol Pharm Pract. 2023 Apr 25:10781552231170358. doi: 10.1177/10781552231170358. Online ahead of print.

PMID: 37122190

Meeting Report on the 2^nd Chinese American Society for Mass Spectrometry (CASMS) Conference Advancing Biological and Pharmaceutical Mass Spectrometry.

Chen Y, Ge Y, Han X, Hao L, Huan T, Li L, Li L, Li W, Liang X, Lin Y, Liu X, Liu Y, Ma S, Peng J, Shou W, Sun L, Tao WA, Tian Y, Wang YK, Wang Y, Wu R, Wu S, Xia J, Yang Z, Zhang H, Zhang H, Zhao S, Weng N, Huang L.

Mol Cell Proteomics. 2023 Apr 25:100559. doi: 10.1016/j.mcpro.2023.100559. Online ahead of print.

PMID: 37105363

Caregivers of patients with malignant pleural mesothelioma: who provides care, what care do they provide and what burden do they experience?

Moore A, Bennett B, Taylor-Stokes G, Daumont MJ.

Qual Life Res. 2023 Apr 25. doi: 10.1007/s11136-023-03410-4. Online ahead of print.

PMID: 37097405

Cappellini MD, Taher AT, Piga A, Shah F, Voskaridou E, Viprakasit V, Porter JB, Hermine O, Neufeld EJ, Thompson AA, Tang D, Yucel A, Lord-Bessen J, Yu P, Guo S, Shetty JK, Miteva D, Zinger T, Backstrom JT, Oliva EN.

Eur J Haematol. 2023 Apr 24. doi: 10.1111/ejh.13975. Online ahead of print.

PMID: 37095595

On Ternary Complex Stability in Protein Degradation: In Silico Molecular Glue Binding Affinity Calculations.

Weiss DR, Bortolato A, Sun Y, Cai X, Lai C, Guo S, Shi L, Shanmugasundaram V.

J Chem Inf Model. 2023 Apr 24;63(8):2382-2392. doi: 10.1021/acs.jcim.2c01386. Epub 2023 Apr 10.

PMID: 37037192

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study.

Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TWJ, Citera G, Huang KG, Wu C, Connolly SE, Elbez Y, Wong R, Lozenski K, Fleischmann R.

Arthritis Res Ther. 2023 Apr 22;25(1):67. doi: 10.1186/s13075-023-03038-2.

PMID: 37087459

Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study.

Abdelmalek MF, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Lawitz EJ, Harrison SA, Jacobson IM, Imajo K, Gunn N, Halegoua-DeMarzio D, Akahane T, Boone B, Yamaguchi M, Chatterjee A, Tirucherai GS, Shevell DE, Du S, Charles ED, Loomba R.

Clin Gastroenterol Hepatol. 2023 Apr 21:S1542-3565(23)00311-7. doi: 10.1016/j.cgh.2023.04.012. Online ahead of print.

PMID: 37088458

Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study.

Loomba R, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Harrison SA, Lawitz EJ, Gunn N, Imajo K, Ravendhran N, Akahane T, Boone B, Yamaguchi M, Chatterjee A, Tirucherai GS, Shevell DE, Du S, Charles ED, Abdelmalek MF.

Clin Gastroenterol Hepatol. 2023 Apr 21:S1542-3565(23)00310-5. doi: 10.1016/j.cgh.2023.04.011. Online ahead of print.

PMID: 37088457

Harmonizing Biopredictive Methodologies Through the Product Quality Research Institute (PQRI) Part I: Biopredictive Dissolution of Ibuprofen and Dipyridamole Tablets.

Tsume Y, Ashworth L, Bermejo M, Cheng J, Cicale V, Dressman J, Fushimi M, Gonzalez-Alvarez I, Guo Y, Jankovsky C, Lu X, Matsui K, Patel S, Sanderson N, Sun CC, Thakral NK, Yamane M, Zöller L.

AAPS J. 2023 Apr 21;25(3):45. doi: 10.1208/s12248-023-00793-7.

PMID: 37085637

Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care.

Tomlinson B, de Lima M, Cogle CR, Thompson MA, Grinblatt DL, Pollyea DA, Komrokji RS, Roboz GJ, Savona MR, Sekeres MA, Abedi M, Garcia-Manero G, Kurtin SE, Maciejewski JP, Patel JL, Revicki DA, George TI, Flick ED, Kiselev P, Louis CU, DeGutis IS, Nifenecker M, Erba HP, Steensma DP, Scott BL.

Transplant Cell Ther. 2023 Apr 20:S2666-6367(23)01243-5. doi: 10.1016/j.jtct.2023.04.011. Online ahead of print.

PMID: 37086851

The AAPS Journal Theme Issue: Compendium of Immunogenicity Risk Assessments: an Industry Guidance Built on Experience and Published Work.

Mora JR, Richards SM.

AAPS J. 2023 Apr 20;25(3):43. doi: 10.1208/s12248-023-00796-4.

PMID: 37081214

Comparison of Protein Particle Formation in IgG1 mAbs Formulated with PS20 Vs. PS80 When Subjected to Interfacial Dilatational Stress.

Vaclaw C, Merritt K, Griffin VP, Whitaker N, Gokhale M, Volkin DB, Ogunyankin MO, Dhar P.

AAPS PharmSciTech. 2023 Apr 20;24(5):104. doi: 10.1208/s12249-023-02561-4.

PMID: 37081185

Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Iberdomide.

Cheng Y, Gaudy A, Liu L, Ye Y, Thomas M, Xue Y, Zhou S, Li Y.

Clin Pharmacol Drug Dev. 2023 Apr 20. doi: 10.1002/cpdd.1254. Online ahead of print.

PMID: 37079714

An interlaboratory capillary zone electrophoresis-UV study of various monoclonal antibodies, instruments, and ε-aminocaproic acid lots.

Wiesner R, Zagst H, Lan W, Bigelow S, Holper P, Hübner G, Josefsson L, Lancaster C, Lo L, Lößner C, Lu H, Neusüß C, Rüttiger C, Schlecht J, Schürrle P, Selsam A, van der Burg D, Wang SC, Zhu Y, Wätzig H, Sänger-van de Griend C.

Electrophoresis. 2023 Apr 20. doi: 10.1002/elps.202200284. Online ahead of print.

PMID: 37079448

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

Egeler MD, van de Poll-Franse LV, Tissier R, Rogiers A, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KPM, Neyns B, Janssen KJ, Blank CU, Retèl VP, Boekhout AH.

Qual Life Res. 2023 Apr 20. doi: 10.1007/s11136-023-03427-9. Online ahead of print.

PMID: 37079262

Transfer learning in a biomaterial fibrosis model identifies in vivo senescence heterogeneity and contributions to vascularization and matrix production across species and diverse pathologies.

Cherry C, Andorko JI, Krishnan K, Mejías JC, Nguyen HH, Stivers KB, Gray-Gaillard EF, Ruta A, Han J, Hamada N, Hamada M, Sturmlechner I, Trewartha S, Michel JH, Davenport Huyer L, Wolf MT, Tam AJ, Peña AN, Keerthivasan S, Le Saux CJ, Fertig EJ, Baker DJ, Housseau F, van Deursen JM, Pardoll DM, Elisseeff JH.

Geroscience. 2023 Apr 20. doi: 10.1007/s11357-023-00785-7. Online ahead of print.

PMID: 37079217

Heart Failure Across the Range of Mildly Reduced and Preserved Ejection Fraction in the United States.

Greene SJ, Spertus JA, Tang W, Kang A, Zhong Y, Myers MC, Shen S, Jiang J, Liu X, Steffen DR, Viola MG, Felker GM.

Circ Heart Fail. 2023 Apr 20:e010430. doi: 10.1161/CIRCHEARTFAILURE.123.010430. Online ahead of print.

PMID: 37078276

Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions.

Ahmad HA, East JE, Panaccione R, Travis S, Canavan JB, Usiskin K, Byrne MF.

Intest Res. 2023 Apr 20. doi: 10.5217/ir.2023.00020. Online ahead of print.

PMID: 37075809

Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238.

Larkin J, Del Vecchio M, Mandala M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, Lutzky J, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill AG, Fecher LA, Millward M, Nathan PD, Khushalani NI, Queirolo P, Ritchings C, Lobo M, Askelson M, Tang H, Dolfi S, Ascierto PA, Weber J.

Clin Cancer Res. 2023 Apr 14:CCR-22-3145. doi: 10.1158/1078-0432.CCR-22-3145. Online ahead of print.

PMID: 37058595

Integrated model of the vertebrate augmin complex.

Travis SM, Mahon BP, Huang W, Ma M, Rale MJ, Kraus J, Taylor DJ, Zhang R, Petry S.

Nat Commun. 2023 Apr 13;14(1):2072. doi: 10.1038/s41467-023-37519-4.

PMID: 37055408

Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer.

Cohen A, Noxon V, Dhamane A, Bruette R, Shah S, Hines DM, Alfred T, Luo X.

Thromb Res. 2023 Apr 13;226:117-126. doi: 10.1016/j.thromres.2023.04.009. Online ahead of print.

PMID: 37146438

Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin as a Breast Cancer Resistance Protein -Specific Endogenous Biomarker that Demonstrates Prediction of Transporter Activity In Vivo.

Zhang Y, Shipkova PA, Warrack BM, Nelson DM, Wang L, Huo R, Chen J, Panfen E, Chen XQ, Fancher M, Ruan Q, Christopher LJ, Xue Y, Sinz M, Shen H.

Drug Metab Dispos. 2023 Apr 13:DMD-AR-2023-001284. doi: 10.1124/dmd.123.001284. Online ahead of print.

PMID: 37055191

Enantioselective Total Synthesis of (+)-KB343.

Bi C, Wang Y, He C, Baran PS.

J Am Chem Soc. 2023 Apr 12;145(14):7753-7757. doi: 10.1021/jacs.3c01991. Epub 2023 Mar 30.

PMID: 36995337

Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1.

Markwalder JA, Balog AJ, Williams DK, Nara SJ, Reddy R, Roy S, Kanyaboina Y, Li X, Johnston K, Fan Y, Lewis H, Marsilio F, Yan C, Critton D, Newitt JA, Traeger SC, Wu DR, Jure-Kunkel MN, Jayaraman L, Lin TA, Sinz MW, Hunt JT, Seitz SP.

Bioorg Med Chem Lett. 2023 Apr 11;88:129280. doi: 10.1016/j.bmcl.2023.129280. Online ahead of print.

PMID: 37054759

Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective.

Ghadessi M, Di J, Wang C, Toyoizumi K, Shao N, Mei C, Demanuele C, Tang RS, McMillan G, Beckman RA.

Orphanet J Rare Dis. 2023 Apr 11;18(1):79. doi: 10.1186/s13023-023-02693-7.

PMID: 37041605

Guest editors' note on special issue on application of estimand.

Seifu Y, Wang W.

J Biopharm Stat. 2023 Apr 11:1-2. doi: 10.1080/10543406.2023.2199835. Online ahead of print.

PMID: 37039452

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.

Campbell KM, Amouzgar M, Pfeiffer SM, Howes TR, Medina E, Travers M, Steiner G, Weber JS, Wolchok JD, Larkin J, Hodi FS, Boffo S, Salvador L, Tenney D, Tang T, Thompson MA, Spencer CN, Wells DK, Ribas A.

Cancer Cell. 2023 Apr 10;41(4):791-806.e4. doi: 10.1016/j.ccell.2023.03.010.

PMID: 37037616

Therapy effect on AI-derived thalamic atrophy using clinical routine MRI protocol: A longitudinal, multi-center, propensity-matched multiple sclerosis study.

Jakimovski D, Silva D, Niels Bergsland, Dwyer MG, Weinstock-Guttman B, Benedict RH, Riolo J, Zivadinov R; DeepGRAI Registry Study group.

Mult Scler Relat Disord. 2023 Apr 9;74:104708. doi: 10.1016/j.msard.2023.104708. Online ahead of print.

PMID: 37084495

The association between brain volume loss and disability in multiple sclerosis: A systematic review.

Matthews PM, Gupta D, Mittal D, Bai W, Scalfari A, Pollock KG, Sharma V, Hill N.

Mult Scler Relat Disord. 2023 Apr 9;74:104714. doi: 10.1016/j.msard.2023.104714. Online ahead of print.

PMID: 37068369

Strategies for controlling afucosylation in monoclonal antibodies during upstream manufacturing.

Rish AJ, Siddiquee K, Huang Z, Xu J, Anderson CA, Borys MC, Khetan A.

Biotechnol J. 2023 Apr 7:e2200604. doi: 10.1002/biot.202200604. Online ahead of print.

PMID: 37029472

Cross-platform dataset of multiplex fluorescent cellular object image annotations.

Aleynick N, Li Y, Xie Y, Zhang M, Posner A, Roshal L, Pe'er D, Vanguri RS, Hollmann TJ.

Sci Data. 2023 Apr 7;10(1):193. doi: 10.1038/s41597-023-02108-z.

PMID: 37029126

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.

Fakih M, Raghav KPS, Chang DZ, Larson T, Cohn AL, Huyck TK, Cosgrove D, Fiorillo JA, Tam R, D'Adamo D, Sharma N, Brennan BJ, Wang YA, Coppieters S, Zebger-Gong H, Weispfenning A, Seidel H, Ploeger BA, Mueller U, Oliveira CSV, Paulson AS.

EClinicalMedicine. 2023 Apr 6;58:101917. doi: 10.1016/j.eclinm.2023.101917. eCollection 2023 Apr.

PMID: 37090438

Gamma secretase inhibition: Effects on fertility and embryo-fetal development in rats.

Sivaraman L, Sanderson T.

Toxicol Appl Pharmacol. 2023 Apr 6;469:116512. doi: 10.1016/j.taap.2023.116512. Online ahead of print.

PMID: 37030625

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.

Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R.

JAMA Oncol. 2023 Apr 6:e230147. doi: 10.1001/jamaoncol.2023.0147. Online ahead of print.

PMID: 37022706

3D Printed Flavor-Rich Chewable Pediatric Tablets Fabricated Using Microextrusion for Point of Care Applications.

Tabriz AG, Hui HW, Boersen N, Roberts S, Jones J, Douroumis D.

Mol Pharm. 2023 Apr 6. doi: 10.1021/acs.molpharmaceut.2c01061. Online ahead of print.

PMID: 37022302

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.

Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC.

Blood. 2023 Apr 6;141(14):1724-1736. doi: 10.1182/blood.2022017094.

PMID: 36603186

Analytical characterization of host-cell-protein-rich aggregates in monoclonal antibody solutions.

Herman CE, Min L, Choe LH, Maurer RW, Xu X, Ghose S, Lee KH, Lenhoff AM.

Biotechnol Prog. 2023 Apr 5:e3343. doi: 10.1002/btpr.3343. Online ahead of print.

PMID: 37020359

Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.

Liu Y, Klein J, Bajpai R, Dong L, Tran Q, Kolekar P, Smith JL, Ries RE, Huang BJ, Wang YC, Alonzo TA, Tian L, Mulder HL, Shaw TI, Ma J, Walsh MP, Song G, Westover T, Autry RJ, Gout AM, Wheeler DA, Wan S, Wu G, Yang JJ, Evans WE, Loh M, Easton J, Zhang J, Klco JM, Meshinchi S, Brown PA, Pruett-Miller SM, Ma X.

Nat Commun. 2023 Apr 5;14(1):1739. doi: 10.1038/s41467-023-37438-4.

PMID: 37019972

Greetings from the ASMS Publications Committee.

Valentine S, Phelan V, Zhou M, Thomas S, Cannon J.

J Am Soc Mass Spectrom. 2023 Apr 5;34(4):519-520. doi: 10.1021/jasms.3c00094.

PMID: 37016835

Determining sequential micellization steps of bile salts with multi-CMC modeling.

Rovnyak D, He J, Kong S, Eckenroad KW, Manley GA, Geffert RM, Krout MR, Strein TG.

J Colloid Interface Sci. 2023 Apr 5;644:496-508. doi: 10.1016/j.jcis.2023.03.146. Online ahead of print.

PMID: 37146486

Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities.

Jurica EA, Wu X, Williams KN, Haque LE, Rampulla RA, Mathur A, Zhou M, Cao G, Cai H, Wang T, Liu H, Xu C, Kunselman LK, Antrilli TM, Hicks MB, Sun Q, Dierks EA, Apedo A, Moore DB, Foster KA, Cvijic ME, Panemangalore R, Khandelwal P, Wilkes JJ, Zinker BA, Robertson DG, Janovitz EB, Galella M, Li YX, Li J, Ramar T, Jalagam PR, Jayaram R, Whaley JM, Barrish JC, Robl JA, Ewing WR, Ellsworth BA.

Bioorg Med Chem. 2023 Apr 4;85:117273. doi: 10.1016/j.bmc.2023.117273. Online ahead of print.

PMID: 37030194

Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.

Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Devlen J, Miera M, Gerould H, Campbell TB, Munshi NC.

Leuk Res. 2023 Apr 3;129:107074. doi: 10.1016/j.leukres.2023.107074. Online ahead of print.

PMID: 37087950

Surface ID: a geometry-aware system for protein molecular surface comparison.

Riahi S, Lee JH, Sorenson T, Wei S, Jager S, Olfati-Saber R, Park A, Wendt M, Minoux H, Qiu Y.

Bioinformatics. 2023 Apr 3;39(4):btad196. doi: 10.1093/bioinformatics/btad196.

PMID: 37067488

Corrigendum to real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States [Urologic oncology: Seminars and original investigations 40 (2022) 195.e1-195.e11].

Geynisman DM, Broughton E, Hao Y, Zhang Y, Le T, Huo S.

Urol Oncol. 2023 Apr 3:S1078-1439(23)00086-8. doi: 10.1016/j.urolonc.2023.03.001. Online ahead of print.

PMID: 37019763

Comparison of Pre-existing Anti-AAV8 Total Antibody Screening and Confirmatory Assays with a Cell-Based Neutralizing Assay in Normal Human Serum.

Dai Y, Dong H, Gleason C, Mora J, Kolaitis G, Balasubramanian N, Surapaneni S, Kozhich A, Jawa V.

AAPS J. 2023 Apr 3;25(3):35. doi: 10.1208/s12248-023-00805-6.

PMID: 37012501

Effect of light source and UVA quotient on monoclonal antibody stability during ambient light exposure studies.

More HT, Bindra DS, Zumba A, Zhou K, Carvalho T, Mantri R.

Eur J Pharm Biopharm. 2023 Apr;185:177-182. doi: 10.1016/j.ejpb.2023.03.001. Epub 2023 Mar 7.

PMID: 36894037

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Cheng Y, Sakai H, Paz-Ares L, Lu S, John T, Sun X, Moisei A, Taylor F, Lawrance R, Zhang X, Sylvester J, Yuan Y, Blum SI, Penrod JR, Carbone DP.

Eur J Cancer. 2023 Apr;183:174-187. doi: 10.1016/j.ejca.2023.01.015. Epub 2023 Jan 28.

PMID: 36871487

Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors.

Wang R, Baxi V, Li Z, Locke D, Hedvat C, Sun Y, Walsh AM, Shao X, Basavanhally T, Greenawalt DM, Patah P, Novosiadly R.

ESMO Open. 2023 Apr;8(2):100784. doi: 10.1016/j.esmoop.2023.100784. Epub 2023 Feb 28.

PMID: 36863094

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder.

Merali SJ, Byon W, Patel YT, Elsrougy A, Marchisin D, Perera V, Chen W, He B, Murthy B.

CPT Pharmacometrics Syst Pharmacol. 2023 Apr;12(4):500-512. doi: 10.1002/psp4.12935. Epub 2023 Mar 5.

PMID: 36861188

Trends and factors associated with outpatient anticoagulant treatment initiation among VTE patients with active cancer.

Dhamane AD, Shah S, Noxon V, Bruette R, Ferri M, Liu X, Jiang J, Luo X.

Thromb Res. 2023 Apr;224:52-59. doi: 10.1016/j.thromres.2023.02.001. Epub 2023 Feb 15.

PMID: 36848784

Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England.

Miret M, Anderson A, Hindocha P, Cirneanu L, Lymperopoulou C, Markov E, Kizito W, Vegni FE.

Leuk Res. 2023 Apr;127:107042. doi: 10.1016/j.leukres.2023.107042. Epub 2023 Feb 14.

PMID: 36812661

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences.

Cohen AT, Sah J, Dhamane AD, Hines DM, Lee T, Rosenblatt L, Emir B, Keshishian A, Yuce H, Luo X.

Adv Ther. 2023 Apr;40(4):1705-1735. doi: 10.1007/s12325-023-02440-1. Epub 2023 Feb 22.

PMID: 36811795

Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study.

Ogdie A, Shaw Y, Almonte M, Maksabedian Hernandez EJ, Stolshek B, Michaud K.

ACR Open Rheumatol. 2023 Apr;5(4):167-172. doi: 10.1002/acr2.11530. Epub 2023 Feb 10.

PMID: 36762609

Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.

Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C.

Ann Hematol. 2023 Apr;102(4):749-754. doi: 10.1007/s00277-023-05109-5. Epub 2023 Feb 3.

PMID: 36732419

Chronic Expression of a Clinical SFTPC Mutation Causes Murine Lung Fibrosis with Idiopathic Pulmonary Fibrosis Features.

Rodriguez L, Tomer Y, Carson P, Dimopoulos T, Zhao M, Chavez K, Iyer S, Huang L, Ebert C, Sereda L, Murthy A, Trujillo G, Beers MF, Katzen J.

Am J Respir Cell Mol Biol. 2023 Apr;68(4):358-365. doi: 10.1165/rcmb.2022-0203MA.

PMID: 36473455

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States.

Kantor D, Pham T, Patterson-Lomba O, Swallow E, Dua A, Gupte-Singh K.

Neurol Ther. 2023 Mar 31. doi: 10.1007/s40120-023-00463-y. Online ahead of print.

PMID: 37000386

A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis.

Cichewicz A, Tencer T, Gupte-Singh K, Egodage S, Burnett H, Kumar J.

Adv Ther. 2023 Mar 31;40(5):2116-46. doi: 10.1007/s12325-023-02488-z. Online ahead of print.

PMID: 37000363

Evolving regulatory perspectives on digital health technologies for medicinal product development.

Colloud S, Metcalfe T, Askin S, Belachew S, Ammann J, Bos E, Kilchenmann T, Strijbos P, Eggenspieler D, Servais L, Garay C, Konstantakopoulos A, Ritzhaupt A, Vetter T, Vincenzi C, Cerreta F.

NPJ Digit Med. 2023 Mar 29;6(1):56. doi: 10.1038/s41746-023-00790-2.

PMID: 36991116

Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.

Menezes DL, See WL, Risueño A, Tsai KT, Lee JK, Ma J, Khan R, Prebet T, Skikne B, Beach CL, Thakurta A, Gandhi A.

Br J Haematol. 2023 Mar 29. doi: 10.1111/bjh.18783. Online ahead of print.

PMID: 36990798

SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol.

Espinasse A, Solovyeva O, Dimairo M, Weir C, Jaki T, Mander A, Kightley A, Evans J, Lee S, Bedding A, Hopewell S, Rantell K, Liu R, Chan AW, De Bono J, Yap C.

BMJ Open. 2023 Mar 29;13(3):e068173. doi: 10.1136/bmjopen-2022-068173.

PMID: 36990492

Morphological distribution mapping: Utilisation of modelling to integrate particle size and shape distributions.

Gamble JF, Akseli I, Ferreira AP, Leane M, Thomas S, Tobyn M, Wadams RC.

Int J Pharm. 2023 Mar 25;635:122743. doi: 10.1016/j.ijpharm.2023.122743. Epub 2023 Feb 17.

PMID: 36804520

TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase.

Chandhasin C, Dang V, Perabo F, Del Rosario J, Chen YK, Filvaroff E, Stafford JA, Clarke M.

Anticancer Drugs. 2023 Mar 24. doi: 10.1097/CAD.0000000000001514. Online ahead of print.

PMID: 37067993

Variables associated with joint involvement and development of a prediction rule for arthritis in patients with psoriasis. An analysis of the Italian PsoReal database.

Heidemeyer K, Cazzaniga S, Dondi L, Ronconi G, Pedrini A, Bellatreccia A, Zhong Y, Martini N, Naldi L.

J Am Acad Dermatol. 2023 Mar 23:S0190-9622(23)00500-5. doi: 10.1016/j.jaad.2023.02.059. Online ahead of print.

PMID: 36965671

Development and validation of a measure of adolescent and young adult goal-based quality of life (MAYA-GQOL).

Darabos K, Tucker CA, Brumley L, King-Dowling S, Butler E, Stevens E, O'Hagan B, Henry-Moss D, Deatrick JA, Szalda D, Barakat LP, Schwartz LA.

Qual Life Res. 2023 Mar 23. doi: 10.1007/s11136-023-03392-3. Online ahead of print.

PMID: 36952075

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial.

Wei AH, Roboz GJ, Dombret H, Dohner H, Schuh AC, Montesinos P, Selleslag D, Bondarenko SN, Prebet T, Lai Y, Skikne B, Beach CL, Ravandi F.

Haematologica. 2023 Mar 23. doi: 10.3324/haematol.2022.282296. Online ahead of print.

PMID: 36951156

Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors.

Hartz RA, Ahuja VT, Sivaprakasam P, Xiao H, Krause CM, Clarke WJ, Kish K, Lewis H, Szapiel N, Ravirala R, Mutalik S, Nakmode D, Shah D, Burton CR, Macor JE, Dubowchik GM.

J Med Chem. 2023 Mar 23;66(6):4231-4252. doi: 10.1021/acs.jmedchem.3c00133. Epub 2023 Mar 9.

PMID: 36950863

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia.

Taher AT, Musallam KM, Viprakasit V, Kattamis A, Lord-Bessen J, Yucel A, Guo S, Pelligra C, Shields AL, Shetty JK, Miteva D, Bueno LM, Cappellini MD.

BMJ Open. 2023 Mar 22;13(3):e066683. doi: 10.1136/bmjopen-2022-066683.

PMID: 36948565

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.

Parker C, Liu FF, Deger KA, Franco-Villalobos C, Proskorovsky I, Keating SJ, Sorensen S.

Adv Ther. 2023 Mar 22;40(5):2355-74. doi: 10.1007/s12325-023-02444-x. Online ahead of print.

PMID: 36947328

Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study.

Pape M, Vissers PAJ, Dijksterhuis WPM, Bertwistle D, McDonald L, Mostert B, Derks S, Oving IM, Verhoeven RHA, van Laarhoven HWM.

Ther Adv Med Oncol. 2023 Mar 21;15:17588359231162576. doi: 10.1177/17588359231162576. eCollection 2023.

PMID: 36970109

Characterization of serum and tissue oxytocinase and tissue oxytocin in the pregnant and non-pregnant mare.

Diel de Amorim M, Dong L, Byron M, Foster RA, Klein C, Saleh M, Saleh T, Card C.

Sci Rep. 2023 Mar 21;13(1):4616. doi: 10.1038/s41598-023-31540-9.

PMID: 36944665

Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

Lin D, Nguyen H, Shah R, Qiao Y, Hartman J, Sugarman R.

Gastric Cancer. 2023 Mar 21;26(3):415-24. doi: 10.1007/s10120-023-01372-7. Online ahead of print.

PMID: 36943511

Comparison of host cell protein removal by depth filters with diatomaceous earth and synthetic silica filter aids using model proteins.

Chu LK, Borujeni EE, Xu X, Ghose S, Zydney AL.

Biotechnol Bioeng. 2023 Mar 16. doi: 10.1002/bit.28386. Online ahead of print.

PMID: 36929487

Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.

Roupret M, Brouquet A, Colrat F, Diez-Andreu P, Prudent A, Chartier M, Gaudin AF, Bugnard F, Chillotti L, Bénard S, Branchoux S, Bellera C, Negrier S.

World J Urol. 2023 Mar 16:1-7. doi: 10.1007/s00345-023-04335-w. Online ahead of print.

PMID: 36929410

Modeling unmeasured baseline information in observational time-to-event data subject to delayed study entry.

Stegherr R, Beyersmann J, Bramlage P, Bluhmki T.

Stat Methods Med Res. 2023 Mar 16:9622802231163334. doi: 10.1177/09622802231163334. Online ahead of print.

PMID: 36924264

A strategy for evaluation of isotopic enrichment and structural integrity of deuterium labelled compounds by using HR-MS and NMR.

Kumar S, Gajjela R, Kumar H, Arulraj RA, Subramaniam S, Kothandaramachandran T, Sudhir V S, Chauthe SK, Gupta A, Mathur A, Roy A, Bagadi M, Caceres-Cortes J.

Anal Methods. 2023 Mar 16;15(11):1470-1477. doi: 10.1039/d2ay01980a.

PMID: 36876453

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S.

N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.c

PMID: 36762851

Machine Learning and Assay Development for Image-based Phenotypic Profiling of Drug Treatments.

Sexton JZ, Fursmidt R, O’Meara MJ, Omta W, Rao A, Egan DA, Haney SA.

2023 Mar 15.

In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin C, Baell J, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Gorshkov K, Haas JV, Hall MD, Hoare S, Inglese J, Iversen PW, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Sittampalam GS, Tarselli M, Trask OJ Jr, Wang Y, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004–.

PMID: 36921077

A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA.

Future Oncol. 2023 Mar 15. doi: 10.2217/fon-2022-1149. Online ahead of print.

PMID: 36919706

Role of the gradient slope during the product internal recycling for the multicolumn countercurrent solvent gradient purification of PEGylated proteins.

Kim TK, Bham AA, Fioretti I, Angelo J, Xu X, Ghose S, Morbidelli M, Sponchioni M.

J Chromatogr A. 2023 Mar 15;1692:463868. doi: 10.1016/j.chroma.2023.463868. Epub 2023 Feb 10.

PMID: 36803771

High Interobserver Variability among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction and Esophageal Adenocarcinoma.

Robert ME, Rüschoff J, Jasani B, Graham RP, Badve SS, Rodriguez-Justo M, Kodach LL, Srivastava A, Wang HL, Tang LH, Troncone G, Rojo F, Van Treeck BJ, Pratt J, Shnitsar I, Kumar G, Karasarides M, Anders RA.

Mod Pathol. 2023 Mar 14:100154. doi: 10.1016/j.modpat.2023.100154. Online ahead of print.

PMID: 36925069

Capillary blood collection: exploring a new method to promote noninvasive prenatal screening access.

Ehrich M, Sagaser KG, Porreco RP, Bellesheim D, Patil AS, Shulman LP, Van Den Boom D.

Am J Obstet Gynecol. 2023 Mar 13:S0002-9378(23)00153-9. doi: 10.1016/j.ajog.2023.03.008. Online ahead of print.

PMID: 36921913

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.

Moreno V, Vieito M, Sepulveda JM, Galvao V, Hernández-Guerrero T, Doger B, Saavedra O, Carlo-Stella C, Michot JM, Italiano A, Magagnoli M, Carpio C, Pinto A, Sarmiento R, Amoroso B, Aronchik I, Filvaroff E, Hanna B, Wei X, Nikolova Z, Braña I.

Nat Commun. 2023 Mar 13;14(1):1359. doi: 10.1038/s41467-023-36976-1.

PMID: 36914652

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.

Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthélémy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albigès L, George S, Shuch B, Sosman J, Staehler M, Vázquez Estévez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A.

Lancet. 2023 Mar 11;401(10379):821-832. doi: 10.1016/S0140-6736(22)02574-0. Epub 2023 Feb 9.

PMID: 36774933

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.

Santoro A, Moskowitz AJ, Ferrari S, Carlo-Stella C, Lisano JM, Francis S, Wen R, Akyol A, Savage KJ.

Blood. 2023 Mar 10:blood.2022017951. doi: 10.1182/blood.2022017951. Online ahead of print.

PMID: 36898084

Sex Differences in Oral Anticoagulation Therapy in Patients Hospitalized With Atrial Fibrillation: A Nationwide Cohort Study.

Lee KK, Doudesis D, Bing R, Astengo F, Perez JR, Anand A, McIntyre S, Bloor N, Sandler B, Lister S, Pollock KG, Qureshi AC, McAllister DA, Shah ASV, Mills NL.

J Am Heart Assoc. 2023 Mar 7;12(5):e027211. doi: 10.1161/JAHA.122.027211. Epub 2023 Mar 2.

PMID: 36864741

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults.

Sagawa ZK, Goman C, Frevol A, Blazevic A, Tennant J, Fisher B, Day T, Jackson S, Lemiale F, Toussaint L, Kalisz I, Jiang J, Ondrejcek L, Mohamath R, Vergara J, Lew A, Beckmann AM, Casper C, Hoft DF, Fox CB.

Nat Commun. 2023 Mar 6;14(1):1138. doi: 10.1038/s41467-023-36789-2.

PMID: 36878897

Silver Nanoparticles in Dental Applications: A Descriptive Review.

Mallineni SK, Sakhamuri S, Kotha SL, AlAsmari ARGM, AlJefri GH, Almotawah FN, Mallineni S, Sajja R.

Bioengineering (Basel). 2023 Mar 5;10(3):327. doi: 10.3390/bioengineering10030327.

PMID: 36978718

Bayesian optimal phase II designs with dual-criterion decision making.

Zhao Y, Li D, Liu R, Yuan Y.

Pharm Stat. 2023 Mar 5. doi: 10.1002/pst.2296. Online ahead of print.

PMID: 36871961

Principled leveraging of external data in the evaluation of diagnostic devices via the propensity score-integrated composite likelihood approach.

Song C, Li H, Chen WC, Lu N, Tiwari R, Wang C, Xu Y, Yue LQ.

Pharm Stat. 2023 Mar 5. doi: 10.1002/pst.2295. Online ahead of print.

PMID: 36871949

HLH-like toxicities predict poor survival following use of tisagenlecleucel in children and young adults with B-ALL.

McNerney KO, Si Lim S, Ishikawa K, Dreyzin A, Vatsayan A, Chen JJ, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Verneris MR, Myers D, Karras NA, Brown PA, Bonifant CL, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Baumeister SHC, Fabrizio VA, Chinnabhandar V, Egeler E, Mavroukakis S, Curran KJ, Mackall CL, Laetsch TW, Schultz LM.

Blood Adv. 2023 Mar 1:bloodadvances.2022008893. doi: 10.1182/bloodadvances.2022008893. Online ahead of print.

PMID: 36857419

Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States.

Turakhia MP, Guo JD, Keshishian A, Delinger R, Sun X, Ferri M, Russ C, Cato M, Yuce H, Hlavacek P.

Clin Cardiol. 2023 Mar 1. doi: 10.1002/clc.23983. Online ahead of print.

PMID: 36855960

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.

Kluger H, Barrett JC, Gainor JF, Hamid O, Hurwitz M, LaVallee T, Moss RA, Zappasodi R, Sullivan RJ, Tawbi H, Sharon E.

J Immunother Cancer. 2023 Mar;11(3):e005921. doi: 10.1136/jitc-2022-005921.

PMID: 36918224

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.

Hu S, Tang Z, Harrison JP, Hertel N, Penrod JR, May JR, Juarez-Garcia A, Holdgate O.

Pharmacoecon Open. 2023 Mar;7(2):273-284. doi: 10.1007/s41669-022-00383-x. Epub 2023 Mar 10.

PMID: 36897427

Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop.

Shankar LK, Schöder H, Sharon E, Wolchok J, Knopp MV, Wahl RL, Ellingson BM, Hall NC, Yaffe MJ, Towbin AJ, Farwell MD, Pryma D, Poussaint TY, Wright CL, Schwartz L, Harisinghani M, Mahmood U, Wu AM, Leung D, de Vries EGE, Tang Y, Beach G, Reeves SA.

Lancet Oncol. 2023 Mar;24(3):e133-e143. doi: 10.1016/S1470-2045(22)00742-2.

PMID: 36858729

Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial.

Burke JM, Yu KS, Mordi U, Bloudek B, Liu N, Phillips T.

J Manag Care Spec Pharm. 2023 Mar;29(3):314-323. doi: 10.18553/jmcp.2023.29.3.314.

PMID: 36840956

Author Correction: FinnGen provides genetic insights from a well-phenotyped isolated population.

Nature. 2023 Mar;615(7952):E19. doi: 10.1038/s41586-023-05837-8.

PMID: 36829046

Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests: A Blood Profiling Atlas in Cancer (BLOODPAC) Community Study.

Hernandez KM, Bramlett KS, Agius P, Baden J, Cao R, Clement O, Corner AS, Craft J, Dean DA 2nd, Dry JR, Grigaityte K, Grossman RL, Hicks J, Higa N, Holzer TR, Jensen J, Johann DJ, Katz S, Kolatkar A, Keynton JL, Lee JSH, Maar D, Martini JF, Meyer CG, Roberts PC, Ryder M, Salvatore L, Schageman JJ, Somiari S, Stetson D, Stern M, Xu L, Leiman LC.

J Mol Diagn. 2023 Mar;25(3):143-155. doi: 10.1016/j.jmoldx.2022.12.003.

PMID: 36828596

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N.

Future Oncol. 2023 Mar;19(8):549-557. doi: 10.2217/fon-2023-0007. Epub 2023 Feb 23.

PMID: 36815433

Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison.

Swallow E, Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, Tencer T, Gupte-Singh K.

Mult Scler Relat Disord. 2023 Mar;71:104551. doi: 10.1016/j.msard.2023.104551. Epub 2023 Feb 6.

PMID: 36791623

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.

Van Le H, Van Naarden Braun K, Nowakowski GS, Sermer D, Radford J, Townsend W, Ghesquieres H, Menne T, Porpaczy E, Fox CP, Schusterbauer C, Liu FF, Yue L, De Benedetti M, Hasskarl J.Leuk Lymphoma. 2023 Mar;64(3):573-585. doi: 10.1080/10428194.2022.2160200. Epub 2023 Feb 8.

PMID: 36755418

Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.

O'Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, Eccles LJ, Varol N, Waser N, Penrod JR, Goring S.

Lung Cancer. 2023 Mar;177:11-20. doi: 10.1016/j.lungcan.2023.01.006. Epub 2023 Jan 11.

PMID: 36669321

Baseline risk factors associated with immune related adverse events and atezolizumab.

Madjar K, Mohindra R, Durán-Pacheco G, Rasul R, Essioux L, Maiya V, Chandler GS.

Front Oncol. 2023 Feb 28;13:1138305. doi: 10.3389/fonc.2023.1138305. eCollection 2023.

PMID: 36925916

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.

Cheng Y, Ye Y, Gaudy A, Ghosh A, Xue Y, Wang A, Zhou S, Li Y.

Clin Pharmacol. 2023 Feb 28;15:9-19. doi: 10.2147/CPAA.S397826. eCollection 2023.

PMID: 36880014

Residue-Level Characterization of Antibody Binding Epitopes Using Carbene Chemical Footprinting.

Hogan JM, Lee PS, Wong SC, West SM, Morishige WH, Bee C, Tapia GC, Rajpal A, Strop P, Dollinger G.

Anal Chem. 2023 Feb 28;95(8):3922-3931. doi: 10.1021/acs.analchem.2c03091. Epub 2023 Feb 15.

PMID: 36791402

Peripheral blood monocytosis is associated with long-term disease severity in pediatric-onset inflammatory bowel disease.

Zhang X, Ramos-Rivers C, Prathapan K, Wang X, Tang G, Kim S, Binion DG.

J Pediatr Gastroenterol Nutr. 2023 Feb 27:e003755. doi: 10.1097/MPG.0000000000003755. Online ahead of print

.PMID: 36827967

Rate of castration-induced prostate stroma regression is reduced in a mouse model of benign prostatic hyperplasia.

Zhang R, Singh S, Pan C, Xu B, Kindblom J, Eng KH, Krolewski JJ, Nastiuk KL.

Am J Clin Exp Urol. 2023 Feb 25;11(1):12-26. eCollection 2023.

PMID: 36923722

A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.

McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Del Tejo V, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C.

Eur Urol Oncol. 2023 Feb 24:S2588-9311(23)00031-7. doi: 10.1016/j.euo.2023.01.012. Online ahead of print.

PMID: 36842942

Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial.

Weisel K, Dimopoulos MA, San-Miguel J, Paner A, Engelhardt M, Taylor F, Lord-Bessen J, Yip C, Greenwood M, Tang J, Cavo M.

Hemasphere. 2023 Feb 24;7(3):e843. doi: 10.1097/HS9.0000000000000843. eCollection 2023 Mar.

PMID: 36860268

Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment.

Xiao H, Bertwistle D, Khela K, Middleton-Dalby C, Hall J.

BMC Cancer. 2023 Feb 23;23(1):186. doi: 10.1186/s12885-023-10553-7.

PMID: 36823552

Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis.

Singh H, Wilson L, Tencer T, Kumar J.

Clinicoecon Outcomes Res. 2023 Feb 22;15:125-138. doi: 10.2147/CEOR.S391413. eCollection 2023.

PMID: 36855750

Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials.

Ahmad HA, East JE, Panaccione R, Travis S, Canavan JB, Usiskin K, Byrne MF.

J Crohns Colitis. 2023 Feb 22:jjad029. doi: 10.1093/ecco-jcc/jjad029. Online ahead of print.

PMID: 36812142

Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium "Long-Acting Injectables" Working Group.

Bauer A, Berben P, Chakravarthi SS, Chattorraj S, Garg A, Gourdon B, Heimbach T, Huang Y, Morrison C, Mundhra D, Palaparthy R, Saha P, Siemons M, Shaik NA, Shi Y, Shum S, Thakral NK, Urva S, Vargo R, Koganti VR, Barrett SE.

Pharm Res. 2023 Feb 22. doi: 10.1007/s11095-022-03391-y. Online ahead of print.

PMID: 36811809 Review.

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma.

Deutsch JS, Lipson EJ, Danilova L, Topalian SL, Jedrych J, Baraban E, Ged Y, Singla N, Choueiri TK, Gupta S, Motzer RJ, McDermott D, Signoretti S, Atkins M, Taube JM.

Cell Rep Med. 2023 Feb 21;4(2):100947. doi: 10.1016/j.xcrm.2023.100947.

PMID: 36812889

Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment.

Szabo PM, Vajdi A, Kumar N, Tolstorukov MY, Chen BJ, Edwards R, Ligon KL, Chasalow SD, Chow KH, Shetty A, Bolisetty M, Holloway JL, Golhar R, Kidd BA, Hull PA, Houser J, Vlach L, Siemers NO, Saha S.

Sci Rep. 2023 Feb 21;13(1):3051. doi: 10.1038/s41598-023-28480-9.

PMID: 36810872

Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.

Williams CD, Allo MA, Gu L, Vashistha V, Press A, Kelley M.

PLoS One. 2023 Feb 21;18(2):e0282020. doi: 10.1371/journal.pone.0282020. eCollection 2023.

PMID: 36809528

Isolation and characterization of pseudo degradation products of acalabrutinib using ESI-HRMS/MS and NMR: Formation of possible geometrical isomers.

Panda S, Das M, Kandula RR, Gajjela R, Ravuri NDH, Kumar H, Kalamse S, Mathur A, Roy A, Bagadi M.

J Pharm Biomed Anal. 2023 Feb 20;225:115214. doi: 10.1016/j.jpba.2022.115214. Epub 2022 Dec 29.

PMID: 36621281

A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan.

Komine M, Kim H, Yi J, Zhong Y, Sakai Y, Crawford B, Habiro K, Hikichi Y, Feldman SR.

J Dermatol. 2023 Feb 20. doi: 10.1111/1346-8138.16746. Online ahead of print.

PMID: 36808765

Nivolumab With or Without Ipilimumab in Pediatric Patients With High-Grade CNS Malignancies: Safety, Efficacy, Biomarker, and Pharmacokinetics: CheckMate 908.

Dunkel IJ, Doz F, Foreman NK, Hargrave D, Lassaletta A, André N, Hansford JR, Hassall T, Eyrich M, Gururangan S, Bartels U, Gajjar A, Howell L, Warad D, Pacius M, Tam R, Wang Y, Zhu L, Cohen K.

Neuro Oncol. 2023 Feb 20:noad031. doi: 10.1093/neuonc/noad031. Online ahead of print.

PMID: 36808285

Structurally Diverse Bench-Stable Nickel(0) Pre-Catalysts: A Practical Toolkit for In Situ Ligation Protocols.

Tran VT, Kim N, Rubel CZ, Wu X, Kang T, Jankins TC, Li ZQ, Joannou MV, Ayers S, Gembicky M, Bailey J, Sturgell EJ, Sanchez BB, Chen JS, Lin S, Eastgate MD, Wisniewski SR, Engle KM.

Angew Chem Int Ed Engl. 2023 Feb 20;62(9):e202211794. doi: 10.1002/anie.202211794. Epub 2023 Jan 18.

PMID: 36524997

In Support of Early-Career Researchers.

Bandichhor R, Borovik AS, Bettencourt-Dias A, Eastgate MD, Radu NS, Shi F, McElwee-White L.

J Org Chem. 2023 Feb 17;88(4):1923-1927. doi: 10.1021/acs.joc.3c00130. Epub 2023 Feb 2.

PMID: 36727963

Reproductive and developmental toxicity following exposure to organophosphate ester flame retardants and plasticizers, triphenyl phosphate and isopropylated phenyl phosphate, in Sprague Dawley rats.

Witchey SK, Sutherland V, Collins B, Roberts G, Shockley KR, Vallant M, Krause J, Cunny H, Waidyanatha S, Mylchreest E, Sparrow B, Moyer R, Behl M.Toxicol Sci. 2023 Feb 17;191(2):374-386. doi: 10.1093/toxsci/kfac135.PMID: 36562586

Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions.

Fisher KJ, Kinsey R, Mohamath R, Phan T, Liang H, Orr MT, Lykins WR, Guderian JA, Bakken J, Argilla D, Ramer-Denisoff G, Larson E, Qi Y, Sivananthan S, Smolyar K, Carter D, Paddon CJ, Fox CB.

NPJ Vaccines. 2023 Feb 16;8(1):14. doi: 10.1038/s41541-023-00608-y.

PMID: 36797262

In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors.

Selkirk JV, Yan YG, Ching N, Paget K, Hargreaves R.

Eur J Pharmacol. 2023 Feb 15;941:175442. doi: 10.1016/j.ejphar.2022.175442. Epub 2022 Dec 5.

PMID: 36470447

Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Connarn JN, Witjes H, van Zutphen-van Geffen M, de Greef R, Campbell TB, Hege K, Zhou S, Lamba M.

CPT Pharmacometrics Syst Pharmacol. 2023 Feb 15. doi: 10.1002/psp4.12922. Online ahead of print.

PMID: 36794354

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.

Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ.

J Clin Oncol. 2023 Feb 13:JCO2202072. doi: 10.1200/JCO.22.02072. Online ahead of print.

PMID: 36780608

In Support of Early-Career Researchers.

Bandichhor R, Borovik AS, Bettencourt-Dias A, Eastgate MD, Radu NS, Shi F, McElwee-White L.

Inorg Chem. 2023 Feb 13;62(6):2489-2493. doi: 10.1021/acs.inorgchem.3c00207. Epub 2023 Feb 2.

PMID: 36727951

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS.

J Clin Oncol. 2023 Feb 10;41(5):943-954. doi: 10.1200/JCO.22.02272.

PMID: 36750016

In Support of Early-Career Researchers.

Bandichhor R, Borovik AS, Bettencourt-Dias A, Eastgate MD, Radu NS, Shi F, McElwee-White L.

Org Lett. 2023 Feb 10;25(5):715-719. doi: 10.1021/acs.orglett.3c00187. Epub 2023 Feb 2.

PMID: 36727953

Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.

Çakar E, Oniangue-Ndza C, Schneider RP, Klijn SL, Vogl UM, Rothermundt C, May JR.

Pharmacoecon Open. 2023 Feb 9. doi: 10.1007/s41669-023-00395-1. Online ahead of print

.PMID: 36757568

Potent Long-Acting Inhibitors Targeting the HIV-1 Capsid Based on a Versatile Quinazolin-4-one Scaffold.

Gillis EP, Parcella K, Bowsher M, Cook JH, Iwuagwu C, Naidu BN, Patel M, Peese K, Huang H, Valera L, Wang C, Kieltyka K, Parker DD, Simmermacher J, Arnoult E, Nolte RT, Wang L, Bender JA, Frennesson DB, Saulnier M, Wang AX, Meanwell NA, Belema M, Hanumegowda U, Jenkins S, Krystal M, Kadow JF, Cockett M, Fridell R.

J Med Chem. 2023 Feb 9;66(3):1941-1954. doi: 10.1021/acs.jmedchem.2c01732. Epub 2023 Jan 31.

PMID: 36719971

A Distributional Model of Bound Ligand Conformational Strain: From Small Molecules up to Large Peptidic Macrocycles.

Jain AN, Brueckner AC, Cleves AE, Reibarkh M, Sherer EC.

J Med Chem. 2023 Feb 9;66(3):1955-1971. doi: 10.1021/acs.jmedchem.2c01744. Epub 2023 Jan 26.

PMID: 36701387

Experimental and computational characterization of mass transfer in high turndown bioreactors.

Schlaich EM, Thomas JA, Kandari L, Tremml G, Khetan A.

Biotechnol Prog. 2023 Feb 8:e3330. doi: 10.1002/btpr.3330. Online ahead of print.

PMID: 36751946

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U.

Blood Cancer J. 2023 Feb 7;13(1):24. doi: 10.1038/s41408-023-00793-y.

PMID: 36746923

Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.

Blackhall F, Girard N, Livartowski A, McDonald L, Roset M, Lara N, Juarez García A.

BMJ Open. 2023 Feb 6;13(2):e052556. doi: 10.1136/bmjopen-2021-052556.

PMID: 36746549

Measurement of LAG-3 Expression Across Multiple Staining Platforms With the 17B4 Antibody Clone.

Wojcik JB, Desai K, Avraam K, Vandebroek A, Dillon LM, Giacomazzi G, Rypens C, Benci JL.

Arch Pathol Lab Med. 2023 Feb 6. doi: 10.5858/arpa.2022-0082-OA. Online ahead of print.

PMID: 36745202

Follow Your Nose: Repeat Nasal Bone Evaluation in First-Trimester Screening for Down Syndrome.

Miller KA, Sagaser KG, Hertenstein CB, Blakemore KJ, Forster KR, Lawson CS, Jelin AC.

J Ultrasound Med. 2023 Feb 6. doi: 10.1002/jum.16190. Online ahead of print.

PMID: 36744578

Amorphous Drug-Polymer Salts: Maximizing Proton Transfer to Enhance Stability and Release.

Neusaenger AL, Yao X, Yu J, Kim S, Hui HW, Huang L, Que C, Yu L.

Mol Pharm. 2023 Feb 6;20(2):1347-1356. doi: 10.1021/acs.molpharmaceut.2c00942. Epub 2023 Jan 20.

PMID: 36668815

Declining enrolment and other challenges in IBD clinical trials: Causes and potential solutions.

Uzzan M, Bouhnik Y, Abreu M, Ahmad HA, Adsul S, Carlier H, Dubinsky M, Germinaro M, Jairath V, Modesto I, Mortensen E, Narula N, Neimark E, Oortwijn A, Protic M, Rubin DT, Oh YS, Wichary J, Peyrin-Biroulet L, Reinisch W.

J Crohns Colitis. 2023 Feb 4:jjad020. doi: 10.1093/ecco-jcc/jjad020. Online ahead of print.

PMID: 36738443

Structure-activity relationship (SAR) studies on substituted N-(pyridin-3-yl)-2-amino-isonicotinamides as highly potent and selective glycogen synthase kinase-3 (GSK-3) inhibitors.

Luo G, Chen L, Jacutin-Porte S, Han Y, Burton CR, Xiao H, Krause CM, Cao Y, Liu N, Kish K, Lewis HA, Macor JE, Dubowchik GM.

Bioorg Med Chem Lett. 2023 Feb 1;81:129143. doi: 10.1016/j.bmcl.2023.129143. Epub 2023 Jan 18.

PMID: 36669575

Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.

Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Antonio JN Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD.

Future Oncol. 2023 Feb;19(6):413-426. doi: 10.2217/fon-2022-1294. Epub 2023 Mar 15.

PMID: 36919916

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.

Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M, Jao K, Barlesi F, Bordenave S, Rijavec E, Urban L, Aucoin JS, Zannori C, Vermaelen K, Arén Frontera O, Curioni Fontecedro A, Sánchez-Gastaldo A, Juan-Vidal O, Linardou H, Poddubskaya E, Spigel DR, Ahmed S, Maio M, Li S, Chang H, Fiore J, Acevedo A, Paz-Ares L.

J Immunother Cancer. 2023 Feb;11(2):e006127. doi: 10.1136/jitc-2022-006127.

PMID: 36725084

The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain.

Prior H, Andrews L, Cauvin A, Chien H, Clarke DO, Datta K, Dempster M, Dybdal N, Freebern W, de Haan L, Herzyk D, Hey A, Kissner T, Kronenberg S, Leach MW, Lee D, Reid K, Schutte K, Sewell F, Trouba K, Ulrich P, van Aerts L, van Meer P, Weir L.

Regul Toxicol Pharmacol. 2023 Feb;138:105339. doi: 10.1016/j.yrtph.2023.105339. Epub 2023 Jan 14.

PMID: 36649820

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.

Germing U, Fenaux P, Platzbecker U, Buckstein R, Santini V, Díez-Campelo M, Yucel A, Tang D, Fabre S, Zhang G, Zoffoli R, Ha X, Miteva D, Hughes C, Komrokji RS, Zeidan AM, Garcia-Manero G.

Ann Hematol. 2023 Feb;102(2):311-321. doi: 10.1007/s00277-022-05071-8. Epub 2023 Jan 13.

PMID: 36635381

Development and Clinical Evaluation of a Rapid Point of Care Test for Ebola Virus Infection in Humans.

Wang Z, Bennett RS, Roehler M, Guillon G, Fischl MJ, Donadi MC, Makovetz J, Holmes N, Zaveri T, Toolan E, Gontz HL, Yearwood GD, Logue J, Bohannon JK, Mistretta L, Byrum R, Ragland D, St Claire M, Kurtz LA, Miller T, Reed MR, Young J, Lee J, Hensley LE, Kardos K, Berry JD.

Viruses. 2023 Jan 25;15(2):336. doi: 10.3390/v15020336.

PMID: 36851550

Apolipoprotein M Attenuates Anthracycline Cardiotoxicity and Lysosomal Injury.

Guo Z, Valenzuela Ripoll C, Picataggi A, Rawnsley DR, Ozcan M, Chirinos JA, Chendamarai E, Girardi A, Riehl T, Evie H, Diab A, Kovacs A, Hyrc K, Ma X, Asnani A, Shewale SV, Scherrer-Crosbie M, Cowart LA, Parks JS, Zhao L, Gordon D, Ramirez-Valle F, Margulies KB, Cappola TP, Desai AA, Pedersen LN, Bergom C, Stitziel NO, Rettig MP, DiPersio JF, Hajny S, Christoffersen C, Diwan A, Javaheri A.

JACC Basic Transl Sci. 2023 Jan 4;8(3):340-355. doi: 10.1016/j.jacbts.2022.09.010. eCollection 2023 Mar.

PMID: 37034289

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.

Brown EA, Minnich A, Sanyal AJ, Loomba R, Du S, Schwarz J, Ehman RL, Karsdal M, Leeming DJ, Cizza G, Charles ED.

JHEP Rep. 2023 Jan 7;5(4):100661. doi: 10.1016/j.jhepr.2022.100661. eCollection 2023 Apr.

PMID: 36866389

Evaluating process utilities for the treatment burden of chemotherapy in multiple myeloma in Japan: a time trade-off valuation study.

Ishida T, Nakakoji M, Murata T, Matsuyama F, Iida S.

J Med Econ. 2023 Jan-Dec;26(1):565-573. doi: 10.1080/13696998.2023.2197811.

PMID: 37010489

Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway.

Winge-Main A, Robsahm TE, Nyakas M, Festervoll G, Torkilseng E, Thybo S, Pati S, Carroll R.

Future Oncol. 2023 Jan;19(3):205-215. doi: 10.2217/fon-2022-0969. Epub 2023 Mar 28.

PMID: 36974621

Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.

Crosbie A, Le TK, Zhang Y, Das R, Ades F, Davis C, Gogate A.

Future Oncol. 2023 Jan;19(3):229-244. doi: 10.2217/fon-2022-0801. Epub 2023 Mar 28.

PMID: 36974619

Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study.

Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Neil EC, Chakravarti A, Willmarth N, Balajonda BC, Menon J, Ma J, Bauer H, Nelson RS, Tan MS, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D.

Future Oncol. 2023 Jan;19(2):173-188. doi: 10.2217/fon-2022-0904. Epub 2023 Mar 28.

PMID: 36974606

In Vitro Generation of Human Cross-Presenting Type 1 Conventional Dendritic Cells (cDC1s) and Plasmacytoid Dendritic Cells (pDCs).

Luo X, Balan S, Arnold-Schrauf C, Dalod M.

Methods Mol Biol. 2023;2618:133-145. doi: 10.1007/978-1-0716-2938-3_10.

PMID: 36905514

Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.

Assié JB, Chouaïd C, Nunes H, Reynaud D, Gaudin AF, Grumberg V, Jolivel R, Jouaneton B, Cotté FE, Duchemann B.

Ther Adv Med Oncol. 2023 Jan 31;15:17588359231152847. doi: 10.1177/17588359231152847. eCollection 2023.

PMID: 36743523

Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients.

Huuhtanen J, Kasanen HH, Peltola K, Lönnberg T, Glumoff V, Brück O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Mäkelä S, Nyakas M, Li B, Hernberg M, Bono P, Lähdesmäki H, Kreutzman A, Mustjoki S.

J Clin Invest. 2023 Jan 31:e164809. doi: 10.1172/JCI164809. Online ahead of print.

PMID: 36719749

Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting.

Parekh K, LeBlang S, Nazarian J, Mueller S, Zacharoulis S, Hynynen K, Powlovich L.

Neoplasia. 2023 Jan 27;37:100876. doi: 10.1016/j.neo.2023.100876. Online ahead of print.

PMID: 36709715

Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States.

Desai NR, Sutton MB, Xie J, Fine JT, Gao W, Owens AT, Naidu SS.

Am J Cardiol. 2023 Jan 27;192:16-23. doi: 10.1016/j.amjcard.2022.12.030. Online ahead of print.

PMID: 36709525

Paving the Road for CAR-Ts: ASTCT 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies.

Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Locke FL.

Transplant Cell Ther. 2023 Jan 26:S2666-6367(23)00045-3. doi: 10.1016/j.jtct.2023.01.021. Online ahead of print.

PMID: 36709800

Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an In Vivo Model of Trypanosoma cruzi Infection.

Tawaraishi T, Ochida A, Akao Y, Itono S, Kamaura M, Akther T, Shimada M, Canan S, Chowdhury S, Cao Y, Condroski K, Engkvist O, Francisco A, Ghosh S, Kaki R, Kelly JM, Kimura C, Kogej T, Nagaoka K, Naito A, Pairaudeau G, Radu C, Roberts I, Shum D, Watanabe NA, Xie H, Yonezawa S, Yoshida O, Yoshida R, Mowbray C, Perry B.

J Med Chem. 2023 Jan 26;66(2):1221-1238. doi: 10.1021/acs.jmedchem.2c00775. Epub 2023 Jan 6.

PMID: 36607408

Rapid Sterility Test Systems in the Pharmaceutical Industry: Applying a Structured Approach to their Evaluation, Validation and Global Implementation.

Deutschmann S, Paul M, Claassen-Willemse M, van den Berg J, IJzerman-Boon P, Grunert da Fonseca V, Brunbech E, Johnson L, Knutsen C, Plourde L, Salvas J, Villari P, Wysocki L, Franz-Riethdorf M.

PDA J Pharm Sci Technol. 2023 Jan 25:pdajpst.2021.012672. doi: 10.5731/pdajpst.2021.012672. Online ahead of print.

PMID: 36697213

Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.

Chatterjee S, Deshpande AA, Shen H.

Biopharm Drug Dispos. 2023 Jan 24. doi: 10.1002/bdd.2345. Online ahead of print.

PMID: 36692150

Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P, Stock W, Jabbour EJ.

Am J Hematol. 2023 Jan 24. doi: 10.1002/ajh.26853. Online ahead of print.

PMID: 36691748

Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.

Minakata D, Ishida T, Ando K, Suzuki R, Tanaka J, Hagiwara S, Ananthakrishnan R, Kuwayama S, Nishio M, Kanda Y, Suzuki K.

Int J Hematol. 2023 Jan 24. doi: 10.1007/s12185-023-03538-6. Online ahead of print.

PMID: 36690910

Correction to: Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.

van Stekelenborg J, Kara V, Haack R, Vogel U, Garg A, Krupp M, Gofman K, Dreyfus B, Hauben M, Bate A.

Drug Saf. 2023 Jan 23. doi: 10.1007/s40264-023-01272-w. Online ahead of print.

PMID: 36689132

A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK.

Cohen AT, Benson G, Bradbury CA, Choudhuri S, Hutchinson Jones N, Maraveyas A, Venugopal B, Young AM, Chapman C, McIntyre S, Burney D, Pollock KG, Morgan AR, Gabb PD, Alikhan R.

Curr Med Res Opin. 2023 Jan 23:1-13. doi: 10.1080/03007995.2023.2167441. Online ahead of print.

PMID: 36629478 Review.

Assessing the Impact of Open-Label Designs in Patient-Reported Outcomes: Investigation in Oncology Clinical Trials.

Lord-Bessen J, Signorovitch J, Yang M, Georgieva M, Roydhouse J.

JNCI Cancer Spectr. 2023 Jan 20:pkad002. doi: 10.1093/jncics/pkad002. Online ahead of print.

PMID: 36661326

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.

Wei AH, Döhner H, Sayar H, Ravandi F, Montesinos P, Dombret H, Selleslag D, Porkka K, Jang JH, Skikne B, Beach CL, Prebet T, Zhang G, Risueño A, Ugidos M, See WL, Menezes D, Roboz GJ.

Am J Hematol. 2023 Jan 19. doi: 10.1002/ajh.26847. Online ahead of print.

PMID: 36655608

A fast and powerful linear mixed model approach for genotype-environment interaction tests in large-scale GWAS.

Zhong W, Chhibber A, Luo L, Mehrotra DV, Shen J.

Brief Bioinform. 2023 Jan 19;24(1):bbac547. doi: 10.1093/bib/bbac547.

PMID: 36545787

Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.

Wheeler MT, Olivotto I, Elliott PM, Saberi S, Owens AT, Maurer MS, Masri A, Sehnert AJ, Edelberg JM, Chen YM, Florea V, Malhotra R, Wang A, Oreziak A, Myers J.

JAMA Cardiol. 2023 Jan 18:e225099. doi: 10.1001/jamacardio.2022.5099. Online ahead of print.

PMID: 36652223

Phosphine-Dependent Photoinitiation of Alkyl Thiols under Near-UV Light Facilitates User-Friendly Peptide Desulfurization.

Venneti NM, Samala G, Morsy RMI, Mendoza LG, Isidro-Llobet A, Tom JK, Mukherjee S, Kopach ME, Stockdill JL.

J Am Chem Soc. 2023 Jan 18;145(2):1053-1061. doi: 10.1021/jacs.2c10625. Epub 2023 Jan 5.

PMID: 36602440

Authentication of Human and Mouse Cell Lines by Short Tandem Repeat (STR) DNA Genotype Analysis.

Almeida JL, Korch CT.

2023 Jan 17. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin C, Baell J, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Gorshkov K, Haas JV, Hall MD, Hoare S, Inglese J, Iversen PW, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Sittampalam GS, Tarselli M, Trask OJ Jr, Wang Y, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004–.

PMID: 23805434

Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network.

Inman RD, Choquette D, Khraishi M, Gladman D, Hussein S, Neish D, Leclerc P.

J Rheumatol. 2023 Jan 15:jrheum.220824. doi: 10.3899/jrheum.220824. Online ahead of print.

PMID: 36642434

Baseline radiomic signature to estimate overall survival in patients with non-small cell lung cancer.

Dercle L, Fronheiser M, Rizvi NA, Hellmann MD, Maier S, Hayes W, Yang H, Guo P, Fojo T, Schwartz LH, Zhao B, Leung DK.

J Thorac Oncol. 2023 Jan 13:S1556-0864(22)01995-5. doi: 10.1016/j.jtho.2022.12.019. Online ahead of print.

PMID: 36646209

Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.

Wolf A, Stratmann JA, Shaid S, Niklas N, Calleja A, Ubhi H, Munro R, Waldenberger D, Carroll R, Daumont MJ, Penrod JR, Lacoin L, Rohde G.

BMC Pulm Med. 2023 Jan 13;23(1):16. doi: 10.1186/s12890-022-02288-1.

PMID: 36639770

A Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma.

Zhang M, Gray F, Cushman I, Wurmser A, Chan H, Couto S, Wang M, Nakayama Y, Hagner P, Al-Masri H, Williams S, Hersey S.

Mod Pathol. 2023 Jan 12;36(4):100050. doi: 10.1016/j.modpat.2022.100050. Online ahead of print.

PMID: 36788077

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Blood Cancer J. 2023 Jan 12;13(1):12. doi: 10.1038/s41408-023-00787-w.

PMID: 36631435

Correction: End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics.

Morales AM, Sreedhara A, Buecheler J, Brosig S, Chou D, Christian T, Das T, de Jong I, Fast J, Jagannathan B, Moussa EM, Nejadnik MR, Prajapati I, Radwick A, Rahman Y, Singh S.

AAPS J. 2023 Jan 11;25(1):15. doi: 10.1208/s12248-023-00780-y.

PMID: 36631711

Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019).

Joy M, Williams J, Emanuel S, Kar D, Fan X, Delanerolle G, Field BC, Heiss C, Pollock KG, Sandler B, Arora J, Sheppard JP, Feher M, Hobbs FR, de Lusignan S.

Heart. 2023 Jan 11;109(3):195-201. doi: 10.1136/heartjnl-2022-321377.

PMID: 36371664

FDA/M-CERSI Co-Processed API Workshop Proceedings.

Schenck L, Patel P, Sood R, Bonaga L, Capella P, Dirat O, Erdemir D, Ferguson S, Gazziola C, Gorka LS, Graham L, Ho R, Hoag S, Hunde E, Kline B, Lee SL, Madurawe R, Marziano I, Merritt JM, Page S, Polli J, Ramanadham M, Sapru M, Stevens B, Watson T, Zhang H.

J Pharm Sci. 2023 Jan 10:S0022-3549(23)00007-2. doi: 10.1016/j.xphs.2023.01.006. Online ahead of print.

PMID: 36638959

Understanding the Impact of Microstructures on Reconstitution and Drying Kinetics of Lyophilized Cake Using X-ray Microscopy and Image-Based Simulation.

Pu YE, Ma L, Dear B, Zhu A, Li J, Zhang S, Shi W.

J Pharm Sci. 2023 Jan 7:S0022-3549(23)00004-7. doi: 10.1016/j.xphs.2023.01.002. Online ahead of print.

PMID: 36627053

Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.

Sengupta S, Ntambwe I, Tan K, Liang Q, Paulucci D, Castellanos E, Fiore J, Lane S, Micsinai Balan M, Viraswami-Apanna K, Sethuraman V, Samant M, Tiwari R.

Clin Pharmacol Ther. 2023 Jan 6. doi: 10.1002/cpt.2841. Online ahead of print.

PMID: 36606735

The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.

Buckstein R, Chodirker L, Yee KWL, Geddes M, Leitch HA, Christou G, Banerji V, Leber B, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Parmentier A, Thambipillai A, Tang D, Westcott C, Cameron C, Spin P.

Leuk Lymphoma. 2023 Jan 6:1-11. doi: 10.1080/10428194.2022.2156793. Online ahead of print.

PMID: 36606533

Coupling-Condensation Strategy for the Convergent Synthesis of an Imidazole-Fused 2-Aminoquinoline NLRP3 Agonist.

Bi C, Chadwick J, Davies ML, DelMonte AJ, Geng P, Glace AW, Green RA, Gurak JA Jr, Haley MW, He BL, Inankur B, Jamison CR, Joe CL, Kolotuchin S, Lin D, Lou S, Nye J, Ortiz A, Purdum GE, Rosso VW, Shah M, Simmons EM, Stevens JM, Strotman NA, Tan Y, Zhang L.

J Org Chem. 2023 Jan 6;88(1):384-394. doi: 10.1021/acs.joc.2c02395. Epub 2022 Dec 14.

PMID: 36516991

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor-free, Belatacept Plus Everolimus-based Immunosuppression.

Peddi VR, Marder B, Gaite L, Oberholzer J, Goldberg R, Pearson T, Yang H, Allamassey L, Polinsky M, Formica RN.

Transplant Direct. 2023 Jan 6;9(2):e1419. doi: 10.1097/TXD.0000000000001419. eCollection 2023 Feb.

PMID: 36700062

A Cartographic Tool to Predict Disease Risk-associated Pseudo-Dynamic Networks from Tissue-specific Gene Expression.

Chen C, Shen B, Zhang L, Yu T, Wang M, Wu R.

Bio Protoc. 2023 Jan 5;13(1):e4583. doi: 10.21769/BioProtoc.4583. eCollection 2023 Jan 5.

PMID: 36789091

Understanding the Association between Red Blood Cell Transfusion Utilization and Humanistic and Economic Burden in Patients with β-Thalassemia from the Patients' Perspective.

Knoth RL, Gupta S, Perkowski K, Costantino H, Inyart B, Ashka L, Clapp K.

J Clin Med. 2023 Jan 4;12(2):414. doi: 10.3390/jcm12020414.

PMID: 36675342

Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report.

Al Shoyaib A, Riedmaier AE, Kumar A, Roy P, Parrott NJ, Fang L, Tampal N, Yang Y, Jereb R, Zhao L, Wu F.

CPT Pharmacometrics Syst Pharmacol. 2023 Jan 3. doi: 10.1002/psp4.12913. Online ahead of print.

PMID: 36597353

The lncRNA LUCAT1 is elevated in inflammatory disease and restrains inflammation by regulating the splicing and stability of NR4A2.

Vierbuchen T, Agarwal S, Johnson JL, Galia L, Lei X, Stein K, Olagnier D, Gaede KI, Herzmann C, Holm CK, Heine H, Pai A, O'Hara Hall A, Hoebe K, Fitzgerald KA.

Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2213715120. doi: 10.1073/pnas.2213715120. Epub 2022 Dec 28.

PMID: 36577072

Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel.

Olson NE, Ragan SP, Reiss DJ, Thorpe J, Kim Y, Abramson JS, McCoy C, Newhall KJ, Fox BA.

Mol Cancer Ther. 2023 Jan 3:MCT-21-0506. doi: 10.1158/1535-7163.MCT-21-0506. Online ahead of print.

PMID: 36595660

Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.

McQuade JL, Hammers H, Furberg H, Engert A, André T, Blumenschein G Jr, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ.

JAMA Oncol. 2023 Jan 1;9(1):102-111. doi: 10.1001/jamaoncol.2022.5409.

PMID: 36480191

Trends in Disease Severity Among Critically Ill Children With Severe Acute Respiratory Syndrome Coronavirus 2: A Retrospective Multicenter Cohort Study in the United States.

Ross CE, Burns JP, Grossestreuer AV, Bhattarai P, McKiernan CA, Franks JD, Lehmann S, Sorcher JL, Sharron MP, Wai K, Al-Wahab H, Boukas K, Hall MW, Ru G, Sen AI, Rajasekhar HR, Kleinman LC, McGuire JK, Arrington AS, Munoz-Rivas F, Osborne CM, Shekerdemian LS.

Pediatr Crit Care Med. 2023 Jan 1;24(1):25-33. doi: 10.1097/PCC.0000000000003105. Epub 2022 Nov 17.

PMID: 36516349

Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.

Khorana AA, Palaia J, Rosenblatt L, Pisupati R, Huang N, Nguyen C, Barron J, Gallagher K, Bond TC.

J Immunother Cancer. 2023 Jan;11(1):e006072. doi: 10.1136/jitc-2022-006072.

PMID: 36657815

Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.

van Stekelenborg J, Kara V, Haack R, Vogel U, Garg A, Krupp M, Gofman K, Dreyfus B, Hauben M, Bate A.

Drug Saf. 2023 Jan;46(1):39-52. doi: 10.1007/s40264-022-01251-7. Epub 2022 Dec 24.

PMID: 36565374

The influence of input material properties on hot melt granules prepared using a counter-rotating batch mixer.

Pafiakis A, Armenante P, Gogos CG.

Pharm Dev Technol. 2023 Jan;28(1):1-17. doi: 10.1080/10837450.2022.2156539. Epub 2022 Dec 30.

PMID: 36533900

Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.

Bodd MH, Locke SC, Wolf SP, Antonia S, Crawford J, Hartman J, Herring KW, Ready NE, Stinchcombe TE, Troy JD, Williams C, Clarke JM, LeBlanc TW.

Lung Cancer. 2023 Jan;175:17-26. doi: 10.1016/j.lungcan.2022.11.010. Epub 2022 Nov 21.

PMID: 36442383

Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.

Zeidan AM, Bewersdorf JP, Hasle V, Shallis RM, Thompson E, de Menezes DL, Rose S, Boss I, Halene S, Haferlach T, Fox B.

Leukemia. 2023 Jan;37(1):240-243. doi: 10.1038/s41375-022-01766-z. Epub 2022 Nov 27.

PMID: 36437356

Economic Burden of Comorbidities in Patients with Psoriasis in the USA.

Wu JJ, Suryavanshi M, Davidson D, Patel V, Jain A, Seigel L.

Dermatol Ther (Heidelb). 2023 Jan;13(1):207-219. doi: 10.1007/s13555-022-00832-9. Epub 2022 Nov 19.

PMID: 36402940

Improvements to in silico skin sensitisation predictions through privacy-preserving data sharing.

Macmillan DS, Chilton ML, Hillegass J.

Regul Toxicol Pharmacol. 2023 Jan;137:105292. doi: 10.1016/j.yrtph.2022.105292. Epub 2022 Nov 15.

PMID: 36400282

Mass spectrometry in gene therapy: Challenges and opportunities for AAV analysis.

Serrano MAC, Furman R, Chen G, Tao L.

Drug Discov Today. 2023 Jan;28(1):103442. doi: 10.1016/j.drudis.2022.103442. Epub 2022 Nov 14.

PMID: 36396118

First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2.

Catlett IM, Aras U, Hansen L, Liu Y, Bei D, Girgis IG, Murthy B.

Clin Transl Sci. 2023 Jan;16(1):151-164. doi: 10.1111/cts.13435. Epub 2022 Nov 22.

PMID: 36325947

FinnGen provides genetic insights from a well-phenotyped isolated population.

Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA, Loukola A, Lahtela E, Mattsson H, Laiho P, Della Briotta Parolo P, Lehisto AA, Kanai M, Mars N, Rämö J, Kiiskinen T, Heyne HO, Veerapen K, Rüeger S, Lemmelä S, Zhou W, Ruotsalainen S, Pärn K, Hiekkalinna T, Koskelainen S, Paajanen T, Llorens V, Gracia-Tabuenca J, Siirtola H, Reis K, Elnahas AG, Sun B, Foley CN, Aalto-Setälä K, Alasoo K, Arvas M, Auro K, Biswas S, Bizaki-Vallaskangas A, Carpen O, Chen CY, Dada OA, Ding Z, Ehm MG, Eklund K, Färkkilä M, Finucane H, Ganna A, Ghazal A, Graham RR, Green EM, Hakanen A, Hautalahti M, Hedman ÅK, Hiltunen M, Hinttala R, Hovatta I, Hu X, Huertas-Vazquez A, Huilaja L, Hunkapiller J, Jacob H, Jensen JN, Joensuu H, John S, Julkunen V, Jung M, Junttila J, Kaarniranta K, Kähönen M, Kajanne R, Kallio L, Kälviäinen R, Kaprio J; FinnGen; Kerimov N, Kettunen J, Kilpeläinen E, Kilpi T, Klinger K, Kosma VM, Kuopio T, Kurra V, Laisk T, Laukkanen J, Lawless N, Liu A, Longerich S, Mägi R, Mäkelä J, Mäkitie A, Malarstig A, Mannermaa A, Maranville J, Matakidou A, Meretoja T, Mozaffari SV, Niemi MEK, Niemi M, Niiranen T, O Donnell CJ, Obeidat ME, Okafo G, Ollila HM, Palomäki A, Palotie T, Partanen J, Paul DS, Pelkonen M, Pendergrass RK, Petrovski S, Pitkäranta A, Platt A, Pulford D, Punkka E, Pussinen P, Raghavan N, Rahimov F, Rajpal D, Renaud NA, Riley-Gillis B, Rodosthenous R, Saarentaus E, Salminen A, Salminen E, Salomaa V, Schleutker J, Serpi R, Shen HY, Siegel R, Silander K, Siltanen S, Soini S, Soininen H, Sul JH, Tachmazidou I, Tasanen K, Tienari P, Toppila-Salmi S, Tukiainen T, Tuomi T, Turunen JA, Ulirsch JC, Vaura F, Virolainen P, Waring J, Waterworth D, Yang R, Nelis M, Reigo A, Metspalu A, Milani L, Esko T, Fox C, Havulinna AS, Perola M, Ripatti S, Jalanko A, Laitinen T, Mäkelä TP, Plenge R, McCarthy M, Runz H, Daly MJ, Palotie A.

Nature. 2023 Jan;613(7944):508-518. doi: 10.1038/s41586-022-05473-8. Epub 2023 Jan 18.

PMID: 36653562

Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction.

Qiu J, Xu B, Ye D, Ren D, Wang S, Benci JL, Xu Y, Ishwaran H, Beltra JC, Wherry EJ, Shi J, Minn AJ.

Nat Cancer. 2023 Jan;4(1):43-61. doi: 10.1038/s43018-022-00490-y. Epub 2023 Jan 16.

PMID: 36646856

Probing the effect of glycosaminoglycan depletion on integrin interactions with collagen I fibrils in the native extracellular matrix environment.

Roth J, Hoop CL, Williams JK, Hayes R, Baum J.

Protein Sci. 2023 Jan;32(1):e4508. doi: 10.1002/pro.4508.

PMID: 36369695

Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.

Karampampa K, Zhang W, Venkatachalam M, Cotte FE, Dhanda D.

J Med Econ. 2023 Jan-Dec;26(1):243-253. doi: 10.1080/13696998.2023.2173466.

PMID: 36705644

Warfarin Time in Therapeutic INR Range and Direct Oral Anticoagulant Adherence for Venous Thromboembolism Across the Spectrum of Weight and Body Mass Index: Findings from Veterans Health Administration.

Din N, Fan J, Schmitt S, Guo JD, Hlavacek P, Pundi K, Russ C, Emir B, Turakhia MP, Perino AC.

Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231152474. doi: 10.1177/10760296231152474.

PMID: 36694957

2022 Publications

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.

Zeleke TZ, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez MJ, Honan E, Yang M, Chia PL, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi MS, Accordino M, Crew KD, Hershman DL, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J.

Nat Cancer. 2022 Dec 30. doi: 10.1038/s43018-022-00489-5. Online ahead of print.

PMID: 36585452

Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.

Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jiménez A, Brunet S, Casaño J, Oiartzabal I, Díez-Campelo M, Ramos F, Romero R, Salido-Fiérrez E, Pedro C, Bargay J, Muñoz-Novas C, López R, Rafel M, Valcárcel D; ERASME study group.

Leuk Lymphoma. 2022 Dec 28:1-12. doi: 10.1080/10428194.2022.2154604. Online ahead of print.

PMID: 36577016

Imaging Non-alcoholic Fatty Liver Disease Model Using H-1 and F-19 MRI.

Lister D, Blizard G, Hosseini M, Messer K, Wellen J, Sirlin CB, Ahrens ET.

Mol Imaging Biol. 2022 Dec 27. doi: 10.1007/s11307-022-01798-y. Online ahead of print.

PMID: 36575339

Analyzing dental fluorosis data using a novel Bayesian model for clustered longitudinal ordinal outcomes with an inflated category.

Kang T, Gaskins J, Levy S, Datta S.

Stat Med. 2022 Dec 27. doi: 10.1002/sim.9641. Online ahead of print.

PMID: 36574753

The autism risk factor CHD8 is a chromatin activator in human neurons and functionally dependent on the ERK-MAPK pathway effector ELK1.

Haddad Derafshi B, Danko T, Chanda S, Batista PJ, Litzenburger U, Lee QY, Ng YH, Sebin A, Chang HY, Südhof TC, Wernig M.

Sci Rep. 2022 Dec 27;12(1):22425. doi: 10.1038/s41598-022-23614-x.

PMID: 36575212

Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.

Chin K, Yamamoto S, Takahashi M, Kadowaki S, Kubota Y, Amanuma Y, Okada M, Kanda M, Kimura Y, Nogi Y, Arimitsu Y, Kitagawa Y.

Esophagus. 2022 Dec 23. doi: 10.1007/s10388-022-00972-z. Online ahead of print.

PMID: 36564602

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor.

Perera V, Wang Z, Lubin S, Christopher LJ, Chen W, Xu S, Seiffert D, DeSouza M, Murthy B.

Sci Rep. 2022 Dec 23;12(1):22239. doi: 10.1038/s41598-022-25936-2.

PMID: 36564395

Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults.

Harker-Murray P, Mauz-Körholz C, Leblanc TM, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano JM, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM, Daw S.

Blood. 2022 Dec 23:blood.2022017118. doi: 10.1182/blood.2022017118. Online ahead of print.

PMID: 36564047

A single-arm phase 2 trial of Sitravatinib in advanced well-differentiated/dedifferentiated liposarcoma.

Ingham M, Lee S, Van Tine BA, Choy E, Oza J, Doshi S, Ge L, Oppelt P, Cote G, Corgiat B, Sender N, Sta Ana S, Panchalingam L, Petricoin E, Schwartz GK.

Clin Cancer Res. 2022 Dec 22:CCR-22-3351. doi: 10.1158/1078-0432.CCR-22-3351. Online ahead of print.

PMID: 36548343

Design of paediatric trials with benefit-risk endpoints using a composite score of adverse events of interest (AEI) and win-statistics.

Seifu Y, Mt-Isa S, Duke K, Gamalo-Siebers M, Wang W, Dong G, Kolassa J.

J Biopharm Stat. 2022 Dec 22:1-12. doi: 10.1080/10543406.2022.2153202. Online ahead of print.

PMID: 36545791

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study.

Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers PGNJ, Hernandez-Ilizaliturri FJ, Izutsu K, Morschhauser F, Lunning MA, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M.

Blood. 2022 Dec 21:blood.2022018730. doi: 10.1182/blood.2022018730. Online ahead of print.

PMID: 36542826

Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis.

Hirano I, Rothenberg ME, Zhang S, de Oliveira C, Charriez CM, Coyne KS, Bacci ED, Dellon ES.

Am J Gastroenterol. 2022 Dec 20. doi: 10.14309/ajg.0000000000002094. Online ahead of print.

PMID: 36647838

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN.

Cancer Immunol Immunother. 2022 Dec 20. doi: 10.1007/s00262-022-03351-w. Online ahead of print.

PMID: 36538061

Using Digestion by IdeS Protease to Improve Quantification of Degradants in Monoclonal Antibodies by Non-Reducing Capillary Gel Electrophoresis.

McClain A, Zhang Y, Yin Y, Wang Q, Hwang LY, Gu Y, Beckman J, Ludwig R.

Anal Chem. 2022 Dec 20;94(50):17388-17395. doi: 10.1021/acs.analchem.2c02630. Epub 2022 Dec 6.

PMID: 36472948

Effect of solution condition on the binding behaviors of monoclonal antibody and fusion protein therapeutics in Protein A chromatography.

Guo J, Noyes S, Jin W, Curtis H, Xu X, Ghose S.

J Chromatogr A. 2022 Dec 20;1686:463652. doi: 10.1016/j.chroma.2022.463652. Epub 2022 Nov 16.

PMID: 36434831

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.

Dhamane AD, Ferri M, Keshishian A, Russ C, Atreja N, Gutierrez C, Emir B, Yuce H, Di Fusco M.

Adv Ther. 2022 Dec 17. doi: 10.1007/s12325-022-02387-9. Online ahead of print.

PMID: 36527598

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.

Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators.

J Clin Oncol. 2022 Dec 15:JCO2201134. doi: 10.1200/JCO.22.01134. Online ahead of print.

PMID: 36521097

Regioselective synthesis of N1-substituted-4-nitropyrazole-5-carboxylates via the cyclocondensation of ethyl 4-(dimethylamino)-3-nitro-2-oxobut-3-enoate with substituted hydrazines.

Zhao R, Hong Z, Wang B, Kempson J, Cornelius L, Li J, Li YX, Mathur A.

Org Biomol Chem. 2022 Dec 14;20(48):9746-9752. doi: 10.1039/d2ob02006h.

PMID: 36444969

Overcoming Photochemical Limitations in Metallaphotoredox Catalysis: Red-Light-Driven C-N Cross-Coupling.

Goldschmid SL, Soon Tay NE, Joe CL, Lainhart BC, Sherwood TC, Simmons EM, Sezen-Edmonds M, Rovis T.

J Am Chem Soc. 2022 Dec 14;144(49):22409-22415. doi: 10.1021/jacs.2c09745. Epub 2022 Nov 23.

PMID: 36417474

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.

Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Cotté FE, Audigier-Valette C, Griesinger F.

Cancers (Basel). 2022 Dec 13;14(24):6148. doi: 10.3390/cancers14246148.

PMID: 36551632

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.

Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassineti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, Piscaglia F.

J Clin Oncol. 2022 Dec 13:JCO2200972. doi: 10.1200/JCO.22.00972. Online ahead of print.

PMID: 36512738

Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia.

Tabah A, Huggar D, Wang ST, Johnson SJ, Copher RM, O'Connell T, McBride A, LeBlanc TW.

Future Oncol. 2022 Dec 12. doi: 10.2217/fon-2022-0820. Online ahead of print.

PMID: 36507931

Collaborative Assessment of Molecular Geometries and Energies from the Open Force Field.

D'Amore L, Hahn DF, Dotson DL, Horton JT, Anwar J, Craig I, Fox T, Gobbi A, Lakkaraju SK, Lucas X, Meier K, Mobley DL, Narayanan A, Schindler CEM, Swope WC, In 't Veld PJ, Wagner J, Xue B, Tresadern G.

J Chem Inf Model. 2022 Dec 12;62(23):6094-6104. doi: 10.1021/acs.jcim.2c01185. Epub 2022 Nov 26.

PMID: 36433835

Strategies for Managing Solid Form Transformation Risk in Drug Product.

Kestur U, Patel A, Badawy S, Mathias N, Zhang L.

J Pharm Sci. 2022 Dec 10:S0022-3549(22)00565-2. doi: 10.1016/j.xphs.2022.12.002. Online ahead of print.

PMID: 36513146

A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma.

Cope S, Chan K, Campbell H, Chen J, Borrill J, May JR, Malcolm W, Branchoux S, Kupas K, Jansen JP.

Value Health. 2022 Dec 9:S1098-3015(22)04749-0. doi: 10.1016/j.jval.2022.11.017. Online ahead of print.

PMID: 36503035

Role of the Clinical Data Managers during the COVID-19 Pandemic: An Overview.

Sajja R.

Rev Recent Clin Trials. 2022 Dec 8. doi: 10.2174/1574887118666221208123724. Online ahead of print.

PMID: 36503462

Pulmonary Thromboembolism Developed During Hospitalization: A Nationwide Retrospective Observational Study Using Claims Data.

Imura M, Yamamoto T, Hiasa KI.

Cardiol Ther. 2022 Dec 8:1-15. doi: 10.1007/s40119-022-00290-6. Online ahead of print.

PMID: 36482141

Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development.

Coutant DE, Boulton DW, Dahal UP, Deslandes A, Grimaldi C, Pereira JNS, Säll C, Sarvaiya H, Schiller H, Tai G, Umehara K, Yuan Y, Dallas S.

Clin Pharmacol Ther. 2022 Dec 8. doi: 10.1002/cpt.2814. Online ahead of print.

PMID: 36477720

Synthesis, Structure-Activity Relationships, and In Vivo Evaluation of Novel C-17 Amine Derivatives Based on GSK3640254 as HIV-1 Maturation Inhibitors with Broad Spectrum Activity.

Hartz RA, Xu L, Sit SY, Chen J, Venables BL, Lin Z, Zhang S, Li Z, Parker D, Simmons TS, Jenkins S, Hanumegowda UM, Dicker I, Krystal M, Meanwell NA, Regueiro-Ren A.

J Med Chem. 2022 Dec 8;65(23):15935-15966. doi: 10.1021/acs.jmedchem.2c01618. Epub 2022 Nov 28.

PMID: 36441509

Biomarkers predictive of response to pembrolizumab in head and neck cancer.

Pfister DG, Haddad RI, Worden FP, Weiss J, Mehra R, Chow LQM, Liu SV, Kang H, Saba NF, Wirth LJ, Sukari A, Massarelli E, Ayers M, Albright A, Webber AL, Mogg R, Lunceford J, Huang L, Cristescu R, Cheng J, Seiwert TY, Bauml JM.

Cancer Med. 2022 Dec 7. doi: 10.1002/cam4.5434. Online ahead of print.

PMID: 36479637

Capacitance spectroscopy enables real-time monitoring of early cell death in mammalian cell culture.

Wu S, Ketcham SA, Corredor CC, Both D, Drennen JK, Anderson CA.

Biotechnol J. 2022 Dec 7:e2200231. doi: 10.1002/biot.202200231. Online ahead of print.

PMID: 36479620

Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML.

de Botton S, Cluzeau T, Vigil CE, Cook R, Rousselot P, Rizzieri DA, Liesveld JL, Fenaux P, Braun T, Banos A, Jurcic JG, Sekeres MA, Savona MR, Roboz GJ, Bixby D, Madigan K, Volkert A, Stephens K, Kang-Fortner Q, Baker K, Paul S, McKeown MR, Carulli JP, Eaton ML, Hodgson G, Fiore C, Kelly M, Roth DA, Stein EM.

Blood Adv. 2022 Dec 7:bloodadvances.2022008806. doi: 10.1182/bloodadvances.2022008806. Online ahead of print.

PMID: 36477975

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.

Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A.

J Clin Oncol. 2022 Dec 6:JCO2200332. doi: 10.1200/JCO.22.00332. Online ahead of print.

PMID: 36473143

Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.

Willis C, Bauer H, Au TH, Menon J, Unni S, Tran D, Rivers Z, Akerley W, Schabath MB, Badin F, Sekhon A, Patel M, Xia B, Gustafson B, Villano JL, Thomas JM, Lubinga SJ, Cantrell MA, Brixner D, Stenehjem D.

Oncotarget. 2022 Dec 6;13:1306. doi: 10.18632/oncotarget.28318.

PMID: 36473137

Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.

Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia DA, Garonzik S, Lopes RD, Mahaffey KW, Matsuda K, Middleton JP, Rymer JA, Sands GH, Thadhani R, Thomas KL, Washam JB, Winkelmayer WC, Granger CB; RENAL-AF Investigators.

Circulation. 2022 Dec 6;146(23):1735-1745. doi: 10.1161/CIRCULATIONAHA.121.054990. Epub 2022 Nov 6.

PMID: 36335914

Quantitative spatial evaluation of tumor-immune interactions in the immunotherapy setting of metastatic melanoma lymph nodes.

Maus RLG, Leontovich AA, Moore RM, Fogarty Z, Guo R, Davidson TM, Tekin B, Atherton C, Schimke JM, Dicke BA, Chen BJ, Markovic SN.

Front Immunol. 2022 Dec 5;13:1024039. doi: 10.3389/fimmu.2022.1024039. eCollection 2022.PMID: 36544759

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.

Piga A, Longo F, Gamberini MR, Voskaridou E, Ricchi P, Caruso V, Pietrangelo A, Zhang X, Shetty JK, Attie KM, Tartaglione I.

Ther Adv Hematol. 2022 Dec 5;13:20406207221134404. doi: 10.1177/20406207221134404. eCollection 2022.

PMID: 36505885

End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics.

Morales AM, Sreedhara A, Buecheler J, Brosig S, Chou D, Christian T, Das T, de Jong I, Fast J, Jagannathan B, Moussa EM, Nejadnik MR, Prajapati I, Radwick A, Rahman Y, Singh S.

AAPS J. 2022 Dec 5;25(1):6. doi: 10.1208/s12248-022-00773-3.

PMID: 36471030

Wuliangye Baijiu but not ethanol reduces cardiovascular disease risks in a zebrafish thrombosis model.

Zhu H, Lan C, Zhao D, Wang N, Du D, Luo H, Lu H, Peng Z, Wang Y, Qiao Z, Huang Y, Sun B.

NPJ Sci Food. 2022 Dec 5;6(1):55. doi: 10.1038/s41538-022-00170-2.

PMID: 36470888

Immunopurification Reagents and Their Application in Biologics and Biomarker Quantitation Using LC-MS/MS in Drug Discovery.

Gautam SS, Singh SP.

J Chromatogr Sci. 2022 Dec 5:bmac096. doi: 10.1093/chromsci/bmac096. Online ahead of print.

PMID: 36469494

Cardiac myosin filaments are directly regulated by calcium.

Ma W, Nag S, Gong H, Qi L, Irving TC.

J Gen Physiol. 2022 Dec 5;154(12):e202213213. doi: 10.1085/jgp.202213213. Epub 2022 Nov 1.

PMID: 36327149

Continuous feeding and blending demonstration with co-processed drug substance.

Erdemir D, Gawel J, Yohannes B, Yates P, Tang D, Ha K, Breza B, DiMaso E, Abebe A, Zombek J.

J Pharm Sci. 2022 Dec 1:S0022-3549(22)00535-4. doi: 10.1016/j.xphs.2022.11.023. Online ahead of print.

PMID: 36462708

iCoreDrop: A robust immune monitoring spectral cytometry assay with six open channels for biomarker flexibility.

Jensen HA, Kim J.

Cytometry A. 2022 Dec 1. doi: 10.1002/cyto.a.24708. Online ahead of print.

PMID: 36458334

Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients With Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations.

Jadon DR, Corp N, van der Windt DA, Coates LC, Soriano ER, Kavanaugh A, Raine T, Rieder F, Siebert S, Zummer M, Schwartzman S, Rosenbaum JT, Michelsen B, Laxminarayan R, Wu D, Gupta L, Ng B, Jethwa H, De Windt N, Gudu T, Hutton J, O'Sullivan D, Luchetti MM, Stoll M, Singh JA, Peluso R, Rademacher J, Husni ME.

J Rheumatol. 2022 Dec 1:jrheum.220317. doi: 10.3899/jrheum.220317. Online ahead of print.

PMID: 36455946

One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.

Ørnbjerg LM, Rugbjerg K, Georgiadis S, Rasmussen SH, Lindström U, Pavelka K, Yilmaz N, Favalli EG, Nissen MJ, Michelsen B, Vieira-Sousa E, Jones GT, Ionescu R, Relas H, Sanchez-Piedra C, Tomšič M, Geirsson AJ, van der Horst-Bruinsma I, Askling J, Loft AG, Nekvindova L, Direskeneli H, Iannone F, Ciurea A, Fagerli KM, Santos MJ, Macfarlane GJ, Codreanu C, Eklund K, Pombo-Suarez M, Rotar Z, Gudbjornsson B, Rusman T, Østergaard M, Hetland ML.

J Rheumatol. 2022 Dec 1:jrheum.220459. doi: 10.3899/jrheum.220459. Online ahead of print.

PMID: 36455943

Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "windowofopportunity" study.

Moreno V, Sepulveda JM, Reardon DA, Pérez-Núñez Á, González León P, Hanna B, Filvaroff E, Aronchik I, Chang H, Amoroso B, Zuraek M, Sanchez-Perez T, Mendez C, Stephens D, Nikolova Z, Vogelbaum MA.

Neuro Oncol. 2022 Dec 1:noac263. doi: 10.1093/neuonc/noac263. Online ahead of print.

PMID: 36455228

A multi-omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti-PD1 response in solid tumors.

Kumar N, Papillon-Cavanagh S, Tang H, Wang S, Stromko C, Ho CP, Soni-Sheth S, Vasquez-Grinnell S, Broz ML, Tenney DJ, Wichroski MJ, Walsh AM, Hu Y, Benci JL.

Int J Cancer. 2022 Dec 1;151(11):2043-2054. doi: 10.1002/ijc.34218. Epub 2022 Aug 6.

PMID: 35932450

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis.

Wu C, Hu Y, Schafer P, Connolly SE, Wong R, Nielsen SH, Bay-Jensen AC, Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TW, Fleischmann R, Liu J.

RMD Open. 2022 Dec;8(2):e002683. doi: 10.1136/rmdopen-2022-002683.

PMID: 36585217

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.

Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM.

J Immunother Cancer. 2022 Dec;10(12):e005445. doi: 10.1136/jitc-2022-005445.

PMID: 36549781

Ovarian cancer mutational processes drive site-specific immune evasion.

Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP.

Nature. 2022 Dec;612(7941):778-786. doi: 10.1038/s41586-022-05496-1. Epub 2022 Dec 14.

PMID: 36517593

Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases.

Qosa H, Hassan HE, Younis IR.

J Clin Pharmacol. 2022 Dec;62 Suppl 2:S72-S78. doi: 10.1002/jcph.2167.

PMID: 36461747

Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.

Cremer PC, Geske JB, Owens A, Jaber WA, Harb SC, Saberi S, Wang A, Sherrid M, Naidu SS, Schaff H, Smedira NG, Wang Q, Wolski K, Lampl KL, Sehnert AJ, Nissen SE, Desai MY.

Circ Cardiovasc Imaging. 2022 Dec;15(12):e014986. doi: 10.1161/CIRCIMAGING.122.014986. Epub 2022 Nov 6.

PMID: 36335645

Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.

Apolo AB, Powles T, Escudier B, Burotto M, Zhang J, Simsek B, Scheffold C, Motzer RJ, Choueiri TK.

Eur J Cancer. 2022 Dec;177:63-71. doi: 10.1016/j.ejca.2022.09.020. Epub 2022 Oct 4.

PMID: 36327527

The Dog as a Second Species for Toxicology Testing Provides Value to Drug Development.

Bower N, Achanzar WE, Boulifard V, Brinck PR, Kittel B, Vahle JL.

Int J Toxicol. 2022 Dec;41(6):431-441. doi: 10.1177/10915818221125670. Epub 2022 Sep 15.

PMID: 36112859

Rejoinder: Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies.

Zhang H, Chiang AY, Wang J.

Stat Med. 2022 Nov 30;41(27):5497-5500. doi: 10.1002/sim.9561.

PMID: 36394103

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.

Ibáñez-Molero S, van Vliet A, Pozniak J, Hummelink K, Terry AM, Monkhorst K, Sanders J, Hofland I, Landeloos E, Van Herck Y, Bechter O, Kuilman T, Zhong W, Marine JC, Wessels L, Peeper DS.

Oncoimmunology. 2022 Nov 29;11(1):2139074. doi: 10.1080/2162402X.2022.2139074. eCollection 2022.

PMID: 36465485

Evaluation of Novel Urinary Biomarkers in Beagle Dogs With Amphotericin B-Induced Kidney Injury.

Adedeji AO, Sonee M, Chen Y, Lynch K, Peron K, King N, McDuffie JE, Vinken P.

Int J Toxicol. 2022 Nov 25:10915818221142542. doi: 10.1177/10915818221142542. Online ahead of print.

PMID: 36427267

Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Wheeler MT, Jacoby D, Elliott PM, Saberi S, Hegde SM, Lakdawala NK, Myers J, Sehnert AJ, Edelberg JM, Li W, Olivotto I.

Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2737. Online ahead of print.

PMID: 36404399

An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).

Lu S, Cheng Y, Zhou J, Wang M, Zhao J, Wang B, Chen G, Feng J, Ma Z, Wu L, Wang C, Ma K, Zhang S, Liang J, Song Y, Wang J, Wu YL, Li A, Huang Y, Chang J.

Ther Adv Med Oncol. 2022 Nov 19;14:17588359221138380. doi: 10.1177/17588359221138380. eCollection 2022.

PMID: 36425873

Ceramic hydroxyapatite chromatography plays a critical role in bispecific antibody purification process for impurity removal.

Waller JA, Zheng J, Dyer R, Slaney T, Wu W, Tao L, Ghose S.

Antib Ther. 2022 Nov 19;6(1):30-37. doi: 10.1093/abt/tbac030. eCollection 2023 Jan.

PMID: 36683764

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).

Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y.

Esophagus. 2022 Nov 19. doi: 10.1007/s10388-022-00970-1. Online ahead of print.

PMID: 36401133

The challenges inherent with anchor-based approaches to the interpretation of important change in clinical outcome assessments.

Wyrwich KW, Norman GR.

Qual Life Res. 2022 Nov 18. doi: 10.1007/s11136-022-03297-7. Online ahead of print.

PMID: 36396874

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.

Royle KL, Coulson AB, Ramasamy K, Cairns DA, Hockaday A, Quezada S, Drayson M, Kaiser M, Owen R, Auner HW, Cook G, Meads D, Olivier C, Barnard L, Lambkin R, Paterson A, Dawkins B, Chapman M, Pratt G, Popat R, Jackson G, Bygrave C, Sive J, de Tute R, Chantry A, Parrish C, Cook M, Asher S, Yong K.

BMJ Open. 2022 Nov 17;12(11):e063037. doi: 10.1136/bmjopen-2022-063037.

PMID: 36396306

Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.

de la Rubia J, González B, Cruz-Jentoft AJ, Iglesias L, Jarque I, Persona EP, Lluch R, Marrero C, Zudaire M, Gironella M, Hernández-Rivas JÁ, Arnan M, Olivier C, Encinas C, Soler JA, Payer ÁR, Casado A, Fernández P, Vilanova D, Bonanad S.

J Geriatr Oncol. 2022 Nov 17:S1879-4068(22)00520-3. doi: 10.1016/j.jgo.2022.10.016. Online ahead of print.

PMID: 36404260

Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.

Tanaka E, Inoue E, Shoji A, Nilsson J, Papagiannopoulos C, Dhanda D, Yoshizawa Y, Abe M, Saka K, Sugano E, Sugitani N, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M.

PLoS One. 2022 Nov 16;17(11):e0277566. doi: 10.1371/journal.pone.0277566. eCollection 2022.

PMID: 36383610

Assessment of spatial transcriptomics for oncology discovery.

Lyubetskaya A, Rabe B, Fisher A, Lewin A, Neuhaus I, Brett C, Brett T, Pereira E, Golhar R, Kebede S, Font-Tello A, Mosure K, Van Wittenberghe N, Mavrakis KJ, MacIsaac K, Chen BJ, Drokhlyansky E.

Cell Rep Methods. 2022 Nov 15;2(11):100340. doi: 10.1016/j.crmeth.2022.100340. eCollection 2022 Nov 21.

PMID: 36452860

Noninvasive Moisture Detection in Lyophilized Drug Product Using NIR Spectrometer and Headspace Moisture Analyzer.

Pu YE, Li Y, Xiang D.

J Pharm Sci. 2022 Nov 15:S0022-3549(22)00524-X. doi: 10.1016/j.xphs.2022.11.009. Online ahead of print.

PMID: 36395899

Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial.

Van den Bosch F, Wei JC, Nash P, Blanco FJ, Graham D, Zang C, Arthur E, Borlenghi C, Tsekouras V, Vlahos B, Deodhar A.

J Rheumatol. 2022 Nov 15:jrheum.220353. doi: 10.3899/jrheum.220353. Online ahead of print.

PMID: 36379575

Frailty in Inflammatory Arthritis: A Fragile Construct.

van Onna M, Boonen A.

J Rheumatol. 2022 Nov 15:jrheum.220954. doi: 10.3899/jrheum.220954. Online ahead of print.

PMID: 36379574

Assessing fatigue and sleep in chronic diseases using physiological signals from wearables: A pilot study.

Antikainen E, Njoum H, Kudelka J, Branco D, Rehman RZU, Macrae V, Davies K, Hildesheim H, Emmert K, Reilmann R, Janneke van der Woude C, Maetzler W, Ng WF, O'Donnell P, Van Gassen G, Baribaud F, Pandis I, Manyakov NV, van Gils M, Ahmaniemi T, Chatterjee M.

Front Physiol. 2022 Nov 14; 13:968185. doi: 10.3389/fphys.2022.968185. eCollection 2022.

PMID: 36452041

Multiplexed and reproducible high content screening of live and fixed cells using Dye Drop.

Mills CE, Subramanian K, Hafner M, Niepel M, Gerosa L, Chung M, Victor C, Gaudio B, Yapp C, Nirmal AJ, Clark N, Sorger PK.

Nat Commun. 2022 Nov 14;13(1):6918. doi: 10.1038/s41467-022-34536-7.

PMID: 36376301

Reversible Myc hypomorphism identifies a key Myc-dependency in early cancer evolution.

Sodir NM, Pellegrinet L, Kortlever RM, Campos T, Kwon YW, Kim S, Garcia D, Perfetto A, Anastasiou P, Swigart LB, Arends MJ, Littlewood TD, Evan GI.

Nat Commun. 2022 Nov 9;13(1):6782. doi: 10.1038/s41467-022-34079-x.

PMID: 36351945

Facile Amide Bond Formation with TCFH-NMI in an Organic Laboratory Course.

M Baldwin OW, Conrad-Marut LH, Beutner GL, Vosburg DA.

J Chem Educ. 2022 Nov 8;99(11):3747-3751. doi: 10.1021/acs.jchemed.2c00760. Epub 2022 Oct 3.

PMID: 36398314

An epitope-enriched immunogen expands responses to a conserved viral site.

Caradonna TM, Ronsard L, Yousif AS, Windsor IW, Hecht R, Bracamonte-Moreno T, Roffler AA, Maron MJ, Maurer DP, Feldman J, Marchiori E, Barnes RM, Rohrer D, Lonberg N, Oguin TH 3rd, Sempowski GD, Kepler TB, Kuraoka M, Lingwood D, Schmidt AG.

Cell Rep. 2022 Nov 8;41(6):111628. doi: 10.1016/j.celrep.2022.111628.

PMID: 36351401

Dose-Blinded Myosin Inhibition in Patients with Obstructive HCM Referred for Septal Reduction Therapy: Outcomes Through 32-Weeks.

Desai MY, Owens AT, Geske JB, Wolski K, Saberi S, Wang A, Sherrid MV, Cremer PC, Naidu SS, Smedira N, Schaff HV, McErlean E, Sewell C, Balasubramanyam A, Lampl K, Sehnert AJ, Nissen SE.

Circulation. 2022 Nov 6. doi: 10.1161/CIRCULATIONAHA.122.062534. Online ahead of print.

PMID: 36335531

Molecular glue CELMoD compounds are regulators of cereblon conformation.

Watson ER, Novick S, Matyskiela ME, Chamberlain PP, H de la Peña A, Zhu J, Tran E, Griffin PR, Wertz IE, Lander GC.

Science. 2022 Nov 4;378(6619):549-553. doi: 10.1126/science.add7574. Epub 2022 Nov 3.

PMID: 36378961

Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.

Iida S, Nakakoji M, Spanopoulos D, Okazuka K, Parulekar V, Ishida T.

Future Oncol. 2022 Nov 4. doi: 10.2217/fon-2022-0846. Online ahead of print.

PMID: 36331578

Quantum Cascade Laser Based Infrared Spectroscopy: A New Paradigm for Protein Secondary Structure Measurement.

Jin C, Patel A, Peters J, Hodawadekar S, Kalyanaraman R.

Pharm Res. 2022 Nov 3. doi: 10.1007/s11095-022-03422-8. Online ahead of print.

PMID: 36329374

On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes.

De Backer M, Legrand C, Péron J, Lambert A, Buyse M.

Pharm Stat. 2022 Nov 2. doi: 10.1002/pst.2271. Online ahead of print.

PMID: 36321470

A Multi-Objective Active Learning Platform and Web App for Reaction Optimization.

Torres JAG, Lau SH, Anchuri P, Stevens JM, Tabora JE, Li J, Borovika A, Adams RP, Doyle AG.

J Am Chem Soc. 2022 Nov 2;144(43):19999-20007. doi: 10.1021/jacs.2c08592. Epub 2022 Oct 19.

PMID: 36260788

Quantification of Utilization Management Barriers for Patients Initiating Therapy to Lower Lipid Levels.

O'Neil A, Calderbank S, Brown J, Vandigo J, Yin P, Bratti K, Howell S.

JAMA Netw Open. 2022 Nov 1;5(11): e2240513. doi: 10.1001/jamanetworkopen.2022.40513.

PMID: 36346635

MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.

Cheng D, Zinker BA, Luo Y, Shipkova P, De Oliveira CH, Krishna G, Brown EA, Boehm SL, Tirucherai GS, Gu H, Ma Z, Chu CH, Onorato JM, Kopcho LM, Ammar R, Smith J, Devasthale P, Lawrence RM, Stryker SA, Dierks EA, Azzara AV, Carayannopoulos L, Charles ED, Lentz KA, Gordon DA.

Cell Metab. 2022 Nov 1;34(11):1732-1748.e5. doi: 10.1016/j.cmet.2022.10.007.

PMID: 36323235

Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.

Laheru D, Antony A, Carneiro S, Di Lernia V, Garg A, Love TJ, Del Rocio Macias Garcia K, Mendonça JA, Mukherjee S, Olteanu R, Perez-Chada L, Rosen CF, Tannenbaum R, Yazbek MA.

J Rheumatol. 2022 Nov 1: jrheum.220313. doi: 10.3899/jrheum.220313. Online ahead of print.

PMID: 36319021

Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.

Campanholo CB, Maharaj AB, Corp N, Bell S, Costa L, de Vlam K, Gullick NJ, Khraishi M, Kishimoto M, Palmou-Fontana N, Reddy S, Scarpa R, Vega L, Duarte GV, Zisman D, van der Windt DA, Duruoz MT, Ogdie A.

J Rheumatol. 2022 Nov 1: jrheum.220310. doi: 10.3899/jrheum.220310. Online ahead of print.

PMID: 36319003

Pseudoprolines as stereoelectronically tunable proline isosteres.

Kashif Khan R, Meanwell NA, Hager HH.

Bioorg Med Chem Lett. 2022 Nov 1; 75:128983. doi: 10.1016/j.bmcl.2022.128983. Epub 2022 Sep 9.

PMID: 36096342

The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.

Padmakar Darne C, Velaparthi U, Saulnier M, Frennesson D, Liu P, Huang A, Tokarski J, Fura A, Spires T, Newitt J, Spires VM, Obermeier MT, Elzinga PA, Gottardis MM, Jayaraman L, Vite GD, Balog A.

Bioorg Med Chem Lett. 2022 Nov 1; 75:128951. doi: 10.1016/j.bmcl.2022.128951. Epub 2022 Aug 27.

PMID: 36031020

Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.

Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J.

JCO Precis Oncol. 2022 Nov;6: e2200454. doi: 10.1200/PO.22.00454.

PMID: 36446042

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.

Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B.

J Immunother Cancer. 2022 Nov;10(11): e005780. doi: 10.1136/jitc-2022-005780.

PMID: 36328377

MAPK activated kinase 2 inhibition shifts the chemokine signature in arthritis synovial fluid mononuclear cells from CXCR3 to CXCR2.

Kragstrup TW, Sørensen AS, Brüner M, Lomholt S, Nielsen MA, Schafer P, Deleuran B.

Int Immunopharmacol. 2022 Nov; 112:109267. doi: 10.1016/j.intimp.2022.109267. Epub 2022 Sep 28.

PMID: 36179420

Correction: Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID‑19 in the United States: a retrospective cohort study.

Deitelzweig S, Luo X, Nguyen JL, Malhotra D, Emir B, Russ C, Li X, Lee TC, Ferri M, Wiederkehr D, Reimbaeva M, Barnes GD, Piazza G.

J Thromb Thrombolysis. 2022 Nov;54(4):696. doi: 10.1007/s11239-022-02708-3. Epub 2022 Sep 19.

PMID: 36121539

Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.

Klink AJ, Gajra A, Knoth RL, Marshall L, Hou Y, McBride A, Copher R.

Leuk Res. 2022 Nov; 122:106946. doi: 10.1016/j.leukres.2022.106946. Epub 2022 Sep 5.

PMID: 36108427

Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.

Dixon JG, Çağlayan Ç, Chihara D, Nielsen T, Dimier N, Zheng J, Wall AK, Salles G, Morschhauser F, Marcus R, Herold M, Kimby E, Blum KA, Ghielmini M, Shi Q, Flowers CR.

Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11): e1009-e1018. doi: 10.1016/j.clml.2022.07.015. Epub 2022 Aug 3.

PMID: 36045021

PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer.

Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L.

Breast Cancer Res Treat. 2022 Nov;196(1):221-227. doi: 10.1007/s10549-022-06712-2. Epub 2022 Aug 26.

PMID: 36028784

Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines.

Trejo-Martin A, Bercu JP, Thresher A, Tennant RE, Thomas RF, Cross K, Czich A, Waese K, Nicolette JJ, Murray J, Sonders P, Kondratiuk A, Cheung JR, Thomas D, Lynch A, Harvey J, Glowienke S, Custer L, Escobar PA.

Regul Toxicol Pharmacol. 2022 Nov; 135:105247. doi: 10.1016/j.yrtph.2022.105247. Epub 2022 Aug 23.

PMID: 35998738

The Role of Titanium Dioxide (E171) and the Requirements for Replacement Materials in Oral Solid Dosage Forms: An IQ Consortium Working Group Review.

Blundell R, Butterworth P, Charlier A, Daurio D, Degenhardt M, Harris D, Hancock B, Johnston M, Kasina R, Kaye J, Kelly R, Lienbacher P, Meehan L, Melnick J, Ojakovo P, Schoell J, Schimmelle B, Tobyn M, Wagner-Hattler L, Wakeman J, Wiedey R.

J Pharm Sci. 2022 Nov;111(11):2943-2954. doi: 10.1016/j.xphs.2022.08.011. Epub 2022 Aug 13.

PMID: 35973604

Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.

Tada Y, Kim H, Spanopoulos D, Habiro K, Tsuritani K, Yamada Y, Mandal A, Zhong Y, Hikichi Y.

J Dermatol. 2022 Nov;49(11):1106-1117. doi: 10.1111/1346-8138.16543. Epub 2022 Aug 10.

PMID: 35946343

Developability Assessments of Monoclonal Antibody Candidates to Minimize Aggregation During Large-Scale Ultrafiltration and Diafiltration (UF-DF) Processing.

Whitaker N, Pace SE, Merritt K, Tadros M, Khossravi M, Deshmukh S, Cheng Y, Joshi SB, Volkin DB, Dhar P.

J Pharm Sci. 2022 Nov;111(11):2998-3008. doi: 10.1016/j.xphs.2022.08.001. Epub 2022 Aug 5.

PMID: 35940242

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma.

Vieito M, Simonelli M, de Vos F, Moreno V, Geurts M, Lorenzi E, Macchini M, van den Bent MJ, Del Conte G, de Jonge M, Martín-Soberón MC, Amoroso B, Sanchez-Perez T, Zuraek M, Hanna B, Aronchik I, Filvaroff E, Chang H, Mendez C, Arias Parro M, Wei X, Nikolova Z, Sepulveda JM.

Neurooncol Adv. 2022 Oct 28;4(1):vdac146. doi: 10.1093/noajnl/vdac146. eCollection 2022 Jan-Dec.

PMID: 36382109

Tracking the Progeny of Virus-specific T-cell Products in Patients Post-Transplant using TCR-Sequencing.

Huisman W, Roex MCJ, Hageman L, Koster EAS, Veld SAJ, Hoogstraten C, van Balen P, van Egmond HME, Van Bergen CAM, Einsele H, Germeroth L, Amsen D, Falkenburg JHF, Jedema I.

Blood Adv. 2022 Sep 19:bloodadvances.2022007270. doi: 10.1182/bloodadvances.2022007270. Online ahead of print.

PMID: 36121440

Preclinical target validation for non-addictive therapeutics development for pain.

Hargreaves R, Akinsanya K, Ajit SK, Dhruv NT, Driscoll J, Farina P, Gavva N, Gill M, Houghton A, Iyengar S, Jones C, Kavelaars A, Kaykas A, Koroshetz WJ, Laeng P, Laird JM, Lo DC, Luthman J, Munro G, Oshinsky ML, Sittampalam GS, Woller SA, Tamiz AP.

Expert Opin Ther Targets. 2022 Sep;26(9):811-822. doi: 10.1080/14728222.2022.2147063.

PMID: 36424892

BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.

Chu Q, Leighl NB, Surmont V, van Herpen C, Sibille A, Markman B, Clarke S, Juergens RA, Rivera MA, Andelkovic V, Rudin CM, Snow S, Kim DW, Sanatani M, Lin H, Sanghavi K, Tannenbaum-Dvir S, Basciano P, Lathers D, Urbanska K, Kollia G, He C, DiPiero A, Liu Y, Ready N.

JTO Clin Res Rep. 2022 Aug 27;3(11):100400. doi: 10.1016/j.jtocrr.2022.100400. eCollection 2022 Nov.

PMID: 36275912

Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study.

Ruperto N, Lovell DJ, Berman A, Ávila-Zapata F, Horneff G, Alessio M, Becker ML, Belot A, Burgos-Vargas R, Gamir ML, Goldenstein-Schainberg C, Scheibel IM, Terreri MT, Zemel L, Zhuo J, Askelson M, Wong R, Martini A, Brunner HI; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation.

Arthritis Care Res (Hoboken). 2022 Aug 3. doi: 10.1002/acr.24989. Online ahead of print.

PMID: 36710243

Identification of undiagnosed atrial fibrillation using a machine learning risk-prediction algorithm and diagnostic testing (PULsE-AI) in primary care: a multi-centre randomized controlled trial in England.

Hill NR, Groves L, Dickerson C, Ochs A, Pang D, Lawton S, Hurst M, Pollock KG, Sugrue DM, Tsang C, Arden C, Wyn Davies D, Martin AC, Sandler B, Gordon J, Farooqui U, Clifton D, Mallen C, Rogers J, Camm AJ, Cohen AT.

Eur Heart J Digit Health. 2022 Mar 23;3(2):195-204. doi: 10.1093/ehjdh/ztac009. eCollection 2022 Jun.

PMID: 36713002

Ru-Catalyzed Enantioselective Hydrogenation of 2-Pyridyl-Substituted Alkenes and Substrate-Mediated H/D Exchange.

Hao W, Joe CL, Ayers S, Darù A, Daley RA, Chen JS, Domanski M, Schmidt MA, Blackmond DG.

ACS Catal. 2022 Jan 21;12(2):1150-1160. doi: 10.1021/acscatal.1c05061. Epub 2022 Jan 4.

PMID: 36386561

Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper.

Ménochet K, Yu H, Wang B, Tibbitts J, Hsu CP, Kamath AV, Richter WF, Baumann A.

MAbs. 2022 Jan-Dec;14(1):2145997. doi: 10.1080/19420862.2022.2145997.

PMID: 36418217

Measurement and valuation of the attributes of innovation of healthcare technologies: a systematic review.

Syeed MS, Poudel N, Ngorsuraches S, Diaz J, Chaiyakunapruk N.

J Med Econ. 2022 Jan-Dec;25(1):1176-1184. doi: 10.1080/13696998.2022.2143170.

PMID: 36346390

Major variation in hepatocellular carcinoma treatment and outcomes in England: a retrospective cohort study.

Beecroft S, O'Connell M, Nassar A, Noon K, Pollock KG, Palmer D, Cross TJS.

Frontline Gastroenterol. 2022 May 9;14(1):19-24. doi: 10.1136/flgastro-2022-102142. eCollection 2023.

PMID: 36561791

Anti-drug Antibody Sample Testing and Reporting Harmonization.

Jani D, Marsden R, Gunsior M, Hay LS, Ward B, Cowan KJ, Azadeh M, Barker B, Cao L, Closson KR, Coble K, Dholakiya SL, Dusseault J, Hays A, Herl C, Hodsdon ME, Irvin SC, Kirshner S, Kolaitis G, Kulagina N, Kumar S, Lai CH, Lipari F, Liu S, Merdek KD, Moldovan IR, Mozaffari R, Pan L, Place C, Snoeck V, Manning MS, Stocker D, Tary-Lehmann M, Turner A, Vainshtein I, Verthelyi D, Williams WT, Yan H, Yan W, Yang L, Yang L, Zemo J, Zhong ZD.

AAPS J. 2022 Oct 28;24(6):113. doi: 10.1208/s12248-022-00762-6.

PMID: 36307592

Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy.

Huggar D, Knoth RL, Copher R, Cao Z, Lipkin C, McBride A, LeBlanc TW.

Future Oncol. 2022 Oct 28. doi: 10.2217/fon-2022-0706. Online ahead of print.

PMID: 36305495

Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response.

Shankar LK, Huang E, Litière S, Hoekstra OS, Schwartz L, Collette S, Boellaard R, Bogaerts J, Seymour L, de Vries EGE.

Clin Cancer Res. 2022 Oct 27:CCR-21-3143. doi: 10.1158/1078-0432.CCR-21-3143. Online ahead of print.

PMID: 36302172

Increased CaMKK2 expression is an adaptive response that maintains the fitness of tumor-infiltrating natural killer cells.

Juras PK, Racioppi L, Mukherjee D, Artham S, Gao X, D'Agostino LA, Chang CY, McDonnell DP.

Cancer Immunol Res. 2022 Oct 27:CIR-22-0391. doi: 10.1158/2326-6066.CIR-22-0391. Online ahead of print.

PMID: 36301267

Embryo-fetal Exposure and Developmental Outcome of Lenalidomide Following Oral Administration to Pregnant Cynomolgus Monkeys.

Hui JY, Fuchs A, Kumar G.

Reprod Toxicol. 2022 Oct 26:S0890-6238(22)00155-1. doi: 10.1016/j.reprotox.2022.10.005. Online ahead of print.

PMID: 36309155

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.

Tomita Y, Kobayashi K, Kimura G, Oya M, Uemura H, Nishiyama H, Galsky MD, Nasroulah F, Collette S, Broughton E, Ünsal-Kaçmaz K, Kamisuki Y, Bajorin DF.

Jpn J Clin Oncol. 2022 Oct 26:hyac155. doi: 10.1093/jjco/hyac155. Online ahead of print.

PMID: 36300304

Synthetic Access to α-Oxoketene Aminals by the Nucleophilic Addition of Enol Silane-Derived Palladium(II) Enolates to Carbodiimides.

Polimera SR, Ilangovan A, Meanwell NA, Subbaiah MAM.J Org Chem. 2022 Oct 26. doi: 10.1021/acs.joc.2c02107. Online ahead of print.

PMID: 36285601

Three-Component Asymmetric Ni-Catalyzed 1,2-Dicarbofunctionalization of Unactivated Alkenes via Stereoselective Migratory Insertion.

Apolinar O, Kang T, Alturaifi TM, Bedekar PG, Rubel CZ, Derosa J, Sanchez BB, Wong QN, Sturgell EJ, Chen JS, Wisniewski SR, Liu P, Engle KM.

J Am Chem Soc. 2022 Oct 26;144(42):19337-19343. doi: 10.1021/jacs.2c06636. Epub 2022 Oct 12.

PMID: 36222701

Autoimmune gene expression profiling of fingerstick whole blood in Chronic Fatigue Syndrome.

Wang Z, Waldman MF, Basavanhally TJ, Jacobs AR, Lopez G, Perichon RY, Ma JJ, Mackenzie EM, Healy JB, Wang Y, Hersey SA.

J Transl Med. 2022 Oct 25;20(1):486. doi: 10.1186/s12967-022-03682-3.

PMID: 36284352

From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology (QSP) Modeling in Cancer Immunotherapy.

Lemaire V, Bassen D, Reed M, Song R, Khalili S, Lien YTK, Huang L, Singh AP, Stamatelos S, Bottino D, Hua F.

Clin Pharmacol Ther. 2022 Oct 25. doi: 10.1002/cpt.2770. Online ahead of print.

PMID: 36282521

Amination of Nitro-Substituted Heteroarenes by Nucleophilic Substitution of Hydrogen.

Mandler MD, Suss N, Ramirez A, Farley CA, Aulakh D, Zhu Y, Traeger SC, Sarjeant A, Davies ML, Ellsworth BA, Regueiro-Ren A.

Org Lett. 2022 Oct 21;24(41):7643-7648. doi: 10.1021/acs.orglett.2c03133. Epub 2022 Oct 10.

PMID: 36214755

Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21.

Sychterz C, Gardner I, Chiang M, Rachumallu R, Neuhoff S, Perera V, Merali S, Schmidt BJ, Gaohua L.

Metabolites. 2022 Oct 20;12(10):1001. doi: 10.3390/metabo12101001.

PMID: 36295903

Use of Monte Carlo simulations for improved facility fit planning in downstream biomanufacturing and technology transfer.

Furcht C, VanSeveren M, Holstein M, Feroz H, Ghose S.

Biotechnol Prog. 2022 Oct 20:e3306. doi: 10.1002/btpr.3306. Online ahead of print.

PMID: 36264017

A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.

Badaracco J, Gitlin M, Keating SJ.

Transplant Cell Ther. 2022 Oct 19:S2666-6367(22)01704-3. doi: 10.1016/j.jtct.2022.10.009. Online ahead of print.

PMID: 36272529

Particle Property Characterization and Data Curation for Effective Powder Property Modeling in the Pharmaceutical Industry.

Wadams RC, Akseli I, Albrecht J, Ferreira AP, Gamble JF, Leane M, Thomas S, Schuman Y, Taylor L, Tobyn M.

AAPS PharmSciTech. 2022 Oct 19;23(8):286. doi: 10.1208/s12249-022-02434-2.

PMID: 36261755

The Effectiveness of Patient Training in Inflammatory Bowel Disease Knowledge via Instagram: Randomized Controlled Trial.

Blunck D, Kastner L, Nissen M, Winkler J.

J Med Internet Res. 2022 Oct 19;24(10):e36767. doi: 10.2196/36767.

PMID: 36260385

Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.

Chaudhary MA, Edmondson-Jones M, Baio G, Mackay E, Penrod JR, Sharpe DJ, Yates G, Rafiq S, Johannesen K, Siddiqui MK, Vanderpuye-Orgle J, Briggs A.

Med Decis Making. 2022 Oct 19:272989X221132257. doi: 10.1177/0272989X221132257. Online ahead of print.

PMID: 36259353

Unexpected Stability of a Prodrug to Enzymatic Hydrolysis within a Hydrated HPMC Matrix Tablet.

Hanley S, Brown J, Timmins P, Davies C, Dennis A.

Pharmaceutics. 2022 Oct 18;14(10):2222. doi: 10.3390/pharmaceutics14102222.

PMID: 36297657

In-process Vapor Composition Monitoring in Application to Lyophilization of Ammonium Salt Formulations.

Strongrich AD, Tobyn M, Iyer L, Park Y, Hong J, Alexeenko AA.

J Pharm Sci. 2022 Oct 18:S0022-3549(22)00456-7. doi: 10.1016/j.xphs.2022.10.004. Online ahead of print.

PMID: 36270539

Safety, Pharmacokinetics, and Pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants.

Ye Y, Gaudy A, Thomas M, Reyes J, Burkhardt B, Horan G, Liu L, Chen J, Ghosh A, Carayannopoulos LN, Tatosian DA, Palmisano M.

Clin Pharmacol Drug Dev. 2022 Oct 18. doi: 10.1002/cpdd.1178. Online ahead of print.

PMID: 36256505

Identification of Rodent Husbandry Refinement Opportunities through Benchmarking and Collaboration.

Bratcher NA, Allen CM, McLahan CL, O'Connell DM, Burr HN, Keen JN, Stanislawczyk LM, Burns MA.

J Am Assoc Lab Anim Sci. 2022 Oct 17. doi: 10.30802/AALAS-JAALAS-21-000099. Online ahead of print.

PMID: 36253074

Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.

Ayers D, Cope S, Towle K, Mojebi A, Marshall T, Dhanda D.

BMC Med Res Methodol. 2022 Oct 15;22(1):272. doi: 10.1186/s12874-022-01745-z.

PMID: 36243687

Prologue: Evidence Informing the GRAPPA 2021 Treatment Recommendations, by Domain.

Soriano ER, Kavanaugh A, Coates LC.

J Rheumatol. 2022 Oct 15:jrheum.220486. doi: 10.3899/jrheum.220486. Online ahead of print.

PMID: 36243414

Drs. Bessette and Kinch reply.

Bessette L, Kinch CD.

J Rheumatol. 2022 Oct 15:jrheum.220909. doi: 10.3899/jrheum.220909. Online ahead of print.

PMID: 36243412

Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.

Leung YY, Korotaeva TV, Candia L, Pedersen SJ, Molano WB, Ruderman EM, Bisoendial R, Perez-Alamino R, Olsder W, Möller B, Grazio S, Gudu T, Mody GM, Pineda C, Raffayova H, Rohekar S, Goldenstein-Schainberg C, Gutierrez Urena SR, Casasola Vargas JC, Meghnathi B, Prasad R, Richette P, Miranda JRS, Malliotis N, Lindqvist U, Simon D, Ezeonyeji A, Soriano ER, FitzGerald O.

J Rheumatol. 2022 Oct 15:jrheum.220315. doi: 10.3899/jrheum.220315. Online ahead of print.

PMID: 36243409

Personalised paediatric chewable Ibuprofen tablets fabricated using 3D micro-extrusion printing technology.

Tabriz AG, Nandi U, Scoutaris N, Sanfo K, Alexander B, Gong Y, Hui HW, Kumar S, Douroumis D.

Int J Pharm. 2022 Oct 15;626:122135. doi: 10.1016/j.ijpharm.2022.122135. Epub 2022 Aug 24.

PMID: 36028083

NMR spectroscopy as a characterization tool enabling biologics formulation development.

Ma J, Pathirana C, Liu DQ, Miller SA.

J Pharm Biomed Anal. 2022 Oct 14;223:115110. doi: 10.1016/j.jpba.2022.115110. Online ahead of print.

PMID: 36308923

Determination of ICH-Q3D Elemental Impurity Leachables in Glass Vials by Inductively Coupled Plasma-Mass Spectrometry.

Breckenridge L, Oni Y, Evans C, Franck J, Wood S, Xu M, Sahin E, Zacour B.

PDA J Pharm Sci Technol. 2022 Oct 14:pdajpst.2021.012655. doi: 10.5731/pdajpst.2021.012655. Online ahead of print.

PMID: 36241213

Payer formulary exclusions of apixaban: how patients respond and potential implications.

Deitelzweig S, Terasawa E, Kang A, Atreja N, Hines DM, Noman A, Luo X.

Curr Med Res Opin. 2022 Oct 14:1-6. doi: 10.1080/03007995.2022.2128189. Online ahead of print.

PMID: 36164763

Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents.

Torrens L, Puigvehí M, Torres-Martín M, Wang H, Maeda M, Haber PK, Leonel T, García-López M, Esteban-Fabró R, Leow WQ, Montironi C, Torrecilla S, Varadarajan AR, Taik P, Campreciós G, Enkhbold C, Taivanbaatar E, Yerbolat A, Villanueva A, Pérez-Del-Pulgar S, Thung S, Chinburen J, Letouzé E, Zucman-Rossi J, Uzilov A, Neely J, Forns X, Roayaie S, Sia D, Llovet JM.

Clin Cancer Res. 2022 Oct 14;28(20):4509-4520. doi: 10.1158/1078-0432.CCR-22-0632.

PMID: 35998012

Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies.

Lee A, Yuan Y, Eccles L, Chitkara A, Dalén J, Varol N.

Cancer Treat Res Commun. 2022 Oct 13;33:100648. doi: 10.1016/j.ctarc.2022.100648. Online ahead of print.

PMID: 36270164

Toxicologic Pathology Forum: Opinion on Not Euthanizing Control Animals in the Recovery Phase of Non-Rodent Toxicology Studies.

Janardhan KS, Sura R, Salian-Mehta S, Flandre T, Palazzi X, Zane D, Singh B, Jacob B, Hukkanen RR, Al-Haddawi M, Bennet B, Laast V, Lee D, Peterson R 2nd, Romeike A, Schorsch F, Guffroy M.

Toxicol Pathol. 2022 Oct 13:1926233221129214. doi: 10.1177/01926233221129214. Online ahead of print.

PMID: 36226581

Comprehensive characterization and optimization of Caco-2 cells enabled the development of a miniaturized 96-well permeability assay.

Cai X, Patel S, Huang C, Paiva A, Sun Y, Barker G, Weller H, Shou W.

Xenobiotica. 2022 Oct 13:1-9. doi: 10.1080/00498254.2022.2133648. Online ahead of print.

PMID: 36217915

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne B, See WL, Ugidos M, Risueño A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D.

Blood. 2022 Oct 13;140(15):1674-1685. doi: 10.1182/blood.2022016293.

PMID: 35960871

Design of a Re-dispersible High Drug Load Amorphous Formulation.

Oberoi HS, Arce F, Purohit HS, Yu M, Fowler CA, Zhou D, Law D.

J Pharm Sci. 2022 Oct 12:S0022-3549(22)00455-5. doi: 10.1016/j.xphs.2022.10.002. Online ahead of print.

PMID: 36243131

Computational prediction of blend time in a large-scale viral inactivation process for monoclonal antibodies biomanufacturing.

Sirasitthichoke C, Hoang D, Phalak P, Armenante PM, Barnoon BI, Shandil I.

Biotechnol Bioeng. 2022 Oct 12. doi: 10.1002/bit.28264. Online ahead of print.

PMID: 36224707

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.

Ansari-Pour N, Samur MK, Flynt E, Gooding S, Towfic F, Stong N, Ortiz Estevez M, Mavrommatis K, Walker BA, Morgan GJ, Munshi NC, Avet Loiseau H, Thakurta A.

Blood. 2022 Oct 12:blood.2022017010. doi: 10.1182/blood.2022017010. Online ahead of print.

PMID: 36223594

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227.

Brahmer JR, Lee JS, Ciuleanu TE, Caro RB, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, Burgers J, Mahave M, Ahmed S, Schoenfeld AJ, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Gupta RG, Bushong J, Li L, Blum SI, Eccles LJ, Ramalingam SS.

J Clin Oncol. 2022 Oct 12:101200JCO2201503. doi: 10.1200/JCO.22.01503. Online ahead of print.

PMID: 36223558

A Sterically Tuned Directing Auxiliary Promotes Catalytic 1,2-Carbofluorination of Alkenyl Carbonyl Compounds.

Liu Z, Oxtoby LJ, Sun J, Li ZQ, Kim N, Davies GHM, Engle KM.

Angew Chem Int Ed Engl. 2022 Oct 11. doi: 10.1002/anie.202214153. Online ahead of print.

PMID: 36221812

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia.

Moujalled DM, Brown FC, Chua CC, Dengler MA, Pomilio G, Anstee NS, Litalien V, Thompson ER, Morley TD, MacRaild S, Tiong IS, Morris R, Dun K, Zordan AC, Shah JS, Banquet S, Halilovic E, Morris EJ, Herold MJ, Lessene GL, Adams JM, Huang DCS, Roberts AW, Blombery P, Wei AH.

Blood. 2022 Oct 11:blood.2022016090. doi: 10.1182/blood.2022016090. Online ahead of print.

PMID: 36219880

Design and economic investigation of a Multicolumn Countercurrent Solvent Gradient Purification unit for the separation of an industrially relevant PEGylated protein.

Kim TK, Sechi B, Romero Conde JJ, Angelo J, Xu X, Ghose S, Morbidelli M, Sponchioni M.

J Chromatogr A. 2022 Oct 11;1681:463487. doi: 10.1016/j.chroma.2022.463487. Epub 2022 Sep 7.

PMID: 36115185

Surface-induced protein aggregation and particle formation in biologics: current understanding of mechanisms, detection and mitigation strategies.

Kopp MRG, Grigolato F, Zürcher D, Das TK, Chou D, Wuchner K, Arosio P.

J Pharm Sci. 2022 Oct 9:S0022-3549(22)00459-2. doi: 10.1016/j.xphs.2022.10.009. Online ahead of print.

PMID: 36223809

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.

Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson PG, Facon T, Weisel K, Larsen JT, Minnema MC, Abdallah AO, Badros AZ, Knop S, Stadtmauer EA, Cheng Y, Amatangelo M, Chen M, Nguyen TV, Amin A, Peluso T, van de Donk NWCJ.

Lancet Haematol. 2022 Oct 6:S2352-3026(22)00290-3. doi: 10.1016/S2352-3026(22)00290-3. Online ahead of print.

PMID: 36209764

Detection of bisphenols in Indian surface water, tap water, and packaged drinking water using dispersive liquid-liquid microextraction: exposure assessment for health risk.

Karsauliya K, Bhateria M, Sonker AK, Yahavi C, Gautam SS, Karsauliya S, Singh SP.

Environ Sci Pollut Res Int. 2022 Oct 6. doi: 10.1007/s11356-022-23293-1. Online ahead of print.

PMID: 36201081

Estimating the prevalence, clinical characteristics, and treatment patterns of hypertrophic cardiomyopathy in Japan: A nationwide medical claims database study.

Terasaka N, Spanopoulos D, Miyagoshi H, Kubo T, Kitaoka H.

J Cardiol. 2022 Oct 5:S0914-5087(22)00247-7. doi: 10.1016/j.jjcc.2022.09.015. Online ahead of print.

PMID: 36208832

Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.

Feagan BG, Schreiber S, Afzali A, Rieder F, Hyams J, Kollengode K, Pearlman J, Son V, Marta C, Wolf DC, D'Haens GG.

Contemp Clin Trials. 2022 Oct 5;122:106958. doi: 10.1016/j.cct.2022.106958. Online ahead of print.

PMID: 36208720

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN.

Cancer Immunol Immunother. 2022 Oct 5. doi: 10.1007/s00262-022-03302-5. Online ahead of print.

PMID: 36197494

Ligand-Enabled C-H Hydroxylation with Aqueous H2O2 at Room Temperature.

Li Z, Park HS, Qiao JX, Yeung KS, Yu JQ.

J Am Chem Soc. 2022 Oct 5;144(39):18109-18116. doi: 10.1021/jacs.2c08332. Epub 2022 Sep 22.

PMID: 36137252

Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.

Thudium K, Selby M, Zorn JA, Rak G, Wang XT, Bunch RT, Hogan JM, Strop P, Korman AJ.

Cancer Immunol Res. 2022 Oct 4;10(10):1175-1189. doi: 10.1158/2326-6066.CIR-22-0057.

PMID: 35981087

Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M.

Cancer Immunol Res. 2022 Oct 4;10(10):1254-1262. doi: 10.1158/2326-6066.CIR-22-0326.

PMID: 35969233

Synthesizing secondary data into survival analysis to improve estimation efficiency.

Chen C, Yu T, Shen B, Wang M.

Biom J. 2022 Oct 3. doi: 10.1002/bimj.202100326. Online ahead of print.

PMID: 36192158

Electrophilic Hydrazination of Cyclopropanols Using Azodicarboxylates via Copper(II) Catalysis: An Umpolung Strategy to Access β-Hydrazino Ketone Motifs.

Ramar T, Ilangovan A, Meanwell NA, Subbaiah MAM.

J Org Chem. 2022 Oct 3. doi: 10.1021/acs.joc.2c01980. Online ahead of print.

PMID: 36190309

Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience.

Foti R, Visalli E, Amato G, Dal Bosco Y, Foti R, Baccano G.

J Rheumatol. 2022 Oct 1:jrheum.220333. doi: 10.3899/jrheum.220333. Online ahead of print.

PMID: 36182113

A perspective on the current use of the phase distribution model for predicting milk-to-plasma drug concentration ratio.

Zhang M, Sychterz C, Chang M, Huang L, Schmidt BJ, Gaohua L.

CPT Pharmacometrics Syst Pharmacol. 2022 Oct 1. doi: 10.1002/psp4.12865. Online ahead of print.

PMID: 36181346

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.

Morschhauser F, Nastoupil L, Feugier P, Schiano de Colella JM, Tilly H, Palomba ML, Bachy E, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Le Gouill S, Daguindau N, Guidez S, Pica GM, García-Sancho AM, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Kalung W, Sehn LH, Izutsu K, Cartron G, Gkasiamis A, Crowe R, Xerri L, Fowler NH, Salles G.

J Clin Oncol. 2022 Oct 1;40(28):3239-3245. doi: 10.1200/JCO.22.00843. Epub 2022 Aug 10.

PMID: 35947804

MPN-036 Treatment Failure and Transition to Next-Line Therapy in Myelofibrosis: A Modified Delphi Panel Approach.

Mascarenhas J, Nguyen H, Saunders A, Oliver L, Tomkinson H, Perry R, McBride A.

Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S323. doi: 10.1016/S2152-2650(22)01431-8.

PMID: 36163980

Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.

Sharma M, Molina CA, Toyoda K, Bereczki D, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A, Shuaib A, Amarenco P, Endres M, Diener HC, Gailani D, Kahl A, Donovan M, Perera V, Li D, Hankey GJ.

J Stroke Cerebrovasc Dis. 2022 Oct;31(10):106742. doi: 10.1016/j.jstrokecerebrovasdis.2022.106742. Epub 2022 Aug 27.

PMID: 36037679

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.

Taher AT, Cappellini MD, Kattamis A, Voskaridou E, Perrotta S, Piga AG, Filosa A, Porter JB, Coates TD, Forni GL, Thompson AA, Tartaglione I, Musallam KM, Backstrom JT, Esposito O, Giuseppi AC, Kuo WL, Miteva D, Lord-Bessen J, Yucel A, Zinger T, Shetty JK, Viprakasit V; BEYOND Investigators.

Lancet Haematol. 2022 Oct;9(10):e733-e744. doi: 10.1016/S2352-3026(22)00208-3. Epub 2022 Aug 22.

PMID: 36007538

Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.

Griesinger F, Pérol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, Jänicke M, Quantin X, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Reynaud D, Thomas M, Chouaid C.

Lung Cancer. 2022 Oct;172:65-74. doi: 10.1016/j.lungcan.2022.08.001. Epub 2022 Aug 6.

PMID: 36007281

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.

Chen Y, Ogasawara K, Wood-Horrall R, Thomas M, Thomas M, He B, Liu L, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G.

Cancer Chemother Pharmacol. 2022 Oct;90(4):325-334. doi: 10.1007/s00280-022-04464-w. Epub 2022 Aug 24.

PMID: 36001108

Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies.

Burns L, Kalesnik-Orszulak R, Spring R, Zeegers F, Rutstein M, Hukkelhoven M, Wruck L, O'Donnell J.

Adv Ther. 2022 Oct;39(10):4772-4778. doi: 10.1007/s12325-022-02257-4. Epub 2022 Aug 16.

PMID: 35972721

Analysis of cellular kinetic models suggest that physiologically based model parameters may be inherently, practically unidentifiable.

Brown LV, Coles MC, McConnell M, Ratushny AV, Gaffney EA.

J Pharmacokinet Pharmacodyn. 2022 Oct;49(5):539-556. doi: 10.1007/s10928-022-09819-7. Epub 2022 Aug 6.

PMID: 35933452

Association between Human Leukocyte Antigen Polymorphism and Human Papillomavirus Infection in Brazilian Women.

de Araujo-Souza PS, El-Zein M, Bolpetti ADN, Maciag PC, Rabachini T, Franco EL, Villa LL.

Sex Transm Dis. 2022 Sep 30. doi: 10.1097/OLQ.0000000000001718. Online ahead of print.

PMID: 36194829

Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases.

Pavel AB, Del Duca E, Cheng J, Wu J, Ungar B, Estrada YD, Jack C, Maari C, Proulx ÉS, Ramirez-Valle F, Krueger JG, Bissonnette R, Guttman-Yassky E.

Allergy. 2022 Sep 30. doi: 10.1111/all.15538. Online ahead of print.

PMID: 36178084

Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study.

Danchin N, Steg G, Mahé I, Hanon O, Jacoud F, Nolin M, Dalon F, Cotte FE, Gollety S, Van Ganse E, Belhassen M.

Arch Cardiovasc Dis. 2022 Sep 29:S1875-2136(22)00174-7. doi: 10.1016/j.acvd.2022.06.006. Online ahead of print.

PMID: 36257903

Design and conduct considerations for studies in patients with hepatic impairment.

Ravenstijn P, Chetty M, Manchandani P, Elmeliegy M, Qosa H, Younis I.

Clin Transl Sci. 2022 Sep 29. doi: 10.1111/cts.13428. Online ahead of print.

PMID: 36176049

Overcoming Limitations in Decarboxylative Arylation via Ag-Ni Electrocatalysis.

Palkowitz MD, Laudadio G, Kolb S, Choi J, Oderinde MS, Ewing TE, Bolduc PN, Chen T, Zhang H, Cheng PTW, Zhang B, Mandler MD, Blasczak VD, Richter JM, Collins MR, Schioldager RL, Bravo M, Dhar TGM, Vokits B, Zhu Y, Echeverria PG, Poss MA, Shaw SA, Clementson S, Petersen NN, Mykhailiuk PK, Baran PS.

J Am Chem Soc. 2022 Sep 28;144(38):17709-17720. doi: 10.1021/jacs.2c08006. Epub 2022 Sep 15.

PMID: 36106767

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).

Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV.

J Clin Oncol. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533. Online ahead of print.

PMID: 36162037

Role of harvest depth filtration in controlling product-related impurities for a bispecific antibody.

Espah Borujeni E, Jin W, Shao C, Chennamsetty N, Xu X, Ghose S.

Antib Ther. 2022 Sep 26;5(4):268-279. doi: 10.1093/abt/tbac023. eCollection 2022 Oct.

PMID: 36299416

Abramson JS, Johnston PB, Kamdar M, Ibrahimi S, Izutsu K, Arnason JE, Glass B, Mutsaers PGNJ, Lunning M, Braverman J, Liu FF, Crotta A, Montheard S, Previtali A, Guo S, Shi L, Solomon SR.

Blood Adv. 2022 Sep 23:bloodadvances.2022008106. doi: 10.1182/bloodadvances.2022008106. Online ahead of print.

PMID: 36149968

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding.

Cohen AT, Sah J, Dhamane AD, Lee T, Rosenblatt L, Hlavacek P, Emir B, Keshishian A, Yuce H, Luo X.

PLoS One. 2022 Sep 23;17(9):e0274969. doi: 10.1371/journal.pone.0274969. eCollection 2022.

PMID: 36149864

The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation.

Regueiro-Ren A, Sit SY, Chen Y, Chen J, Swidorski JJ, Liu Z, Venables BL, Sin N, Hartz RA, Protack T, Lin Z, Zhang S, Li Z, Wu DR, Li P, Kempson J, Hou X, Gupta A, Rampulla R, Mathur A, Park H, Sarjeant A, Benitex Y, Rahematpura S, Parker D, Phillips T, Haskell R, Jenkins S, Santone KS, Cockett M, Hanumegowda U, Dicker I, Meanwell NA, Krystal M.

J Med Chem. 2022 Sep 22;65(18):11927-11948. doi: 10.1021/acs.jmedchem.2c00879. Epub 2022 Aug 31.

PMID: 36044257

Preclinical Characterization and Phase 1 Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies.

Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, Schoenfeld HA, Choi SM, Iaconis LA, Lee LH, Pelletier MR, Dranoff G, Askoxylakis V, Siena S.

Cancer Immunol Res. 2022 Sep 21:CIR-21-0722. doi: 10.1158/2326-6066.CIR-21-0722. Online ahead of print.

PMID: 36129967

Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: Promise to reality.

Maass KF, Barfield MD, Ito M, James CA, Kavetska O, Kozinn M, Kumar P, Lepak M, Leuthold LA, Li W, Mikhailov D, Patel S, Perez NL, Jackson Rudd D, Vakkalagadda B, Williams TM, Zha J, Zhang X, Anderson MD.

Clin Transl Sci. 2022 Sep 21. doi: 10.1111/cts.13411. Online ahead of print.

PMID: 36129129

Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.

Morga A, Latimer NR, Scott M, Hawkins N, Schlichting M, Wang J.

Value Health. 2022 Sep 20:S1098-3015(22)02148-9. doi: 10.1016/j.jval.2022.08.008. Online ahead of print.

PMID: 36150999

Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.

McGregor B, Geynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, Del Tejo V, Du EX, Yang X, Sendhil SR, Betts KA, Huo S.

Oncologist. 2022 Sep 19:oyac186. doi: 10.1093/oncolo/oyac186. Online ahead of print.

PMID: 36124890

First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.

Liu T, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Yang N, Lu J, Shitara K, Lei M, Li M, Bao N, Chen T, Shen L.

Int J Cancer. 2022 Sep 19. doi: 10.1002/ijc.34296. Online ahead of print.

PMID: 36121651

Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy.

Sidhom JW, Oliveira G, Ross-MacDonald P, Wind-Rotolo M, Wu CJ, Pardoll DM, Baras AS.

Sci Adv. 2022 Sep 16;8(37):eabq5089. doi: 10.1126/sciadv.abq5089. Epub 2022 Sep 16.

PMID: 36112691

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade.

Johannet P, Liu W, Fenyo D, Wind-Rotolo M, Krogsgaard M, Mehnert JM, Weber JS, Zhong J, Osman I.

Clin Cancer Res. 2022 Sep 15;28(18):4121-4130. doi: 10.1158/1078-0432.CCR-22-0404.

PMID: 36106402

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial.

Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA.

J Am Acad Dermatol. 2022 Sep 14:S0190-9622(22)02643-3. doi: 10.1016/j.jaad.2022.08.061. Online ahead of print.

PMID: 36115523

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.

George DJ, Spigel DR, Gordan LN, Kochuparambil ST, Molina AM, Yorio J, Rezazadeh Kalebasty A, McKean H, Tchekmedyian N, Tykodi SS, Zhang J, Askelson M, Johansen JL, Hutson TE.

BMJ Open. 2022 Sep 14;12(9):e058396. doi: 10.1136/bmjopen-2021-058396.

PMID: 36104138

Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial Infarction.

Lupisella J, St-Onge S, Carrier M, Cook EM, Wang T, Sum C, Fernando G, Apgar K, Zhang R, Carson N, Snyder BJ, Ryan CS, Ma X, Dierks EA, Little S, Kick EK, Wurtz NR, Bouvier M, Héroux M, Garcia RA.

ACS Pharmacol Transl Sci. 2022 Sep 14;5(10):892-906. doi: 10.1021/acsptsci.2c00042. eCollection 2022 Oct 14.

PMID: 36268126

Photochemical Identification of Auxiliary Severe Acute Respiratory Syndrome Coronavirus 2 Host Entry Factors Using μMap.

Suzuki S, Geri JB, Knutson SD, Bell-Temin H, Tamura T, Fernández DF, Lovett GH, Till NA, Heller BL, Guo J, MacMillan DWC, Ploss A.

J Am Chem Soc. 2022 Sep 14;144(36):16604-16611. doi: 10.1021/jacs.2c06806. Epub 2022 Sep 1.

PMID: 36049228

Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus.

Sangesland M, Torrents de la Peña A, Boyoglu-Barnum S, Ronsard L, Mohamed FAN, Moreno TB, Barnes RM, Rohrer D, Lonberg N, Ghebremichael M, Kanekiyo M, Ward A, Lingwood D.Immunity. 2022 Sep 13;55(9):1693-1709.e8. doi: 10.1016/j.immuni.2022.07.006. Epub 2022 Aug 10.PMID: 35952670

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.

Buckstein R, Chodirker L, Mozessohn L, Yee KWL, Geddes M, Zhu N, Shamy A, Leitch HA, Christou G, Banerji V, Brian L, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Delage R, Parmentier A, Thambipillai A, Siddiqui M, Westcott C, Cameron C, Mamedov A, Spin P, Tang D.

Leuk Lymphoma. 2022 Sep 12:1-10. doi: 10.1080/10428194.2022.2109154. Online ahead of print.

PMID: 36095125

Attribute Analytics Performance Metrics from the MAM Consortium Interlaboratory Study.

Mouchahoir T, Schiel JE, Rogers R, Heckert A, Place BJ, Ammerman A, Li X, Robinson T, Schmidt B, Chumsae CM, Li X, Manuilov AV, Yan B, Staples GO, Ren D, Veach AJ, Wang D, Yared W, Sosic Z, Wang Y, Zang L, Leone AM, Liu P, Ludwig R, Tao L, Wu W, Cansizoglu A, Hanneman A, Adams GW, Perdivara I, Walker H, Wilson M, Brandenburg A, DeGraan-Weber N, Gotta S, Shambaugh J, Alvarez M, Yu XC, Cao L, Shao C, Mahan A, Nanda H, Nields K, Nightlinger N, Niu B, Wang J, Xu W, Leo G, Sepe N, Liu YH, Patel BA, Richardson D, Wang Y, Tizabi D, Borisov OV, Lu Y, Maynard EL, Gruhler A, Haselmann KF, Krogh TN, Sönksen CP, Letarte S, Shen S, Boggio K, Johnson K, Ni W, Patel H, Ripley D, Rouse JC, Zhang Y, Daniels C, Dawdy A, Friese O, Powers TW, Sperry JB, Woods J, Carlson E, Sen KI, Skilton SJ, Busch M, Lund A, Stapels M, Guo X, Heidelberger S, Kaluarachchi H, McCarthy S, Kim J, Zhen J, Zhou Y, Rogstad S, Wang X, Fang J, Chen W, Yu YQ, Hoogerheide JG, Scott R, Yuan H.

J Am Soc Mass Spectrom. 2022 Sep 7;33(9):1659-1677. doi: 10.1021/jasms.2c00129. Epub 2022 Aug 26.

PMID: 36018776

Kinetics of Surface Enrichment of a Polymer in a Glass-Forming Molecular Liquid.

Yu J, Yao X, Que C, Huang L, Hui HW, Gong Y, Qian F, Yu L.

Mol Pharm. 2022 Sep 5;19(9):3350-3357. doi: 10.1021/acs.molpharmaceut.2c00484. Epub 2022 Aug 19.

PMID: 35985030

How Dangerous Is Too Dangerous? A Perspective on Azide Chemistry.

Treitler DS, Leung S.

J Org Chem. 2022 Sep 2;87(17):11293-11295. doi: 10.1021/acs.joc.2c01402.

PMID: 36052475

Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis.

Broughton EI, Chun DS, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G.

Curr Urol. 2022 Sep;16(3):147-153. doi: 10.1097/CU9.0000000000000072. Epub 2022 Aug 2.

PMID: 36204362

Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Javaheri A, Diab A, Zhao L, Qian C, Cohen JB, Zamani P, Kumar A, Wang Z, Ebert C, Maranville J, Kvikstad E, Basso M, van Empel V, Richards AM, Doughty RN, Rietzschel E, Kammerhoff K, Gogain J, Schafer P, Seiffert DA, Gordon DA, Ramirez-Valle F, Mann DL, Cappola TP, Chirinos JA.

Circ Heart Fail. 2022 Sep;15(9):e009693. doi: 10.1161/CIRCHEARTFAILURE.121.009693. Epub 2022 Aug 9.

PMID: 36126144

Epilogue to the Gerald Maggiora Festschrift: a tribute to an exemplary mentor, colleague, collaborator, and innovator.

Shanmugasundaram V, Bajorath J, Christoffersen RE, Petke JD, Howe WJ, Johnson MA, Agrafiotis DK, Lee P, Kuhn LA, Goodwin JT, Holloway MK, Doman TN, Walters WP, Schreyer S, Medina-Franco JL, Martinez-Mayorga K, Restifo LL.

J Comput Aided Mol Des. 2022 Sep;36(9):623-638. doi: 10.1007/s10822-022-00473-2. Epub 2022 Sep 17.

PMID: 36114380

Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report.

Schlichting M, Hennig M, Rudell K, McLeod L, Bennett B, Shaw J, Doward L, Molsen-David E, Chassany O.

Value Health. 2022 Sep;25(9):1463-1468. doi: 10.1016/j.jval.2022.07.010.

PMID: 36049796

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067.

Baker T, Johnson H, Kotapati S, Moshyk A, Hamilton M, Kurt M, Paly VF.

Pharmacoecon Open. 2022 Sep;6(5):697-710. doi: 10.1007/s41669-022-00348-0. Epub 2022 Aug 25.

PMID: 36006606

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

Larkin J, Weber J, Del Vecchio M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, De la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Long GV, Lobo M, Askelson M, Ascierto PA, Mandalá M.

Eur J Cancer. 2022 Sep;173:285-296. doi: 10.1016/j.ejca.2022.06.041. Epub 2022 Aug 11.

PMID: 35964471

Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.

Armstrong A, Xia Q, John AR, Patel V, Seigel L.

Dermatol Ther (Heidelb). 2022 Sep;12(9):2087-2103. doi: 10.1007/s13555-022-00775-1. Epub 2022 Aug 10.

PMID: 35947341

Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model.

Aulin J, Hijazi Z, Lindbäck J, Alexander JH, Gersh BJ, Granger CB, Hanna M, Horowitz J, Lopes RD, McMurray JJV, Oldgren J, Siegbahn A, Wallentin L; ARISTOTLE Investigators.

Am Heart J. 2022 Sep;251:13-24. doi: 10.1016/j.ahj.2022.03.009. Epub 2022 May 13.

PMID: 35569564

Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19.

Deitelzweig S, Zhu J, Jiang J, Luo X, Keshishian A, Ferri M, Rosenblatt L, Schuler P, Gutierrez C, Dhamane AD.

Curr Med Res Opin. 2022 Aug 30:1-6. doi: 10.1080/03007995.2022.2112871. Online ahead of print.

PMID: 36000258

Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.

Amin A, Keshishian A, Hines DM, Dina O, Le H, Rosenblatt L, Liu X, Zhang Q, Vo L.

Curr Med Res Opin. 2022 Aug 30:1-10. doi: 10.1080/03007995.2022.2115772. Online ahead of print.

PMID: 35993487

Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.

Paz-Ares LG, Ciuleanu T, Pluzanski A, Lee JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker M, Linardou H, Caro RB, Provencio M, Zurawski B, Lee KH, Kim SW, Caserta C, Ramalingam SS, Spigel DR, Brahmer JR, Reck M, O'Byrne KJ, Girard N, Popat S, Peters S, Memaj A, Nathan F, Aanur N, Borghaei H.

J Thorac Oncol. 2022 Aug 29:S1556-0864(22)01556-8. doi: 10.1016/j.jtho.2022.08.014. Online ahead of print.

PMID: 36049658

Application of Immunocompetent Microphysiological Systems in Drug Development: Current Perspective and Recommendations.

Wang X, Kopec AK, Collinge M, David R, Grant C, Hardwick RN, Navratil A, Patel N, Rowan W, Marshall N.

ALTEX. 2022 Aug 29. doi: 10.14573/altex.2205311. Online ahead of print.

PMID: 36044561

New Development in Understanding Drug-Polymer Interactions in Pharmaceutical Amorphous Solid Dispersions from Solid-State Nuclear Magnetic Resonance.

Pugliese A, Tobyn M, Hawarden LE, Abraham A, Blanc F.

Mol Pharm. 2022 Aug 29. doi: 10.1021/acs.molpharmaceut.2c00479. Online ahead of print.

PMID: 36037249

Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France.

Belhassen M, Hanon O, Steg PG, Mahé I, Née M, Jacoud F, Dalon F, Cotté FE, Guitard-Dehoux D, Marant-Micallef C, Van Ganse E, Danchin N.

Eur J Health Econ. 2022 Aug 28. doi: 10.1007/s10198-022-01513-2. Online ahead of print.

PMID: 36030485

A Combined Rheological and Thermomechanical Analysis Approach for the Assessment of Pharmaceutical Polymer Blends.

Isreb M, Chalkia M, Gough T, Forbes RT, Timmins P.

Polymers (Basel). 2022 Aug 27;14(17):3527. doi: 10.3390/polym14173527.

PMID: 36080602

Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study.

Halvorsen S, Smith JA, Söderdahl F, Thuresson M, Solli O, Ulvestad M, Jonasson C.

BMC Prim Care. 2022 Aug 25;23(1):214. doi: 10.1186/s12875-022-01824-6.

PMID: 36008778

Discovery of Substituted Di(pyridin-2-yl)-1,2,4-thiadiazol-5-amines as Novel Macrofilaricidal Compounds for the Treatment of Human Filarial Infections.

Hawryluk N, Robinson D, Shen Y, Kyne G, Bedore M, Menon S, Canan S, von Geldern T, Townson S, Gokool S, Ehrens A, Koschel M, Lhermitte-Vallarino N, Martin C, Hoerauf A, Hernandez G, Dalvie D, Specht S, Hübner MP, Scandale I.

J Med Chem. 2022 Aug 25;65(16):11388-11403. doi: 10.1021/acs.jmedchem.2c00960. Epub 2022 Aug 16.

PMID: 35972896

Identification of Monosaccharide Derivatives as Potent, Selective, and Orally Bioavailable Inhibitors of Human and Mouse Galectin-3.

Liu C, Jalagam PR, Feng J, Wang W, Raja T, Sura MR, Manepalli RKVLP, Aliphedi BR, Medavarapu S, Nair SK, Muthalagu V, Natesan R, Gupta A, Beno B, Panda M, Ghosh K, Shukla JK, Sale H, Haldar P, Kalidindi N, Shah D, Patel D, Mathur A, Ellsworth BA, Cheng D, Regueiro-Ren A.

J Med Chem. 2022 Aug 25;65(16):11084-11099. doi: 10.1021/acs.jmedchem.2c00517. Epub 2022 Aug 15.

PMID: 35969688

Improving Drug Delivery While Tailoring Prodrug Activation to Modulate Cmax and Cmin by Optimization of (Carbonyl)oxyalkyl Linker-Based Prodrugs of Atazanavir.

A M Subbaiah M, Subramani L, Ramar T, Desai S, Sinha S, Mandlekar S, Kadow JF, Jenkins S, Krystal M, Subramanian M, Sridhar S, Padmanabhan S, Bhutani P, Arla R, Meanwell NA.

J Med Chem. 2022 Aug 25;65(16):11150-11176. doi: 10.1021/acs.jmedchem.2c00632. Epub 2022 Aug 11.

PMID: 35952307

BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.

Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, Ünsal-Kaçmaz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, Diamond JR.

Cancers (Basel). 2022 Aug 23;14(17):4079. doi: 10.3390/cancers14174079.

PMID: 36077617

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.

Platzbecker U, Götze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlägel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A.

J Clin Oncol. 2022 Aug 23:JCO2102476. doi: 10.1200/JCO.21.02476. Online ahead of print.

PMID: 35998303

Population-based study of treatment and outcome of recurrent oesophageal or junctional cancer.

Pape M, Vissers PAJ, Bertwistle D, McDonald L, Beerepoot LV, van Berge Henegouwen MI, Lagarde SM, Mook S, Mohammad NH, Jeene PM, van Laarhoven HWM, Verhoeven RHA.

Br J Surg. 2022 Aug 23:znac290. doi: 10.1093/bjs/znac290. Online ahead of print.

PMID: 35998093

Identification of cognitive impairment, depression, and fatigue among multiple sclerosis patients in a large comprehensive care center: A mixed-methods, qualitative study.

Tornatore C, Ahmad A, Pham T, Gupte-Singh K, Wahid N, Lynch J, Pratt KJ.

Mult Scler Relat Disord. 2022 Aug 20;68:104117. doi: 10.1016/j.msard.2022.104117. Online ahead of print.

PMID: 36037754

Container Closure Integrity of Vial Primary Packaging Systems under Frozen Storage Conditions: A Case Study.

Oni Y, Franck J, Evans C, Paniagua D, Kulshrestha A, Mantri RV.

PDA J Pharm Sci Technol. 2022 Aug 19:pdajpst.2021.012719. doi: 10.5731/pdajpst.2021.012719. Online ahead of print.

PMID: 35987519

Location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of high-risk NDMM patients.

Stong N, Ortiz Estevez M, Towfic F, Samur MK, Agarwal A, Corre J, Flynt E, Munshi NC, Avet-Loiseau H, Thakurta A.

Blood. 2022 Aug 19:blood.2022016212. doi: 10.1182/blood.2022016212. Online ahead of print.

PMID: 35984902

CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production.

Gaur R, Mensah KA, Stricker J, Adams M, Parton A, Cedzik D, Connarn J, Thomas M, Horan G, Schafer P, Mair S, Palmisano M, Ramírez-Valle F.

Arthritis Res Ther. 2022 Aug 18;24(1):199. doi: 10.1186/s13075-022-02850-6.

PMID: 35982464

Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma.

Cheng Y, Xue Y, Chen L, Masin M, Maciag P, Peluso T, Zhou S, Li Y.

Br J Clin Pharmacol. 2022 Aug 18. doi: 10.1111/bcp.15498. Online ahead of print.

PMID: 35981078

Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry.

Ogdie A, Harrison RW, McLean RR, Lin TC, Lebwohl M, Strober BE, Zhuo J, Patel V, Mease PJ.

J Am Acad Dermatol. 2022 Aug 17:S0190-9622(22)02543-9. doi: 10.1016/j.jaad.2022.07.060. Online ahead of print.

PMID: 35987397

Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease.

Venkataraman AV, Mansur A, Rizzo G, Bishop C, Lewis Y, Kocagoncu E, Lingford-Hughes A, Huiban M, Passchier J, Rowe JB, Tsukada H, Brooks DJ, Martarello L, Comley RA, Chen L, Schwarz AJ, Hargreaves R, Gunn RN, Rabiner EA, Matthews PM.

Sci Transl Med. 2022 Aug 17;14(658):eabk1051. doi: 10.1126/scitranslmed.abk1051. Epub 2022 Aug 17.

PMID: 35976998

Intensive behavioural interventions based on applied behaviour analysis (ABA) for young children with autism: A cost-effectiveness analysis.

Hodgson R, Biswas M, Palmer S, Marshall D, Rodgers M, Stewart L, Simmonds M, Rai D, Le Couteur A.

PLoS One. 2022 Aug 16;17(8):e0270833. doi: 10.1371/journal.pone.0270833. eCollection 2022.

PMID: 35972929

Prevalence of psoriatic arthritis among patients with psoriasis in Italy.

Cazzaniga S, Heidemeyer K, Dondi L, Ronconi G, Pedrini A, Bellatreccia A, Zhong Y, Naldi L, Martini N.

J Eur Acad Dermatol Venereol. 2022 Aug 16. doi: 10.1111/jdv.18528. Online ahead of print.

PMID: 35972199

Women With Psoriatic Arthritis Experience Higher Disease Burden Than Men: Findings From a Real-World Survey in the United States and Europe.

Gossec L, Walsh JA, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Chakravarty SD, Ogdie A.

J Rheumatol. 2022 Aug 15:jrheum.220154. doi: 10.3899/jrheum.220154. Online ahead of print.

PMID: 35970531

Impact of Physician-Defined Flares on Quality of Life and Work Impairment: An International Survey of 2,238 Psoriatic Arthritis Patients.

Orbai AM, Tillett W, Grieb S, Peterson S, Holdsworth E, Booth N, Chakravarty S, Gossec L.

J Rheumatol. 2022 Aug 15:jrheum.211302. doi: 10.3899/jrheum.211302. Online ahead of print.

PMID: 35970528

A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies.

Palmer S, Borget I, Friede T, Husereau D, Karnon J, Kearns B, Medin E, Peterse EFP, Klijn SL, Verburg-Baltussen EJM, Fenwick E, Borrill J.

Value Health. 2022 Aug 13:S1098-3015(22)02105-2. doi: 10.1016/j.jval.2022.07.009. Online ahead of print.

PMID: 35970706

Investigating the feasibility of recruitment to an observational, quality-of-life study of patients diagnosed with atrial fibrillation (AF) who have experienced a bleed while anticoagulated: EQUAL-AF feasibility study protocol.

Hutchings HA, Lanyon K, Lister S, Alikhan R, Halcox J, Holland G, Hughes A, Jenkins R, Laing H, Lobban T, Owen D, Pollock KG, Todd C, Wareham K.

Pilot Feasibility Stud. 2022 Aug 12;8(1):180. doi: 10.1186/s40814-022-01135-8.

PMID: 35962446

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J.

J Clin Oncol. 2022 Aug 12:JCO2102815. doi: 10.1200/JCO.21.02815. Online ahead of print.

PMID: 35960908

Ni/Photoredox-Catalyzed C(sp2)-C(sp3) Cross-Coupling of Alkyl Pinacolboronates and (Hetero)Aryl Bromides.

Cauley AN, Ramirez A, Barhate CL, Donnell AF, Khandelwal P, Sezen-Edmonds M, Sherwood TC, Sloane JL, Cavallaro CL, Simmons EM.

Org Lett. 2022 Aug 12;24(31):5663-5668. doi: 10.1021/acs.orglett.2c01942. Epub 2022 Aug 3.

PMID: 35920644

Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response.

Stefanovic F, Gomez-Caminero A, Jacobs DM, Subramanian P, Puzanov I, Chilbert MR, Feuerstein SG, Yatsynovich Y, Switzer B, Schentag JJ.

Clin Pharmacol. 2022 Aug 10;14:69-90. doi: 10.2147/CPAA.S369008. eCollection 2022.

PMID: 35975122

The win odds: statistical inference and regression.

Song J, Verbeeck J, Huang B, Hoaglin DC, Gamalo-Siebers M, Seifu Y, Wang D, Cooner F, Dong G.

J Biopharm Stat. 2022 Aug 10:1-11. doi: 10.1080/10543406.2022.2089156. Online ahead of print.

PMID: 35946932

Association between transfusion status and clinical and economic outcomes in patients with myelodysplastic syndromes from the physicians' perspective.

Gupta S, Kulasekararaj AG, Costantino H, Grisolano J, Tang J, Jones S, Tang D.

Cancer Rep (Hoboken). 2022 Aug 9:e1680. doi: 10.1002/cnr2.1680. Online ahead of print.

PMID: 35942648

Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium.

Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris MR, Keating AK, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Egeler E, Mavroukakis S, Curran KJ, Mackall CL, Laetsch TW, Schultz LM.

Blood Adv. 2022 Aug 8:bloodadvances.2022007246. doi: 10.1182/bloodadvances.2022007246. Online ahead of print.

PMID: 35938863

ELIMINATOR: essentiality analysis using multisystem networks and integer programming.

Antoranz A, Ortiz M, Pey J.

BMC Bioinformatics. 2022 Aug 6;23(1):324. doi: 10.1186/s12859-022-04855-z.

PMID: 35933325

Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies.

Easton A, Jensen ML, Wang C, Hagedorn PH, Li Y, Weed M, Meredith JE, Guss V, Jones K, Gill M, Krause C, Brown JM, Hunihan L, Natale J, Fernandes A, Lu Y, Polino J, Bookbinder M, Cadelina G, Benitex Y, Sane R, Morrison J, Drexler D, Mercer SE, Bon C, Pandya NJ, Jagasia R, Ou Yang TH, Distler T, Grüninger F, Meldgaard M, Terrigno M, Macor JE, Albright CF, Loy J, Hoeg AM, Olson RE, Cacace AM.

Mol Ther Nucleic Acids. 2022 Aug 4;29:625-642. doi: 10.1016/j.omtn.2022.07.027. eCollection 2022 Sep 13.

PMID: 36090761

Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study).

Kojima T, Kato R, Sazuka T, Yamamoto H, Fukuda S, Yamana K, Nakaigawa N, Sugino Y, Hamamoto S, Ito H, Murakami H, Obara W.

Jpn J Clin Oncol. 2022 Aug 3:hyac124. doi: 10.1093/jjco/hyac124. Online ahead of print.

PMID: 35920793

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper.

Yang TY, Braun M, Lembke W, McBlane F, Kamerud J, DeWall S, Tarcsa E, Fang X, Hofer L, Kavita U, Upreti VV, Gupta S, Loo L, Johnson AJ, Chandode RK, Stubenrauch KG, Vinzing M, Xia CQ, Jawa V.

Mol Ther Methods Clin Dev. 2022 Aug 2;26:471-494. doi: 10.1016/j.omtm.2022.07.018. eCollection 2022 Sep 8.

PMID: 36092368

External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices.

Nauwelaers I, Laudus N, Peeters D, Acs B, Denkert C, Michiels S, Horlings H, Siziopikou KP, Ely S, Zardavas D, Mustimbo R, Bartlett J, Floris G, Hartman J, van Deurzen CHM, Ceusters D, Dequeker E, Salgado R.

Cancers (Basel). 2022 Aug 2;14(15):3762. doi: 10.3390/cancers14153762.

PMID: 35954426

Joint semiparametric models for case-cohort designs.

Zhong W, Diao G.

Biometrics. 2022 Aug 2. doi: 10.1111/biom.13728. Online ahead of print.

PMID: 35917392

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.

Hagner PR, Chiu H, Chopra VS, Colombo M, Patel N, Estevez MO, Waldman MF, Loos R, Towfic F, Gandhi AK.

Clin Cancer Res. 2022 Aug 2;28(15):3367-3377. doi: 10.1158/1078-0432.CCR-21-3347.

PMID: 35583604

Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.

Dowlati A, Abbas A, Chan T, Henick B, Wang X, Doshi P, Fu P, Patel J, Kuo F, Chang H, Balli D.

JCO Precis Oncol. 2022 Aug;6:e2200257. doi: 10.1200/PO.22.00257.

PMID: 36044718

Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.

Lip GYH, Murphy RR, Sahiar F, Ingall TJ, Dhamane AD, Ferri M, Hlavacek P, Preib MT, Keshishian A, Russ C, Rosenblatt L, Yuce H, Deitelzweig S.

JAMA Netw Open. 2022 Aug 1;5(8):e2229333. doi: 10.1001/jamanetworkopen.2022.29333.

PMID: 36044214

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.

Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, Fléchon A, Saad F, Grimm MO, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP, Ünsal-Kaçmaz K, Wang X, Li J, Loehr A, Pachynski RK.

J Immunother Cancer. 2022 Aug;10(8):e004761. doi: 10.1136/jitc-2022-004761.

PMID: 35977756

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

Vega DM, Nishimura KK, Zariffa N, Thompson JC, Hoering A, Cilento V, Rosenthal A, Anagnostou V, Baden J, Beaver JA, Chaudhuri AA, Chudova D, Fine AD, Fiore J, Hodge R, Hodgson D, Hunkapiller N, Klass DM, Kobie J, Peña C, Pennello G, Peterman N, Philip R, Quinn KJ, Raben D, Rosner GL, Sausen M, Tezcan A, Xia Q, Yi J, Young AG, Stewart MD, Carpenter EL, Aggarwal C, Allen J.

JCO Precis Oncol. 2022 Aug;6:e2100372. doi: 10.1200/PO.21.00372.

PMID: 35952319

(-)-Epicatechin Ameliorates Cardiac Fibrosis in a Female Rat Model of Pre-Heart Failure with Preserved Ejection Fraction.

Bustamante-Pozo M, Ramirez-Sanchez I, Garate-Carrillo A, Ito B, Navarrete V, Haro M, Garcia R, Carson N, Ceballos G, Villarreal F.

J Med Food. 2022 Aug;25(8):836-844. doi: 10.1089/jmf.2021.0158. Epub 2022 Aug 2.

PMID: 35917528

Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Nassif M, Fine JT, Dolan C, Reaney M, Addepalli P, Allen VD, Sehnert AJ, Gosch K, Spertus JA.

JACC Heart Fail. 2022 Aug;10(8):531-539. doi: 10.1016/j.jchf.2022.03.002. Epub 2022 May 4.

PMID: 35902155

Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer.

Li C, Horton JK, Sale M, Curd L, Goti V, Tao W, Beelen A.

Clin Drug Investig. 2022 Aug;42(8):679-692. doi: 10.1007/s40261-022-01179-x. Epub 2022 Jul 16.

PMID: 35842567

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.

Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI.

Lancet Oncol. 2022 Aug;23(8):1066-1077. doi: 10.1016/S1470-2045(22)00339-4. Epub 2022 Jul 12.

PMID: 35839786

An Industry Survey on Managing the Pharmacovigilance System Master File in a Global Environment: The Need for a Pragmatic Approach.

Lavery C, Emmott J, Jeck-Thole S, Rouben P, Usher D, van der Spuij W, Woodward L.

Pharmaceut Med. 2022 Aug;36(4):233-245. doi: 10.1007/s40290-022-00422-2. Epub 2022 Jun 20.

PMID: 35723862

Increasing the Reuse of Protein Non-Naïve Nonhuman Primates in Pharmaceutical Drug Discovery and Development: An Overview and Industry Position on the Challenges and Benefits.

Mattis C, Bratcher N, Burns M, Carosino C, de Zafra C, Fancher RM, Georgi K, Graff C, Hukkanen RR, Johnson C, Lao Y, Lange A, Lee D, Lepherd M, Maguire S, Malisauskas M, Manuel M, Miranda S, Reed L, Santos R, Sayers B, Shaw D, Shuster D.

Int J Toxicol. 2022 Aug;41(4):291-296. doi: 10.1177/10915818221101791. Epub 2022 Jun 2.

PMID: 35656559

Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid.

Zhang Y, Chen SJ, Chen C, Chen XQ, Chatterjee S, Shuster DJ, Dexter H, Armstrong L, Joshi EM, Yang Z, Shen H.Drug Metab Dispos. 2022 Aug;50(8):1077-1086. doi: 10.1124/dmd.122.000875. Epub 2022 May 30.

PMID: 35636769

Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.

Holstein SA, Asimakopoulos F, Azab AK, Bianchi G, Bhutani M, Crews LA, Cupedo T, Giles H, Gooding S, Hillengass J, John L, Kaiser S, Lee L, Maclachlan K, Pasquini MC, Pichiorri F, Shah N, Shokeen M, Shy BR, Smith EL, Verona R, Usmani SZ, McCarthy PL.

Transplant Cell Ther. 2022 Aug;28(8):446-454. doi: 10.1016/j.jtct.2022.05.019. Epub 2022 May 21.

PMID: 35605882

Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of HIV-1 allosteric integrase inhibitors.

Parcella K, Patel M, Tu Y, Eastman K, Peese K, Gillis E, Belema M, Dicker IB, McAuliffe B, Ding B, Falk P, Simmermacher J, Parker DD, Sivaprakasam P, Khan JA, Kish K, Lewis H, Hanumegowda U, Jenkins S, Kadow JF, Krystal M, Meanwell NA, Naidu BN.

Bioorg Med Chem. 2022 Aug 1;67:116833. doi: 10.1016/j.bmc.2022.116833. Epub 2022 May 19.

PMID: 35605346

Patel V, Pulungan Z, Shah A, Jones B, Petrilla A, Ferri L, Han X, Michaud K.

Rheumatol Ther. 2022 Aug;9(4):1091-1107. doi: 10.1007/s40744-022-00453-w. Epub 2022 May 23.

PMID: 35604547

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.

Alten R, Mariette X, Flipo RM, Caporali R, Buch MH, Patel Y, Marsal S, Sanmartí R, Nurmohamed MT, Griffiths H, Peichl P, Bannert B, Chartier M, Connolly SE, Lozenski K, Rauch C.

Clin Rheumatol. 2022 Aug;41(8):2361-2373. doi: 10.1007/s10067-022-06176-1. Epub 2022 May 10.

PMID: 35536413

Enhanced aqueous dissolution of hydrophobic apixaban via direct incorporation of hydrophilic nanographene oxide.

Islam MS, Renner F, Foster K, Oderinde MS, Stefanski K, Mitra S.

Colloids Surf B Biointerfaces. 2022 Aug;216:112512. doi: 10.1016/j.colsurfb.2022.112512. Epub 2022 Apr 26.

PMID: 35533561

Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.

Tehlirian C, Singh RSP, Pradhan V, Roberts ES, Tarabar S, Peeva E, Vincent MS, Gale JD.

J Am Acad Dermatol. 2022 Aug;87(2):333-342. doi: 10.1016/j.jaad.2022.03.059. Epub 2022 Apr 6.

PMID: 35398218

Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates.

Swanson MD, Rios S, Mittal S, Soder G, Jawa V.

Front Immunol. 2022 Jul 27;13:915412. doi: 10.3389/fimmu.2022.915412. eCollection 2022.

PMID: 35967308

Association of Use of Statins with Progression of Diabetic Retinopathy at a Tertiary Care Hospital in Southern India.

Priyadarshini P, Chogtu B, Bhandary SV, Kabirdev, Magazine R.

J Curr Ophthalmol. 2022 Jul 26;34(2):234-240. doi: 10.4103/joco.joco_70_21. eCollection 2022 Apr-Jun.

PMID: 36147261

Creating standards for liquid biopsies: the BLOODPAC experience.

Leiman LC, Baden J, D'Auria K, Lin CJ, Meier K.

Expert Rev Mol Diagn. 2022 Jul;22(7):677-679. doi: 10.1080/14737159.2022.2113059. Epub 2022 Aug 24.

PMID: 35979936

Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK.

Carpenter L, Rockenschaub P, Hatton GB, D'Abrantes S, Sims E, Scott-Ram N, Ducès A, Emanuel G, Mead AJ, Drummond MW, Lipunova N.

EJHaem. 2022 Jun 29;3(3):785-793. doi: 10.1002/jha2.519. eCollection 2022 Aug.

PMID: 36051073

Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients.

Cheng Y, Hong K, Chen N, Yu X, Peluso T, Zhou S, Li Y.

EJHaem. 2022 Jun 2;3(3):815-827. doi: 10.1002/jha2.494. eCollection 2022 Aug.

PMID: 36051011

Reply to T. Olivier et al.

Wolchok JD, Kluger H, Campigotto F, Larkin J, Hodi FS.

J Clin Oncol. 2022 May 10;40(14):1597-1598. doi: 10.1200/JCO.22.00209. Epub 2022 Mar 8.

PMID: 35258992

Cobalt-Catalyzed C(sp2)-C(sp3) Suzuki-Miyaura Cross-Coupling Enabled by Well-Defined Precatalysts with L,X-Type Ligands.

Mills LR, Gygi D, Ludwig JR, Simmons EM, Wisniewski SR, Kim J, Chirik PJ.

ACS Catal. 2022 Feb 4;12(3):1905-1918. doi: 10.1021/acscatal.1c05586. Epub 2022 Jan 20.

PMID: 36034100

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.

Perera V, Abelian G, Li D, Wang Z, Zhang L, Lubin S, Bello A, Murthy B.

Clin Pharmacokinet. 2022 Jul 30. doi: 10.1007/s40262-022-01150-1. Online ahead of print.

PMID: 35906349

Relationship between Serum Ferritin and Outcomes in β-Thalassemia: A Systematic Literature Review. Shah F, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E, Yucel A, Moro Bueno L, Oliva EN. J Clin Med. 2022 Jul 30;11(15):4448. doi: 10.3390/jcm11154448. PMID: 35956067

Imaging the Alternatively Spliced D Domain of Tenascin C in a Preclinical Model of Inflammatory Bowel Disease.

Zhang L, Wang Y, Homan KT, Gaudette SM, McCluskey AJ, Chan Y, Murphy J, Abdalla M, Nelson CM, Sun VZ, Erickson JE, Knight HL, Clabbers A, Sterman AJS, Mitra S.

Mol Imaging Biol. 2022 Jul 29. doi: 10.1007/s11307-022-01758-6. Online ahead of print.

PMID: 35906512

Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression.

Zivadinov R, Bergsland N, Jakimovski D, Weinstock-Guttman B, Benedict RHB, Riolo J, Silva D, Dwyer MG; DeepGRAI Registry Study group.

J Neurol Neurosurg Psychiatry. 2022 Jul 28:jnnp-2022-329333. doi: 10.1136/jnnp-2022-329333. Online ahead of print.

PMID: 35902228

Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium.

Rusyn I, Sakolish C, Kato Y, Stephan C, Vergara L, Hewitt P, Bhaskaran V, Davis M, Hardwick RN, Ferguson SS, Stanko JP, Bajaj P, Adkins K, Sipes NS, Hunter ES, Baltazar MT, Carmichael PL, Sadh K, Becker RA.

Toxicol Sci. 2022 Jul 28;188(2):143-152. doi: 10.1093/toxsci/kfac061.

PMID: 35689632

Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference.

Schnabel RB, Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM, Camm AJ, Casadei B, Chua W, Dagres N, de Melis M, Desteghe L, Diederichsen SZ, Duncker D, Eckardt L, Eisert C, Engler D, Fabritz L, Freedman B, Gillet L, Goette A, Guasch E, Svendsen JH, Hatem SN, Haeusler KG, Healey JS, Heidbuchel H, Hindricks G, Hobbs FDR, Hübner T, Kotecha D, Krekler M, Leclercq C, Lewalter T, Lin H, Linz D, Lip GYH, Løchen ML, Lucassen W, Malaczynska-Rajpold K, Massberg S, Merino JL, Meyer R, Mont L, Myers MC, Neubeck L, Niiranen T, Oeff M, Oldgren J, Potpara TS, Psaroudakis G, Pürerfellner H, Ravens U, Rienstra M, Rivard L, Scherr D, Schotten U, Shah D, Sinner MF, Smolnik R, Steinbeck G, Steven D, Svennberg E, Thomas D, True Hills M, van Gelder IC, Vardar B, Palà E, Wakili R, Wegscheider K, Wieloch M, Willems S, Witt H, Ziegler A, Daniel Zink M, Kirchhof P.

Europace. 2022 Jul 27:euac062. doi: 10.1093/europace/euac062. Online ahead of print.

PMID: 35894842

Differential Surface Adsorption Phenomena for Conventional and Novel Surfactants Correlates with Changes in Interfacial mAb Stabilization.

Kanthe AD, Carnovale MR, Katz JS, Jordan S, Krause ME, Zheng S, Ilott A, Ying W, Bu W, Bera MK, Lin B, Maldarelli C, Tu RS.

Mol Pharm. 2022 Jul 26. doi: 10.1021/acs.molpharmaceut.2c00152. Online ahead of print.

PMID: 35882380

Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma.

Samlowski W, Robert NJ, Chen L, Schenkel B, Davis C, Moshyk A, Kotapati S, Poretta T, Weber JS.

Cancer Med. 2022 Jul 25. doi: 10.1002/cam4.5061. Online ahead of print.

PMID: 35880244

Bioactivation and Reactivity Research Advances - 2021 year in review.

Jackson KD, Argikar UA, Cho S, Crouch RD, Driscoll JP, Heck C, King L, Maw HH, Miller GP, Seneviratne HK, Wang S, Wei C, Zhang D, Khojasteh SC.

Drug Metab Rev. 2022 Jul 25:1-83. doi: 10.1080/03602532.2022.2097254. Online ahead of print.

PMID: 35876116

Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial. Shah N, Delforge M, San-Miguel J, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Miera M, Williams A, Murphy R, Devlen J, Hege K, Campbell TB, Munshi NC. Leuk Res. 2022 Jul 21;120:106921. doi: 10.1016/j.leukres.2022.106921. Online ahead of print. PMID: 35930999

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.

Ding X, Zhu Z, Lapek J, McMillan EA, Zhang A, Chung CY, Dubbury S, Lapira J, Firdaus S, Kang X, Gao J, Oyer J, Chionis J, Rollins RA, Li L, Niessen S, Bagrodia S, Zhang L, VanArsdale T.

Sci Rep. 2022 Jul 21;12(1):12501. doi: 10.1038/s41598-022-16623-3.

PMID: 35864202

Optimization of antidote stocking, availability, and administration practices for a large multihospital organization.

Antoniello AA, Pauls P, Awad NI, Sobolewski K, Fernández D, Bridgeman P.

Am J Health Syst Pharm. 2022 Jul 21:zxac191. doi: 10.1093/ajhp/zxac191. Online ahead of print.

PMID: 35861156

One-Step Synthesis of β-Alkylidene-γ-lactones via Ligand-Enabled β,γ-Dehydrogenation of Aliphatic Acids.

Sheng T, Zhuang Z, Wang Z, Hu L, Herron AN, Qiao JX, Yu JQ.

J Am Chem Soc. 2022 Jul 20;144(28):12924-12933. doi: 10.1021/jacs.2c04779. Epub 2022 Jul 8.

PMID: 35802794

Current Approaches for Predicting Human PK for Small Molecule Development Candidates: Findings from the IQ Human PK Prediction Working Group Survey.

Petersson C, Zhou X, Berghausen J, Cebrian D, Davies M, DeMent K, Eddershaw P, Riedmaier AE, Leblanc AF, Manveski N, Marathe P, Mavroudis PD, McDougall R, Parrott N, Reichel A, Rotter C, Tess D, Volak LP, Xiao G, Yang Z, Baker J.

AAPS J. 2022 Jul 19;24(5):85. doi: 10.1208/s12248-022-00735-9.

PMID: 35854202

Comparing patient global impression of severity and patient global impression of change to evaluate test-retest reliability of depression, non-small cell lung cancer, and asthma measures.

Eremenco S, Chen WH, Blum SI, Bush EN, Bushnell DM, DeBusk K, Gater A, Nelsen L, Coons SJ; PRO Consortium’s Communication Subcommittee.

Qual Life Res. 2022 Jul 19. doi: 10.1007/s11136-022-03180-5. Online ahead of print.

PMID: 35854060

Loss Of COP9-Signalosome Genes At 2q37 Is Associated With IMiD Agent Resistance In Multiple Myeloma.

Gooding S, Ansari-Pour N, Kazeroun MH, Karagoz K, Polonskaia A, Angulo Salazar M, Fitzsimons E, Sirinukunwattana K, Chavda SJ, Ortiz Estevez M, Towfic F, Flynt E, Pierceall W, Royston D, Yong KL, Ramasamy K, Vyas P, Thakurta A.

Blood. 2022 Jul 19:blood.2022015909. doi: 10.1182/blood.2022015909. Online ahead of print.

PMID: 35853156

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.

Casulo C, Santoro A, Cartron G, Ando K, Munoz J, Le Gouill S, Izutsu K, Rule S, Lugtenburg P, Ruan J, Arcaini L, Casadebaig ML, Fox B, Kilavuz N, Rettby N, Dell'Aringa J, Taningco L, Delarue R, Czuczman M, Witzig T.

Cancer Rep (Hoboken). 2022 Jul 19:e1662. doi: 10.1002/cnr2.1662. Online ahead of print.

PMID: 35852004

Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.

Baxi V, Lee G, Duan C, Pandya D, Cohen DN, Edwards R, Chang H, Li J, Elliott H, Pokkalla H, Glass B, Agrawal N, Lahiri A, Wang D, Khosla A, Wapinski I, Beck A, Montalto M.

Mod Pathol. 2022 Jul 15. doi: 10.1038/s41379-022-01119-2. Online ahead of print.

PMID: 35840720

The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.

Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG 3rd, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD Jr, Mullins RD, Eyquem J, Wells JA, Wiita AP.

Nat Commun. 2022 Jul 15;13(1):4121. doi: 10.1038/s41467-022-31810-6.

PMID: 35840578

Challenges Encountered in the Implementation of Bio-Fluorescent Particle Counting Systems as a Routine Microbial Monitoring Tool.

Scott A, Vanbroekhoven A, Joossen C, Knutsen C, Govezensky D, Anders HJ, Cannon J, Salvas J, Dingle M, Hutchins P, Merker P, Villari P, Ramsey S, Cundell AM, Navarro V, Franz-Riethdorf M.

PDA J Pharm Sci Technol. 2022 Jul 15:pdajpst.2021.012726. doi: 10.5731/pdajpst.2021.012726. Online ahead of print.

PMID: 35840344

Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey.

Gossec L, Walsh JA, Michaud K, Holdsworth E, Peterson S, Meakin S, Yang F, Booth N, Chakravarty SD, Piercy J, Dennis N, Ogdie A.

J Rheumatol. 2022 Jul 15:jrheum.211288. doi: 10.3899/jrheum.211288. Online ahead of print.

PMID: 35840154

Development and validation of a self-administered questionnaire measuring essential knowledge in patients with axial spondyloarthritis.

Beauvais C, Pereira B, Pham T, Sordet C, Claudepierre P, Fayet F, Wendling D, Costantino F, Carton L, Grange L, Soubrier M, Legoupil N, Perdriger A, Tavares I, Dernis E, Gossec L, Rodère M.

J Rheumatol. 2022 Jul 15:jrheum.211314. doi: 10.3899/jrheum.211314. Online ahead of print.

PMID: 35840152

Low rate of subsequent malignant neoplasms following CAR T-cell therapy.

Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard JD, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble A.

Blood Adv. 2022 Jul 14:bloodadvances.2022008093. doi:10.1182/bloodadvances.2022008093.Online ahead of print.

PMID: 35834728

Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.

Priestley ES, Banville J, Deon D, Dubé L, Gagnon M, Guy J, Lapointe P, Lavallée JF, Martel A, Plamondon S, Rémillard R, Ruediger E, Tremblay F, Posy SL, Guarino VR, Richter JM, Li J, Gupta A, Vetrichelvan M, Balapragalathan TJ, Mathur A, Hua J, Callejo M, Guay J, Sum CS, Cvijic ME, Watson C, Wong P, Yang J, Bouvier M, Gordon DA, Wexler RR, Marinier A.

J Med Chem. 2022 Jul 14;65(13):8843-8854. doi: 10.1021/acs.jmedchem.2c00359. Epub 2022 Jun 21.

PMID: 35729784

Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis.

Nara SJ, Jogi S, Cheruku S, Kandhasamy S, Jaipuri F, Kathi PK, Reddy S, Sarodaya S, Cook EM, Wang T, Sitkoff D, Rossi KA, Ruzanov M, Kiefer SE, Khan JA, Gao M, Reddy S, Sivaprasad Lvj S, Sane R, Mosure K, Zhuo X, Cao GG, Ziegler M, Azzara A, Krupinski J, Soars MG, Ellsworth BA, Wacker DA.

J Med Chem. 2022 Jul 14;65(13):8948-8960. doi: 10.1021/acs.jmedchem.2c00165. Epub 2022 Jun 15.

PMID: 35704802

Applications of bio-predictive dissolution tools for the development of solid oral dosage forms: current industry experience.

Xu J, Zhang L, Shao X.

Drug Dev Ind Pharm. 2022 Jul 13:1-19. doi: 10.1080/03639045.2022.2098315. Online ahead of print.

PMID: 35786119

Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.

Gao K, Wang R, Chen J, Cheng L, Frishcosy J, Huzumi Y, Qiu Y, Schluckbier T, Wei X, Wei GW.

Chem Rev. 2022 Jul 13;122(13):11287-11368. doi: 10.1021/acs.chemrev.1c00965. Epub 2022 May 20.

PMID: 35594413

Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium.

Starcevic Manning M, Hassanein M, Partridge MA, Jawa V, Mora J, Ryman J, Barker B, Braithwaite C, Carleton K, Hay L, Hottenstein C, Kubiak RJ, Devanarayan V.

AAPS J. 2022 Jul 12;24(4):81. doi: 10.1208/s12248-022-00728-8.

PMID: 35821280

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.

Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, Cremer PC, Schaff H, McErlean E, Sewell C, Li W, Sterling L, Lampl K, Edelberg JM, Sehnert AJ, Nissen SE.

J Am Coll Cardiol. 2022 Jul 12;80(2):95-108. doi: 10.1016/j.jacc.2022.04.048.

PMID: 35798455

Ablation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse model.

Axelsson Raja A, Wakimoto H, DeLaughter DM, Reichart D, Gorham J, Conner DA, Lun M, Probst CK, Sakai N, Knipe RS, Montesi SB, Shea B, Adam LP, Leinwand LA, Wan W, Choi ES, Lindberg EL, Patone G, Noseda M, Hübner N, Seidman CE, Tager AM, Seidman JG, Ho CY.

Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2204174119. doi: 10.1073/pnas.2204174119. Epub 2022 Jul 5.

PMID: 35787042

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.

Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A.

J Am Acad Dermatol. 2022 Jul 9:S0190-9622(22)02256-3. doi: 10.1016/j.jaad.2022.07.002. Online ahead of print.

PMID: 35820547

Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database.

Munir MB, Hlavacek P, Keshishian A, Guo JD, Mallampati R, Ferri M, Russ C, Emir B, Cato M, Yuce H, Hsu JC.

J Interv Card Electrophysiol. 2022 Jul 9. doi: 10.1007/s10840-022-01274-1. Online ahead of print.

PMID: 35804258

Design and preparation of N-linked hydroxypyridine-based APJ agonists.

Richter JM, Alex Bates J, Gargalovic P, Onorato JM, Generaux C, Wang T, Gordon DA, Wexler RR, Finlay HJ.

Bioorg Med Chem Lett. 2022 Jul 8;73:128882. doi: 10.1016/j.bmcl.2022.128882. Online ahead of print.

PMID: 35817293

Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.

Denize T, Hou Y, Pignon JC, Walton E, West DJ, Freeman GJ, Braun DA, Wu CJ, Gupta S, Motzer RJ, Atkins MB, McDermott D, Choueiri TK, Shukla SA, Signoretti S.

Clin Cancer Res. 2022 Jul 8:ccr.22.0923. doi: 10.1158/1078-0432.CCR-22-0923. Online ahead of print.

PMID: 35802667

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.

Zeidan AM, Platzbecker U, Garcia-Manero G, Sekeres MA, Fenaux P, DeZern AE, Greenberg PL, Savona MR, Jurcic JG, Verma A, Mufti Obe GJ, Buckstein RJ, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji RS.

Blood. 2022 Jul 7:blood.2022016171. doi: 10.1182/blood.2022016171. Online ahead of print.

PMID: 35797468

Ligand-Enabled β-C(sp3 )-H Lactamization of Tosyl-Protected Aliphatic Amides Using a Practical Oxidant.

Zhuang Z, Liu S, Cheng JT, Yeung KS, Qiao JX, Meanwell NA, Yu JQ.

Angew Chem Int Ed Engl. 2022 Jul 5:e202207354. doi: 10.1002/anie.202207354. Online ahead of print.

PMID: 35790471

Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties.

Hill MD, Fang H, Norris D, Delucca GV, Huang H, DeBenedetto M, Quesnelle C, Schmitz WD, Tokarski JS, Sheriff S, Yan C, Fanslau C, Haarhoff Z, Huang C, Kramer M, Madari S, Menard K, Monereau L, Morrison J, Raghavan N, Shields EE, Simmermacher-Mayer J, Sinz M, Tye CK, Westhouse R, Xie C, Zhang H, Zhang L, Zvyaga T, Lee F, Gavai AV, Degnan AP.

ACS Med Chem Lett. 2022 Jul 5;13(7):1165-1171. doi: 10.1021/acsmedchemlett.2c00219. eCollection 2022 Jul 14.

PMID: 35859878

Trends in FDA Transporter-Based Post Marketing Requirements and Commitments Over the Last Decade.

Younis IR, Manchandani P, Hassan HE, Qosa H.

Clin Pharmacol Ther. 2022 Jul 3. doi: 10.1002/cpt.2701. Online ahead of print.

PMID: 35780478

hERG block potencies for 5 positive control drugs obtained per ICH E14/S7B Q&As best practices: Impact of recording temperature and drug loss.

Alvarez Baron C, Thiebaud N, Ren M, Viatchenko-Karpinski S, Indapurkar A, King T, Matta MK, Ismaiel OA, Patel V, Mashaee M, Vicente J, Wu WW.

J Pharmacol Toxicol Methods. 2022 Jul 2:107193. doi: 10.1016/j.vascn.2022.107193. Online ahead of print.

PMID: 35792285

Adherence to Adjuvant Therapy in Patients with Resected Melanoma: An Application of the Theory of Planned Behavior.

Beisel C, Poretta T, Sheppard VB, Hurtado-de Mendoza A, Sipsma H, Fuqua E, Stwalley B, Salvatore A, Yang M.

Adv Ther. 2022 Jul 1. doi: 10.1007/s12325-022-02221-2. Online ahead of print.

PMID: 35776398

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.

Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun MH, Hsu CC, Wang L, Fitzsimons E, Salminen O, Blaney P, Czader M, Williams J, Abu Zaid MI, Ansari-Pour N, Yong KL, van Rhee F, Pierceall WE, Morgan GJ, Flynt E, Gooding S, Abonour R, Ramasamy K, Thakurta A, Walker BA.

Clin Cancer Res. 2022 Jul 1;28(13):2854-2864. doi: 10.1158/1078-0432.CCR-21-3695.

PMID: 35522533

Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.

Bahit MC, Vora AN, Li Z, Wojdyla DM, Thomas L, Goodman SG, Aronson R, Jordan JD, Kolls BJ, Dombrowski KE, Vinereanu D, Halvorsen S, Berwanger O, Windecker S, Mehran R, Granger CB, Alexander JH, Lopes RD.

JAMA Cardiol. 2022 Jul 1;7(7):682-689. doi: 10.1001/jamacardio.2022.1166. PMID: 35612866

A comparison of the lowest effective concentration in culture media for detection of chromosomal damage in vitro and in blood or plasma for detection of micronuclei in vivo.

Kirkland D, Whitwell J, Smith R, Hashimoto K, Ji Z, Kenny J, Koyama N, Lovell DP, Martus HJ, Meurer K, Roberts D, Takeiri A, Uno Y, van der Leede BJ, White P, Zeller A.

Mutat Res Genet Toxicol Environ Mutagen. 2022 Jul-Aug;879-880:503503. doi: 10.1016/j.mrgentox.2022.503503. Epub 2022 May 28.

PMID: 35914859

Why 90% of clinical drug development fails and how to improve it?

Sun D, Gao W, Hu H, Zhou S.

Acta Pharm Sin B. 2022 Jul;12(7):3049-3062. doi: 10.1016/j.apsb.2022.02.002. Epub 2022 Feb 11.

PMID: 35865092

Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.

Hatemi G, Mahr A, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y.

RMD Open. 2022 Jul;8(2):e002235. doi: 10.1136/rmdopen-2022-002235.

PMID: 35798511

Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer.

Zhu L, Zhou X, Gu M, Kim J, Li Y, Ko CJ, Xie X, Gao T, Cheng X, Sun SC.

Nat Cell Biol. 2022 Jul;24(7):1165-1176. doi: 10.1038/s41556-022-00942-8. Epub 2022 Jun 30.

PMID: 35773432

Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial.

Reaney M, Addepalli P, Allen V, Spertus JA, Dolan C, Sehnert AJ, Fine JT.

Pharmacoecon Open. 2022 Jul;6(4):575-586. doi: 10.1007/s41669-022-00340-8. Epub 2022 Jun 20.

PMID: 35718845

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.

Geynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, Huo S, Del Tejo V, Du EX, Yang X, Betts KA, Choueiri TK, McGregor B.

Clin Drug Investig. 2022 Jul;42(7):611-622. doi: 10.1007/s40261-022-01170-6. Epub 2022 Jun 13.

PMID: 35696045

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK.

Lancet Oncol. 2022 Jul;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Epub 2022 Jun 7.

PMID: 35688173

An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.

Cheng Y, Liu L, Xue Y, Zhou S, Li Y.

Eur J Drug Metab Pharmacokinet. 2022 Jul;47(4):579-592. doi: 10.1007/s13318-022-00776-7. Epub 2022 Jun 3.

PMID: 35657581

Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument.

Reaney M, Allen V, Sehnert AJ, Fang L, Hagège AA, Naidu SS, Olivotto I.

Pharmacoecon Open. 2022 Jul;6(4):563-574. doi: 10.1007/s41669-022-00335-5. Epub 2022 Jun 2.

PMID: 35653062

Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.

Ajani JA, Leung L, Singh P, Kurt M, Kim I, Pourrahmat MM, Kanters S.

Eur J Cancer. 2022 Jul;170:119-130. doi: 10.1016/j.ejca.2022.04.027. Epub 2022 May 20.

PMID: 35605522

Compatibility rules of human enhancer and promoter sequences.

Bergman DT, Jones TR, Liu V, Ray J, Jagoda E, Siraj L, Kang HY, Nasser J, Kane M, Rios A, Nguyen TH, Grossman SR, Fulco CP, Lander ES, Engreitz JM.

Nature. 2022 Jul;607(7917):176-184. doi: 10.1038/s41586-022-04877-w. Epub 2022 May 20.

PMID: 35594906

Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.

Lip GYH, Keshishian A, Kang A, Luo X, Atreja N, Zhang Y, Schuler P, Jiang J, Yuce H, Deitelzweig S.

J Thromb Thrombolysis. 2022 Jul;54(1):33-46. doi: 10.1007/s11239-022-02660-2. Epub 2022 May 17.

PMID: 35579733

Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active Doses.

Yang Z, Rajendran S, Spires V, Poirson B, Gururajan M, Lin Z, Arbanas J, Krystek S, Loy J, Cheng Y, Carl S, Pace S, Wang Y, Mehl J, Xu S, Vasudevan K, Broz M, Lehman-McKeeman L, Morin P, Graziano RF.

Drug Metab Dispos. 2022 Jul;50(7):898-908. doi: 10.1124/dmd.121.000799. Epub 2022 May 11.

PMID: 35545256

Statistical and Operational Considerations for 2-Stage Adaptive Designs with Simultaneous Evaluation of Overall and Marker-Selected Populations in Oncology Confirmatory Trials.

Zhang W, Ro S, Jiang Q, Li X, Liu R, Lu C', Marchenko O, Zhao J, Xu Z.

Ther Innov Regul Sci. 2022 Jul;56(4):552-560. doi: 10.1007/s43441-022-00407-y. Epub 2022 May 3.

PMID: 35503503

End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.

Dixon JG, Dimier N, Nielsen T, Zheng J, Marcus R, Morschhauser F, Evens AM, Federico M, Blum KA, Shi Q.

Br J Haematol. 2022 Jul;198(2):333-337. doi: 10.1111/bjh.18217. Epub 2022 May 2.

PMID: 35491747

Combination elotuzumab and lenalidomide treatment efficacy is dependent on crosstalk between NK cells, monocytes and myeloma cells.

Richardson K, Keam SP, Zhu JJ, Meyran D, D'Souza C, Macdonald S, Campbell K, Robbins M, Bezman NA, Todd K, Quach H, Ritchie DS, Harrison SJ, Prince HM, Trapani JA, Jenkins MR, Beavis PA, Darcy PK, Neeson PJ.

Haematologica. 2022 Jun 30. doi: 10.3324/haematol.2021.279930. Online ahead of print.

PMID: 35770527

Quantification of Linrodostat and its metabolites: Overcoming bioanalytical challenges in support of a discovery Indoleamine 2,3 dioxygenase program.

Discenza LN, Balog A, Huang C, Moore R, Ranasinghe A, Lin TA, D'Arienzo C, Olah TV.

J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Jun 28;1207:123305. doi: 10.1016/j.jchromb.2022.123305. Online ahead of print.

PMID: 35839627

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.

Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA.

Mult Scler. 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584. Online ahead of print.

PMID: 35765217

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany.

Ziemssen T, Richter S, Mäurer M, Buttmann M, Kreusel B, Poehler AM, Lampl M, Linker RA.

Front Neurol. 2022 Jun 27;13:913616. doi: 10.3389/fneur.2022.913616. eCollection 2022.

PMID: 35832177

Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes.

Dong G, Huang B, Verbeeck J, Cui Y, Song J, Gamalo-Siebers M, Wang D, Hoaglin DC, Seifu Y, Mütze T, Kolassa J.

Pharm Stat. 2022 Jun 27. doi: 10.1002/pst.2251. Online ahead of print.

PMID: 35757986

New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans.

Merali S, Wang Z, Frost C, Callejo M, Hedrick M, Hui L, Meadows Shropshire S, Xu K, Bouvier M, DeSouza MM, Yang J.

Platelets. 2022 Jun 26:1-10. doi: 10.1080/09537104.2022.2088719. Online ahead of print.

PMID: 35758258

Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ.

Ann Oncol. 2022 Jun 25:S0923-7534(22)01737-9. doi: 10.1016/j.annonc.2022.06.008. Online ahead of print.

PMID: 35764271

Filarial nematode phenotypic screening cascade to identify compounds with anti-parasitic activity for drug discovery optimization.

Hawryluk N, Zhiru L, Carlow C, Gokool S, Townson S, Kreiss T, Chojnowski A, Prorok M, Siekierka J, Ehrens A, Koschel M, Lhermitte-Vallarino N, Martin C, Hoerauf A, Hernandez G, Canan S, Khetani V, Zeldis J, Specht S, Hübner MP, Scandale I.

Int J Parasitol Drugs Drug Resist. 2022 Jun 23;19:89-97. doi: 10.1016/j.ijpddr.2022.06.002. Online ahead of print.

PMID: 35834918

Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.

Moore A, Bennett B, Taylor-Stokes G, McDonald L, Daumont MJ.

BMC Cancer. 2022 Jun 23;22(1):693. doi: 10.1186/s12885-022-09750-7.

PMID: 35739480

Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.

Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, Moreno V, de Braud F, de Villambrosia SG, Martin-Romano P, Baudin E, Arias M, de Alvaro J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS.

Cancer. 2022 Jun 23. doi: 10.1002/cncr.34366. Online ahead of print.

PMID: 35737639

Propensity score matching and stratification using multiparty data without pooling.

Wang J, Marion-Gallois R.

Pharm Stat. 2022 Jun 22. doi: 10.1002/pst.2250. Online ahead of print.

PMID: 35733398

Considerations for Human ADME strategy and design paradigm shift(s) - an Industry white paper.

Young GC, Spracklin DK, James AD, Hvenegaard MG, Scarfe G, Wagner DS, Georgi K, Schieferstein H, Bjornsdottir I, van Groen B, Romeo AA, Cassidy KC, Da-Violante G, Bister B, Blech S, Lyer R, Schulz SI, Cuyckens F, Moliner P.

Clin Pharmacol Ther. 2022 Jun 22. doi: 10.1002/cpt.2691. Online ahead of print.

PMID: 35733280

Systematic identification of genomic elements that regulate FCGR2A expression and harbor variants linked with autoimmune disease.

Dahlqvist J, Fulco CP, Ray JP, Liechti T, de Boer CG, Lieb DJ, Eisenhaure TM, Engreitz JM, Roederer M, Hacohen N.

Hum Mol Genet. 2022 Jun 22;31(12):1946-1961. doi: 10.1093/hmg/ddab372.

PMID: 34970970

Application of Pharmacokinetic/Pharmacodynamic Modeling to Bridge Mouse Antitumor Efficacy and Monkey Toxicology Data for Determining the Therapeutic Index of an Interleukin-10 Fc Fusion Protein.

Yang Z, Loy J, Poirson B, Dai Y, Rajendran S, Xu S, Spires V, Gururajan M, Lin Z, Arbanas J, Carl S, Pace S, Wang Y, Mehl J, Vasudevan K, Spires T, Novosiadly R, Coker S, Perez R, Covello K, Morin P, Graziano R, Broz M, Lehman-McKeeman L.

Front Pharmacol. 2022 Jun 20;13:829063. doi: 10.3389/fphar.2022.829063. eCollection 2022.

PMID: 35795558

An Evaluation of the Occupational Health Hazards of Peptide Couplers.

Graham JC, Trejo-Martin A, Chilton ML, Kostal J, Bercu J, Beutner GL, Bruen US, Dolan DG, Gomez S, Hillegass J, Nicolette J, Schmitz M.

Chem Res Toxicol. 2022 Jun 20;35(6):1011-1022. doi: 10.1021/acs.chemrestox.2c00031. Epub 2022 May 9.

PMID: 35532537

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators.

Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6.

PMID: 35717989

Oral Cryotherapy for Oral Mucositis in Patients Receiving Busulfan: A Retrospective/Prospective Descriptive Study.

Grossman A, Froggatt N, Hendricks L, Kannenberg M, Klink K, Koch N, Reid K, Pitcher D, Bullock P, Neubauer J.

Oncol Nurs Forum. 2022 Jun 17;49(4):327-335. doi: 10.1188/22.ONF.327-335.

PMID: 35788737

Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5.

Selkirk JV, Bortolato A, Yan YG, Ching N, Hargreaves R.

Front Pharmacol. 2022 Jun 17;13:892097. doi: 10.3389/fphar.2022.892097. eCollection 2022.

PMID: 35784713

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.

de Botton S, Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei AH, Ommen HB, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol FR, Chromik J, Byrne JL, Pigneux A, Thomas X, Salamero O, Vidriales MB, Doronin VA, Döhner H, Fathi AT, Laille E, Yu X, Hasan M, Martín-Regueira P, DiNardo CD.

Blood. 2022 Jun 17:blood.2021014901. doi: 10.1182/blood.2021014901. Online ahead of print.

PMID: 35714312

Confirmatory efficacy testing for individual dose-placebo comparisons using serial gatekeeping procedure in dose-finding trials with multiple comparison procedures-modeling.

Yamaguchi Y, Sugitani T, Yoshida S, Maruo K.

Pharm Stat. 2022 Jun 16. doi: 10.1002/pst.2246. Online ahead of print.

PMID: 35708144

Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.

Goring S, Varol N, Waser N, Popoff E, Lozano-Ortega G, Lee A, Yuan Y, Eccles L, Tran P, Penrod JR.

Lung Cancer. 2022 Jun 15;170:122-132. doi: 10.1016/j.lungcan.2022.06.009. Online ahead of print.

PMID: 35767923

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.

Puengel T, Lefere S, Hundertmark J, Kohlhepp M, Penners C, Van de Velde F, Lapauw B, Hoorens A, Devisscher L, Geerts A, Boehm S, Zhao Q, Krupinski J, Charles ED, Zinker B, Tacke F.

Int J Mol Sci. 2022 Jun 15;23(12):6696. doi: 10.3390/ijms23126696.

PMID: 35743140

Evaluation of patients with rheumatoid arthritis in teleconsultation during the first wave of the COVID-19 pandemic.

Avouac J, Molto A, Frantz C, Wanono S, Descamps E, Fogel O, Combier A, Poiroux L, Miceli-Richard C, Allanore Y.

J Rheumatol. 2022 Jun 15:jrheum.220073. doi: 10.3899/jrheum.220073. Online ahead of print.

PMID: 35705239

Long-term behavioral changes during the COVID-19 pandemic and impact of vaccination in patients with inflammatory rheumatic diseases.

Glintborg B, Jensen DV, Terslev L, Hendricks O, Østergaard M, Rasmussen SH, Pfeiffer Jensen M, Adelsten T, Colic A, Danebod K, Kildemand M, Loft AG, Munk HL, Pedersen JK, Østgård RD, Sørensen CM, Krogh NS, Agerbo JN, Ziegler C, Hetland ML.

J Rheumatol. 2022 Jun 15:jrheum.211280. doi: 10.3899/jrheum.211280. Online ahead of print.

PMID: 35705237

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.

Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, Awada A, Camidge DR, Hodi FS, McArthur GA, Miller WH, Cervantes A, Chow LQ, Lesokhin AM, Rutten A, Sznol M, Rishipathak D, Chen SC, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu LL.

Clin Cancer Res. 2022 Jun 14:clincanres.4020.2021. doi: 10.1158/1078-0432.CCR-21-4020. Online ahead of print.

PMID: 35699599

An overview of the BOIN design and its current extensions for novel early-phase oncology trials.

Ananthakrishnan R, Lin R, He C, Chen Y, Li D, LaValley M.

Contemp Clin Trials Commun. 2022 Jun 13;28:100943. doi: 10.1016/j.conctc.2022.100943. eCollection 2022 Aug.

PMID: 35812822

Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians.

Mocek A, Weber V, Schmölders J, Witt H, Gothe H.

Prev Med Rep. 2022 Jun 13;28:101861. doi: 10.1016/j.pmedr.2022.101861. eCollection 2022 Aug.

PMID: 35757576

Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes.

Pandey A, Achrafie L, Kodjamanova P, Tencer T, Kumar J.

Curr Med Res Opin. 2022 Jun 11:1-11. doi: 10.1080/03007995.2022.2081453. Online ahead of print.

PMID: 35608153

Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics.

Humphreys SC, Davis JA, Iqbal S, Kamel A, Kulmatycki K, Lao Y, Liu X, Rodgers J, Snoeys J, Vigil A, Weng Y, Wiethoff CM, Wittwer MB.

Nucleic Acids Res. 2022 Jun 10;50(11):6020-37. doi: 10.1093/nar/gkac456. Online ahead of print.

PMID: 35687098

Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders.

Malona J, Chuaqui C, Seletsky BM, Beebe L, Cantin S, VAN Kalken D, Fahnoe K, Wang Z, Browning B, Szabo H, Koopman LA, Oravecz T, McDonald JJ, Ramirez-Valle F, Gaur R, Mensah KA, Thomas M, Connarn JN, Hu H, Alexander MD, Corin AF.

Transl Res. 2022 Jun 9:S1931-5244(22)00138-4. doi: 10.1016/j.trsl.2022.06.005. Online ahead of print.

PMID: 35691544

A statistical perspective on baseline adjustment in pharmacogenomic genome-wide association studies of quantitative change.

Zhang H, Chhibber A, Shaw PM, Mehrotra DV, Shen J.

NPJ Genom Med. 2022 Jun 9;7(1):33. doi: 10.1038/s41525-022-00303-2.

PMID: 35680959

The Relevance of Experimental Charge Density Analysis in Unraveling Noncovalent Interactions in Molecular Crystals.

Thomas SP, Dikundwar AG, Sarkar S, Pavan MS, Pal R, Hathwar VR, Row TNG.

Molecules. 2022 Jun 8;27(12):3690. doi: 10.3390/molecules27123690.

PMID: 35744821

Propensity score-integrated approach to survival analysis: leveraging external evidence in single-arm studies.

Chen WC, Lu N, Wang C, Li H, Song C, Tiwari R, Xu Y, Yue LQ.

J Biopharm Stat. 2022 Jun 8:1-14. doi: 10.1080/10543406.2022.2080701. Online ahead of print.

PMID: 35675348

Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2.

Meanwell NA, Loiseleur O.

J Agric Food Chem. 2022 Jun 8. doi: 10.1021/acs.jafc.2c00729. Online ahead of print.

PMID: 35675052

Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 1.

Meanwell NA, Loiseleur O.

J Agric Food Chem. 2022 Jun 8. doi: 10.1021/acs.jafc.2c00726. Online ahead of print.

PMID: 35675050

Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.

Awad MM, Le Bruchec Y, Lu B, Ye J, Miller JA, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A.

Front Oncol. 2022 Jun 7;12:889996. doi: 10.3389/fonc.2022.889996. eCollection 2022.

PMID: 35747830

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.

Fox RJ, Mehta R, Pham T, Park J, Wilson K, Bonafede M.

BMC Neurol. 2022 Jun 7;22(1):211. doi: 10.1186/s12883-022-02738-7.

PMID: 35672686

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study.

Waddell T, Fife K, Griffiths R, Sharma A, Dhokia P, Groves L, Hurst M, Tsang C, Sugrue D, McKenna S, Houghton J, Carroll R.

BMC Cancer. 2022 Jun 6;22(1):617. doi: 10.1186/s12885-022-09694-y.

PMID: 35668384

Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome.

Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, Velu P, Leo P, Beig N, Li H, Toro P, Berezowska S, Baxi V, Balli D, Belete M, Rimm DL, Velcheti V, Schalper K, Madabhushi A.

NPJ Precis Oncol. 2022 Jun 3;6(1):33. doi: 10.1038/s41698-022-00277-5.

PMID: 35661148

Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.

Lai Y, Chu X, Di L, Gao W, Guo Y, Liu X, Lu C, Mao J, Shen H, Tang H, Xia CQ, Zhang L, Ding X.

Acta Pharm Sin B. 2022 Jun;12(6):2751-2777. doi: 10.1016/j.apsb.2022.03.009. Epub 2022 Mar 17.

PMID: 35755285

Calibration and validation of the rabbit model of electrolytic-mediated arterial thrombosis against the standard-of-care anticoagulant apixaban.

Wong PC, Crain E.

Pharmacol Res Perspect. 2022 Jun;10(3):e00963. doi: 10.1002/prp2.963.

PMID: 35680619

Combining SNP-to-gene linking strategies to identify disease genes and assess disease omnigenicity.

Gazal S, Weissbrod O, Hormozdiari F, Dey KK, Nasser J, Jagadeesh KA, Weiner DJ, Shi H, Fulco CP, O'Connor LJ, Pasaniuc B, Engreitz JM, Price AL.

Nat Genet. 2022 Jun;54(6):827-836. doi: 10.1038/s41588-022-01087-y. Epub 2022 Jun 6.

PMID: 35668300

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.

Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH.

Nat Med. 2022 Jun;28(6):1167-1177. doi: 10.1038/s41591-022-01829-9. Epub 2022 Jun 3.

PMID: 35662283

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.

Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators.

Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9.

PMID: 35550060

Impact of clinical pathways on treatment patterns and outcomes for patients with non-small-cell lung cancer: real-world evidence from a community oncology practice.

Dickson NR, Beauchamp KD, Perry TS, Roush A, Goldschmidt D, Edwards ML, Blakely LJ.

J Comp Eff Res. 2022 Jun;11(8):609-619. doi: 10.2217/cer-2021-0290. Epub 2022 May 12.

PMID: 35546311

Corrigendum to a cross-industry collaboration to assess if acute toxicity (Q)SAR models are fit-for-purpose for GHS classification and labelling. Regulatory toxicology and pharmacology (2021) 104843.

Bercu J, Masuda Herrera MJ, Trejo-Martin A, Hasselgren C, Lord J, Graham J, Schmitz M, Milchak L, Owens C, Lal SH, Robinson RM, Whalley S, Bellion P, Vuorinen A, Gromek K, Hawkins WA, Van de Gevel I, Vriens K, Kemper R, Naven R, Ferrer P, Myatt GJ.

Regul Toxicol Pharmacol. 2022 Jun;131:105165. doi: 10.1016/j.yrtph.2022.105165. Epub 2022 Apr 23.

PMID: 35474000

Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?

Zardavas D.

Expert Opin Investig Drugs. 2022 Jun;31(6):633-644. doi: 10.1080/13543784.2022.2070064. Epub 2022 May 2.

PMID: 35451891

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor.

Perera V, Wang Z, Lubin S, Christopher LJ, Chen W, Xu S, Seiffert D, DeSouza M, Murthy B.

Cardiol Ther. 2022 May 31. doi: 10.1007/s40119-022-00266-6. Online ahead of print.

PMID: 35641780

Dual-detection approach for a charge variant analysis of monoclonal antibody combination products using imaged capillary isoelectric focusing.

Candreva J, Esterman AL, Ge D, Patel P, Flagg SC, Das TK, Li X.

Electrophoresis. 2022 May 30. doi: 10.1002/elps.202200026. Online ahead of print.

PMID: 35634791

Fibronectin extra domain A as a drug delivery targeting epitope for rheumatoid arthritis.

Sun VZ, Melim TL, Mitra S, Erickson JE, Bryant SH, Farnham A, Westmoreland S, Knight H, Zhang L, Ritacco W, Homan K, Benatuil L, Sterman AJS, Goodearl AD.

Adv Rheumatol. 2022 May 27;62(1):17. doi: 10.1186/s42358-022-00247-2.

PMID: 35624488

Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis.

Tsutsué S, Makita S, Yi J, Crawford B.

PLoS One. 2022 May 27;17(5):e0269169. doi: 10.1371/journal.pone.0269169. eCollection 2022.

PMID: 35622820

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Makita S, Yamamoto G, Maruyama D, Asano-Mori Y, Kaji D, Ananthakrishnan R, Ogasawara K, Stepan L, Schusterbauer C, Rettby N, Hasskarl J, Izutsu K.

Cancer Med. 2022 May 26. doi: 10.1002/cam4.4820. Online ahead of print.

PMID: 35619325

Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists.

Wurtz NR, Johnson JA, Viet A, Shirude PS, Baligar V, Madduri S, Cheney DL, Park H, Lupisella JA, Hsu MY, Abousleiman M, Galella MA, Aulakh D, Dierks EA, Garcia RA, Ostrowski J, Kick EK, Wexler RR.

ACS Med Chem Lett. 2022 May 25;13(6):943-948. doi: 10.1021/acsmedchemlett.2c00079. eCollection 2022 Jun 9.

PMID: 35707160

Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?

Zheng S, Prell R, Sheng J, Wang YM, Hamuro L.

Clin Transl Sci. 2022 May 25. doi: 10.1111/cts.13345. Online ahead of print.

PMID: 35611545

The impact of phosphorylated PTEN at threonine 366 on cortical connectivity and behaviour.

Ledderose JMT, Benitez JA, Roberts AJ, Reed R, Bintig W, Larkum ME, Sachdev RNS, Furnari F, Eickholt BJ.

Brain. 2022 May 23:awac188. doi: 10.1093/brain/awac188. Online ahead of print.

PMID: 35603900

Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.

Santini V, Giagounidis A, Pelligra CG, Franco-Villalobos C, Tang D, Morison J, Beach CL, Hu A, Platzbecker U, Fenaux P.

Clin Lymphoma Myeloma Leuk. 2022 May 21:S2152-2650(22)00152-5. doi: 10.1016/j.clml.2022.05.001. Online ahead of print.

PMID: 35710702

Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications.

Teoh J, Brown LF.

Cytotherapy. 2022 May 21:S1465-3249(22)00611-9. doi: 10.1016/j.jcyt.2022.03.013. Online ahead of print.

PMID: 35610089

The influence of a solvent environment on direct non-covalent interactions between two molecules: A symmetry-adapted perturbation theory study of polarization tuning of π-π interactions by water.

Sirianni DA, Zhu X, Sitkoff DF, Cheney DL, Sherrill CD.

J Chem Phys. 2022 May 21;156(19):194306. doi: 10.1063/5.0087302.

PMID: 35597646

Optimal adaptive promising zone designs.

Mehta C, Bhingare A, Liu L, Senchaudhuri P.

Stat Med. 2022 May 20;41(11):1950-1970. doi: 10.1002/sim.9339. Epub 2022 Feb 14.

PMID: 35165917

PP2 protects from keratin mutation-associated liver injury and filament disruption via SRC kinase inhibition in male but not female mice.

Li P, Maitra D, Kuo N, Kwan R, Song Y, Tang W, Chen L, Xie Q, Liu L, Omary MB.

Hepatology. 2022 May 19. doi: 10.1002/hep.32574. Online ahead of print.

PMID: 35586977

Nivolumab in Esophageal Squamous-Cell Carcinoma. Reply.

Kato K, Lei M.

N Engl J Med. 2022 May 19;386(20):1961. doi: 10.1056/NEJMc2202880.

PMID: 35584169

ACPA-negative and ACPA-positive RA-patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation.

Verstappen M, Matthijssen XME, Connolly SE, Maldonado MA, Huizinga TWJ, van der Helm-van Mil AHM.

Rheumatology (Oxford). 2022 May 18:keac294. doi: 10.1093/rheumatology/keac294. Online ahead of print.

PMID: 35583256

Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in HematologY Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools.

Cerisoli F, Ali F, Bereczky T, Bolaños N, Bullinger L, Dhanasiri S, Gallagher J, Pérez SG, Geissler J, Guillevic Y, Harrison K, Naoum A, Portulano C, Rodríguez Vicente AE, Schulze-Rath R, Gómez GY, Sanz G, Hernández Rivas JM.

Value Health. 2022 May 17:S1098-3015(22)01931-3. doi: 10.1016/j.jval.2022.04.1729. Online ahead of print.

PMID: 35595634

2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (Part 3 - Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization).

Loo L, Harris S, Milton M, Meena, Lembke W, Berisha F, Bertholet S, Dessy F, Dodge R, Fang X, Fiscella M, Garofolo F, Gorovits B, Gupta S, Jawa V, Ishii-Watabe A, Long B, Lu Y, Mack T, McGuire K, Nolan K, Pan L, Potthoff B, Purushothama S, Smith D, Solstad T, Sonderegger I, Taddeo F, Tangri S, Wagner L, Wu B, Xu Y, Kirshner S, Verthelyi D, Yan H, Maxfield K, Pedras-Vasconcelos J, Abhari MR, Gupta S, Wu Y, Rajadhyaksha M, Andisik M, Baltrukonis D, Cherry E, Cludts I, Gunn G, Millner AH, Jordan G, Kar S, Kubiak R, Lotz GP, Palmer R, Peng K, Poetzl J, Richards S, Savoie N, Staack RF, Stubenrauch K, Wadhwa M, Waxenecker G, Yang TY, Zhang L.

Bioanalysis. 2022 May 17. doi: 10.4155/bio-2022-0081. Online ahead of print.

PMID: 35578991

Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data.

Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C.

Am J Cardiovasc Drugs. 2022 May 16. doi: 10.1007/s40256-022-00524-x. Online ahead of print.

PMID: 35570249

Impact of Axial Spondyloarthritis on Quality of Life: Results From the European Map of Axial Spondyloarthritis (EMAS) Study in France.

Kedra J, Claudepierre P, Flipo RM, Garrido-Cumbrera M, Alliot-Launois F, Desfleurs E, Grange L, Gossec L.

J Rheumatol. 2022 May 15:jrheum.210864. doi: 10.3899/jrheum.210864. Online ahead of print.

PMID: 35569828

Establishment of baseline profiles of 50 bile acids in preclinical toxicity species: A comprehensive assessment of translational differences and study design considerations for biomarker development.

Sangaraju D, Katavolos P, Liang X, Chou C, Zabka TS, Dean B, Maher J.

Toxicol Appl Pharmacol. 2022 May 15;443:116008. doi: 10.1016/j.taap.2022.116008. Epub 2022 Apr 1.

PMID: 35378153

Label-free plasma proteomics for the identification of the putative biomarkers of oral squamous cell carcinoma.

Gautam SS, Singh RP, Karsauliya K, Sonker AK, Reddy PJ, Mehrotra D, Gupta S, Singh S, Kumar R, Singh SP.

J Proteomics. 2022 May 15;259:104541. doi: 10.1016/j.jprot.2022.104541. Epub 2022 Feb 26.

PMID: 35231661

Synthesis of a dual carbon-14-labeled calcitonin gene-related peptide receptor antagonist for use in a human absorption-distribution-metabolism-elimination study.

Turley WA, Easter JA, Burrell RC, Bonacorsi SJ Jr.

J Labelled Comp Radiopharm. 2022 May 15;65(5):126-139. doi: 10.1002/jlcr.3966. Epub 2022 Mar 10.

PMID: 35199393

A novel high-throughput screening strategy for targeting alpha-synuclein and other long-lived proteins.

Casalino E, Stine LB, Corin AJ, Thai CT, Quiroz J, Wilson SC, Labow M, Mittal S.

SLAS Discov. 2022 May 14:S2472-5552(22)13673-7. doi: 10.1016/j.slasd.2022.05.001. Online ahead of print.

PMID: 35580766

Transporters in Drug Development: International Transporter Consortium Update on Emerging Transporters of Clinical Importance.

Zamek-Gliszczynski MJ, Sangha V, Shen H, Feng B, Wittwer MB, Varma MVS, Liang X, Sugiyama Y, Zhang L, Bendayan R; International Transporter Consortium.

Clin Pharmacol Ther. 2022 May 13. doi: 10.1002/cpt.2644. Online ahead of print.

PMID: 35561119

When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.

Lotz GP, Benstein K, Bloem K, Buddiger H, Calonder C, Elm S, Fernandez E, Goodman J, Gorovits B, Grudzinska-Goebel J, Janssen M, Jawa V, Kramer D, Luo L, Malisauskas M, Michaut L, Schäfer M, Spindeldreher S, Ullmann M, Nana Weldingh K, Kromminga A, Snoeck V.

AAPS J. 2022 May 12;24(3):68. doi: 10.1208/s12248-022-00712-2.

PMID: 35554731

National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey.

McBride A, Hudson-DiSalle S, Pilz J, Hamm M, Boring B, Buie LW, DeRemer DL.

JCO Oncol Pract. 2022 May 11:OP2100883. doi: 10.1200/OP.21.00883. Online ahead of print.

PMID: 35544740

X-linked genes exhibit miR6891-5p-regulated skewing in Sjögren's syndrome.

Shaw TM, Zhang W, McCoy SS, Pagenkopf A, Carp DM, Garg S, Parker MH, Qiu X, Scofield RH, Galipeau J, Liang Y.

J Mol Med (Berl). 2022 May 10. doi: 10.1007/s00109-022-02205-3. Online ahead of print.

PMID: 35538149

Antibody charge variant modulation by in vitro enzymatic treatment in different Chinese hamster ovary cell cultures.

Xu J, Santos J, Anderson NS, Borys MC, Pendse G, Li ZJ.

Biotechnol Prog. 2022 May 10:e3268. doi: 10.1002/btpr.3268. Online ahead of print.

PMID: 35536540

Circumventing glass vial and diluent effects on solution stability of small molecule analytes during analytical method development and validation.

Huang Y, Hu Y, Yuill EM, Marriott AS, Chadwick J, Li J, Zang J, Miller SA.

J Pharm Biomed Anal. 2022 May 10;213:114676. doi: 10.1016/j.jpba.2022.114676. Epub 2022 Feb 24.

PMID: 35240407

Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor.

Parcella K, Wang T, Eastman K, Zhang Z, Yin Z, Patel M, Tu Y, Zheng BZ, Walker MA, Saulnier MG, Frennesson D, Bowsher M, Gillis E, Peese K, Belema M, Cianci C, Dicker IB, McAuliffe B, Ding B, Falk P, Simmermacher J, Parker DD, Sivaprakasam P, Kish K, Lewis H, Hanumegowda U, Jenkins S, Kadow JF, Krystal M, Meanwell NA, Naidu BN.

ACS Med Chem Lett. 2022 May 9;13(6):972-980. doi: 10.1021/acsmedchemlett.2c00115. eCollection 2022 Jun 9.

PMID: 35707159

Biomarker Assay Validation by Mass Spectrometry.

Fernández-Metzler C, Ackermann B, Garofolo F, Arnold ME, DeSilva B, Gu H, Laterza O, Mao Y, Rose M, Vazvaei-Smith F, Steenwyk R.

AAPS J. 2022 May 9;24(3):66. doi: 10.1208/s12248-022-00707-z.

PMID: 35534647

Development of a LAG-3 immunohistochemistry assay for melanoma.

Johnson L, McCune B, Locke D, Hedvat C, Wojcik JB, Schroyer C, Yan J, Johnson K, Sanders-Cliette A, Samala S, Dillon LM, Anderson S, Shuster J.

J Clin Pathol. 2022 May 9:jclinpath-2022-208254. doi: 10.1136/jclinpath-2022-208254. Online ahead of print.

PMID: 35534200

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.

Homicsko K, Dummer R, Hoeller C, Wolchok JD, Hodi FS, Larkin J, Ascierto PA, Atkinson V, Robert C, Postow MA, Re S, Paulucci D, Dobler D, Michielin O.

Cancers (Basel). 2022 May 5;14(9):2300. doi: 10.3390/cancers14092300.

PMID: 35565428

Is Incurred Sample Reanalysis (ISR) Applicable in Biomarker Assays?

Hays A, Amaravadi L, Fernandez-Metzler C, King L, Mathews J, Ni Y, Quadrini K, Tinder C, Vazvaei F, Zeng J.

AAPS J. 2022 May 5;24(3):65. doi: 10.1208/s12248-022-00708-y.

PMID: 35511303

Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.

Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A.

Neuro Oncol. 2022 May 2:noac116. doi: 10.1093/neuonc/noac116. Online ahead of print.

PMID: 35511454

CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma.

Wang J, Saung MT, Li K, Fu J, Fujiwara K, Niu N, Muth S, Wang J, Xu Y, Rozich N, Zlomke H, Chen S, Espinoza B, Henderson M, Funes V, Herbst B, Ding D, Twyman-Saint Victor C, Zhao Q, Narang A, He J, Zheng L.

J Exp Med. 2022 May 2;219(5):e20211631. doi: 10.1084/jem.20211631. Epub 2022 Apr 11.

PMID: 35404390

Tim-3 mediates T cell trogocytosis to limit antitumor immunity.

Pagliano O, Morrison RM, Chauvin JM, Banerjee H, Davar D, Ding Q, Tanegashima T, Gao W, Chakka SR, DeBlasio R, Lowin A, Kara K, Ka M, Zidi B, Amin R, Raphael I, Zhang S, Watkins SC, Sander C, Kirkwood JM, Bosenberg M, Anderson AC, Kuchroo VK, Kane LP, Korman AJ, Rajpal A, West SM, Han M, Bee C, Deng X, Schebye XM, Strop P, Zarour HM.

J Clin Invest. 2022 May 2;132(9):e152864. doi: 10.1172/JCI152864.

PMID: 35316223

Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety.

Gao W, Hu H, Dai L, He M, Yuan H, Zhang H, Liao J, Wen B, Li Y, Palmisano M, Traore MDM, Zhou S, Sun D.

Acta Pharm Sin B. 2022 May;12(5):2462-2478. doi: 10.1016/j.apsb.2022.02.015. Epub 2022 Feb 23.

PMID: 35646532

2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A - Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine).

Kaur S, Alley SC, Szapacs M, Wilson A, Ciccimaro E, Su D, Henderson N, Chen L, Garofolo F, Hengel S, Jian W, Kellie JF, Lee A, Mehl J, Palandra J, Qiu H, Savoie N, Shakleya D, Staelens L, Sugimoto H, Sumner G, Welink J, Wheller R, Xue YJ, Zeng J, Zhang J, Zhou H, Wang J, Summerfield S, Kavetska O, Dillen L, Ramanathan R, Baratta M, Dasgupta A, Edmison A, Ferrari L, Fischer S, Fraier D, Haidar S, Heermeier K, James C, Ji A, Luo L, Lima Santos GM, Post N, Rosenbaum AI, Sporring S, Surapaneni S, Vinter S, Wan K, Woolf E, Kavetska O, Cho SJ, Kossary E, Prior S, Abhari MR, Soo C, Wang YM, Bandukwala A, Cherry E, Cludts I, Ghosh S, Hopper S, Ishii-Watabe A, Kirshner S, Maher K, Maxfield K, Pedras-Vasconcelos J, Saito Y, Smith D, Solstad T, Verthelyi D, Wadhwa M, Wagner L, Waxenecker G, Yan H, Zhang L.

Bioanalysis. 2022 May;14(9):505-580. doi: 10.4155/bio-2022-0078. Epub 2022 May 17.

PMID: 35578993

2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry (Part 2 - Recommendations on Biomarkers/CDx Assays Development & Validation, Cytometry Validation & Innovation, Biotherapeutics PK LBA Regulated Bioanalysis, Critical Reagents & Positive Controls Generation).

Hersey S, Keller S, Mathews J, King L, Bandukwala A, Berisha F, Birchler M, Bower J, Clausen V, Duarte J, Garofolo F, Hopper S, Kar S, Mabrouk O, Marshall JC, McGuire K, Naughton M, Saito Y, Schuhmann I, Sperinde G, Teixeira P, Vitaliti A, Wang YM, Wnek R, Zhang Y, Spitz S, Decman V, Eck S, Estevam J, Goihberg P, Alcaide EG, Gonneau C, Hedrick MN, Hopkins G, Junker F, Nuti S, Sommer U, Standifer N, Stevens C, Stevens E, Hendricks C, Wadhwa M, Torri A, Ma M, Harris S, Kumar S, Partridge MA, Caiazzo T, Chilewski S, Cludts I, Coble K, Gorovits B, Grimaldi C, Jordan G, Kamerud J, Leary B, Liang M, Lim H, Mayer A, O'Connor E, Palackal N, Poetzl J, Prior S, Abhari MR, Savoie N, Soo C, Ware M, Wu B, Xu Y, Yang TY, Zoghbi J.

Bioanalysis. 2022 May;14(10):627-692. doi: 10.4155/bio-2022-0080. Epub 2022 May 17.

PMID: 35578974

The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review.

Mansfield AS, Brown RJ, Sammon C, Daumont MJ, McKenna M, Sanzari JK, Forde PM.\

TO Clin Res Rep. 2022 Mar 22;3(5):100315. doi: 10.1016/j.jtocrr.2022.100315. eCollection 2022 May.

PMID: 35516726

Landscape of helper and regulatory antitumour CD4+ T cells in melanoma.

Oliveira G, Stromhaug K, Cieri N, Iorgulescu JB, Klaeger S, Wolff JO, Rachimi S, Chea V, Krause K, Freeman SS, Zhang W, Li S, Braun DA, Neuberg D, Carr SA, Livak KJ, Frederick DT, Fritsch EF, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon CH, Keskin DB, Ott PA, Rodig SJ, Boland GM, Wu CJ.

Nature. 2022 May;605(7910):532-538. doi: 10.1038/s41586-022-04682-5. Epub 2022 May 4.

PMID: 35508657

Private Spaceflight: A New Landscape for Dealing with Medical Risk.

Griko YV, Loftus DJ, Stolc V, Peletskaya E.

Life Sci Space Res (Amst). 2022 May;33:41-47. doi: 10.1016/j.lssr.2022.03.001. Epub 2022 Mar 23.

PMID: 35491028

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.

Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas P.

Lung Cancer. 2022 May;167:8-16. doi: 10.1016/j.lungcan.2022.03.012. Epub 2022 Mar 21.

PMID: 35367910

A global perspective in second-line treatment patterns for patients with advanced esophageal squamous cell carcinoma.

Jaffe DH, Gricar J, DeCongelio M, Mackie DS.

Thorac Cancer. 2022 May;13(9):1240-1257. doi: 10.1111/1759-7714.14334. Epub 2022 Mar 30.

PMID: 35355433

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A.

Leukemia. 2022 May;36(5):1432-1435. doi: 10.1038/s41375-022-01521-4. Epub 2022 Feb 26.

PMID: 35220402

Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma.

Howell TA, Matza LS, Jun MP, Garcia J, Powers A, Maloney DG.

Pharmacoecon Open. 2022 May;6(3):367-376. doi: 10.1007/s41669-021-00316-0. Epub 2022 Feb 7.

PMID: 35129829

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.

Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G.

Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3.

PMID: 35124183

Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).

Sreekantha RK, Mussari CP, Dodd DS, Pasunoori L, Hegde S, Posy SL, Critton D, Ruepp S, Subramanian M, Salter-Cid LM, Tagore DM, Sarodaya S, Dudhgaonkar S, Poss MA, Schieven GL, Carter PH, Macor JE, Dyckman AJ.

ACS Med Chem Lett. 2022 Apr 25;13(5):812-818. doi: 10.1021/acsmedchemlett.2c00049. eCollection 2022 May 12.

PMID: 35586440

A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies.

Serelli-Lee V, Ito K, Koibuchi A, Tanigawa T, Ueno T, Matsushima N, Imai Y.

J Pers Med. 2022 Apr 21;12(5):669. doi: 10.3390/jpm12050669.

PMID: 35629092

Development of an enhanced formulation to minimize pharmacokinetic variabilities of a weakly basic drug compound.

Pu YE, Menger R, Tong Z, Gaebele T.

Pharm Dev Technol. 2022 Apr;27(4):406-413. doi: 10.1080/10837450.2022.2070206. Epub 2022 May 11.

PMID: 35502986

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.

Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL.

Oncologist. 2022 Mar 4;27(2):e194-e198. doi: 10.1093/oncolo/oyab036.

PMID: 35641218

Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.

Nastoupil LJ, Kuruvilla J, Chavez JC, Bijou F, Witzig TE, Santoro A, Flinn IW, Boccomini C, Kenkre VP, Corradini P, Isufi I, Andorsky DJ, Klein LM, Greenwald DR, Sangha R, Shen F, Hagner P, Li Y, Dobmeyer J, Gong N, Uttamsingh S, Pourdehnad M, Ribrag V.

EJHaem. 2022 Feb 14;3(2):394-405. doi: 10.1002/jha2.394. eCollection 2022 May.

PMID: 35846031

Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, Gandhi AK, Shen F, Michelliza S, Haeske H, Hege K, Pourdehnad M, Kuruvilla J.

EJHaem. 2022 Jan 14;3(1):139-153. doi: 10.1002/jha2.375. eCollection 2022 Feb.

PMID: 35846221

Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England.

Hill NR, Groves L, Dickerson C, Boyce R, Lawton S, Hurst M, Pollock KG, Sugrue DM, Lister S, Arden C, Davies DW, Martin AC, Sandler B, Gordon J, Farooqui U, Clifton D, Mallen C, Rogers J, Camm AJ, Cohen AT.

J Med Econ. 2022 Jan-Dec;25(1):974-983. doi: 10.1080/13696998.2022.2102355.

PMID: 35834373

The impact of remission duration on the long-term economic burden of acute myeloid leukemia among patients without hematopoietic stem cell transplant in the United States.

Tabah A, Brady BL, Huggar D, Jariwala-Parikh K, Huey K, Copher R, LeBlanc TW.

J Med Econ. 2022 Jan-Dec;25(1):903-911. doi: 10.1080/13696998.2022.2091879.

PMID: 35723576

Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.

Berling M, Chaudhary MA, Yuan Y, Varol N, Dale P, Testa E, Klint J, Lee A, Lubinga SJ, Penrod JR.

J Med Econ. 2022 Jan-Dec;25(1):703-711. doi: 10.1080/13696998.2022.2077549.

PMID: 35659172

Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.

Polyzoi M, Sandhu H, Maervoet J, Yuan Y, Chaudhary MA, Varol N, Lee A, Dale P, Jones C, Lubinga SJ, Penrod JR.

J Med Econ. 2022 Jan-Dec;25(1):660-668. doi: 10.1080/13696998.2022.2048573.

PMID: 35658806

Response to "Critical Analysis of Apixaban Dose Adjustment Criteria".

Mandt SR, Gaitonde P, Ajavon-Hartmann A, Klem C, Chan A, Bastien A.

Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221078841. doi: 10.1177/10760296221078841.

PMID: 35603638

Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France.

Grumberg V, Chouaïd C, Cotté FE, Jouaneton B, Jolivel R, Gaudin AF, Reynaud D, Assié JB, Borget I.

J Med Econ. 2022 Jan-Dec;25(1):691-699. doi: 10.1080/13696998.2022.2079291.

PMID: 35587018

Optimization of Recombinant GPCR Proteins for Biophysical and Structural Studies Using Virus-like Particles.

Aertgeerts K, Ho TT, Yan YG.

Methods Mol Biol. 2022;2507:327-336. doi: 10.1007/978-1-0716-2368-8_17.

PMID: 35773590

Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study.

Deitelzweig S, Luo X, Nguyen JL, Malhotra D, Emir B, Russ C, Li X, Lee TC, Ferri M, Wiederkehr D, Reimbaeva M, Barnes GD, Piazza G.

J Thromb Thrombolysis. 2022 Apr 30:1-11. doi: 10.1007/s11239-022-02644-2. Online ahead of print.

PMID: 35489004

Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.

Shah N, Mojebi A, Ayers D, Cope S, Dhanasiri S, Davies FE, Hari P, Patel P, Hege K, Dhanda D.

J Comp Eff Res. 2022 Apr 29. doi: 10.2217/cer-2022-0045. Online ahead of print.

PMID: 35485211

A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.

Boetzel R, Schlingemann J, Hickert S, Korn C, Kocks G, Luck B, Blom G, Harrison M, François M, Allain L, Wu Y, Bousraf Y.

J Pharm Sci. 2022 Apr 29:S0022-3549(22)00168-X. doi: 10.1016/j.xphs.2022.04.016. Online ahead of print.

PMID: 35500671

Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels.

Yu L, Lopez G, Rassa J, Wang Y, Basavanhally T, Browne A, Huang CP, Dorsey L, Jen J, Hersey S.

PLoS One. 2022 Apr 28;17(4):e0266889. doi: 10.1371/journal.pone.0266889. eCollection 2022.

PMID: 35482763

Biological impact of iberdomide in patients with active systemic lupus erythematosus.

Lipsky PE, Vollenhoven RV, Dörner T, Werth VP, Merrill JT, Furie R, Petronijevic M, Velasco Zamora B, Majdan M, Irazoque-Palazuelos F, Terbrueggen R, Delev N, Weiswasser M, Korish S, Stern M, Hersey S, Ye Y, Gaudy A, Liu Z, Gagnon R, Tang S, Schafer PH.

Ann Rheum Dis. 2022 Apr 27:annrheumdis-2022-222212. doi: 10.1136/annrheumdis-2022-222212. Online ahead of print.

PMID: 35477518

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Zhang J, Sy O, Mesa RA.

Br J Haematol. 2022 Apr 27. doi: 10.1111/bjh.18207. Online ahead of print.

PMID: 35476316

Assessment of Resonant Acoustic Mixing for Low-Dose Pharmaceutical Powder Blends.

Gupta S, Pu YE, Li M, Li Z, Osorio JG.

AAPS PharmSciTech. 2022 Apr 26;23(5):126. doi: 10.1208/s12249-022-02262-4.

PMID: 35474151

ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor.

Singer DE, Atlas SJ, Go AS, Lopes RD, Lubitz SA, McManus DD, Revkin JH, Mills D, Crosson LA, Lenane JC, Aronson RS.

Am Heart J. 2022 Apr 23:S0002-8703(22)00080-1. doi: 10.1016/j.ahj.2022.04.005. Online ahead of print.

PMID: 35472303

5-HT2A receptor dysregulation in a schizophrenia relevant mouse model of NMDA receptor hypofunction.

Nakao K, Singh M, Sapkota K, Fitzgerald A, Hablitz JJ, Nakazawa K.

Transl Psychiatry. 2022 Apr 22;12(1):168. doi: 10.1038/s41398-022-01930-0.

PMID: 35459266

Next generation automated traceless cell chromatography platform for GMP-compliant cell isolation and activation.

Radisch S, Poltorak MP, Wagner M, Cletiu V, Radisch C, Treise I, Pann S, Weigt A, Artner S, Dreher S, Fechner F, Borjan B, Fraessle SP, Effenberger M, Benke E, Navratil G, Hentschel N, Busch DH, Schmidt T, Stemberger C, Germeroth L.

Sci Rep. 2022 Apr 21;12(1):6572. doi: 10.1038/s41598-022-10320-x.

PMID: 35449227

Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.

Yamazoe S, Kotapati S, Hogan JM, West SM, Deng XA, Diong SJ, Arbanas J, Nguyen TA, Jashnani A, Gupta D, Rajpal A, Dollinger G, Strop P.

Bioconjug Chem. 2022 Apr 20;33(4):576-585. doi: 10.1021/acs.bioconjchem.1c00572. Epub 2022 Mar 28.

PMID: 35344340

Building consensus on author selection practices for industry-sponsored research: recommendations from an expert task force of medical publication professionals.

Carfagno ML, Schweers SA, Whann EA, Hodgson MB, Mittleman KD, Nastasee SA, Sorgenfrei T, Kodukulla MI; International Society for Medical Publication Professionals Authorship Task Force.

Curr Med Res Opin. 2022 Apr 19:1-8. doi: 10.1080/03007995.2022.2050111. Online ahead of print.

PMID: 35437066

The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review.

Edelberg JM, Sehnert AJ, Mealiffe ME, Del Rio CL, McDowell R.

Am J Cardiovasc Drugs. 2022 Apr 18. doi: 10.1007/s40256-022-00532-x. Online ahead of print.

PMID: 35435607

Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.

Torres AZ, Nussbaum NC, Parrinello CM, Bourla AB, Bowser BE, Wagner S, Tabano DC, George D, Miksad RA.

Adv Ther. 2022 Apr 17. doi: 10.1007/s12325-022-02091-8. Online ahead of print.

PMID: 35430670

Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.

Matsue K, Sunami K, Matsumoto M, Kuroda J, Sugiura I, Iwasaki H, Chung W, Kuwayama S, Nishio M, Lee K, Iida S.

Int J Hematol. 2022 Apr 16. doi: 10.1007/s12185-022-03338-4. Online ahead of print.

PMID: 35429329

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-Cloning.

He Q, Rehmann MS, Tian J, Xu J, Sabino L, Vandermark E, Basson Z, Po I, Bierilo K, Tremml G, Rizzi G, Langsdorf EF, Qian NX, Borys MC, Khetan A, Li ZJ.

Bioengineering (Basel). 2022 Apr 15;9(4):173. doi: 10.3390/bioengineering9040173.

PMID: 35447733

Secukinumab in US Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.

Nguyen T, Churchill M, Levin R, Valenzuela G, Merola JF, Ogdie A, Orbai AM, Scher JU, Kavanaugh A, Kianifard F, Rollins C, Calheiros R, Chambenoit O.

J Rheumatol. 2022 Apr 15:jrheum.210912. doi: 10.3899/jrheum.210912. Online ahead of print.

PMID: 35428722

Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase 3 Results in DMARD-Naive Patients With Psoriatic Arthritis.

Mease PJ, Kavanaugh A, Ogdie A, Wells AF, Bergman M, Gladman DD, Richter S, Teng L, Jardon S, Smolen JS.

J Rheumatol. 2022 Apr 15:jrheum.210906. doi: 10.3899/jrheum.210906. Online ahead of print.

PMID: 35428720

Potential Impact of Sex and Body Mass Index on Response to Therapy in Psoriatic Arthritis: Post-hoc Analysis of Results From the SEAM-PsA Trial.

Mease PJ, Gladman DD, Merola JF, Deodhar A, Ogdie A, Collier DH, Liu L, Kavanaugh A.

J Rheumatol. 2022 Apr 15:jrheum.211037. doi: 10.3899/jrheum.211037. Online ahead of print.

PMID: 35428718

Effectiveness of 6-Month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Blachley T, Dube B, McLean RR, Kim N, Hur P, Ogdie A.

J Rheumatol. 2022 Apr 15:jrheum.211033. doi: 10.3899/jrheum.211033. Online ahead of print.

PMID: 35428716

Challenges in the Diagnosis and Assessment of Psoriatic Arthritis.

Ogdie A, Lindsay CA, Mease PJ, Callis Duffin K, Rosen CF, Siebert S.

J Rheumatol. 2022 Apr 15:jrheum.211337. doi: 10.3899/jrheum.211337. Online ahead of print.

PMID: 35428713

2021 GRAPPA Meet the Experts Session: A Summary of Presentations.

Armstrong AW, Reddy RM, FitzGerald O, Callis Duffin K, Helliwell PS, Mease PJ, Kavanaugh A, Merola JF, Tillet W, de Wit M.

J Rheumatol. 2022 Apr 15:jrheum.211326. doi: 10.3899/jrheum.211326. Online ahead of print.

PMID: 35428707

Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies.

Zhang H, Chiang AY, Wang J.

Stat Med. 2022 Apr 15. doi: 10.1002/sim.9402. Online ahead of print.

PMID: 35428037

Thrombotic and Cardiovascular Events and Treatment Patterns Among Patients Hospitalized with COVID-19 in Japan: An Analysis of a Nationwide Medical Claims Database.

Terasaka N, Matsuo Y, Kataoka H, Miyata Y, Anazawa Y.

Cardiol Ther. 2022 Apr 15:1-12. doi: 10.1007/s40119-022-00263-9. Online ahead of print.

PMID: 35426621

Evaluation of chiral normal-phase liquid chromatography as a secondary tier in pharmaceutical chiral screening strategy.

Tai HC, Lin Z, Fabiano A, Zhou Y, Saurer EM, Ye YK, He BL.

J Chromatogr A. 2022 Apr 14;1672:463053. doi: 10.1016/j.chroma.2022.463053.

PMID: 35460990

Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.

Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M.

Neuro Oncol. 2022 Apr 14:noac099. doi: 10.1093/neuonc/noac099. Online ahead of print.

PMID: 35419607

Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study.

Durez P, Westhovens R, Baeke F, Elbez Y, Robert S, Ahmad HA.

BMC Rheumatol. 2022 Apr 14;6(1):24. doi: 10.1186/s41927-022-00252-4.

PMID: 35418172

Report of the First International Symposium on NUT Carcinoma.

French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI.

Clin Cancer Res. 2022 Apr 13:clincanres.0591.2022. doi: 10.1158/1078-0432.CCR-22-0591. Online ahead of print.

PMID: 35417004

2-Pyridine Carboxaldehyde for Semi-Automated Soft Spot Identification in Cyclic Peptides.

Zhang H, Chacko S, Cannon JR.

Int J Mol Sci. 2022 Apr 12;23(8):4269. doi: 10.3390/ijms23084269.

PMID: 35457087

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N Engl J Med. 2022 Apr 11. doi: 10.1056/NEJMoa2202170. Online ahead of print.

PMID: 35403841

A vision for integrated publicly available information on regulated medical products.

Roberts K, Thakkar R, Aljuburi L, Boyce D, Curtis S, Dudinak J, Fitton H, Garner C, Garvin M, Longman S, Reilly E, Maitland J, Reisin Miller A, Pasté M, Rohrer M, Taisey M, Van Baelen K, Wegner M.

Clin Transl Sci. 2022 Apr 9. doi: 10.1111/cts.13275. Online ahead of print.

PMID: 35397194

Influence of Concomitant Methotrexate use on the Clinical Effectiveness, Retention, and Safety of Abatacept in Biologic-Naïve Patients with Rheumatoid Arthritis: Post-hoc Subgroup Analysis of ORIGAMI Study.

Azuma T, Misaki K, Kusaoi M, Suzuki Y, Higa S, Kumon Y, Yoshitama T, Naniwa T, Yamada S, Okano T, Takeuchi K, Ikeda K, Higami K, Inoo M, Sawada T, Kang C, Hayashi M, Nagaya Y, Hagiwara T, Shono E, Himeno S, Tanaka E, Inoue E, Yoshizawa Y, Kadode M, Yamanaka H, Harigai M.

Mod Rheumatol. 2022 Apr 7:roac032. doi: 10.1093/mr/roac032. Online ahead of print.

PMID: 35389481

Advances in mass spectrometry-based epitope mapping of protein therapeutics.

Liu XR, Huang RY, Zhao F, Chen G, Tao L.

J Pharm Biomed Anal. 2022 Apr 6;215:114754. doi: 10.1016/j.jpba.2022.114754. Online ahead of print.

PMID: 35427962

Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.

Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Powles T, Donskov F, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, McHenry MB, Lee CW, McCarthy J, Ejzykowicz F, Tannir NM.

Cancer. 2022 Apr 5. doi: 10.1002/cncr.34180. Online ahead of print.

PMID: 35383908

Ni-Electrocatalytic C(sp³)-C(sp³) Doubly Decarboxylative Coupling.

Zhang B, Gao Y, Hioki Y, Oderinde MS, Qiao JX, Rodriguez KX, Zhang HJ, Kawamata Y, Baran PS. Nature. 2022 Apr 5. doi: 10.1038/s41586-022-04691-4. Online ahead of print.

PMID: 35381598

The benefits, limitations and opportunities of preclinical models for neonatal drug development.

Campion S, Inselman A, Hayes B, Casiraghi C, Joseph D, Facchinetti F, Salomone F, Schmitt G, Hui J, Davis-Bruno K, Van Malderen K, Morford L, De Schaepdrijver L, Wiesner L, Kourula S, Seo S, Laffan S, Urmaliya V, Chen C.

Dis Model Mech. 2022 Apr 1;15(4):dmm049065. doi: 10.1242/dmm.049065. Epub 2022 Apr 25.

PMID: 35466995

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.

Kang YK, Reck M, Nghiem P, Feng Y, Plautz G, Kim HR, Owonikoko TK, Boku N, Chen LT, Lei M, Chang H, Lin WH, Roy A, Bello A, Sheng J.

J Immunother Cancer. 2022 Apr;10(4):e004273. doi: 10.1136/jitc-2021-004273.

PMID: 35383114

Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects.

Waddington JC, Coleman O, Mease PJ, Chandran V, O'Sullivan D, FitzGerald O, Pennington SR.

J Rheumatol. 2022 Apr 1:jrheum.211320. doi: 10.3899/jrheum.211320. Online ahead of print.

PMID: 35365582

Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.

Stober C, McInnes IB, Raychaudhuri S, Mease PJ, Pennington SR, Scher JU, Chandran V, Armstrong AW, de Wit M, Cauli A, Jadon DR, Löve TJ, Ogdie A, O'Sullivan D, van Mens LJJ, Ritchlin CT, FitzGerald O.

J Rheumatol. 2022 Apr 1:jrheum.211336. doi: 10.3899/jrheum.211336. Online ahead of print.

PMID: 35365578

Hallmarks of Resistance to Immune-Checkpoint Inhibitors.

Karasarides M, Cogdill AP, Robbins PB, Bowden M, Burton EM, Butterfield LH, Cesano A, Hammer C, Haymaker CL, Horak CE, McGee HM, Monette A, Rudqvist NP, Spencer CN, Sweis RF, Vincent BG, Wennerberg E, Yuan J, Zappasodi R, Lucey VMH, Wells DK, LaVallee T.

Cancer Immunol Res. 2022 Apr 1;10(4):372-383. doi: 10.1158/2326-6066.CIR-20-0586.

PMID: 35362046

Meningococcal Vaccination Rates Among People With a New Diagnosis of HIV Infection in the US.

Ghaswalla PK, Marshall GS, Bengtson LGS, Buikema AR, Bancroft T, Koep E, Novy P, Hogea CS.

JAMA Netw Open. 2022 Apr 1;5(4):e228573. doi: 10.1001/jamanetworkopen.2022.8573.

PMID: 35486405

Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.

Juarez-Garcia A, Sharma R, Hunger M, Kayaniyil S, Penrod JR, Chouaïd C.

Lung Cancer. 2022 Apr;166:205-220. doi: 10.1016/j.lungcan.2022.03.008. Epub 2022 Mar 9.

PMID: 35316754

RP-HPLC separation of interconvertible rotamers of a 5-tetrahydroisoquinolin-6-yl-pyridin-3-yl acetic acid derivative and confirmation by VT NMR and DFT study.

Chauthe SK, Sidduri P, Reddy M, Sistla R, Byri V, Uttaravalli MD, Botlagunta M, Kumar H, Gupta A, Gupta AK, Bajpai L, Bagadi M, Mathur A.

J Pharm Biomed Anal. 2022 Apr 1;212:114675. doi: 10.1016/j.jpba.2022.114675. Epub 2022 Feb 17.

PMID: 35192992

Synthesis of carbon-14 and stable isotope labeled Censavudine.

Burrell RC, Bonacorsi SJ Jr, Ortiz A, Benkovics T, Shi Z.

J Labelled Comp Radiopharm. 2022 Apr;65(4):112-122. doi: 10.1002/jlcr.3964. Epub 2022 Feb 10.

PMID: 35106813

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.

Moore K, Thakkar N, Magee M, Sevinsky H, Vakkalagadda B, Lubin S, Llamoso C, Ackerman P. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0225121. doi: 10.1128/aac.02251-21. Epub 2022 Mar 22.

PMID: 35315687

Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.

Passamonti F, Heidel FH, Parikh RC, Ajmera M, Tang D, Nadal JA, Davis KL, Abraham P.

Future Oncol. 2022 Apr 7. doi: 10.2217/fon-2021-1358. Online ahead of print.

PMID: 35388710

Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors.

Ellingson BM, Gerstner ER, Lassman AB, Chung C, Colman H, Cole PE, Leung D, Allen JE, Ahluwalia MS, Boxerman J, Brown M, Goldin J, Nduom E, Hassan I, Gilbert MR, Mellinghoff IK, Weller M, Chang S, Arons D, Meehan C, Selig W, Tanner K, Yung WKA, van den Bent M, Wen PY, Cloughesy TF.

Neuro Oncol. 2022 Apr 5:noac086. doi: 10.1093/neuonc/noac086. Online ahead of print.

PMID: 35380705

The Association of Illness-Related Uncertainty with Mental Health in Systemic Autoimmune Rheumatic Diseases.

Wallace ZS, Cook C, Finkelstein-Fox L, Fu X, Castelino FV, Choi HK, Perugino C, Stone JH, Park ER, Hall DL.

J Rheumatol. 2022 Apr 1:jrheum.211084. doi: 10.3899/jrheum.211084. Online ahead of print.

PMID: 35365580

Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.

Deitelzweig S, Bergrath E, di Fusco M, Kang A, Savone M, Cappelleri JC, Russ C, Betts M, Cichewicz A, Schaible K, Tarpey J, Fahrbach K.

Future Cardiol. 2022 Apr 1. doi: 10.2217/fca-2021-0120. Online ahead of print.

PMID: 35360925

Kick-off meeting of the TOWWERS showcase project: 1^st collaborative value-based healthcare anchored on real-world data involving the 5P.

Frappier J, Krelenbaum M, Villalba E, Martin P, Nour N, L'Espérance J, Perrault A, Decelle B, Larose AM, Viau V, Fahey R, Denault JF, Fauchon I, Huard M, Frappier M.

Expert Rev Pharmacoecon Outcomes Res. 2022 Apr 1:1-5. doi: 10.1080/14737167.2022.2055549. Online ahead of print.

PMID: 35312399

Orchestrating a β-Hydride Elimination Pathway in Palladium(II)-Catalyzed Arylation/Alkenylation of Cyclopropanols Using Organoboron Reagents.

Ramar T, Subbaiah MAM, Ilangovan A.

J Org Chem. 2022 Apr 1;87(7):4508-4523. doi: 10.1021/acs.joc.1c02735. Epub 2022 Mar 15.

PMID: 35289619

Analyzing longitudinal binary data in clinical studies.

Li Y, Feng D, Sui Y, Li H, Song Y, Zhan T, Cicconetti G, Jin M, Wang H, Chan I, Wang X.

Contemp Clin Trials. 2022 Apr;115:106717. doi: 10.1016/j.cct.2022.106717. Epub 2022 Feb 28.

PMID: 35240309

Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3-selective GABAkine KRM-II-81.

Golani LK, Divović B, Sharmin D, Pandey KP, Mian MY, Cerne R, Zahn NM, Meyer MJ, Tiruveedhula VVNPB, Smith JL, Ping X, Jin X, Lippa A, Schkeryantz JM, Arnold LA, Cook JM, Savić MM, Witkin JM. Biopharm Drug Dispos. 2022 Apr;43(2):66-75. doi: 10.1002/bdd.2313. Epub 2022 Mar 10.

PMID: 35194800

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.

John T, Sakai H, Ikeda S, Cheng Y, Kasahara K, Sato Y, Nakahara Y, Takeda M, Kaneda H, Zhang H, Maemondo M, Minato K, Hisada T, Misumi Y, Satouchi M, Hotta K, Li A, Oukessou A, Lu S.

Int J Clin Oncol. 2022 Apr;27(4):695-706. doi: 10.1007/s10147-022-02120-0. Epub 2022 Feb 19.

PMID: 35182247

Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects.

Chimalakonda A, Singhal S, Darbenzio R, Dockens R, Marchisin D, Banerjee S, Girgis IG, Throup J, He B, Aras U, Murthy B.

Clin Pharmacol Drug Dev. 2022 Apr;11(4):442-453. doi: 10.1002/cpdd.1056. Epub 2022 Feb 19.

PMID: 35182043

The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity.

Zhuo J, Xia Q, Sharma N, Gao S, Lama S, Cui J, Feathers V, Shadick N, Weinblatt ME.

Rheumatol Ther. 2022 Apr;9(2):637-647. doi: 10.1007/s40744-022-00427-y. Epub 2022 Feb 16.

PMID: 35174462

Use of In Vitro Human Skin Models to Assess Potential Immune Activation In Response to Biotherapeutic Attributes and Process-related Impurities.

Tokuda JM, Xie J, Jawa V, Hawkins JM, Ferbas J, Joh NH, Joubert MK.

J Pharm Sci. 2022 Apr;111(4):1012-1023. doi: 10.1016/j.xphs.2022.02.001. Epub 2022 Feb 6.

PMID: 35139332

Financial toxicity and its impact on health outcomes and caregiver burden among adult cancer survivors in the USA.

Inguva S, Priyadarshini M, Shah R, Bhattacharya K.

Future Oncol. 2022 Apr;18(13):1569-1581. doi: 10.2217/fon-2021-1282. Epub 2022 Feb 7.

PMID: 35129377

Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma.

Nordstrom BL, Hamilton M, Collins JM, Earle D, Zhang Y, Srivastava S, Hernandez-Aya L.

Future Oncol. 2022 Apr;18(11):1343-1355. doi: 10.2217/fon-2021-0340. Epub 2022 Feb 7.

PMID: 35129375

Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs.

Jawa V, Maamary J, Swanson M, Zhang S, Montgomery D.

J Pharm Sci. 2022 Apr;111(4):960-969. doi: 10.1016/j.xphs.2022.01.032. Epub 2022 Feb 3.

PMID: 35122828

Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study.

Kwon S, Ma W, Drew DA, Klempner SJ, Leonardo BM, Flynn JJ, Cao Y, Giovannucci EL, Bao Y, Fuchs CS, Song M, Chan AT.

Cancer Prev Res (Phila). 2022 Apr 1;15(4):265-272. doi: 10.1158/1940-6207.CAPR-21-0413.

PMID: 34980677

Enzymatic removal of sialic acid enables iCIEF stability monitoring of charge variants of a highly sialylated bispecific antibody.

Peters BH, Bautista J, Slaney TR, Guo H, Huang RY, Krause ME, Zeng M, Cheng J, Chen Z. Electrophoresis. 2022 Mar 31. doi: 10.1002/elps.202100259. Online ahead of print.

PMID: 35362108

A vasculature niche orchestrates stromal cell phenotype through PDGF signaling: Importance in human fibrotic disease.

Layton TB, Williams L, Yang N, Zhang M, Lee C, Feldmann M, Trujillo G, Furniss D, Nanchahal J.

Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2120336119. doi: 10.1073/pnas.2120336119. Epub 2022 Mar 23.

PMID: 35320046

Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.

Liu J, Yin R, Wu L, Zhu J, Lou G, Wu X, Zhou Q, Gao Y, Kong B, Lu X, Wang J, Chen Y, Cheng Y, Wang Y, Lu W, Li W, Ma X, Hsu K.

Asia Pac J Clin Oncol. 2022 Mar 31. doi: 10.1111/ajco.13753. Online ahead of print.

PMID: 35357078

Current Approaches for Dissolution Similarity Assessment, Requirements, and Global Expectations.

Abend AM, Zhang L, Fredro-Kumbaradzi E, Hoffelder T, Cohen MJ, Anand O, Delvadia P, Mandula H, Zhang Z, Kotzagiorgis E, Lum S, Pereira VG, Barker A, Lavrich D, Kraemer J, Sharp-Suarez S.

AAPS J. 2022 Mar 29;24(3):50. doi: 10.1208/s12248-022-00691-4.

PMID: 35352186

An IQ Consortium Perspective on Connecting Dissolution Methods to In Vivo Performance: Analysis of an Industrial Database and Case Studies to Propose a Workflow.

Aburub A, Chen Y, Chung J, Gao P, Good D, Hansmann S, Hawley M, Heimbach T, Hingle M, Kesisoglou F, Li R, Rose J, Tisaert C.

AAPS J. 2022 Mar 29;24(3):49. doi: 10.1208/s12248-022-00699-w.

PMID: 35348922

An optimized agonist peptide of protease-activated receptor 4 and its use in a validated platelet-aggregation assay.

Yang J, Mapelli C, Wang Z, Sum CS, Hua J, Lawrence RM, Ni Y, Seiffert DA.

Platelets. 2022 Mar 28:1-8. doi: 10.1080/09537104.2022.2053091. Online ahead of print.

PMID: 35343875

Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.

Keating SJ, Gu T, Jun MP, McBride A.

Transplant Cell Ther. 2022 Mar 27:S2666-6367(22)01186-1. doi: 10.1016/j.jtct.2022.03.021. Online ahead of print.

PMID: 35354101

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.

Federico Paly V, Kurt M, Zhang L, Butler MO, Michielin O, Amadi A, Hernlund E, Johnson HM, Kotapati S, Moshyk A, Borrill J.

MDM Policy Pract. 2022 Mar 26;7(1):23814683221089659. doi: 10.1177/23814683221089659. eCollection 2022 Jan-Jun.

PMID: 35356551

Health state utilities for beta-thalassemia: a time trade-off study.

Martin AP, Ferri Grazzi E, Mighiu C, Chevli M, Shah F, Maher L, Shaikh A, Sagar A, Hubberstey H, Franks B, Ramos-Goñi JM, Oppe M, Tang D.

Eur J Health Econ. 2022 Mar 26. doi: 10.1007/s10198-022-01449-7. Online ahead of print.

PMID: 35347553

Liposome-Tethered Gold Nanoparticles Triggered by Pulsed NIR Light for Rapid Liposome Contents Release and Endosome Escape.

Veeren A, Ogunyankin MO, Shin JE, Zasadzinski JA.

Pharmaceutics. 2022 Mar 25;14(4):701. doi: 10.3390/pharmaceutics14040701.

PMID: 35456535

Methodological Considerations in Development of UV Imaging for Characterization of Intra-Tumoral Injectables Using cAMP as a Model Substance.

Bock F, Bøtker JP, Larsen SW, Lu X, Østergaard J.

Int J Mol Sci. 2022 Mar 25;23(7):3599. doi: 10.3390/ijms23073599.

PMID: 35408971

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.

Perera V, Wang Z, Lubin S, Ueno T, Shiozaki T, Chen W, Xu X, Seiffert D, DeSouza M, Murthy B.

Sci Rep. 2022 Mar 25;12(1):5165. doi: 10.1038/s41598-022-08768-y.

PMID: 35338177

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.

Cartron G, Fox CP, Liu FF, Kostic A, Hasskarl J, Li D, Bonner A, Zhang Y, Maloney DG, Kuruvilla J.

Exp Hematol Oncol. 2022 Mar 25;11(1):17. doi: 10.1186/s40164-022-00268-z.

PMID: 35337365

A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities.

Grumberg V, Roze S, Chevalier J, Borrill J, Gaudin AF, Branchoux S.

Int J Technol Assess Health Care. 2022 Mar 25;38(1):e28. doi: 10.1017/S0266462322000125.

PMID: 35331347

Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain.

Luo G, Chen L, Kostich WA, Hamman B, Allen J, Easton A, Bourin C, Gulianello M, Lippy J, Nara S, Pattipati SN, Dandapani K, Dokania M, Vattikundala P, Sharma V, Elavazhagan S, Verma MK, Lal Das M, Wagh S, Balakrishnan A, Johnson BM, Santone KS, Thalody G, Denton R, Saminathan H, Holenarsipur VK, Kumar A, Rao A, Putlur SP, Sarvasiddhi SK, Shankar G, Louis JV, Ramarao M, Conway CM, Li YW, Pieschl R, Tian Y, Hong Y, Bristow L, Albright CF, Bronson JJ, Macor JE, Dzierba CD.

J Med Chem. 2022 Mar 24;65(6):4534-4564. doi: 10.1021/acs.jmedchem.1c02132. Epub 2022 Mar 9.

PMID: 35261239

Discovery of (S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain.

Luo G, Chen L, Kostich WA, Hamman B, Allen J, Easton A, Bourin C, Gulianello M, Lippy J, Nara S, Maishal TK, Thiyagarajan K, Jalagam P, Pattipati SN, Dandapani K, Dokania M, Vattikundala P, Sharma V, Elavazhagan S, Verma MK, Das ML, Wagh S, Balakrishnan A, Johnson BM, Santone KS, Thalody G, Denton R, Saminathan H, Holenarsipur VK, Kumar A, Rao A, Putlur SP, Sarvasiddhi SK, Shankar G, Louis JV, Ramarao M, Conway CM, Li YW, Pieschl R, Tian Y, Hong Y, Ditta J, Mathur A, Li J, Smith D, Pawluczyk J, Sun D, Yip S, Wu DR, Vetrichelvan M, Gupta A, Wilson A, Gopinathan S, Wason S, Bristow L, Albright CF, Bronson JJ, Macor JE, Dzierba CD.

J Med Chem. 2022 Mar 24;65(6):4457-4480. doi: 10.1021/acs.jmedchem.1c02131. Epub 2022 Mar 8.

PMID: 35257579

The Current States, Challenges, Ongoing Efforts, and Future Perspectives of Pharmaceutical Excipients in Pediatric Patients in Each Country and Region.

Saito J, Agrawal A, Patravale V, Pandya A, Orubu S, Zhao M, Andrews GP, Petit-Turcotte C, Landry H, Croker A, Nakamura H, Yamatani A, Salunke S.

Children (Basel). 2022 Mar 23;9(4):453. doi: 10.3390/children9040453.

PMID: 35455497

N-1 Perfusion Platform Development Using a Capacitance Probe for Biomanufacturing.

Rittershaus ESC, Rehmann MS, Xu J, He Q, Hill C, Swanberg J, Borys MC, Li ZJ, Khetan A. Bioengineering (Basel). 2022 Mar 22;9(4):128. doi: 10.3390/bioengineering9040128.

PMID: 35447688

Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.

Willumsen N, Jensen C, Green G, Nissen NI, Neely J, Nelson DM, Pedersen RS, Frederiksen P, Chen IM, Boisen MK, Johansen AZ, Madsen DH, Svane IM, Lipton A, Leitzel K, Ali SM, Erler JT, Hurkmans DP, Mathijssen RHJ, Aerts J, Eslam M, George J, Christiansen C, Bissel MJ, Karsdal MA.

Cell Mol Life Sci. 2022 Mar 25;79(4):204. doi: 10.1007/s00018-022-04226-0.

PMID: 35332383

A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma.

Pape M, Vissers PAJ, Bertwistle D, McDonald L, Slingerland M, Haj Mohammad N, Beerepoot LV, Ruurda JP, Nieuwenhuijzen GAP, Jeene PM, van Laarhoven HWM, Verhoeven RHA.

Ther Adv Med Oncol. 2022 Mar 24;14:17588359221085557. doi: 10.1177/17588359221085557. eCollection 2022.

PMID: 35356260

A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.

Johnston SE, Lipkovich I, Dmitrienko A, Zhao YD.

Pharm Stat. 2022 Mar 24. doi: 10.1002/pst.2208. Online ahead of print.

PMID: 35322520

Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs.

Naidu BN, Patel M, McAuliffe B, Ding B, Cianci C, Simmermacher J, Jenkins S, Parker DD, Sivaprakasam P, Khan JA, Kish K, Lewis H, Hanumegowda U, Krystal M, Meanwell NA, Kadow JF.

J Med Chem. 2022 Mar 24;65(6):4949-4971. doi: 10.1021/acs.jmedchem.1c02169. Epub 2022 Mar 2.

PMID: 35235334

Androgen receptor activity in T cells limits checkpoint blockade efficacy.

Guan X, Polesso F, Wang C, Sehrawat A, Hawkins RM, Murray SE, Thomas GV, Caruso B, Thompson RF, Wood MA, Hipfinger C, Hammond SA, Graff JN, Xia Z, Moran AE.

Nature. 2022 Mar 23. doi: 10.1038/s41586-022-04522-6. Online ahead of print.

PMID: 35322234

Cold Denaturation of Proteins in the Absence of Solvent: Implications for Protein Storage.

Norgate EL, Upton R, Hansen K, Bellina B, Brookes C, Politis A, Barran PE.

Angew Chem Int Ed Engl. 2022 Mar 21:e202115047. doi: 10.1002/anie.202115047. Online ahead of print.

PMID: 35313047

An open-label, phase 1, randomized, three treatments, three-period, crossover, relative bioavailability study of CC-292, a potent and orally available inhibitor of bruton tyrosine kinase.

Cheng Y, Liu L, Xue Y, Zhou S, Li Y.

J Clin Pharm Ther. 2022 Mar 20. doi: 10.1111/jcpt.13653. Online ahead of print.

PMID: 35307850

LPA₁ antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis.

Decato BE, Leeming DJ, Sand JMB, Fischer A, Du S, Palmer SM, Karsdal M, Luo Y, Minnich A.

Respir Res. 2022 Mar 18;23(1):61. doi: 10.1186/s12931-022-01980-4.

PMID: 35303880

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.

Merrill JT, Werth VP, Furie R, van Vollenhoven R, Dörner T, Petronijevic M, Velasco J, Majdan M, Irazoque-Palazuelos F, Weiswasser M, Korish S, Ye Y, Gaudy A, Schafer PH, Liu Z, Agafonova N, Delev N.

N Engl J Med. 2022 Mar 17;386(11):1034-1045. doi: 10.1056/NEJMoa2106535.

PMID: 35294813

A Systematic Approach for the Evaluation, Validation and Implementation of Automated Colony Counting Systems.

Deutschmann S, Carpenter B, Duignan C, Knutsen C, Salvas J, Wysocki L, Plourde L, Johnson L, Eder W, Franz-Riethdorf M.

PDA J Pharm Sci Technol. 2022 Mar 16:pdajpst.2021.012646. doi: 10.5731/pdajpst.2021.012646. Online ahead of print.

PMID: 35296561

Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3).

Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Matsumura Y, Takazawa A, Kitagawa Y.

Clin Cancer Res. 2022 Mar 16:clincanres.0985.2021. doi: 10.1158/1078-0432.CCR-21-0985. Online ahead of print.

PMID: 35294546

Hospitalizations for Acute Gout: Process Mapping the Inpatient Journey and Identifying Predictors of Admission.

Russell MD, Nagra D, Clarke BD, Balachandran S, Buazon A, Boalch A, Bechman K, Adas MA, Alveyn EG, Rutherford AI, Galloway JB.

J Rheumatol. 2022 Mar 15:jrheum.211203. doi: 10.3899/jrheum.211203. Online ahead of print.

PMID: 35293331

Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis.

Nash P.

J Rheumatol. 2022 Mar 15:jrheum.211329. doi: 10.3899/jrheum.211329. Online ahead of print.

PMID: 35293326

Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies.

McDermott G, Gill R, Gagne S, Byrne S, Huang W, Wang X, Prisco LC, Zaccardelli A, Martin LW, Masto L, Kronzer VL, Shadick N, Dellaripa PF, Doyle TJ, Sparks JA.

J Rheumatol. 2022 Mar 15:jrheum.211242. doi: 10.3899/jrheum.211242. Online ahead of print.

PMID: 35293341

GRAPPA 2020 Research Award Recipients.

Castillo RL, Yan D, Ashhurst AS, Elliott A, Angioni MM, Scher JU, Naik S, Neimann A, Byrne SN, Payne RJ, FitzGerald O, Pennington SR, Cauli A, Chandran V.

J Rheumatol. 2022 Mar 15:jrheum.211335. doi: 10.3899/jrheum.211335. Online ahead of print.

PMID: 35293338

Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases.

Takeshita J, Chau J, Callis Duffin K, Goel N.

J Rheumatol. 2022 Mar 15:jrheum.211330. doi: 10.3899/jrheum.211330. Online ahead of print.

PMID: 35293335

Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.

Carroll R, Bortolini M, Calleja A, Munro R, Kong S, Daumont MJ, Penrod JR, Lakhdari K, Lacoin L, Cheung WY.

BMC Cancer. 2022 Mar 10;22(1):255. doi: 10.1186/s12885-022-09342-5.

PMID: 35264135

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132).

Shi Y, Wang Y, Meng W, Brigance RP, Ryono DE, Bolton S, Zhang H, Chen S, Smirk R, Tao S, Tino JA, Williams KN, Sulsky R, Nielsen L, Ellsworth B, Wong MKY, Sun JH, Leith LW, Sun D, Wu DR, Gupta A, Rampulla R, Mathur A, Chen BC, Wang A, Fuentes-Catanio HG, Kunselman L, Cap M, Zalaznick J, Ma X, Liu H, Taylor JR, Zebo R, Jones B, Kalinowski S, Swartz J, Staal A, O'Malley K, Kopcho L, Muckelbauer JK, Krystek SR Jr, Spronk SA, Marcinkeviciene J, Everlof G, Chen XQ, Xu C, Li YX, Langish RA, Yang Y, Wang Q, Behnia K, Fura A, Janovitz EB, Pannacciulli N, Griffen S, Zinker BA, Krupinski J, Kirby M, Whaley J, Zahler R, Barrish JC, Robl JA, Cheng PTW.

J Med Chem. 2022 Mar 10;65(5):4291-4317. doi: 10.1021/acs.jmedchem.1c02110. Epub 2022 Feb 18.

PMID: 35179904

Bicyclic Heterocyclic Replacement of an Aryl Amide Leading to Potent and Kinase-Selective Adaptor Protein 2-Associated Kinase 1 Inhibitors.

Hartz RA, Ahuja VT, Nara SJ, Kumar CMV, Manepalli RKVLP, Sarvasiddhi SK, Honkhambe S, Patankar V, Dasgupta B, Rajamani R, Muckelbauer JK, Camac DM, Ghosh K, Pokross M, Kiefer SE, Brown JM, Hunihan L, Gulianello M, Lewis M, Lippy JS, Surti N, Hamman BD, Allen J, Kostich WA, Bronson JJ, Macor JE, Dzierba CD.

J Med Chem. 2022 Mar 10;65(5):4121-4155. doi: 10.1021/acs.jmedchem.1c01966. Epub 2022 Feb 16.

PMID: 35171586

Witjes JA, Galsky MD, Gschwend JE, Broughton E, Braverman J, Nasroulah F, Maira-Arce M, Ye X, Shi L, Guo S, Hamilton M, Bajorin DF.

Eur Urol Oncol. 2022 Mar 11:S2588-9311(22)00028-1. doi: 10.1016/j.euo.2022.02.003. Online ahead of print.

PMID: 35288066

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.

Copher R, Kee A, Gerds A.

Oncologist. 2022 Mar 11;27(3):228-235. doi: 10.1093/oncolo/oyab058.

PMID: 35274711

Homologous Recombination Deficiency: Concepts, Definitions, and Assays.

Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, Collins G, French T, Ghahramani N, Hinson P, Jelinic P, Marton MJ, McGregor K, Parsons J, Ramamurthy L, Sausen M, Sokol ES, Stenzinger A, Stires H, Timms KM, Turco D, Wang I, Williams JA, Wong-Ho E, Allen J. Oncologist. 2022 Mar 11;27(3):167-174. doi: 10.1093/oncolo/oyab053.

PMID: 35274707

Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles.

Jecs E, Tahirovic YA, Wilson RJ, Miller EJ, Kim M, Truax V, Nguyen HH, Akins NS, Saindane M, Wang T, Sum CS, Cvijic ME, Schroeder GM, Burton SL, Derdeyn CA, Xu L, Jiang Y, Wilson LJ, Liotta DC.

J Med Chem. 2022 Mar 10;65(5):4058-4084. doi: 10.1021/acs.jmedchem.1c01564. Epub 2022 Feb 18.

PMID: 35179893

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.

Perera V, Abelian G, Li D, Wang Z, Zhang L, Lubin S, Chen W, Bello A, Murthy B.

Clin Pharmacokinet. 2022 Mar 9. doi: 10.1007/s40262-022-01110-9. Online ahead of print.

PMID: 35262846

Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer.

Ali AA, Tawk R, Xiao H, Semykina A, Montero AJ, Moussa RK, Popoola O, Diaby V.

Expert Rev Pharmacoecon Outcomes Res. 2022 Mar 9:1-7. doi: 10.1080/14737167.2022.2044309. Online ahead of print.

PMID: 35189767

Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.

Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating M, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MTS.

Leuk Lymphoma. 2022 Mar 8:1-14. doi: 10.1080/10428194.2022.2043299. Online ahead of print.

PMID: 35259043

Formyl peptide receptor 2 and heart disease.

Lupisella JA, Shirude PS, Wurtz NR, Garcia RA.

Semin Immunol. 2022 Mar 8:101602. doi: 10.1016/j.smim.2022.101602. Online ahead of print.

PMID: 35277300

Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer.

Chiappori AA, Creelan B, Tanvetyanon T, Gray JE, Haura EB, Thapa R, Barlow ML, Chen Z, Chen DT, Beg AA, Boyle TA, Castro J, Morgan L, Morris E, Aregay M, Hurtado FK, Manenti L, Antonia S.

Clin Cancer Res. 2022 Mar 7:clincanres.2742.2021. doi: 10.1158/1078-0432.CCR-21-2742. Online ahead of print.

PMID: 35254415

Understanding Poor Milling Behavior of Voriconazole from Crystal Structure and Intermolecular Interactions.

Kaur A, Yadav JP, Sathe RY, Puri V, Bharatam PV, Bansal AK.

Mol Pharm. 2022 Mar 7;19(3):985-997. doi: 10.1021/acs.molpharmaceut.1c00978. Epub 2022 Feb 21.

PMID: 35188397

Global intercompany assessment of ICIEF platform comparability for the characterization of therapeutic proteins.

Madren S, McElroy W, Schultz-Kuszak K, Boumajny B, Shu Y, Sautter S, Zhao HC, Schadock-Hewitt A, Chumsae C, Ball N, Zhang X, Rish K, Zhang S, Wurm C, Cai S, Bauer SP, Stella C, Zheng L, Roper B, Michels DA, Wu G, Kocjan B, Birk M, Erdmann SE, He X, Whittaker B, Song Y, Barrett H, Strozyk K, Jing Y, Huang L, Mhatre V, McLean P, Yu T, Yang H, Mattila M.

Electrophoresis. 2022 Mar 4. doi: 10.1002/elps.202100348. Online ahead of print.

PMID: 35245390

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.

Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S.

Ann Rheum Dis. 2022 Mar 3:annrheumdis-2021-221664. doi: 10.1136/annrheumdis-2021-221664. Online ahead of print.

PMID: 35241426

Pathogen-associated T follicular helper cell plasticity is critical in anti-viral immunity.

Feng H, Zhao X, Xie J, Bai X, Fu W, Chen H, Tang H, Wang X, Dong C.

Sci China Life Sci. 2022 Mar 2. doi: 10.1007/s11427-021-2055-x. Online ahead of print.

PMID: 35258743

Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining Progress.

Rivera DR, Kluetz PG, Abdallah K, Agrawal S, Angus DC, Califf RM, Garrett-Mayer E, Hyer R, Lowy DR, Khleif SN.

Cancer J. 2022 Mar-Apr 01;28(2):151-156. doi: 10.1097/PPO.0000000000000589.

PMID: 35333502

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model.

Zorn JA, Wheeler ML, Barnes RM, Kaberna J, Morishige W, Harris M, Huang RY, Lohre J, Chang YC, Chau B, Powers K, Schindler I, Neradugomma N, Thomas W, Liao X, Zhou Y, West SM, Wang F, Kotapati S, Chen G, Yamazoe S, Kosenko A, Dollinger G, Sproul T, Rajpal A, Strop P.

Sci Rep. 2022 Mar 3;12(1):3530. doi: 10.1038/s41598-022-06953-7.

PMID: 35241687

Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials.

Bessette L, Mysler E, Kinch CD, Kwok K, Lukic T, On PV, van Vollenhoven RF.

J Rheumatol. 2022 Mar 1:jrheum.210707. doi: 10.3899/jrheum.210707. Online ahead of print.

PMID: 35232809

Young-GRAPPA at the Annual GRAPPA Meeting: Presentation of a New Group Within GRAPPA and Its Vision.

van Mens L, Ayan G, Coates LC, Coras R, Silva DLF, Herrera S, Ishchenko A, Jethwa H, Johnsson H, Simon D, Vivekanantham A, Proft F.

J Rheumatol. 2022 Mar 1:jrheum.211327. doi: 10.3899/jrheum.211327. Online ahead of print.

PMID: 35232806

Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study.

Owens AT, Sutton MB, Gao W, Fine JT, Xie J, Naidu SS, Desai NR.

Cardiol Ther. 2022 Mar 1. doi: 10.1007/s40119-022-00257-7. Online ahead of print.

PMID: 35230625

WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee.

Conaghan PG, Dworkin RH, Schnitzer TJ, Berenbaum F, Bushmakin AG, Cappelleri JC, Viktrup L, Abraham L.

J Rheumatol. 2022 Mar 1:jrheum.210543. doi: 10.3899/jrheum.210543. Online ahead of print.

PMID: 35232805

Morphometrics and blood analytes of leatherback sea turtle hatchlings (Dermochelys coriacea) from Florida: reference intervals, temporal trends with clutch deposition date, and body size correlations.

Perrault JR, Page-Karjian A, Morgan AN, Burns LK, Stacy NI.

J Comp Physiol B. 2022 Mar;192(2):313-324. doi: 10.1007/s00360-021-01422-5. Epub 2022 Jan 8.

PMID: 34997274

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.

Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY.

Nature. 2022 Mar;603(7903):942-948. doi: 10.1038/s41586-022-04508-4. Epub 2022 Mar 23.

PMID: 35322232

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.

Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry MB, Ross-Macdonald P, Wind-Rotolo M.

J Immunother Cancer. 2022 Mar;10(3):e004316. doi: 10.1136/jitc-2021-004316.

PMID: 35304405

Quantifying uncertainty in method of moments estimates of the heterogeneity variance in random effects meta-analysis.

Sidik K, Jonkman JN.

Biom J. 2022 Mar;64(3):598-616. doi: 10.1002/bimj.202000222. Epub 2021 Dec 11.

PMID: 35285063

PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment.

Collins NB, Al Abosy R, Miller BC, Bi K, Zhao Q, Quigley M, Ishizuka JJ, Yates KB, Pope HW, Manguso RT, Shrestha Y, Wadsworth M, Hughes T, Shalek AK, Boehm JS, Hahn WC, Doench JG, Haining WN.

J Immunother Cancer. 2022 Mar;10(3):e003402. doi: 10.1136/jitc-2021-003402.

PMID: 35264433

An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.

Chan S, Belmar N, Ho S, Rogers B, Stickler M, Graham M, Lee E, Tran N, Zhang D, Gupta P, Sho M, MacDonough T, Woolley A, Kim H, Zhang H, Liu W, Zheng P, Dezso Z, Halliwill K, Ceccarelli M, Rhodes S, Thakur A, Forsyth CM, Xiong M, Tan SS, Iyer R, Lake M, Digiammarino E, Zhou L, Bigelow L, Longenecker K, Judge RA, Liu C, Trumble M, Remis JP, Fox M, Cairns B, Akamatsu Y, Hollenbaugh D, Harding F, Alvarez HM.

Nat Cancer. 2022 Mar;3(3):337-354. doi: 10.1038/s43018-022-00334-9. Epub 2022 Mar 7.

PMID: 35256819

Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.

Chang M, Bathena S, Christopher LJ, Shen H, Roy A.

Cancer Chemother Pharmacol. 2022 Mar;89(3):383-392. doi: 10.1007/s00280-021-04394-z. Epub 2022 Feb 11.

PMID: 35147740

Future of Biotransformation Science in the Pharmaceutical Industry.

Kramlinger VM, Dalvie D, Heck CJS, Kalgutkar AS, O'Neill J, Su D, Teitelbaum AM, Totah RA.

Drug Metab Dispos. 2022 Mar;50(3):258-267. doi: 10.1124/dmd.121.000658. Epub 2021 Dec 17.

PMID: 34921097

Simultaneous measurement of mouse and human albumin in chimeric mice with humanized livers.

Landry F, Shen H, Zhang Y, Uchiyama A, Miyata Y, Morikawa Y, Joshi B, Shipkova P.

Bioanalysis. 2022 Mar;14(5):267-278. doi: 10.4155/bio-2021-0250. Epub 2022 Feb 23.

PMID: 35195037

Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World.

Burns L, Roux NL, Kalesnik-Orszulak R, Christian J, Hukkelhoven M, Rockhold F, O'Donnell J.

Clin Ther. 2022 Mar;44(3):420-437. doi: 10.1016/j.clinthera.2022.01.012. Epub 2022 Feb 15.

PMID: 35181179

Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study.

Page JH, Londhe AA, Brooks C, Zhang J, Sprafka JM, Bennett C, Braunlin M, Brown CA, Charuworn P, Cheng A, Gill K, He F, Ma J, Petersen J, Ayodele O, Bao Y, Carlson KB, Chang SC, Devercelli G, Jonsson-Funk M, Jiang J, Keenan HA, Ren K, Roehl KA, Sanders L, Wang L, Wei Z, Xia Q, Yu P, Zhou L, Zhu J, Gondek K, Critchlow CW, Bradbury BD.

BMJ Open. 2022 Feb 28;12(2):e055137. doi: 10.1136/bmjopen-2021-055137.

PMID: 35228287

Budget impact analysis of a machine learning algorithm to predict high risk of atrial fibrillation among primary care patients.

Szymanski T, Ashton R, Sekelj S, Petrungaro B, Pollock KG, Sandler B, Lister S, Hill NR, Farooqui U. Europace. 2022 Feb 28:euac016. doi: 10.1093/europace/euac016. Online ahead of print.

PMID: 35226101

Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Broughton EI, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G.

BMC Urol. 2022 Feb 26;22(1):27. doi: 10.1186/s12894-022-00959-z.

PMID: 35219307

Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.

Omuro A, Reardon DA, Sampson JH, Baehring J, Sahebjam S, Cloughesy TF, Chalamandaris AG, Potter V, Butowski N, Lim M.

Neurooncol Adv. 2022 Feb 26;4(1):vdac025. doi: 10.1093/noajnl/vdac025. eCollection 2022 Jan-Dec.

PMID: 35402913

Using a Model-based Material Sparing Approach for Formulation and Process Development of a Roller Compacted Drug Product.

Vasudevan KV, Pu YE, Amini H, Guarino C, Agrawal A, Akseli I.

Pharm Res. 2022 Feb 26. doi: 10.1007/s11095-022-03192-3. Online ahead of print.

PMID: 35218443

Discovery of Non-Nucleotide Small-Molecule STING Agonists via Chemotype Hybridization.

Cherney EC, Zhang L, Lo J, Huynh T, Wei D, Ahuja V, Quesnelle C, Schieven GL, Futran A, Locke GA, Lin Z, Monereau L, Chaudhry C, Blum J, Li S, Fereshteh M, Li-Wang B, Gangwar S, Pan C, Chong C, Zhu X, Posy SL, Sack JS, Zhang P, Ruzanov M, Harner M, Akhtar F, Schroeder GM, Vite G, Fink B.

J Med Chem. 2022 Feb 24;65(4):3518-3538. doi: 10.1021/acs.jmedchem.1c01986. Epub 2022 Feb 2.

PMID: 35108011

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.

Stewart MD, McCall B, Pasquini M, Yang AS, Britten CD, Chuk M, De Claro RA, George B, Gormley N, Horowitz MM, Kowack E, McCoy C, Morrow PK, Okoye E, Ricafort R, Rossi J, Sharon E, Theoret M, Vegni F, Yu T, Allen J.

Cytotherapy. 2022 Feb 23:S1465-3249(22)00023-8. doi: 10.1016/j.jcyt.2022.01.004. Online ahead of print.

PMID: 35219582

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.

Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM.

Gut. 2022 Feb 23:gutjnl-2021-325918. doi: 10.1136/gutjnl-2021-325918. Online ahead of print.

PMID: 35197323

Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database.

Munir MB, Hlavacek P, Keshishian A, Guo JD, Mallampati R, Ferri M, Russ C, Emir B, Cato M, Yuce H, Hsu JC.

PLoS One. 2022 Feb 17;17(2):e0263903. doi: 10.1371/journal.pone.0263903. eCollection 2022.

PMID: 35176074

Superiority of Mesoporous Silica-Based Amorphous Formulations over Spray-Dried Solid Dispersions.

Zhang H, Li M, Li J, Agrawal A, Hui HW, Liu D.

Pharmaceutics. 2022 Feb 16;14(2):428. doi: 10.3390/pharmaceutics14020428.

PMID: 35214159

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.

Ahmad HA, Baker JF, Conaghan PG, Emery P, Huizinga TWJ, Elbez Y, Banerjee S, Østergaard M. Arthritis Res Ther. 2022 Feb 16;24(1):47. doi: 10.1186/s13075-022-02735-8.

PMID: 35172859

Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic Arthritis.

Jadon DR, Kavanaugh A, Leung YY.

J Rheumatol. 2022 Feb 15:jrheum .211325. doi: 10.3899/jrheum.211325. Online ahead of print.

PMID: 35169062

Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis.

Lubberts E, Scher JU, FitzGerald O.

J Rheumatol. 2022 Feb 15:jrheum.211321. doi: 10.3899/jrheum.211321. Online ahead of print.

PMID: 35169059

Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features.

Hagedorn PH, Brown JM, Easton A, Pierdomenico M, Jones K, Olson RE, Mercer SE, Li D, Loy J, Høg AM, Jensen ML, Gill M, Cacace AM.

Nucleic Acid Ther. 2022 Feb 14. doi: 10.1089/nat.2021.0071. Online ahead of print.

PMID: 35166597

Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Callis Duffin K, Gladman DD, Goel N, Gottlieb AB, FitzGerald O, McFarland LV.

J Rheumatol. 2022 Feb 15:jrheum.211317. doi: 10.3899/jrheum.211317. Online ahead of print.

PMID: 35169061

In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.

Ogasawara K, Lymp J, Mack T, Dell'Aringa J, Huang CP, Smith J, Peiser L, Kostic A.

Clin Pharmacol Ther. 2022 Feb 13. doi: 10.1002/cpt.2561. Online ahead of print.

PMID: 35156195

Repeatability and Reproducibility Assessment of the Apparent Diffusion Coefficient in the Prostate: A Trial of the ECOG-ACRIN Research Group (ACRIN 6701).

Boss MA, Snyder BS, Kim E, Flamini D, Englander S, Sundaram KM, Gumpeni N, Palmer SL, Choi H, Froemming AT, Persigehl T, Davenport MS, Malyarenko D, Chenevert TL, Rosen MA.

J Magn Reson Imaging. 2022 Feb 10. doi: 10.1002/jmri.28093. Online ahead of print.

PMID: 35143059

Redefining nonmeasurable multiple myeloma using mass spectrometry.

Giles HV, Cook MA, Drayson MT, Cook G, Wright NJ, North SJ, Harding S, Cairns DA, Hockaday A, Kaiser MF, Moss P, Davies FE, Morgan GJ, Jackson G, Pratt G.

Blood. 2022 Feb 10;139(6):946-950. doi: 10.1182/blood.2021013794.

PMID: 34871382

A Systematic Literature Review of the Relationship between Serum Ferritin and Outcomes in Myelodysplastic Syndromes.

Oliva EN, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E, Tang D, Yucel A, Hughes C, Shah F. J Clin Med. 2022 Feb 8;11(3):895. doi: 10.3390/jcm11030895.

PMID: 35160344

Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.

Harskamp RE, Fanaroff AC, Lopes RD, Wojdyla DM, Goodman SG, Thomas LE, Aronson R, Windecker S, Mehran R, Granger CB, Alexander JH.

J Am Coll Cardiol. 2022 Feb 8;79(5):417-427. doi: 10.1016/j.jacc.2021.11.035.

PMID: 35115097

Estimands in observational studies: Some considerations beyond ICH E9 (R1).

Li H, Wang C, Chen WC, Lu N, Song C, Tiwari R, Xu Y, Yue LQ.

Pharm Stat. 2022 Feb 6. doi: 10.1002/pst.2196. Online ahead of print.

PMID: 35128808

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators.

N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.

PMID: 35108470

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.

Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ, Hutson T, Zhang J, Zoco J, Johansen JL, Rezazadeh Kalebasty A.

J Immunother Cancer. 2022 Feb;10(2):e003844. doi: 10.1136/jitc-2021-003844.

PMID: 35210307

Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.

Welsh RC, Dehghani P, Lopes R, Wojdyla DM, Aronson R, Granger CB, Windecker S, Vora AN, Vinereanu D, Halvorsen S, Parkhomenko A, Mehran R, Alexander JH, Goodman S.

Open Heart. 2022 Feb;9(1):e001892. doi: 10.1136/openhrt-2021-001892.

PMID: 35172988

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.

O'Byrne KJ, Lee KH, Kim SW, Park K, Nishio M, Sakai H, Ohe Y, Fukuhara T, Kang JH, Daga H, Yu CJ, Hotta K, Tanaka H, Takeda M, Yokoyama T, Nathan FE, Lee JS.

ESMO Open. 2022 Feb;7(1):100394. doi: 10.1016/j.esmoop.2022.100394. Epub 2022 Feb 12.

PMID: 35158207

Soluble PD-L1 as an early marker of progressive disease on nivolumab.

Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, McDermott DF, Stephen Hodi F, Choueiri TK, Freeman GJ.

J Immunother Cancer. 2022 Feb;10(2):e003527. doi: 10.1136/jitc-2021-003527.

PMID: 35131863

Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab.

Chouaïd C, Grumberg V, Batisse A, Corre R, Giaj Levra M, Gaudin AF, Prodel M, Lortet-Tieulent J, Assié JB, Cotté FE.

JCO Clin Cancer Inform. 2022 Feb;6:e2100108. doi: 10.1200/CCI.21.00108.

PMID: 35113656

PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.

Khadka P, Reitman ZJ, Lu S, Buchan G, Gionet G, Dubois F, Carvalho DM, Shih J, Zhang S, Greenwald NF, Zack T, Shapira O, Pelton K, Hartley R, Bear H, Georgis Y, Jarmale S, Melanson R, Bonanno K, Schoolcraft K, Miller PG, Condurat AL, Gonzalez EM, Qian K, Morin E, Langhnoja J, Lupien LE, Rendo V, Digiacomo J, Wang D, Zhou K, Kumbhani R, Guerra Garcia ME, Sinai CE, Becker S, Schneider R, Vogelzang J, Krug K, Goodale A, Abid T, Kalani Z, Piccioni F, Beroukhim R, Persky NS, Root DE, Carcaboso AM, Ebert BL, Fuller C, Babur O, Kieran MW, Jones C, Keshishian H, Ligon KL, Carr SA, Phoenix TN, Bandopadhayay P.

Nat Commun. 2022 Feb 1;13(1):604. doi: 10.1038/s41467-022-28198-8.

PMID: 35105861

Two heads are better than one: current landscape of integrating QSP and machine learning : An ISoP QSP SIG white paper by the working group on the integration of quantitative systems pharmacology and machine learning.

Zhang T, Androulakis IP, Bonate P, Cheng L, Helikar T, Parikh J, Rackauckas C, Subramanian K, Cho CR; Working Group.

J Pharmacokinet Pharmacodyn. 2022 Feb;49(1):5-18. doi: 10.1007/s10928-022-09805-z. Epub 2022 Feb 1.

PMID: 35103884

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways.

Karagoz K, Stokes M, Ortiz-Estévez M, Towfic F, Flynt E, Gooding S, Pierceall W, Thakurta A.

Front Genet. 2022 Feb 9;13:831779. doi: 10.3389/fgene.2022.831779. eCollection 2022.

PMID: 35222546

Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis.

Østergaard M, Bird P, Pachai C, Du S, Wu C, Landis J, Fuerst T, Ahmad HA, Connolly SE, Conaghan PG. Rheumatology (Oxford). 2022 Feb 8:keac073. doi: 10.1093/rheumatology/keac073. Online ahead of print.

PMID: 35137002

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.

Bahlis NJ, Siegel DS, Schiller GJ, Samaras C, Sebag M, Berdeja J, Ganguly S, Matous J, Song K, Seet CS, Acosta-Rivera M, Bar M, Quick D, Anz B, Fonseca G, Chung W, Lee K, Mouro J, Agarwal A, Reece D. Leuk Lymphoma. 2022 Feb 8:1-11. doi: 10.1080/10428194.2022.2030477. Online ahead of print.

PMID: 35133221

Systematic Screening for Atrial Fibrillation in Patients at Moderate-to-High Risk of Stroke　- Potential to Increase the Atrial Fibrillation Detection Rate (SCAN-AF).

Watanabe E, Takahashi N, Aronson R, Ohsawa A, Ishibashi Y, Murakawa Y; SCAN-AF Investigators. Circ J. 2022 Feb 5. doi: 10.1253/circj.CJ-21-0813. Online ahead of print.

PMID: 35125371

Doppler signal and bone erosions at the enthesis are independently associated with ultrasound joint erosive damage in psoriatic arthritis.

Smerilli G, Cipolletta E, Destro Castaniti GM, Di Matteo A, Di Carlo M, Moscioni E, Francioso F, Mashadi Mirza R, Grassi W, Filippucci E.

J Rheumatol. 2022 Feb 1:jrheum.210974. doi: 10.3899/jrheum.210974. Online ahead of print.

PMID: 35105703

Diagnosis and Management of Multiple Myeloma: A Review.

Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN.

JAMA. 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003.

PMID: 35103762

Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target.

Feng Y, Liu L, Li J, Huang J, Xie JH, Menard L, Shi Y, Zhao X, Xie S, Zang W, Tan H, Yang Z, Ni L.

Oncol Rep. 2022 Feb;47(2):38. doi: 10.3892/or.2021.8249. Epub 2021 Dec 27.

PMID: 34958112

Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.

Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D.

Support Care Cancer. 2022 Feb;30(2):1377-1378. doi: 10.1007/s00520-021-06691-y.

PMID: 34792647

Systematic assessment of process analytical technologies for biologics.

Gillespie C, Wasalathanthri DP, Ritz DB, Zhou G, Davis KA, Wucherpfennig T, Hazelwood N.

Biotechnol Bioeng. 2022 Feb;119(2):423-434. doi: 10.1002/bit.27990. Epub 2021 Dec 13.

PMID: 34778948

Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.

Wong PC, Crain EJ, Bozarth JM, Wu Y, Dilger AK, Wexler RR, Ewing WR, Gordon D, Luettgen JM.

J Thromb Haemost. 2022 Feb;20(2):399-408. doi: 10.1111/jth.15588. Epub 2021 Nov 24.

PMID: 34752670

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.

Mantia CM, Werner L, Stwalley B, Ritchings C, Tarhini AA, Atkins MB, McDermott DF, Regan MM. Melanoma Res. 2022 Feb 1;32(1):35-44. doi: 10.1097/CMR.0000000000000793.

PMID: 34855329

Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.

Furie RA, Hough DR, Gaudy A, Ye Y, Korish S, Delev N, Weiswasser M, Zhan X, Schafer PH, Werth VP. Lupus Sci Med. 2022 Feb;9(1):e000581. doi: 10.1136/lupus-2021-000581.

PMID: 35169036

Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.

Oncotarget. 2022 Jan 31;13:257-270. doi: 10.18632/oncotarget.28178. eCollection 2022.

PMID: 35111281

An imidazoacridine-based TADF material as an effective organic photosensitizer for visible-light-promoted [2 + 2] cycloaddition.

Sauvé ER, Mayder DM, Kamal S, Oderinde MS, Hudson ZM.

Chem Sci. 2022 Jan 27;13(8):2296-2302. doi: 10.1039/d1sc05098b. eCollection 2022 Feb 23.

PMID: 35310486

Improved therapeutic index of an acidic pH-selective antibody.

Lee PS, MacDonald KG, Massi E, Chew PV, Bee C, Perkins P, Chau B, Thudium K, Lohre J, Nandi P, Deyanova EG, Barman I, Gudmundsson O, Dollinger G, Sproul T, Engelhardt JJ, Strop P, Rajpal A. MAbs. 2022 Jan-Dec;14(1):2024642. doi: 10.1080/19420862.2021.2024642.

PMID: 35192429

Synthesis and evaluation of potent yaku'amide A analogs.

Lo CCL, Joaquin D, Moyá DA, Ramos A, Kastner DW, White SM, Christensen BL, Naglich JG, Degnen WJ, Castle SL.

Chem Sci. 2022 Jan 3;13(7):1899-1905. doi: 10.1039/d1sc05992k. eCollection 2022 Feb 16.

PMID: 35308852

Defining a Standard Set of Health Outcomes for Patients With Squamous Cell Carcinoma of the Head and Neck in Spain.

Arrazubi V, Cajaraville G, Cantero D, Giralt J, Mesia R, Monje F, Rueda A, Sistiaga A, Suarez J, Mut A, Comellas M, Lizán L.

Front Oncol. 2022 Jan 24;11:747520. doi: 10.3389/fonc.2021.747520. eCollection 2021.

PMID: 35141139

The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis.

Tremblay D, Cavalli L, Sy O, Rose S, Mascarenhas J.

Clin Lymphoma Myeloma Leuk. 2022 Jan 8:S2152-2650(22)00004-0. doi: 10.1016/j.clml.2022.01.003. Online ahead of print.

PMID: 35120852

Procedural complications associated with invasive diagnostic procedures after lung cancer screening with low-dose computed tomography.

Yang S, Shih YT, Huo J, Mehta HJ, Wu Y, Salloum RG, Alvarado M, Zhang D, Braithwaite D, Guo Y, Bian J.

Lung Cancer. 2022 Jan 4;165:141-144. doi: 10.1016/j.lungcan.2021.12.020. Online ahead of print.

PMID: 35124410

Upstream cell culture process characterization and in-process control strategy development at pandemic speed.

Xu J, Ou J, McHugh KP, Borys MC, Khetan A.

MAbs. 2022 Jan-Dec;14(1):2060724. doi: 10.1080/19420862.2022.2060724.

PMID: 35380922

Modification of treatment-sequence model with a customizable number of treatments to better reflect contemporary and future clinical practice in moderate to severe psoriasis.

van de Wetering G, Ignacio T, Dhanda D, Patel V, Zhang Y, Zhuo J.

J Med Econ. 2022 Jan-Dec;25(1):421-427. doi: 10.1080/13696998.2022.2051912.

PMID: 35297738

Apixaban for Secondary Stroke Prevention: Coexistant Cerebral Atherosclerosis May Increase Recurrent Strokes.

Kim JS, Koo J, Shin DI, Kim BS, Kim J, Kim EG, Hong KS, Yi H.

J Stroke. 2022 Jan;24(1):118-127. doi: 10.5853/jos.2021.02355. Epub 2022 Jan 31.

PMID: 35135065

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators.

N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.

PMID: 34986285

Relationship Between Endoscopic and Clinical Disease Activity With Fatigue in Inflammatory Bowel Disease.

Kamp KJ, Clark-Snustad K, Barahimi M, Lee S.

Gastroenterol Nurs. 2022 Jan-Feb 01;45(1):21-28. doi: 10.1097/SGA.0000000000000600.

PMID: 35020629

The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors.

Wang T, Kadow JF, Meanwell NA, Krystal M.

Adv Exp Med Biol. 2022;1366:45-64. doi: 10.1007/978-981-16-8702-0_4.

PMID: 35412134

Virtual Populations for Quantitative Systems Pharmacology Models.

Cheng Y, Straube R, Alnaif AE, Huang L, Leil TA, Schmidt BJ.

Methods Mol Biol. 2022;2486:129-179. doi: 10.1007/978-1-0716-2265-0_8.

PMID: 35437722

Removal of lycopene substrate inhibition enables high carotenoid productivity in Yarrowia lipolytica.

Ma Y, Liu N, Greisen P, Li J, Qiao K, Huang S, Stephanopoulos G.

Nat Commun. 2022 Jan 31;13(1):572. doi: 10.1038/s41467-022-28277-w.

PMID: 35102143

TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.

Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y.

Stat Med. 2022 Jan 31. doi: 10.1002/sim.9337. Online ahead of print.

PMID: 35098585

Design for Solubility May Reveal Induction of Amide Hydrogen/Deuterium Exchange by Protein Self-Association.

Trainor K, Doyle CM, Metcalfe-Roach A, Steckner J, Lipovšek D, Malakian H, Langley D, Krystek SR Jr, Meiering EM.

J Mol Biol. 2022 Jan 30;434(2):167398. doi: 10.1016/j.jmb.2021.167398. Epub 2021 Dec 10.

PMID: 34902431

Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis.

Tang H, Li J, Zinker B, Boehm S, Mauer A, Rex-Rabe S, Glaser KJ, Fronheiser M, Bradstreet T, Nakao Y, Petrone T, Pena A, Villano M, Chow P, Malhi H, Charles ED, Hayes W, Ehman RL, Du S, Yin M.

J Magn Reson Imaging. 2022 Jan 29. doi: 10.1002/jmri.28077. Online ahead of print.

PMID: 35092323

Nucleation in protein aggregation in biotherapeutic development: a look into the heart of the event.

Das TK, Chou DK, Jiskoot W, Arosio P.

J Pharm Sci. 2022 Jan 27:S0022-3549(22)00029-6. doi: 10.1016/j.xphs.2022.01.017. Online ahead of print.

PMID: 35093334

Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data.

Danese M, Gricar J, Abraham P.

Future Oncol. 2022 Jan 27. doi: 10.2217/fon-2021-0460. Online ahead of print.

PMID: 35081734

Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278.

Gill MW, Murphy BJ, Cheng PPT, Sivaraman L, Davis M, Lehman-McKeeman L.

Toxicol Appl Pharmacol. 2022 Jan 25:115885. doi: 10.1016/j.taap.2022.115885. Online ahead of print.

PMID: 35090952

Real-world treatment patterns in resectable (stages I-III) non-small-cell lung cancer: a systematic literature review.

Waser N, Vo L, McKenna M, Penrod JR, Goring S.

Future Oncol. 2022 Jan 25. doi: 10.2217/fon-2021-1417. Online ahead of print.

PMID: 35073732

Treatment Patterns Among Patients with Rheumatoid Arthritis in Puerto Rico.

Miranda EM, Han X, Park SH, Suri S, Suryavanshi M.

Rheumatol Ther. 2022 Jan 24. doi: 10.1007/s40744-021-00408-7. Online ahead of print.

PMID: 35076904

Mechanistic insights into inter-chain disulfide bond reduction of IgG1 and IgG4 antibodies.

Song Y, Cai H, Tan Z, Mussa N, Li ZJ.

Appl Microbiol Biotechnol. 2022 Jan 24. doi: 10.1007/s00253-022-11778-5. Online ahead of print.

PMID: 35072737

Stress Factors in Primary Packaging, Transportation and Handling of Protein Drug Products and Their Impact on Product Quality.

Narhi LO, Chou DK, Christian TR, Gibson S, Jagannathan B, Jiskoot W, Jordan S, Sreedhara A, Waxman L, Das TK.

J Pharm Sci. 2022 Jan 23:S0022-3549(22)00021-1. doi: 10.1016/j.xphs.2022.01.011. Online ahead of print.

PMID: 35081407

[RWD] conditional borrowing external data to establish a hybrid control arm in randomized clinical trials.

Li H, Tiwari R, Li QH.

J Biopharm Stat. 2022 Jan 23:1-15. doi: 10.1080/10543406.2021.2021227. Online ahead of print.

PMID: 35067183

Cation Exchange as a Single Polishing Step for Conjugated Peptides.

Rockwell L, Bao H, Insaidoo F, Ikechukwu I, Tugcu N, Kandula S.

Biotechnol Prog. 2022 Jan 23:e3238. doi: 10.1002/btpr.3238. Online ahead of print.

PMID: 35066999

Zero-Inflated Binomial Model for Meta-Analysis and Safety-Signal Detection.

Chakraborty A, Xu J, Tiwari R.

Ther Innov Regul Sci. 2022 Jan 22. doi: 10.1007/s43441-021-00353-1. Online ahead of print.

PMID: 35064554

Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate).

Baran SW, Brown PC, Baudy AR, Fitzpatrick SC, Frantz C, Fullerton A, Gan J, Hardwick RN, Hillgren KM, Kopec AK, Liras JL, Mendrick DL, Nagao R, Proctor WR, Ramsden D, Ribeiro AJS, Stresser D, Sung KE, Sura R, Tetsuka K, Tomlinson L, Van Vleet T, Wagoner MP, Wang Q, Arslan SY, Yoder G, Ekert JE.

ALTEX. 2022 Jan 21. doi: 10.14573/altex.2112203. Online ahead of print.

PMID: 35064273

Comparison of approaches for measuring adherence and persistence to oral oncologic therapies in patients diagnosed with metastatic renal cell carcinoma.

Chun DS, Hicks B, Peacock Hinton S, Jonsson-Funk M, Gooden K, Keil AP, Tan HJ, Stürmer T, Lund JL.

Cancer Epidemiol Biomarkers Prev. 2022 Jan 21:cebp.0341.2021. doi: 10.1158/1055-9965.EPI-21-0341. Online ahead of print.

PMID: 35064061

Surface Enrichment of Surfactants in Amorphous Drugs: An X-ray Photoelectron Spectroscopy Study.

Yu J, Li Y, Yao X, Que C, Huang L, Hui HW, Gong Y, Qian F, Yu L.

Mol Pharm. 2022 Jan 21. doi: 10.1021/acs.molpharmaceut.1c00786. Online ahead of print.

PMID: 35060740

Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).

Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue MH, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R.

J Clin Oncol. 2022 Jan 20;40(3):242-251. doi: 10.1200/JCO.21.01815. Epub 2021 Nov 29.

PMID: 34843406

Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.

Shah H, Wang Y, Cheng SC, Gunasti L, Chen YH, Lako A, Guenette J, Rodig S, Jo VY, Uppaluri R, Haddad R, Schoenfeld JD, Jacene HA.

JAMA Otolaryngol Head Neck Surg. 2022 Jan 20. doi: 10.1001/jamaoto.2021.4052. Online ahead of print.

PMID: 35050348

Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma.

Signorovitch J, Moshyk A, Zhao J, Le TK, Burns L, Gooden K, Hamilton M.

Future Oncol. 2022 Jan 20. doi: 10.2217/fon-2021-1054. Online ahead of print.

PMID: 35048743

Emotional processing intervention (EMOPRINT): A blinded randomized control trial to treat facial affect recognition deficits in multiple sclerosis.

Genova HM, Lancaster K, Myszko Z, Morecraft J, Leddy J, Smith A, Chiaravalloti N, Lengenfelder J.

Mult Scler Relat Disord. 2022 Jan 19;59:103536. doi: 10.1016/j.msard.2022.103536. Online ahead of print.

PMID: 35093842

GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile.

Dicker I, Jeffrey JL, Protack T, Lin Z, Cockett M, Chen Y, Sit SY, Gartland M, Meanwell NA, Regueiro-Ren A, Drexler D, Cantone J, McAuliffe B, Krystal M.

Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0187621. doi: 10.1128/AAC.01876-21. Epub 2021 Nov 15.

PMID: 34780263

Patterned microfluidic devices for rapid screening of metal-organic frameworks yield insights into polymorphism and non-monotonic growth.

Coliaie P, Bhawnani RR, Prajapati A, Ali R, Verma P, Giri G, Kelkar MS, Korde A, Langston M, Liu C, Nazemifard N, Patience D, Rosenbaum T, Skliar D, Nere NK, Singh MR.

Lab Chip. 2022 Jan 18;22(2):211-224. doi: 10.1039/d1lc01086g.

PMID: 34989369

Nonclinical toxicology development of a novel antibody antibiotic conjugate for treating invasive Staphylococcus Aureus infections.

Stagg NJ, Katavolos P, Achilles Poon K, Zhong S, Ljumanovic N, Kamath A, Cai H, Carrasco-Triguero M, Halpern W.

Toxicol Appl Pharmacol. 2022 Jan 15;435:115811. doi: 10.1016/j.taap.2021.115811. Epub 2021 Dec 9.

PMID: 34896194

Industry White Paper: Contemporary Opportunities and Challenges in Characterizing Crystallinity in Amorphous Solid Dispersions.

Chasse T, Conway SL, Danzer GD, Feng L, Leone AM, McNevin M, Smoliga J, Stroud PA, van Lishaut H.

J Pharm Sci. 2022 Jan 15:S0022-3549(22)00009-0. doi: 10.1016/j.xphs.2022.01.007. Online ahead of print.

PMID: 35041831

Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs.

Deitelzweig S, Sah J, Kang A, Russ C, Preib M, Dhamane AD, Ratiu A, Cato M, Alfred T, Levi E, Di Fusco M.

Am J Cardiol. 2022 Jan 15;163:43-49. doi: 10.1016/j.amjcard.2021.09.047.

PMID: 34930532

Correction to: Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.

Abbiati RA, Pourdehnad M, Carrancio S, Pierce DW, Kasibhatla S, McConnell M, Trotter MWB, Loos R, Santini CC, Ratushny AV.

AAPS J. 2022 Jan 14;24(1):29. doi: 10.1208/s12248-021-00673-y.

PMID: 35038051

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB.

Dermatol Ther (Heidelb). 2022 Jan 13. doi: 10.1007/s13555-021-00649-y. Online ahead of print.

PMID: 35025062

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.

Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, Apolo AB, Choueiri TK.

Lancet Oncol. 2022 Jan 12:S1470-2045(21)00693-8. doi: 10.1016/S1470-2045(21)00693-8. Online ahead of print.

PMID: 35032437

Assessing detergent-mediated virus inactivation, protein stability and impurity clearance in biologics downstream processes.

Feroz H, Chennamsetty N, Byers S, Holstein M, Li ZJ, Ghose S.

Biotechnol Bioeng. 2022 Jan 12. doi: 10.1002/bit.28034. Online ahead of print.

PMID: 35023152

5-Bromo-2-chloro-4-fluoro-3-iodopyridine as a Halogen-rich Intermediate for the Synthesis of Pentasubstituted Pyridines.

Wu YJ, Porter GJ, Frennesson DB, Saulnier MG.

J Org Chem. 2022 Jan 12. doi: 10.1021/acs.joc.1c02507. Online ahead of print.

PMID: 35020387

Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations.

Wilczynski O, Boisbouvier A, Radoszycki L, Cotté FE, Gaudin AF, Lemasson H.

J Med Internet Res. 2022 Jan 11;24(1):e25792. doi: 10.2196/25792.

PMID: 35014969

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS.

J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24.

PMID: 34818112

Predicting Food Effects: Are We There Yet?

Emami Riedmaier A.

AAPS J. 2022 Jan 10;24(1):25. doi: 10.1208/s12248-021-00674-x.

PMID: 35006448

Targeted protein degradation: from small molecules to complex organelles-a Keystone Symposia report.

Cable J, Weber-Ban E, Clausen T, Walters KJ, Sharon M, Finley DJ, Gu Y, Hanna J, Feng Y, Martens S, Simonsen A, Hansen M, Zhang H, Goodwin JM, Reggio A, Chang C, Ge L, Schulman BA, Deshaies RJ, Dikic I, Harper JW, Wertz IE, Thomä NH, Słabicki M, Frydman J, Jakob U, David DC, Bennett EJ, Bertozzi CR, Sardana R, Eapen VV, Carra S.

Ann N Y Acad Sci. 2022 Jan 8. doi: 10.1111/nyas.14745. Online ahead of print.

PMID: 35000205

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors.

Gordon MS, Shapiro GI, Sarantopoulos J, Juric D, Lu B, Zarotiadou A, Connarn JN, Le Bruchec Y, Dumitru CD, Harvey RD.

Front Oncol. 2022 Jan 7;11:786120. doi: 10.3389/fonc.2021.786120. eCollection 2021.

PMID: 35070991

Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.

Fernández O, Lázaro-Quintela M, Crespo G, Soto de Prado D, Pinto Á, Basterretxea L, Gómez de Liaño A, Etxaniz O, Blasco S, Gabás-Rivera C, Aceituno S, Palomar V, Polanco-Sánchez C.

Front Oncol. 2022 Jan 7;11:773366. doi: 10.3389/fonc.2021.773366. eCollection 2021.

PMID: 35070976

Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.

Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne BS, Zhong J, Beach CL, Risueño A, Lopes de Menezes D, Ossenkoppele GJ, Döhner H.

Blood. 2022 Jan 7:blood.2021013404. doi: 10.1182/blood.2021013404. Online ahead of print.

PMID: 34995344

Role of membrane structure on the filtrate flux during monoclonal antibody filtration through virus retentive membranes.

Billups M, Minervini M, Holstein M, Feroz H, Ranjan S, Hung J, Bao H, Li ZJ, Ghose S, Zydney AL.

Biotechnol Prog. 2022 Jan 7:e3231. doi: 10.1002/btpr.3231. Online ahead of print.

PMID: 34994527

Pyrazole Containing Anti-HIV Agents: An Update.

Kumar S, Gupta S, Rani V, Sharma P.

Med Chem. 2022 Jan 6. doi: 10.2174/1573406418666220106163846. Online ahead of print.

PMID: 34994333

Patient and caregiver socioeconomic burden of first-line systemic therapy for advanced gastroesophageal adenocarcinoma.

Xiao H, Bertwistle D, Khela K, Middleton-Dalby C, Hall J.

Future Oncol. 2022 Jan 5. doi: 10.2217/fon-2021-1449. Online ahead of print.

PMID: 34984914

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W.

Ann Hematol. 2022 Jan 4. doi: 10.1007/s00277-021-04734-2. Online ahead of print.

PMID: 34981142

Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes.

Vasalou C, Ferguson D, Li W, Muse V, Gibbons FD, Sonzini S, Zhang G, Pop-Damkov P, Gangl E, Balachander SB, Wen S, Schuller AG, Puri S, Mazza M, Ashford M, Fretland AJ, McGinnity DF, Jones RDO.

Mol Pharm. 2022 Jan 3;19(1):172-187. doi: 10.1021/acs.molpharmaceut.1c00715. Epub 2021 Dec 10.

PMID: 34890209

Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.

Hamuro L, Hu Z, Passarell J, Barcomb H, Zhang J, Goldstein S, Bello A, Roy A, Zhu L.

Clin Cancer Res. 2022 Jan 3:clincanres.3149.2021. doi: 10.1158/1078-0432.CCR-21-3149. Online ahead of print.

PMID: 34980597

Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis.

Meehan M, Shah A, Lobo J, Oates J, Clinton C, Annapureddy N, Xie F, Zhuo J, Danila MI, England BR, Curtis JR.

Arthritis Res Ther. 2022 Jan 3;24(1):2. doi: 10.1186/s13075-021-02655-z.

PMID: 34980225

X-ray structure of a human cardiac muscle troponin C/troponin I chimera in two crystal forms.

Yan C, Sack JS.

Acta Crystallogr F Struct Biol Commun. 2022 Jan 1;78(Pt 1):17-24. doi: 10.1107/S2053230X21012395. Epub 2022 Jan 1.

PMID: 34981771

CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial.

Popmihajlov Z, Sutherland DJ, Horan GS, Ghosh A, Lynch DA, Noble PW, Richeldi L, Reiss TF, Greenberg S.

BMJ Open Respir Res. 2022 Jan;9(1):e001060. doi: 10.1136/bmjresp-2021-001060.

PMID: 35058236

The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension.

Yap C, Bedding A, de Bono J, Dimairo M, Espinasse A, Evans J, Hopewell S, Jaki T, Kightley A, Lee S, Liu R, Mander A, Solovyeva O, Weir CJ.

Nat Med. 2022 Jan;28(1):6-7. doi: 10.1038/s41591-021-01594-1.

PMID: 34992264

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B.

Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.

PMID: 34914889

Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.

Reich K, Korge B, Magnolo N, Manasterski M, Schwichtenberg U, Staubach-Renz P, Kaiser S, Roemmler-Zehrer J, Gómez NN, Lorenz-Baath K.

Dermatol Ther (Heidelb). 2022 Jan;12(1):203-221. doi: 10.1007/s13555-021-00658-x. Epub 2021 Dec 15.

PMID: 34913153

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.

Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M.

Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 9.

PMID: 34895481

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Pearson AD, Rossig C, Mackall C, Shah NN, Baruchel A, Reaman G, Ricafort R, Heenen D, Bassan A, Berntgen M, Bird N, Bleickardt E, Bouchkouj N, Bross P, Brownstein C, Cohen SB, de Rojas T, Ehrlich L, Fox E, Gottschalk S, Hanssens L, Hawkins DS, Horak ID, Taylor DH, Johnson C, Karres D, Ligas F, Ludwinski D, Mamonkin M, Marshall L, Masouleh BK, Matloub Y, Maude S, McDonough J, Minard-Colin V, Norga K, Nysom K, Pappo A, Pearce L, Pieters R, Pule M, Quintás-Cardama A, Richardson N, Schüßler-Lenz M, Scobie N, Sersch MA, Smith MA, Sterba J, Tasian SK, Weigel B, Weiner SL, Zwaan CM, Lesa G, Vassal G.

Eur J Cancer. 2022 Jan;160:112-133. doi: 10.1016/j.ejca.2021.10.016. Epub 2021 Nov 25.

PMID: 34840026

Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.

Ide T, Osawa M, Sanghavi K, Vezina HE.

Cancer Chemother Pharmacol. 2022 Jan;89(1):129-140. doi: 10.1007/s00280-021-04365-4. Epub 2021 Nov 26.

PMID: 34825942

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.

Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, Vázquez Limón JC, Sánchez López HM, Armstrong AJ, Horvath L, Bastos DA, Amin NP, Li J, Unsal-Kacmaz K, Retz M, Saad F, Petrylak DP, Pachynski RK.

Eur J Cancer. 2022 Jan;160:61-71. doi: 10.1016/j.ejca.2021.09.043. Epub 2021 Nov 18.

PMID: 34802864

Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study.

Sorensen JB, Horvat P, Rosenlund M, Kejs AM, Patel D, Juarez-Garcia A, Lacoin L, Daumont MJ, Penrod JR, O'Donnell JC, Brustugun OT, Ekman S.

Future Oncol. 2022 Jan;18(2):205-214. doi: 10.2217/fon-2021-0746. Epub 2021 Nov 17.

PMID: 34784783

Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study.

Yasumatsu R, Shimizu Y, Hanai N, Kariya S, Yokota T, Fujii T, Tsukahara K, Ando M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Nekado T, Yamada T, Homma A.

Int J Clin Oncol. 2022 Jan;27(1):95-104. doi: 10.1007/s10147-021-02047-y. Epub 2021 Nov 13.

PMID: 34773525

Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays.

Ducret A, Ackaert C, Bessa J, Bunce C, Hickling T, Jawa V, Kroenke MA, Lamberth K, Manin A, Penny HL, Smith N, Terszowski G, Tourdot S, Spindeldreher S.

MAbs. 2022 Jan-Dec;14(1):1993522. doi: 10.1080/19420862.2021.1993522.

PMID: 34923896

Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.

Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP.

J Med Econ. 2022 Jan-Dec;25(1):51-58. doi: 10.1080/13696998.2021.2011301.

PMID: 34907813

Machine Learning for In Silico ADMET Prediction.

Jia L, Gao H.

Methods Mol Biol. 2022;2390:447-460. doi: 10.1007/978-1-0716-1787-8_20.

PMID: 34731482

2021 Publications

A Randomized Phase 2 Trial of Azacitidine ± Durvalumab as First-line Therapy for Higher-Risk Myelodysplastic Syndromes.

Zeidan AM, Boss IW, Beach CL, Copeland WB, Thompson EG, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G.

Blood Adv. 2021 Dec 31:bloodadvances.2021005487. doi: 10.1182/bloodadvances.2021005487. Online ahead of print.

PMID: 34972214

Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA₁) antagonists.

Sivaraman L, Gill M, Nelson DM, Chadwick KD.

Toxicol Appl Pharmacol. 2021 Dec 30:115846. doi: 10.1016/j.taap.2021.115846. Online ahead of print.

PMID: 34974053

Ligand Enabled Pd(II)-Catalyzed γ-C(sp³)-H Lactamization of Native Amides.

Liu S, Zhuang Z, Qiao JX, Yeung KS, Su S, Cherney EC, Ruan Z, Ewing WR, Poss MA, Yu JQ.

J Am Chem Soc. 2021 Dec 29;143(51):21657-21666. doi: 10.1021/jacs.1c10183. Epub 2021 Dec 16.

PMID: 34914877

Characterization of the Morphological Nature of Hollow Spray Dried Dispersion Particles Using X-ray Submicron-Computed Tomography.

Gamble JF, Tobyn M, Zhang S, Zhu A, Šalplachta J, Matula J, Zikmund T, Kaiser J, Oberta P. AAPS PharmSciTech. 2021 Dec 28;23(1):40. doi: 10.1208/s12249-021-02184-7.

PMID: 34964066

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.

Cohen AT, Sah J, Dhamane AD, Lee T, Rosenblatt L, Hlavacek P, Emir B, Delinger R, Yuce H, Luo X.

Thromb Haemost. 2021 Dec 28. doi: 10.1055/s-0041-1740254. Online ahead of print.

PMID: 34963185

Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021.

Ayodele O, Ren K, Zhao J, Signorovitch J, Jonsson Funk M, Zhu J, Bao Y, Gondek K, Keenan H; R&D COVID Alliance.

PLoS One. 2021 Dec 28;16(12):e0261707. doi: 10.1371/journal.pone.0261707. eCollection 2021.

PMID: 34962924

Behavior of weakly adsorbing protein impurities in flow-through ion-exchange chromatography.

Herman CE, Xu X, Traylor SJ, Ghose S, Li ZJ, Lenhoff AM.

J Chromatogr A. 2021 Dec 27;1664:462788. doi: 10.1016/j.chroma.2021.462788. Online ahead of print.

PMID: 34998025

Effect of Manufacturing Process on the Retention of Abuse-Deterrent Properties of PEO-Matrix Tablets.

Rezaei L, Meruva S, Donovan MD.

AAPS PharmSciTech. 2021 Dec 27;23(1):38. doi: 10.1208/s12249-021-02169-6.

PMID: 34961912

A novel approach to augment single-arm clinical studies with real-world data.

Sachdeva A, Tiwari RC, Guha S.

J Biopharm Stat. 2021 Dec 27:1-17. doi: 10.1080/10543406.2021.2011902. Online ahead of print.

PMID: 34958629

Synergy and Complementarity between Focused Machine Learning and Physics-Based Simulation in Affinity Prediction.

Cleves AE, Johnson SR, Jain AN.

J Chem Inf Model. 2021 Dec 27;61(12):5948-5966. doi: 10.1021/acs.jcim.1c01382. Epub 2021 Dec 10.

PMID: 34890185

Knowledge and Perceptions Regarding Coronavirus (COVID-19) among Pediatric Dentists during Lockdown Period.

Mallineni SK, Nuvvula S, Bhumireddy JC, Ismail AF, Verma P, Sajja R, Alassaf A, Almulhim B, Alghamdi S, Saha A, Goyal V, Namineni S.

Int J Environ Res Public Health. 2021 Dec 25;19(1):209. doi: 10.3390/ijerph19010209.

PMID: 35010473

Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study.

Grimm MO, Grünwald V, Müller-Huesmann H, Ivanyi P, Schostak M, von der Heyde E, Schultze-Seemann W, Belz H, Bögemann M, Wang M, Herber M, Bedke J; NORA Study Group.

Eur Urol Focus. 2021 Dec 23:S2405-4569(21)00306-0. doi: 10.1016/j.euf.2021.11.006. Online ahead of print.

PMID: 34953677

Inter-individual variability and differential tissue abundance of mitochondrial amidoxime reducing component (mARC) in humans.

Ahire D, Basit A, Christopher LJ, Iyer R, Leeder JS, Prasad B.

Drug Metab Dispos. 2021 Dec 23:DMD-AR-2021-000805. doi: 10.1124/dmd.121.000805. Online ahead of print.

PMID: 34949674

Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA.

Harrold LR, Connolly SE, Wittstock K, Zhuo J, Kelly S, Lehman T, Shan Y, Rebello S, Guo L, Khaychuk V.

Rheumatol Ther. 2021 Dec 23. doi: 10.1007/s40744-021-00401-0. Online ahead of print.

PMID: 34940957

Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.

Geynisman DM, Du EX, Yang X, Sendhil SR, Tejo VD, Betts KA, Huo S.

Future Oncol. 2021 Dec 23. doi: 10.2217/fon-2021-1109. Online ahead of print.

PMID: 34939424

Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001.

Nagy MA, Hilgraf R, Mortensen DS, Elsner J, Norris S, Tikhe J, Yoon W, Paisner D, Delgado M, Erdman P, Haelewyn J, Khambatta G, Xu L, Romanow WJ, Condroski K, Bahmanyar S, McCarrick M, Benish B, Blease K, LeBrun L, Moghaddam MF, Apuy J, Canan SS, Bennett BL, Satoh Y.

J Med Chem. 2021 Dec 23;64(24):18193-18208. doi: 10.1021/acs.jmedchem.1c01716. Epub 2021 Dec 13.

PMID: 34894681

Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure.

Meng W, Pi Z, Brigance R, Rossi KA, Schumacher WA, Bostwick JS, Gargalovic PS, Onorato JM, Luk CE, Generaux CN, Wang T, Wexler RR, Finlay HJ.

J Med Chem. 2021 Dec 23;64(24):18102-18113. doi: 10.1021/acs.jmedchem.1c01504. Epub 2021 Dec 2.

PMID: 34855405

Oliva EN, Platzbecker U, Garcia-Manero G, Mufti GJ, Santini V, Sekeres MA, Komrokji RS, Shetty JK, Tang D, Guo S, Liao W, Zhang G, Ha X, Ito R, Lord-Bessen J, Backstrom JT, Fenaux P.

J Clin Med. 2021 Dec 22;11(1):27. doi: 10.3390/jcm11010027.

PMID: 35011768

Overcoming IMiD Resistance in T-cell Lymphomas Through Potent Degradation of ZFP91 and IKZF1.

Wu W, Nelson G, Koch R, Donovan KA, Nowak RP, Heavican-Foral TB, Nirmal AJ, Liu H, Yang L, Duffy J, Powers F, Stevenson KE, Jones M, Ng SY, Wu G, Jain S, Xu R, Amaka S, Trevisani C, Donaldson N, Hagner PR, de Leval L, Gaulard P, Iqbal J, Thakurta A, Fischer ES, Adelman K, Weinstock DM.

Blood. 2021 Dec 22:blood.2021014701. doi: 10.1182/blood.2021014701. Online ahead of print.

PMID: 34936696

Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia.

Zeidan AM, Boss IW, Beach CL, Copeland WB, Thompson EG, Fox BA, Hasle VE, Hellmann A, Taussig D, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR. Blood Adv. 2021 Dec 21:bloodadvances.2021006138. doi: 10.1182/bloodadvances.2021006138. Online ahead of print.

PMID: 34933333

Delforge M, Shah N, San-Miguel JF, Braverman J, Dhanda DS, Shi L, Guo S, Yu P, Liao W, Campbell TB, Munshi NC.

Blood Adv. 2021 Dec 21:bloodadvances.2021005913. doi: 10.1182/bloodadvances.2021005913. Online ahead of print.

PMID: 34933328

Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.

Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF, Choudhury L, Zemanek D, Zwas DR, Jacoby D, Wang A, Ho CY, Li W, Sehnert AJ, Olivotto I, Abraham TP.

J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381.

PMID: 34915982

Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial.

Fudim M, Wojdyla DM, Alexander JH, Goodman SG, Mehran R, Windecker S, Aronson R, Vinereanu D, Halvorsen S, Bahit MC, Granger CB, Lopes RD.

J Am Heart Assoc. 2021 Dec 21;10(24):e023143. doi: 10.1161/JAHA.121.023143. Epub 2021 Dec 7.

PMID: 34873913

Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation.

Mamas MA, Batson S, Pollock KG, Grundy S, Matthew A, Chapman C, Manuel JA, Farooqui U, Mitchell SA.

Am J Cardiol. 2021 Dec 20:S0002-9149(21)01148-6. doi: 10.1016/j.amjcard.2021.11.021. Online ahead of print.

PMID: 34949473

Rapid at-line early cell death quantification using capacitance spectroscopy.

Wu S, Ketcham SA, Corredor CC, Both D, Drennen JK, Anderson CA.

Biotechnol Bioeng. 2021 Dec 19. doi: 10.1002/bit.28011. Online ahead of print.

PMID: 34927241

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways.

Ortiz-Estévez M, Towfic F, Flynt E, Stong N, Jang IS, Wang K, Trotter MWB, Thakurta A.

BMC Med Genomics. 2021 Dec 18;14(1):295. doi: 10.1186/s12920-021-01140-5.

PMID: 34922559

Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial.

Branchoux S, Sofeu CL, Gaudin AF, Kurt M, Moshyk A, Italiano A, Bellera C, Rondeau V.

ESMO Open. 2021 Dec 17;7(1):100340. doi: 10.1016/j.esmoop.2021.100340.

PMID: 34929616

Prevalence of pre-existing neutralizing antibodies against AAV serotypes 1, 2, 5, 6, 8, and 9 in sera of different pig strains.

Dai Y, Kavita U, Lampen MH, Gielen S, Banks G, Levesque PC, Kozhich A, Pillutla RC, Zhang YJ, Jawa V, Adam LP.

Hum Gene Ther. 2021 Dec 16. doi: 10.1089/hum.2021.213. Online ahead of print.

PMID: 34913759

A Cluster of Articles in Memory of Wim Jiskoot, Ph.D.

Crommelin DJA, Narhi LO, Das TK.

J Pharm Sci. 2021 Dec 15:S0022-3549(21)00688-2. doi: 10.1016/j.xphs.2021.12.010. Online ahead of print.

PMID: 34919968

Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung).

Sebastian M, Gröschel A, Gütz S, Schulz H, Müller-Huesmann H, Liersch R, von der Heyde E, Wiegand J, Ukena D, Bargon J, Schütte W, Riera-Knorrenschild J, Fischer JR, Griesinger F, Allan V, Waldenberger D, Schumann C.

J Immunother. 2021 Dec 15. doi: 10.1097/CJI.0000000000000397. Online ahead of print.

PMID: 34908007

Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn's Disease.

Bhattacharya A, Travis D, Osterman MT, Lewis JD, Bhagya Rao B, Lee H, Lichtenstein GR.

J Clin Gastroenterol. 2021 Dec 15. doi: 10.1097/MCG.0000000000001637. Online ahead of print.

PMID: 34907922

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.

Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF.

Clin Cancer Res. 2021 Dec 15;27(24):6687-6695. doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10.

PMID: 34759043

High-Throughput Surface Plasmon Resonance Biosensors for Identifying Diverse Therapeutic Monoclonal Antibodies.

Matharu Z, Bee C, Schwarz F, Chen H, Tomlinson M, Wu G, Rakestraw G, Hornsby M, Drake A, Strop P, Rajpal A, Dollinger G.

Anal Chem. 2021 Dec 14;93(49):16474-16480. doi: 10.1021/acs.analchem.1c03548. Epub 2021 Dec 2.

PMID: 34854675

Mass spectrometric based investigation of differentially protected Azatryptophan derivatives by using Orbitrap MS: Differentiation of positional isomers under protonation and alkali-cationization conditions.

Gajjela R, Kandula RR, Kuppusamy P, Nimje RY, Gupta A, Bagadi M, Mathur A.

Rapid Commun Mass Spectrom. 2021 Dec 13:e9239. doi: 10.1002/rcm.9239. Online ahead of print.

PMID: 34904316

Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.

Desai N, Xie J, Wang Y, Sutton MB, Whang J, Fine JT, Garrison LP.

Jr. Clin Ther. 2021 Dec 12:S0149-2918(21)00460-4. doi: 10.1016/j.clinthera.2021.11.006. Online ahead of print.

PMID: 34911641

Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.

Geynisman DM, Broughton E, Hao Y, Zhang Y, Le T, Huo S.

Urol Oncol. 2021 Dec 11:S1078-1439(21)00510-X. doi: 10.1016/j.urolonc.2021.11.014. Online ahead of print.

PMID: 34906410

Development, psychometric evaluation and cognitive debriefing of the rheumatoid arthritis symptom and impact questionnaire (RASIQ).

Becker B, Bracher M, Chauhan D, Rendas-Baum R, Lin X, Raymond K, O'Connor M, Kosinski M.

J Patient Rep Outcomes. 2021 Dec 11;5(1):129. doi: 10.1186/s41687-021-00400-3.

PMID: 34894330

Comparative Safety and Effectiveness of Apixaban vs. Warfarin in Oral Anticoagulant-Naïve Japanese Patients With Non-Valvular Atrial Fibrillation　- A Retrospective Chart Review Study.

Koretsune Y, Hoshino H, Matsuo Y, Ibuki T, Morimoto T.

Circ J. 2021 Dec 10. doi: 10.1253/circj.CJ-21-0682. Online ahead of print.

PMID: 34897136

Cynomolgus Monkey as an Emerging Animal Model to Study Drug Transporters: In Vitro, In Vivo, In Vitro-To-In Vivo Translation.

Shen H, Yang Z, Rodrigues AD.

Drug Metab Dispos. 2021 Dec 10:DMD-MR-2021-000695. doi: 10.1124/dmd.121.000695. Online ahead of print.

PMID: 34893475

Impact of Swelling of Spray Dried Dispersions in Dissolution Media on their Dissolution: An Investigation Based on UV Imaging.

Li J, Zordan C, Ponce S, Lu X.

J Pharm Sci. 2021 Dec 9:S0022-3549(21)00680-8. doi: 10.1016/j.xphs.2021.12.007. Online ahead of print.

PMID: 34896344

Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.

Jabado O, Maldonado MA, Schiff M, Weinblatt ME, Fleischmann R, Robinson WH, He A, Patel V, Greenfield A, Saini J, Galbraith D, Connolly SE.

Rheumatol Ther. 2021 Dec 8. doi: 10.1007/s40744-021-00404-x. Online ahead of print.

PMID: 34878629

Virus inactivation at moderately low pH varies with virus and buffer properties.

Joshi PU, Meingast CL, Xu X, Holstein M, Feroz H, Ranjan S, Ghose S, Li ZJ, Heldt CL. Biotechnol J. 2021 Dec 7:e2100320. doi: 10.1002/biot.202100320. Online ahead of print.

PMID: 34874097

Emerging Challenges and Innovations in Surfactant-mediated Stabilization of Biologic Formulations.

Katz JS, Chou DK, Christian TR, Das TK, Patel M, Singh SN, Wen Y.

J Pharm Sci. 2021 Dec 6:S0022-3549(21)00655-9. doi: 10.1016/j.xphs.2021.12.002. Online ahead of print.

PMID: 34883096

Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective.

Hariparsad N, Ramsden D, Taskar K, Badée J, Venkatakrishnan K, Reddy MB, Cabalu T, Mukherjee D, Rehmel J, Bolleddula J, Emami Riedmaier A, Prakash C, Chanteux H, Mao J, Umehara K, Shah K, De Zwart L, Dowty M, Kotsuma M, Li M, Pilla Reddy V, McGinnity DF, Parrott N.

Clin Pharmacol Ther. 2021 Dec 4. doi: 10.1002/cpt.2503. Online ahead of print.

PMID: 34862964

What makes a good prediction? Feature importance and beginning to open the black box of machine learning in genetics.

Musolf AM, Holzinger ER, Malley JD, Bailey-Wilson JE.

Hum Genet. 2021 Dec 4. doi: 10.1007/s00439-021-02402-z. Online ahead of print.

PMID: 34862561

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults.

Spencer S, Chung JR, Belongia EA, Sundaram M, Meece J, Coleman LA, Zimmerman RK, Nowalk MP, Moehling Geffel K, Ross T, Carter CE, Shay D, Levine M, Liepkalns J, Kim JH, Sambhara S, Thompson MG, Flannery B.

Influenza Other Respir Viruses. 2021 Dec 3. doi: 10.1111/irv.12933. Online ahead of print.

PMID: 34859584

Ligand-controlled divergent dehydrogenative reactions of carboxylic acids via C-H activation.

Wang Z, Hu L, Chekshin N, Zhuang Z, Qian S, Qiao JX, Yu JQ.

Science. 2021 Dec 3;374(6572):1281-1285. doi: 10.1126/science.abl3939. Epub 2021 Nov 11.

PMID: 34762490

Thermodynamic Understanding of an Aza-Michael Reaction Enables Five-Step Synthesis of the Potent Integrin Inhibitor MK-0429.

Gupta A, Condakes ML.

J Org Chem. 2021 Dec 3;86(23):17523-17527. doi: 10.1021/acs.joc.1c02375. Epub 2021 Nov 1.

PMID: 34723526

Fluorescent quantum dots enable SARS-CoV-2 antiviral drug discovery and development.

Gorshkov K, Susumu K, Wolak M, Oh E.

Expert Opin Drug Discov. 2021 Dec 2:1-6. doi: 10.1080/17460441.2022.2005025. Online ahead of print.

PMID: 34817309

Anti-drug Antibody Validation Testing and Reporting Harmonization.

Myler H, Pedras-Vasconcelos J, Phillips K, Hottenstein CS, Chamberlain P, Devanaryan V, Gleason C, Goodman J, Manning MS, Purushothama S, Richards S, Shen H, Zoghbi J, Amaravadi L, Barger T, Bowen S, Bowsher RR, Clements-Egan A, Geng D, Goletz TJ, Gunn GR, Hallett W, Hodsdon ME, Janelsins BM, Jawa V, Kamondi S, Kirshner S, Kramer D, Liang M, Lindley K, Liu S, Liu Z, McNally J, Mikulskis A, Nelson R, Ahbari MR, Qu Q, Ruppel J, Snoeck V, Song A, Yan H, Ware M.

AAPS J. 2021 Dec 1;24(1):4. doi: 10.1208/s12248-021-00649-y.

PMID: 34853961

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD).

Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A.

BMJ Open Respir Res. 2021 Dec;8(1):e001026. doi: 10.1136/bmjresp-2021-001026.

PMID: 34969771

Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T.

ESMO Open. 2021 Dec;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 2.

PMID: 34864501

A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma.

Kato R, Kojima T, Sazuka T, Yamamoto H, Fukuda S, Yamana K, Sugino Y, Hamamoto S, Nakaigawa N, Kabu K, Murakami H, Obara W.

Anticancer Res. 2021 Dec;41(12):6199-6209. doi: 10.21873/anticanres.15439.

PMID: 34848474

Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.

Baas P, Daumont MJ, Lacoin L, Penrod JR, Carroll R, Venkatesan S, Ubhi H, Calleja A, Snee M.

Lung Cancer. 2021 Dec;162:185-193. doi: 10.1016/j.lungcan.2021.11.001. Epub 2021 Nov 10.

PMID: 34823894

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.

Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA.

Lancet Oncol. 2021 Dec;22(12):1692-1704. doi: 10.1016/S1470-2045(21)00545-3. Epub 2021 Nov 10.

PMID: 34774225

High throughput screening data for a case study of CHO cell culture process development.

He Q, Xu J, Vandermark E, Tian J, Qian Y, Chelius C, Lee J, Borys MC, Li ZJ, Pendse G.

Data Brief. 2021 Oct 17;39:107491. doi: 10.1016/j.dib.2021.107491. eCollection 2021 Dec.

PMID: 34712760

Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas.

Gibson EG, Campagne O, Selvo NS, Gajjar A, Stewart CF.

Cancer Chemother Pharmacol. 2021 Dec;88(6):1009-1020. doi: 10.1007/s00280-021-04357-4. Epub 2021 Sep 29.

PMID: 34586478

Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.

Ogasawara K, Wood-Horrall RN, Thomas M, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G.

Cancer Chemother Pharmacol. 2021 Dec;88(6):941-952. doi: 10.1007/s00280-021-04346-7. Epub 2021 Sep 3.

PMID: 34477937

A Metabolomics Approach to Increasing Chinese Hamster Ovary (CHO) Cell Productivity.

Yao G, Aron K, Borys M, Li Z, Pendse G, Lee K.

Metabolites. 2021 Nov 30;11(12):823. doi: 10.3390/metabo11120823.

PMID: 34940581

Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.

Meier-Schiesser B, Mellett M, Ramirez-Fort MK, Maul JT, Klug A, Winkelbeiner N, Fenini G, Schafer P, Contassot E, French LE. Int J Mol Sci. 2021 Nov 28;22(23):12878. doi: 10.3390/ijms222312878.

PMID: 34884681

Dynamic Regulatory Assessment: evolving the European Regulatory Framework for the Benefit of Patients and Public Health-an EFPIA View.

Herrero-Martinez E, Hussain N, Roux NL, MacDonald J, Mayer M, Palacios R, Kühler TC.

Clin Ther. 2021 Nov 27:S0149-2918(21)00456-2. doi: 10.1016/j.clinthera.2021.11.001. Online ahead of print.

PMID: 34848082

Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis.

Heijke R, Björk M, Thyberg I, Kastbom A, McDonald L, Sjöwall C.

Clin Rheumatol. 2021 Nov 27. doi: 10.1007/s10067-021-05982-3. Online ahead of print.

PMID: 34839415

An Interlaboratory Comparison on the Characterization of a Sub-micrometer Polydisperse Particle Dispersion.

Benkstein KD, Balakrishnan G, Bhirde A, Chalus P, Das TK, Do N, Duewer DL, Filonov N, Cheong FC, Garidel P, Gill NS, Grabarek AD, Grier DG, Hadley J, Hollingsworth AD, Howard WW, Jarzębski M, Jiskoot W, Kar SR, Kestens V, Khasa H, Kim YJ, Koulov A, Matter A, Philips LA, Probst C, Ramaye Y, Randolph TW, Ripple DC, Romeijn S, Saggu M, Schleinzer F, Snell JR, Tatarkiewicz JK, Wright HA, Yang DT.

J Pharm Sci. 2021 Nov 20:S0022-3549(21)00612-2. doi: 10.1016/j.xphs.2021.11.006. Online ahead of print.

PMID: 34808214

Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.

Nowakowski GS, Willenbacher W, Greil R, Larsen TS, Patel K, Jäger U, Manges RF, Trümper L, Everaus H, Kalakonda N, Brown P, Jørgensen JM, Cunningham D, Dell'Aringa J, Fox B, Rubio ND, Kilavuz N, Casadebaig ML, Manzke O, Munoz J.

Int J Hematol. 2021 Nov 19. doi: 10.1007/s12185-021-03241-4. Online ahead of print.

PMID: 34797531

Analysis of the Immunogenicity from Abatacept-Treated Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical Trials.

Mora JR, Wong R, Shaikh M, Askelson M.

ACR Open Rheumatol. 2021 Nov 18. doi: 10.1002/acr2.11375. Online ahead of print.

PMID: 34792858

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.

Emamekhoo H, Olsen MR, Carthon BC, Drakaki A, Percent IJ, Molina AM, Cho DC, Bendell JC, Gordan LN, Rezazadeh Kalebasty A, George DJ, Hutson TE, Arrowsmith ER, Zhang J, Zoco J, Johansen JL, Leung DK, Tykodi SS.

Cancer. 2021 Nov 16. doi: 10.1002/cncr.34016. Online ahead of print.

PMID: 34784056

Correction to: Considerations for Updates to ICH Q1 and Q5C Stability Guidelines: Embracing Current Technology and Risk Assessment Strategies.

McMahon ME, Abbott A, Babayan Y, Carhart J, Chen CW, Debie E, Fu M, Hoaglund-Hyzer C, Lennard A, Li H, Mazzeo T, McCaig L, Pischel S, Qiu F, Stephens D, Timpano R, Webb D, Wolfe C, Woodlief K, Wu Y.

AAPS J. 2021 Nov 15;23(6):118. doi: 10.1208/s12248-021-00646-1.

PMID: 34782955

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.

Luo Y, Decato BE, Charles ED, Shevell DE, McNaney C, Shipkova P, Apfel A, Tirucherai GS, Sanyal AJ.

JHEP Rep. 2021 Nov 12;4(1):100392. doi: 10.1016/j.jhepr.2021.100392. eCollection 2022 Jan.

PMID: 34977519

Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.

Rivolo S, Di Fusco M, Polanco C, Kang A, Dhanda D, Savone M, Skandamis A, Kongnakorn T, Soto J.

PLoS One. 2021 Nov 12;16(11):e0259251. doi: 10.1371/journal.pone.0259251. eCollection 2021.

PMID: 34767564

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.

Garcia-Manero G, Mufti Obe GJ, Fenaux P, Buckstein RJ, Santini V, Díez-Campelo M, Finelli C, Ilhan O, Sekeres MA, Zeidan AM, Ito R, Zhang J, Rampersad A, Sinsimer D, Backstrom JT, Platzbecker U, Komrokji RS.

Blood. 2021 Nov 10:blood.2021012589. doi: 10.1182/blood.2021012589. Online ahead of print.

PMID: 34758066

Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.

Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG.

J Allergy Clin Immunol. 2021 Nov 10:S0091-6749(21)01690-0. doi: 10.1016/j.jaci.2021.11.001. Online ahead of print.

PMID: 34767869

Small molecule allosteric inhibitors of RORγt block Th17-dependent inflammation and associated gene expression in vivo.

Saenz SA, Local A, Carr T, Shakya A, Koul S, Hu H, Chourb L, Stedman J, Malley J, D'Agostino LA, Shanmugasundaram V, Malona J, Schwartz CE, Beebe L, Clements M, Rajaraman G, Cho J, Jiang L, Dubrovskiy A, Kreilein M, Shimanovich R, Hamann LG, Escoubet L, Ellis JM.

PLoS One. 2021 Nov 9;16(11):e0248034. doi: 10.1371/journal.pone.0248034. eCollection 2021.

PMID: 34752458

Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.

Soeratram TT, Creemers A, Meijer SL, de Boer OJ, Vos W, Hooijer GK, van Berge Henegouwen MI, Hulshof MC, Bergman JJ, Lei M, Bijlsma MF, Ylstra B, van Grieken NC, van Laarhoven HW.

J Pathol. 2021 Nov 7. doi: 10.1002/path.5832. Online ahead of print.

PMID: 34743329

Development and equivalence of new faces for inclusion in the Childhood Asthma Control Test (C-ACT) response scale.

Sully K, Bonner N, Bradley H, von Maltzahn R, Arbuckle R, Walker-Nthenda L, Mahon A, Becker B, O'Hara L, Bevans KB, Kosinski M, Zeiger RS, Mackenzie R, Nelsen L.

J Patient Rep Outcomes. 2021 Nov 6;5(1):118. doi: 10.1186/s41687-021-00390-2.

PMID: 34743264

Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.

Cathelin S, Sharon D, Subedi A, Cojocari D, Phillips DC, Leverson JD, MacBeth KJ, Nicolay B, Narayanaswamy R, Ronseaux S, Liu G, Chan SM.

Leukemia. 2021 Nov 6. doi: 10.1038/s41375-021-01468-y. Online ahead of print.

PMID: 34743189

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.

Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Leung D, Saggi SS, Lee CW, McHenry MB, Motzer RJ.

Eur Urol. 2021 Nov 5:S0302-2838(21)02069-8. doi: 10.1016/j.eururo.2021.10.001. Online ahead of print.

PMID: 34750035

Acoustic ejection mass spectrometry: Development, applications, and future perspective.

Shou WZ.

Biomed Chromatogr. 2021 Nov 5:e5278. doi: 10.1002/bmc.5278. Online ahead of print.

PMID: 34741338

A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data.

Dudášová J, Laube R, Valiathan C, Wiener MC, Gheyas F, Fišer P, Ivanauskaite J, Liu F, Sachs JR.

NPJ Vaccines. 2021 Nov 4;6(1):133. doi: 10.1038/s41541-021-00377-6.

PMID: 34737322

Evaluating the Combined Impact of Temperature and Application of Interfacial Dilatational Stresses on Surface-mediated Protein Particle Formation in Monoclonal Antibody Formulations.

Griffin VP, Merritt K, Vaclaw C, Whitaker N, Volkin DB, Ogunyankin MO, Pace S, Dhar P.

J Pharm Sci. 2021 Nov 3:S0022-3549(21)00605-5. doi: 10.1016/j.xphs.2021.10.038. Online ahead of print.

PMID: 34742729

Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection.

Chiarot E, Naimo E, Corrado A, Giannetti P, Ros IMY, Bensi G.

Sci Rep. 2021 Nov 1;11(1):21384. doi: 10.1038/s41598-021-00941-z.

PMID: 34725414

Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype.

Hill MD, Quesnelle C, Tokarski J, Fang H, Fanslau C, Haarhoff Z, Kramer M, Madari S, Wiebesiek A, Morrison J, Simmermacher-Mayer J, Sinz M, Westhouse R, Xie C, Zhao J, Huang L, Sheriff S, Yan C, Marsilio F, Everlof G, Zvyaga T, Lee F, Gavai AV, Degnan AP.

Bioorg Med Chem Lett. 2021 Nov 1;51:128376. doi: 10.1016/j.bmcl.2021.128376. Epub 2021 Sep 21.

PMID: 34560263

Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge.

Vincent BG, Szustakowski JD, Doshi P, Mason M, Guinney J, Carbone DP.

JCO Precis Oncol. 2021 Nov;5:51-54. doi: 10.1200/PO.20.00371.

PMID: 34994587

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.

Regan MM, Mantia CM, Werner L, Tarhini AA, Larkin J, Stephen Hodi F, Wolchok J, Postow MA, Stwalley B, Moshyk A, Ritchings C, Re S, van Dijck W, McDermott DF, Atkins MB.

J Immunother Cancer. 2021 Nov;9(11):e003743. doi: 10.1136/jitc-2021-003743.

PMID: 34799400

Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer.

Stump CT, Roehle K, Manjarrez Orduno N, Dougan SK.

Open Biol. 2021 Nov;11(11):210245. doi: 10.1098/rsob.210245. Epub 2021 Nov 17.

PMID: 34784792

Utility of a next-generation framework for assessment of genomic damage: A case study using the pharmaceutical drug candidate etoposide.

Nicolette J, Luijten M, Sasaki JC, Custer L, Embry M, Froetschl R, Johnson G, Ouedraogo G, Settivari R, Thybaud V, Dearfield KL.

Environ Mol Mutagen. 2021 Nov;62(9):512-525. doi: 10.1002/em.22467. Epub 2021 Nov 22.

PMID: 34775645

Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study.

Dhanasiri S, Hollier-Hann G, Stothard C, Dhanda DS, Davies FE, Rodriguez-Otero P.

Clin Ther. 2021 Nov;43(11):1983-1996.e3. doi: 10.1016/j.clinthera.2021.09.013. Epub 2021 Nov 2.

PMID: 34736769

Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration.

Perino AC, Fan J, Schmitt S, Guo JD, Hlavacek P, Din N, Kothari M, Pundi K, Russ C, Emir B, Turakhia MP.

Circ Cardiovasc Qual Outcomes. 2021 Nov;14(11):e008005. doi: 10.1161/CIRCOUTCOMES.121.008005. Epub 2021 Nov 2.

PMID: 34724801

A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.

Shaw JW, Bennett B, Trigg A, DeRosa M, Taylor F, Kiff C, Ntais D, Noon K, King MT, Cocks K.

Value Health. 2021 Nov;24(11):1651-1659. doi: 10.1016/j.jval.2021.05.022. Epub 2021 Aug 26.

PMID: 34711366

Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status.

Cohen AT, Sah J, Dhamane AD, Lee T, Rosenblatt L, Hlavacek P, Emir B, Keshishian A, Yuce H, Luo X.

Adv Ther. 2021 Nov;38(11):5519-5533. doi: 10.1007/s12325-021-01918-0. Epub 2021 Sep 27.

PMID: 34570310

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.

Prawitz T, Popat R, Suvannasankha A, Sarri G, Hughes R, Wang F, Hogea C, Ferrante SA, Gorsh B, Willson J, Kapetanakis V.

Adv Ther. 2021 Nov;38(11):5501-5518. doi: 10.1007/s12325-021-01884-7. Epub 2021 Sep 24.

PMID: 34561812

Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany.

Singh P, McDonald L, Waldenberger D, Welslau M, von der Heyde E, Gauler T, Dietz A.

Head Neck. 2021 Nov;43(11):3540-3551. doi: 10.1002/hed.26853. Epub 2021 Sep 6.

PMID: 34487397

Calculating qualified non-mutagenic impurity levels: Harmonization of approaches.

Graham JC, Powley MW, Udovic E, Glowienke S, Nicolette J, Parris P, Kenyon M, White A, Maisey A, Harvey J, Martin EA, Dowdy E, Masuda-Herrera M, Trejo-Martin A, Bercu J.

Regul Toxicol Pharmacol. 2021 Nov;126:105023. doi: 10.1016/j.yrtph.2021.105023. Epub 2021 Aug 4.

PMID: 34363920

Structural and Thermal Characterization of Halogenated Azidopyridines: Under-Reported Synthons for Medicinal Chemistry.

Mandler MD, Degnan AP, Zhang S, Aulakh D, Georges K, Sandhu B, Sarjeant A, Zhu Y, Traeger SC, Cheng PT, Ellsworth BA, Regueiro-Ren A.

Org Lett. 2021 Oct 29. doi: 10.1021/acs.orglett.1c03201. Online ahead of print.

PMID: 34714083

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases.

Cheng PTW, Kaltenbach RF 3rd, Zhang H, Shi J, Tao S, Li J, Kennedy LJ, Walker SJ, Shi Y, Wang Y, Dhanusu S, Reddigunta R, Kumaravel S, Jusuf S, Smith D, Krishnananthan S, Li J, Wang T, Heiry R, Sum CS, Kalinowski SS, Hung CP, Chu CH, Azzara AV, Ziegler M, Burns L, Zinker BA, Boehm S, Taylor J, Sapuppo J, Mosure K, Everlof G, Guarino V, Zhang L, Yang Y, Ruan Q, Xu C, Apedo A, Traeger SC, Cvijic ME, Lentz KA, Tirucherai G, Sivaraman L, Robl J, Ellsworth BA, Rosen G, Gordon DA, Soars MG, Gill M, Murphy BJ.

J Med Chem. 2021 Oct 28. doi: 10.1021/acs.jmedchem.1c01256. Online ahead of print.

PMID: 34709814

Degradation of Protein Kinases: Ternary Complex, Cooperativity, and Selectivity.

Grigglestone CE, Yeung KS.

ACS Med Chem Lett. 2021 Oct 27;12(11):1629-1632. doi: 10.1021/acsmedchemlett.1c00543. eCollection 2021 Nov 11.

PMID: 34795847

Conversion from Calcineurin Inhibitor to Belatacept-based Maintenance Immunosuppression in Renal Transplant Recipients: a Randomized Phase 3b Trial.

Budde K, Prashar R, Haller H, Rial M, Kamar N, Agarwal A, de Fijter J, Rostaing L, Berger S, Djamali A, Leca N, Allamassey L, Gao S, Polinsky M, Vincenti F.

J Am Soc Nephrol. 2021 Oct 27:ASN.2021050628. doi: 10.1681/ASN.2021050628. Online ahead of print.

PMID: 34706967

Signal transfer in human protein tyrosine phosphatase PTP1B from allosteric inhibitor P00058.

Chirgadze YN, Battaile KP, Likhachev IV, Balabaev NK, Gordon RD, Romanov V, Lin A, Karisch R, Lam R, Ruzanov M, Brazhnikov EV, Pai EF, Neel BG, Chirgadze NY.

J Biomol Struct Dyn. 2021 Oct 27:1-10. doi: 10.1080/07391102.2021.1994879. Online ahead of print.

PMID: 34705594

Long-Acting Tumor-Activated Prodrug of a TGFβR Inhibitor.

Zhang Y, Parrish KE, Tortolani DR, Poss MA, Huang A, Wan H, Purandare AV, Donnell AF, Kempson J, Hou X, Pawluczyk J, Yip S, Luk E, Raghavan N, Swanson J, Smalley J, Murtaza A, Yang Z, Augustine-Rauch K, Lombardo LJ, Borzilleri R.

J Med Chem. 2021 Oct 27. doi: 10.1021/acs.jmedchem.0c02043. Online ahead of print.

PMID: 34704759

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.

Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG.

Blood. 2021 Oct 26:blood.2021011895. doi: 10.1182/blood.2021011895. Online ahead of print.

PMID: 34699592

Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.

Danese MD, Daumont M, Nwokeji E, Gleeson M, Penrod JR, Lubeck D.

Cancer Rep (Hoboken). 2021 Oct 26:e1568. doi: 10.1002/cnr2.1568. Online ahead of print.

PMID: 34698447

A chemometric model for the quantitative determination of isotopic impurities in d3-methylamine hydrochloride by Fourier-transform infrared spectroscopy.

Marriott AS, Boyd AM, Quirk E, Chadwick J.

J Pharm Biomed Anal. 2021 Oct 25;205:114337. doi: 10.1016/j.jpba.2021.114337. Epub 2021 Aug 21.

PMID: 34474232

Integrated plasma proteomics and lung transcriptomics reveal novel biomarkers in idiopathic pulmonary fibrosis.

Sivakumar P, Ammar R, Thompson JR, Luo Y, Streltsov D, Porteous M, McCoubrey C, Cantu E 3rd, Beers MF, Jarai G, Christie JD.

Respir Res. 2021 Oct 24;22(1):273. doi: 10.1186/s12931-021-01860-3.

PMID: 34689792

A Tribute to Professor Saranjit Singh - A Critical Thinker, Innovator, Mentor, and Educator.

Ladumor MK, Paudel A, Modhave D, Sharma S, Balhara A, Singh DK, Ramalingam M, Shah R, Pavankumarraju S, Kurmi M, Mariappan TT, Bhutani H, Prasad B.

J Pharm Sci. 2021 Oct 23:S0022-3549(21)00566-9. doi: 10.1016/j.xphs.2021.10.024. Online ahead of print.

PMID: 34699842

Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists.

Pi Z, Johnson JA, Meng W, Phillips M, Schumacher WA, Bostwick JS, Gargalovic PS, Onorato JM, Generaux CN, Wang T, He Y, Gordon DA, Wexler RR, Finlay HJ.

ACS Med Chem Lett. 2021 Oct 22;12(11):1766-1772. doi: 10.1021/acsmedchemlett.1c00385. eCollection 2021 Nov 11.

PMID: 34795866

Microscale purification in support of high-throughput medicinal chemistry.

Barhate CL, Donnell AF, Davies M, Li L, Zhang Y, Yang F, Black R, Zipp G, Zhang Y, Cavallaro CL, Priestley ES, Weller HN.

Chem Commun (Camb). 2021 Oct 21;57(84):11037-11040. doi: 10.1039/d1cc03791a.

PMID: 34608906

A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.

Tan AR, Chan N, Kiesel BF, Stein MN, Moss RA, Malhotra J, Aisner J, Shah M, Gounder M, Lin H, Kane MP, Lin Y, Ji J, Chen A, Beumer JH, Mehnert JM.

Cancer Chemother Pharmacol. 2021 Oct 20. doi: 10.1007/s00280-021-04350-x. Online ahead of print.

PMID: 34669023

Analysis of N¹⁵-rat growth hormone after incubation with rat subcutaneous tissue and immune cells using ultra-pressure chromatography-mass spectrometry.

Varkhede N, Björn-Hendrik P, Moulder KR, Gao P, Schöneich C, Forrest ML.

Anal Biochem. 2021 Oct 19:114425. doi: 10.1016/j.ab.2021.114425. Online ahead of print.

PMID: 34678250

An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission.

Biavati L, Huff CA, Ferguson A, Sidorski A, Stevens MA, Rudraraju L, Zucchinetti C, Ali SA, Imus P, Gocke CB, Gittelman RM, Johnson S, Sanders C, Vignali M, Gandhi A, Ye X, Noonan KA, Borrello I.

Clin Cancer Res. 2021 Oct 19:clincanres.CCR-21-1916-A.2021. doi: 10.1158/1078-0432.CCR-21-1916. Online ahead of print.

PMID: 34667029

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Döhner H.

Lancet Oncol. 2021 Oct 18:S1470-2045(21)00494-0. doi: 10.1016/S1470-2045(21)00494-0. Online ahead of print.

PMID: 34672961

Sustainable Pd(OAc)₂ /Hydroquinone Cocatalyst System for Cis-Selective Dibenzoyloxylation of 1,3-Cyclohexadiene.

Stamoulis AG, Geng P, Schmidt MA, Eastgate MD, Borovika A, Fraunhoffer KJ, Stahl SS.

Angew Chem Int Ed Engl. 2021 Oct 18;60(43):23182-23186. doi: 10.1002/anie.202108499. Epub 2021 Sep 17.

PMID: 34399005

Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An IQ Consortium Perspective.

Li C, Menon R, Walles M, Singh R, Upreti VV, Brackman D, Lee AJ, Endres CJ, Kumar S, Zhang D, Barletta F, Suri A, Haninzl D, Liao KH, Lalovic B, Beaumont M, Zuo P, Mayer AP, Wei D.

Clin Pharmacol Ther. 2021 Oct 17. doi: 10.1002/cpt.2448. Online ahead of print.

PMID: 34657311

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.

Weber JS, Ascierto PA, Middleton MR, Hennicken D, Zoffoli R, Pieters A, Amadi A, Kupas K, Kotapati S, Moshyk A, Schadendorf D.

Eur J Cancer. 2021 Oct 15:S0959-8049(21)00555-4. doi: 10.1016/j.ejca.2021.08.028. Online ahead of print.

PMID: 34663559

Corrigendum to "Investigation on hot melt extrusion and prediction on 3D printability of pharmaceutical grade polymers" [Int. J. Pharm. 604 (2021) 120755].

Tabriz AG, Scoutaris N, Gong Y, Hui HW, Kumar S, Douroumis D.

Int J Pharm. 2021 Oct 15:121187. doi: 10.1016/j.ijpharm.2021.121187. Online ahead of print.

PMID: 34663522

Real-world assessment of myelodysplastic syndrome: Japanese claims data analysis.

Tsutsué S, Suzuki T, Kim H, Crawford B.

Future Oncol. 2021 Oct 15. doi: 10.2217/fon-2021-0988. Online ahead of print.

PMID: 34652217

Identification of 6-hydroxy-5-phenyl sulfonylpyrimidin-4(1H)-one APJ receptor agonists.

Tora G, Jiang J, Bostwick JS, Gargalovic PS, Onorato JM, Luk CE, Generaux C, Xu C, Galella MA, Wang T, He Y, Wexler RR, Finlay HJ.

Bioorg Med Chem Lett. 2021 Oct 15;50:128325. doi: 10.1016/j.bmcl.2021.128325. Epub 2021 Aug 14.

PMID: 34403724

BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate.

Cherney RJ, Anjanappa P, Selvakumar K, Batt DG, Brown GD, Rose AV, Vuppugalla R, Chen J, Pang J, Xu S, Yarde M, Tebben AJ, Paidi VR, Cvijic ME, Mathur A, Barrish JC, Mandlekar S, Zhao Q, Carter PH.

ACS Med Chem Lett. 2021 Oct 15;12(11):1753-1758.

doi: 10.1021/acsmedchemlett.1c00373. eCollection 2021 Nov 11.

PMID: 34795864

B Cell Mobilization, Dissemination, Fine Tuning of Local Antigen Specificity and Isotype Selection in Asthma.

Ohm-Laursen L, Meng H, Hoehn KB, Nouri N, Jiang Y, Clouser C, Johnstone TG, Hause R, Sandhar BS, Upton NEG, Chevretton EB, Lakhani R, Corrigan CJ, Kleinstein SH, Gould HJ.

Front Immunol. 2021 Oct 14;12:702074. doi: 10.3389/fimmu.2021.702074. eCollection 2021.

PMID: 34721376

Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design.

Subbaiah MAM, Meanwell NA.

J Med Chem. 2021 Oct 14;64(19):14046-14128. doi: 10.1021/acs.jmedchem.1c01215. Epub 2021 Sep 30.

PMID: 34591488

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.

Gavai AV, Norris D, Delucca G, Tortolani D, Tokarski JS, Dodd D, O'Malley D, Zhao Y, Quesnelle C, Gill P, Vaccaro W, Huynh T, Ahuja V, Han WC, Mussari C, Harikrishnan L, Kamau M, Poss M, Sheriff S, Yan C, Marsilio F, Menard K, Wen ML, Rampulla R, Wu DR, Li J, Zhang H, Li P, Sun D, Yip H, Traeger SC, Zhang Y, Mathur A, Zhang H, Huang C, Yang Z, Ranasinghe A, Everlof G, Raghavan N, Tye CK, Wee S, Hunt JT, Vite G, Westhouse R, Lee FY.

J Med Chem. 2021 Oct 14;64(19):14247-14265. doi: 10.1021/acs.jmedchem.1c00625. Epub 2021 Sep 20.

PMID: 34543572

BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage.

Kang Z, Fu P, Alcivar AL, Fu H, Redon C, Foo TK, Zuo Y, Ye C, Baxley R, Madireddy A, Buisson R, Bielinsky AK, Zou L, Shen Z, Aladjem MI, Xia B.

Nat Commun. 2021 Oct 13;12(1):5966. doi: 10.1038/s41467-021-26227-6.

PMID: 34645815

Chemoselective Electrosynthesis Using Rapid Alternating Polarity.

Kawamata Y, Hayashi K, Carlson E, Shaji S, Waldmann D, Simmons BJ, Edwards JT, Zapf CW, Saito M, Baran PS.

J Am Chem Soc. 2021 Oct 13;143(40):16580-16588. doi: 10.1021/jacs.1c06572. Epub 2021 Oct 1.

PMID: 34596395

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S.

J Clin Oncol. 2021 Oct 12:JCO2101015. doi: 10.1200/JCO.21.01015. Online ahead of print.

PMID: 34637336

Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure.

Cheng L, Qiu Y, Schmidt BJ, Wei GW.

J Pharmacokinet Pharmacodyn. 2021 Oct 12. doi: 10.1007/s10928-021-09785-6. Online ahead of print.

PMID: 34637069

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, Kim SW, Borghaei H, O'Byrne KJ, Hellmann MD, Memaj A, Nathan FE, Bushong J, Tran P, Brahmer JR, Reck M.

J Thorac Oncol. 2021 Oct 11:S1556-0864(21)03207-X. doi: 10.1016/j.jtho.2021.09.010. Online ahead of print.

PMID: 34648948

A Selection of Macrocyclic Peptides That Bind STING From an mRNA-Display Library With Split Degenerate Codons.

Lin CW, Harner MJ, Douglas AE, Lafont V, Yu F, Lee VG, Poss MA, Swain JF, Wright M, Lipovšek D.

Angew Chem Int Ed Engl. 2021 Oct 11;60(42):22640-22645. doi: 10.1002/anie.202103043. Epub 2021 Sep 6.

PMID: 34383389

Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis.

Vidula MK, Orlenko A, Zhao L, Salvador L, Small AM, Horton E, Cohen JB, Adusumalli S, Denduluri S, Kobayashi T, Hyman M, Fiorilli P, Magro C, Singh B, Pourmussa B, Greczylo C, Basso M, Ebert C, Yarde M, Li Z, Cvijic ME, Wang Z, Walsh A, Maranville J, Kick E, Luettgen J, Adam L, Schafer P, Ramirez-Valle F, Seiffert D, Moore JH, Gordon D, Chirinos JA.

Eur J Heart Fail. 2021 Oct 10. doi: 10.1002/ejhf.2361. Online ahead of print.

PMID: 34632675

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.

Konecny GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, Ma S, Mahner S, Sehouli J, Fasching PA, Feisel-Schwickardi G, Poelcher M, Roman LD, Rody A, Karlan BY, Mullany SA, Chen H, Ray-Coquard IL, Provencher DM, Yachnin A, Cottu PH, Glaspy JA, Haluska P, Slamon DJ.

Gynecol Oncol. 2021 Oct 9:S0090-8258(21)01413-X. doi: 10.1016/j.ygyno.2021.09.025. Online ahead of print.

PMID: 34642026

The burden of undertreatment and non-treatment among patients with non-valvular atrial fibrillation and elevated stroke risk: a systematic review.

Sussman M, Barnes GD, Guo JD, Tao CY, Gillespie JA, Ferri M, Adair N, Cato MS, Shirkhorshidian I, Di Fusco M.

Curr Med Res Opin. 2021 Oct 9:1-12. doi: 10.1080/03007995.2021.1982684. Online ahead of print.

PMID: 34632887

iNucs: Inter-Nucleosome Interactions.

Oveisi M, Shukla M, Seymen N, Ohno M, Taniguchi Y, Nahata S, Loos R, Mufti GJ, Allshire RC, Dimitrov S, Karimi MM.

Bioinformatics. 2021 Oct 8:btab698. doi: 10.1093/bioinformatics/btab698. Online ahead of print.

PMID: 34623394

Effectiveness and safety of subcutaneous abatacept in biologic-naïve RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study).

Tamura N, Azuma T, Misaki K, Yamaguchi R, Hirano F, Sugiyama E, Kanai D, Murakawa Y, Oribe M, Kimata T, Aoki K, Sugiura T, Takasugi K, Takakubo Y, Tomita Y, Isozaki T, Nanki T, Katsuyama N, Kuroiwa T, Oshikawa H, Kaneko M, Fujinaga H, Saito K, Tanaka E, Inoue E, Yoshizawa Y, Matsumoto S, Yamanaka H, Harigai M.

Mod Rheumatol. 2021 Oct 8:roab090. doi: 10.1093/mr/roab090. Online ahead of print.

PMID: 34915575

Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.

Garcia-Manero G, Döhner H, Wei AH, La Torre I, Skikne B, Beach CL, Santini V.

Clin Lymphoma Myeloma Leuk. 2021 Oct 8:S2152-2650(21)02070-X. doi: 10.1016/j.clml.2021.09.021. Online ahead of print.

PMID: 34758945

Two classes of myosin inhibitors, blebbistatin, and mavacamten, stabilize β-cardiac myosin in different structural and functional states.

Gollapudi SK, Ma W, Chakravarthy S, Combs AC, Sa N, Langer S, Irving TC, Nag S.

J Mol Biol. 2021 Oct 7:167295. doi: 10.1016/j.jmb.2021.167295. Online ahead of print.

PMID: 34627791

Assessment of Transporter-Mediated Drug Interactions for Enasidenib based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Cheng Y, Wang X, Tong Z, Reyes J, Carayannopoulos L, Zhou S, Li Y.

J Clin Pharmacol. 2021 Oct 6. doi: 10.1002/jcph.1979. Online ahead of print.

PMID: 34617279

Phase 1/2a trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors.

Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS.

Clin Cancer Res. 2021 Oct 6:clincanres.1181.2021. doi: 10.1158/1078-0432.CCR-21-1181. Online ahead of print.

PMID: 34615718

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials.

Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster H, Hiddemann W, Marcus RE, Kimby EK, Herold M, Sebban CJ, Gyan E, Foon KA, Nielsen TG, Vitolo U, Salles GA, Shi Q, Flowers CR.

Blood. 2021 Oct 6:blood.2020010263. doi: 10.1182/blood.2020010263. Online ahead of print.

PMID: 34614146

Digital pathology and artificial intelligence in translational medicine and clinical practice.

Baxi V, Edwards R, Montalto M, Saha S.

Mod Pathol. 2021 Oct 5:1-10. doi: 10.1038/s41379-021-00919-2. Online ahead of print.

PMID: 34611303

SMaSh: A Streptavidin Mass Shift Assay for Rapidly Quantifying Target Occupancy by Irreversible Inhibitors.

Labenski MT, Bateman LA, Voortman LT, Giammo G, Cantin S, Qiao L, Corin AF.

Biochemistry. 2021 Oct 5;60(39):2915-2924. doi: 10.1021/acs.biochem.1c00422. Epub 2021 Sep 23.

PMID: 34554726

Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings.

Nguyen HH, Tahirovic YA, Truax VM, Wilson RJ, Jecs E, Miller EJ, Kim MB, Akins NS, Xu L, Jiang Y, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.

ACS Med Chem Lett. 2021 Oct 4;12(10):1605-1612. doi: 10.1021/acsmedchemlett.1c00449. eCollection 2021 Oct 14.

PMID: 34676043

Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma.

Qi YA, Maity TK, Gao S, Gong T, Bahta M, Venugopalan A, Zhang X, Guha U.

Cancers (Basel). 2021 Oct 4;13(19):4977. doi: 10.3390/cancers13194977.

PMID: 34638461

Multi-arm multi-stage clinical trials for time-to-event outcomes.

Dixit V, Mitra P, Simonsen K.

J Biopharm Stat. 2021 Oct 4:1-14. doi: 10.1080/10543406.2021.1979575. Online ahead of print.

PMID: 34606418

BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.

Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, Coste A, Poordad F, Karsdal M, Nielsen M, Goodman Z, Charles ED.

Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181. Online ahead of print.

PMID: 34605045

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.

Bota DA, Mason W, Kesari S, Magge R, Winograd B, Elias I, Reich SD, Levin N, Trikha M, Desjardins A.

Neurooncol Adv. 2021 Oct 2;3(1):vdab142. doi: 10.1093/noajnl/vdab142. eCollection 2021 Jan-Dec.

PMID: 34729484

Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans.

Sharda N, Khandelwal P, Zhang L, Caceres-Cortes J, Marathe P, Chimalakonda A.

Eur J Pharm Sci. 2021 Oct 1;165:105928. doi: 10.1016/j.ejps.2021.105928. Epub 2021 Jul 12.

PMID: 34265405

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach.

Heilbroner SP, Few R, Mueller J, Chalwa J, Charest F, Suryadevara S, Kratt C, Gomez-Caminero A, Dreyfus B, Neilan TG.

J Immunother Cancer. 2021 Oct;9(10):e002545. doi: 10.1136/jitc-2021-002545.

PMID: 34607896

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

ESMO Open. 2021 Oct;6(5):100273. doi: 10.1016/j.esmoop.2021.100273. Epub 2021 Oct 1.

PMID: 34607285

Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project.

Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, Fabrizio D, Funari V, Newberg J, Bruce LK, Chen SJ, Baden J, Barrett JC, Beer P, Butler M, Cheng JH, Conroy J, Cyanam D, Eyring K, Garcia E, Green G, Gregersen VR, Hellmann MD, Keefer LA, Lasiter L, Lazar AJ, Li MC, Macconaill LE, Meier K, Mellert H, Pabla S, Pallavajjalla A, Pestano G, Salgado R, Samara R, Sokol ES, Stafford P, Budczies J, Stenzinger A, Tom W, Valkenburg KC, Wang X, Weigman V, Xie M, Xie Q, Zehir A, Zhao C, Zhao Y, Stewart MD, Allen J; TMB Consortium.

Ann Oncol. 2021 Oct 1:S0923-7534(21)04495-1. doi: 10.1016/j.annonc.2021.09.016. Online ahead of print.

PMID: 34606929

Spatiotemporal proteomic profiling of the pro-inflammatory response to lipopolysaccharide in the THP-1 human leukaemia cell line.

Mulvey CM, Breckels LM, Crook OM, Sanders DJ, Ribeiro ALR, Geladaki A, Christoforou A, Britovšek NK, Hurrell T, Deery MJ, Gatto L, Smith AM, Lilley KS.

Nat Commun. 2021 Oct 1;12(1):5773. doi: 10.1038/s41467-021-26000-9.

PMID: 34599159

The Interplay between Covid-19 and Spondyloarthritis or Its Treatment.

Rosenbaum JT, Weisman MH, Hamilton H, Shafer C, Aslanyan E, Howard RA, Ogle K, Reveille JD, Winthrop KL, Choi D.

J Rheumatol. 2021 Oct 1:jrheum.210742. doi: 10.3899/jrheum.210742. Online ahead of print.

PMID: 34599048

Endogenous plasma kynurenic acid in human: a newly discovered biomarker for drug-drug interactions involving in OAT1 and OAT3 inhibition.

Tang J, Shen H, Zhao X, Holenarsipur VK, Mariappan TT, Zhang Y, Panfen E, Zheng J, Humphreys WG, Lai Y.

Drug Metab Dispos. 2021 Oct 1:DMD-AR-2021-000486. doi: 10.1124/dmd.121.000486.

PMID: 34599018

Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysis.

Tang CH, Furnback W, Wang BCM, Tang J, Tang D, Lu MY, Huang VW, Musallam KM.

Transfusion. 2021 Oct;61(10):2906-2917. doi: 10.1111/trf.16636. Epub 2021 Sep 10.

PMID: 34505291

Yucel E, Zhang S, Panjabi S.

Adv Ther. 2021 Oct;38(10):5002-5024. doi: 10.1007/s12325-021-01872-x. Epub 2021 Sep 9.

PMID: 34499319

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.

Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, Patel A, Shen J, Girgis IG, Banerjee S, Throup J.

Dermatol Ther (Heidelb). 2021 Oct;11(5):1763-1776. doi: 10.1007/s13555-021-00596-8. Epub 2021 Aug 30.

PMID: 34471993

Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.

Mangum DS, Meyer JA, Mason CC, Shams S, Maese LD, Gardiner JD, Downie JM, Pei D, Cheng C, Gleason A, Luo M, Pui CH, Aplenc R, Hunger SP, Loh M, Greaves M, Trede N, Raetz E, Frazer JK, Mullighan CG, Engel ME, Miles RR, Rabin KR, Schiffman JD.

JAMA Oncol. 2021 Oct 1;7(10):1521-1528. doi: 10.1001/jamaoncol.2021.2723.

PMID: 34410295

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.

Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, Tang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA.

Cancer Immunol Res. 2021 Oct;9(10):1202-1213. doi: 10.1158/2326-6066.CIR-20-0983. Epub 2021 Aug 13.

PMID: 34389558

Synthesis of tritium labeled 30-KDa PEG and conjugation to form [3 H]Pegbelfermin.

Easter JA, Tian Y, Burrell RC, Hong Y, Bonacorsi SJ Jr.

J Labelled Comp Radiopharm. 2021 Oct;64(12):477-481. doi: 10.1002/jlcr.3940. Epub 2021 Aug 23.

PMID: 34386991

Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally-mature monkeys.

Thompson KE, Guillot M, Graziano MJ, Mangipudy RS, Chadwick KD.

Toxicol Appl Pharmacol. 2021 Oct 1;428:115673. doi: 10.1016/j.taap.2021.115673. Epub 2021 Aug 6.

PMID: 34364948

Bosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human Hepatocytes.

Oorts M, an Brantegem P, Deferm N, Chatterjee S, Dreesen E, Cooreman A, Vinken M, Richert L, Annaert P.

J Pharmacol Exp Ther. 2021 Oct;379(1):20-32. doi: 10.1124/jpet.121.000695. Epub 2021 Aug 4.

PMID: 34349015

An Intercompany Perspective on Compatibility and In-use Stability Studies to Enable Administration Of Biopharmaceutical Drug Products.

Kamen DE, Crotts G, Narasimhan C, Hu Q, Bhargava AC, Muthurania K, Burton L, Gbormittah FO, Mathews L, Mills B, Hodge T, Saluja S, Singh SN, Tabish T, Wu Y, Stokes ESE.

J Pharm Sci. 2021 Sep 30:S0022-3549(21)00504-9. doi: 10.1016/j.xphs.2021.09.043. Online ahead of print.

PMID: 34600941

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group.

N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.

PMID: 34587385

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.

Van Bockstal MR, Cooks M, Nederlof I, Brinkhuis M, Dutman A, Koopmans M, Kooreman L, van der Vegt B, Verhoog L, Vreuls C, Westenend P, Kok M, van Diest PJ, Nauwelaers I, Laudus N, Denkert C, Rimm D, Siziopikou KP, Ely S, Zardavas D, Roberts M, Floris G, Hartman J, Acs B, Peeters D, Bartlett JMS, Dequeker E, Salgado R, Giudici F, Michiels S, Horlings H, van Deurzen CHM.

Cancers (Basel). 2021 Sep 29;13(19):4910. doi: 10.3390/cancers13194910.

PMID: 34638394

Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.

Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M.

Jpn J Clin Oncol. 2021 Sep 29:hyab161. doi: 10.1093/jjco/hyab161. Online ahead of print.

PMID: 34585728

Ensuring exchangeability in data-based priors for a Bayesian analysis of clinical trials.

Lin J, Gamalo-Siebers M, Tiwari R.

Pharm Stat. 2021 Sep 29. doi: 10.1002/pst.2172. Online ahead of print.

PMID: 34585501

Derivatization and determination of residual N,N-Carbonyldiimidazole by LC for an in-process control test.

Borges-Muñoz A, Patel H, Tattersall P.

J Pharm Biomed Anal. 2021 Sep 28;207:114395. doi: 10.1016/j.jpba.2021.114395. Online ahead of print.

PMID: 34628292

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir.

Wang T, Kadow JF, Meanwell NA.

Med Chem Res. 2021 Sep 28:1-26. doi: 10.1007/s00044-021-02787-6. Online ahead of print.

PMID: 34602806

G protein-coupled receptor kinase 5 regulates thrombin signaling in platelets via PAR-1.

Downes K, Zhao X, Gleadall NS, McKinney H, Kempster C, Batista J, Thomas P, Cooper M, Michael JV, Kreuzhuber R, Wedderburn K, Waller K, Varney B, Verdier H, Kriek N, Ashford SE, Stirrups KE, Dunster JL, McKenzie SE, Ouwehand WH, Gibbins JM, Yang J, Astle WJ, Ma P.

Blood Adv. 2021 Sep 28:bloodadvances.2021005453. doi: 10.1182/bloodadvances.2021005453. Online ahead of print.

PMID: 34581777

Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics.

Chen G, Tao L, Li Z.

Drug Discov Today. 2021 Sep 24:S1359-6446(21)00404-9. doi: 10.1016/j.drudis.2021.09.010. Online ahead of print.

PMID: 34571276

First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.

Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, Seiffert D.

Clin Transl Sci. 2021 Sep 24. doi: 10.1111/cts.13148. Online ahead of print.

PMID: 34558200

Stress Factors in Protein Drug Product Manufacturing and Their Impact on Product Quality.

Das TK, Sreedhara A, Colandene JD, Chou DK, Filipe V, Grapentin C, Searles J, Christian TR, Narhi LO, Jiskoot W. J Pharm Sci. 2021 Sep 23:S0022-3549(21)00500-1. doi: 10.1016/j.xphs.2021.09.030. Online ahead of print.

PMID: 34563537

Matrix and Sampling Effects on Quantification of Protein Biomarkers of Drug-Induced Liver Injury.

Anselm V, Sommersdorf C, Carrasco-Triguero M, Katavolos P, Planatscher H, Steinhilber A, Joos T, Poetz O.

J Proteome Res. 2021 Sep 23. doi: 10.1021/acs.jproteome.1c00478. Online ahead of print.

PMID: 34554759

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.

Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK.

JAMA Oncol. 2021 Sep 23:e213836. doi: 10.1001/jamaoncol.2021.3836. Online ahead of print.

PMID: 34554208

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.

Roboz GJ, Döhner H, Pocock C, Dombret H, Ravandi F, Jang JH, Selleslag D, Mayer J, Martens UM, Liesveld J, Bernal T, Wang MC, Yu P, Shi L, Guo S, La Torre I, Skikne B, Dong Q, Braverman J, Nehme SA, Beach CL, Wei AH.

Haematologica. 2021 Sep 23. doi: 10.3324/haematol.2021.279174. Online ahead of print.

PMID: 34551506

XRCC3 loss leads to midgestational embryonic lethality in mice.

Prakash R, Freyer L, Saiz N, Gavrilov S, Wang RQ, Romanienko PJ, Lacy E, Hadjantonakis AK, Jasin M.

DNA Repair (Amst). 2021 Sep 22;108:103227. doi: 10.1016/j.dnarep.2021.103227. Online ahead of print.

PMID: 34601382

Nature Chose Phosphates and Chemists Should Too: How Emerging P(V) Methods Can Augment Existing Strategies.

Knouse KW, Flood DT, Vantourout JC, Schmidt MA, Mcdonald IM, Eastgate MD, Baran PS.

ACS Cent Sci. 2021 Sep 22;7(9):1473-1485. doi: 10.1021/acscentsci.1c00487. Epub 2021 Sep 10.

PMID: 34584948

TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.

Varricchio L, Iancu-Rubin C, Upadhyaya B, Zingariello M, Martelli F, Verachi P, Clementelli C, Denis JF, Rahman AH, Tremblay G, Mascarenhas J, Mesa RA, O'Connor-McCourt M, Migliaccio AR, Hoffman R.

JCI Insight. 2021 Sep 22;6(18):e145651. doi: 10.1172/jci.insight.145651.

PMID: 34383713

Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer.

Deitelzweig S, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, Klem C, Ferri M, Jiang J, Yuce H, Lip GYH.

JACC CardioOncol. 2021 Sep 21;3(3):411-424. doi: 10.1016/j.jaccao.2021.06.004. eCollection 2021 Sep.

PMID: 34604802

HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.

Rigby W, Buckner JH, Louis Bridges S Jr, Nys M, Gao S, Polinsky M, Ray N, Bykerk V.

Arthritis Res Ther. 2021 Sep 18;23(1):245. doi: 10.1186/s13075-021-02607-7.

PMID: 34537057

Application of natural language processing techniques to identify off-label drug usage from various online health communities.

Dreyfus B, Chaudhary A, Bhardwaj P, Shree VK.

J Am Med Inform Assoc. 2021 Sep 18;28(10):2147-2154. doi: 10.1093/jamia/ocab124.

PMID: 34333625

Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine-1 Phosphate Receptor Subtypes 1 and 5.

Selkirk JV, Dines KC, Yan YG, Ching N, Dalvie D, Biswas S, Bortolato A, Schkeryantz JM, Lopez C, Ruiz I, Hargreaves R.

J Pharmacol Exp Ther. 2021 Sep 17:JPET-AR-2021-000741. doi: 10.1124/jpet.121.000741. Online ahead of print.

PMID: 34535564

Identifying transcriptional programs underlying cancer drug response with TraCe-seq.

Chang MT, Shanahan F, Nguyen TTT, Staben ST, Gazzard L, Yamazoe S, Wertz IE, Piskol R, Yang YA, Modrusan Z, Haley B, Evangelista M, Malek S, Foster SA, Ye X.

Nat Biotechnol. 2021 Sep 16. doi: 10.1038/s41587-021-01005-3. Online ahead of print.

PMID: 34531539

Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays.

Gorovits B, Azadeh M, Buchlis G, Harrison T, Havert M, Jawa V, Long B, McNally J, Milton M, Nelson R, O'Dell M, Richards K, Vettermann C, Wu B.

AAPS J. 2021 Sep 16;23(6):108. doi: 10.1208/s12248-021-00628-3.

PMID: 34529177

Considerations for Updates to ICH Q1 and Q5C Stability Guidelines: Embracing Current Technology and Risk Assessment Strategies.

McMahon ME, Abbott A, Babayan Y, Carhart J, Chen CW, Debie E, Fu M, Hoaglund-Hyzer C, Lennard A, Li H, Mazzeo T, McCaig L, Pischel S, Qiu F, Stephens D, Timpano R, Webb D, Wolfe C, Woodlief K, Wu Y. AAPS

J. 2021 Sep 16;23(6):107. doi: 10.1208/s12248-021-00641-6.

PMID: 34529169

GPR120 inhibits colitis through regulation of CD4+T cell IL-10 production.

Yang W, Liu H, Xu L, Yu T, Zhao X, Yao S, Zhao Q, Barnes S, Cohn SM, Dann SM, Zhang H, Zuo X, Li Y, Cong Y.

Gastroenterology. 2021 Sep 15:S0016-5085(21)03497-1. doi: 10.1053/j.gastro.2021.09.018. Online ahead of print.

PMID: 34536451

Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative.

Snee M, Cheeseman S, Thompson M, Riaz M, Sopwith W, Lacoin L, Chaib C, Daumont MJ,Penrod JR, Hall G.

BMJ Open. 2021 Sep 15;11(9):e046396. doi: 10.1136/bmjopen-2020-046396.

PMID: 34526333

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.

Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA.

Invest New Drugs. 2021 Sep 13. doi: 10.1007/s10637-021-01175-6. Online ahead of print.

PMID: 34515877

Soejima K, Sato H, Hisaka A.

Clin Pharmacokinet. 2021 Sep 13. doi: 10.1007/s40262-021-01069-z. Online ahead of print.

PMID: 34514537

Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.

Support Care Cancer. 2021 Sep 11. doi: 10.1007/s00520-021-06514-0. Online ahead of print.

PMID: 34510238

Decreased cortical Nrf2 gene expression in autism and its relationship to thiol and cobalamin status.

Schrier MS, Zhang Y, Trivedi MS, Deth RC.

Biochimie. 2021 Sep 10:S0300-9084(21)00209-1. doi: 10.1016/j.biochi.2021.09.006. Online ahead of print.

PMID: 34517051

A P(V) platform for oligonucleotide synthesis.

Huang Y, Knouse KW, Qiu S, Hao W, Padial NM, Vantourout JC, Zheng B, Mercer SE, Lopez-Ogalla J, Narayan R, Olson RE, Blackmond DG, Eastgate MD, Schmidt MA, McDonald IM, Baran PS.

Science. 2021 Sep 10;373(6560):1265-1270. doi: 10.1126/science.abi9727. Epub 2021 Sep 9.

PMID: 34516793

Surrogate model to screen for inactivation-based clearance of enveloped viruses during biotherapeutics process development.

Feroz H, Cetnar D, Hewlett R, Sharma S, Holstein M, Ghose S, Li ZJ.

Biotechnol J. 2021 Sep 10:e2100176. doi: 10.1002/biot.202100176. Online ahead of print.

PMID: 34506679

Engineering an Antibody V Gene-Selective Vaccine.

Ronsard L, Yousif AS, Peabody J, Okonkwo V, Devant P, Mogus AT, Barnes RM, Rohrer D, Lonberg N, Peabody D, Chackerian B, Lingwood D.

Front Immunol. 2021 Sep 9;12:730471. doi: 10.3389/fimmu.2021.730471. eCollection 2021.

PMID: 34566992

¹⁸F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study.

Nienhuis PH, Antunes IF, Glaudemans AWJM, Jalving M, Leung D, Noordzij W, Slart RHJA, de Vries EF, Hospers GAP.

J Nucl Med. 2021 Sep 9:jnumed.121.262368. doi: 10.2967/jnumed.121.262368. Online ahead of print.

PMID: 34503964

Mild and Chemoselective Phosphorylation of Alcohols Using a Ψ-Reagent.

Ociepa M, Knouse KW, He D, Vantourout JC, Flood DT, Padial NM, Chen JS, Sanchez BB, Sturgell EJ, Zheng B, Qiu S, Schmidt MA, Eastgate MD, Baran PS.

Org Lett. 2021 Sep 9. doi: 10.1021/acs.orglett.1c02736. Online ahead of print.

PMID: 34499517

Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity.

Elsner J, Cashion D, Robinson D, Bahmanyar S, Tehrani L, Fultz KE, Narla RK, Peng X, Tran T, Apuy J, LeBrun L, Leftheris K, Boylan JF, Zhu D, Riggs JR.

J Med Chem. 2021 Sep 9;64(17):12670-12679. doi: 10.1021/acs.jmedchem.1c00635. Epub 2021 Aug 30.

PMID: 34459599

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.

Richardson PG, Schjesvold F, Weisel K, Moreau P, Anderson LD Jr, White D, Rodriguez-Otero P, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Beksac M, Oriol A, Lindsay J, Liberati AM, Galli M, Robak P, Larocca A, Yagci M, Vural F, Kanate AS, Jiang R, Grote L, Peluso T, Dimopoulos M.

Eur J Haematol. 2021 Sep 8. doi: 10.1111/ejh.13706. Online ahead of print.

PMID: 34496096

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.

Dilger AK, Pabbisetty KB, Corte JR, De Lucca I, Fang T, Yang W, Pinto DJP, Wang Y, Zhu Y, Mathur A, Li J, Hou X, Smith D, Sun D, Zhang H, Krishnananthan S, Wu DR, Myers JE Jr, Sheriff S, Rossi KA, Chacko S, Zheng JJ, Galella MA, Ziemba T, Dierks EA, Bozarth JM, Wu Y, Crain E, Wong PC, Luettgen JM, Wexler RR, Ewing WR.

J Med Chem. 2021 Sep 8. doi: 10.1021/acs.jmedchem.1c00613. Online ahead of print.

PMID: 34494428

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.

Maloney DG, Kuruvilla J, Liu FF, Kostic A, Kim Y, Bonner A, Zhang Y, Fox CP, Cartron G.

J Hematol Oncol. 2021 Sep 8;14(1):140. doi: 10.1186/s13045-021-01144-9.

PMID: 34493319

Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.

Awad MM, Le Bruchec Y, Lu B, Ye J, Miller J, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A.

Front Oncol. 2021 Sep 6;11:696512. doi: 10.3389/fonc.2021.696512. eCollection 2021.

PMID: 34552864

Drug-Polymer Interactions in Acetaminophen/Hydroxypropylmethylcellulose Acetyl Succinate Amorphous Solid Dispersions Revealed by Multidimensional Multinuclear Solid-State NMR Spectroscopy.

Pugliese A, Toresco M, McNamara D, Iuga D, Abraham A, Tobyn M, Hawarden LE, Blanc F.

Mol Pharm. 2021 Sep 6;18(9):3519-3531. doi: 10.1021/acs.molpharmaceut.1c00427. Epub 2021 Aug 10.

PMID: 34375100

Quantitative GC determination of sodium triacetoxyborohydride (STAB).

Hale I, Chadwick J, Wethman R.

J Pharm Biomed Anal. 2021 Sep 5;203:114213. doi: 10.1016/j.jpba.2021.114213. Epub 2021 Jun 16.

PMID: 34252843

Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance.

Harigai M, Tsuritani K, Yoshizawa Y, Atsumi T, Tanaka Y.

Mod Rheumatol. 2021 Sep 4:roab050. doi: 10.1093/mr/roab050. Online ahead of print.

PMID: 34910191

The Super-Relaxed State and Length Dependent Activation in Porcine Myocardium.

Ma W, Henze M, Anderson RL, Gong H, Wong FL, Del Rio CL, Irving T.

Circ Res. 2021 Sep 3;129(6):617-630. doi: 10.1161/CIRCRESAHA.120.318647. Epub 2021 Aug 9.

PMID: 34365814

Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma. Reply.

Bajorin DF, Collette S, Galsky MD.

N Engl J Med. 2021 Sep 2;385(10):957. doi: 10.1056/NEJMc2110897.

PMID: 34469656

Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view.

Thielen FW, Kersten MJ, Kuizenga P, Hoogendoorn M, Posthuma EF, Stevens WB, A Uyl-de Groot C, Blommestein HM.

Expert Rev Anticancer Ther. 2021 Sep 2:1-12. doi: 10.1080/14737140.2021.1971520. Online ahead of print.

PMID: 34428992

Structure of the human marker of self 5-transmembrane receptor CD47.

Fenalti G, Villanueva N, Griffith M, Pagarigan B, Lakkaraju SK, Huang RY, Ladygina N, Sharma A, Mikolon D, Abbasian M, Johnson J, Hadjivassiliou H, Zhu D, Chamberlain PP, Cho H, Hariharan K.

Nat Commun. 2021 Sep 1;12(1):5218. doi: 10.1038/s41467-021-25475-w.

PMID: 34471125

Nickel-Catalyzed 1,2-Carboamination of Alkenyl Alcohols.

Kang T, Kim N, Cheng PT, Zhang H, Foo K, Engle KM.

J Am Chem Soc. 2021 Sep 1;143(34):13962-13970. doi: 10.1021/jacs.1c07112. Epub 2021 Aug 20.

PMID: 34415748

Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study.

Annavarapu S, Gogate A, Pham T, Davies K, Singh P, Robert N.

CNS Oncol. 2021 Sep 1;10(3):CNS76. doi: 10.2217/cns-2021-0007. Epub 2021 Aug 11.

PMID: 34378977

Performance of 3 Composite Measures for Disease Activity in Peripheral Spondyloarthritis.

Beckers E, Been M, Webers C, Boonen A, Ten Klooster PM, Vonkeman HE, van Tubergen A.

J Rheumatol. 2021 Sep 1:jrheum.210075. doi: 10.3899/jrheum.210075. Online ahead of print.

PMID: 34470791

Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.

Desai MY, Wolski K, Owens A, Naidu SS, Geske JB, Smedira NG, Schaff H, Lampl K, McErlean E, Sewell C, Zhang D, Edelberg JM, Sehnert AJ, Nissen SE.

Am Heart J. 2021 Sep;239:80-89. doi: 10.1016/j.ahj.2021.05.007. Epub 2021 May 24.

PMID: 34038706

Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration.

Frost C, Garonzik S, Shenker A, Barrett YC, LaCreta F.

Clin Pharmacol Drug Dev. 2021 Sep;10(9):974-984. doi: 10.1002/cpdd.990. Epub 2021 Aug 2.

PMID: 34342172

Cloud solutions for GxP laboratories: considerations for data storage.

Davis S, Usansky J, Mitra-Kaushik S, Kellie J, Honrine K, Woolf E, Adams J, Kelly R, Evens J, Pine S, Hochreiner H, Dawes M, Kentner J,

Crawford S. Bioanalysis. 2021 Sep;13(17):1313-1321. doi: 10.4155/bio-2021-0137. Epub 2021 Sep 13.

PMID: 34515519

Mapping EQ-5D-3L to EQ-5D-5L.

van Hout BA, Shaw JW.

Value Health. 2021 Sep;24(9):1285-1293. doi: 10.1016/j.jval.2021.03.009. Epub 2021 May 18.

PMID: 34452708

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.

de Botton S, Brandwein JM, Wei AH, Pigneux A, Quesnel B, Thomas X, Legrand O, Recher C, Chantepie S, Hunault-Berger M, Boissel N, Nehme SA, Frattini MG, Tosolini A, Marion-Gallois R, Wang JJ, Cameron C, Siddiqui M, Hutton B, Milkovich G, Stein EM.

Cancer Med. 2021 Sep;10(18):6336-6343. doi: 10.1002/cam4.4182. Epub 2021 Aug 24.

PMID: 34427990

Reduced Compensatory β-Cell Proliferation in Nfatc3-Deficient Mice Fed on High-Fat Diet.

Hu L, He F, Luo Y, Luo H, Hai L, Li Y, Zhou Z, Liu F, Dai YS.

Exp Clin Endocrinol Diabetes. 2021 Sep;129(9):651-660. doi: 10.1055/a-1008-9110. Epub 2019 Sep 23.

PMID: 31546271

Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity Issues.

Li QH, Deng Q, Ting N.

Ther Innov Regul Sci. 2021 Sep;55(5):1001-1005. doi: 10.1007/s43441-021-00299-4. Epub 2021 May 24.

PMID: 34028669

Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.

Ogasawara K, Kam J, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G.

Cancer Chemother Pharmacol. 2021 Sep;88(3):369-377. doi: 10.1007/s00280-021-04292-4. Epub 2021 May 21.

PMID: 34019108

A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma.

Ozawa T, Rodriguez M, Zhao G, Yao TW, Fischer WN, Jandeleit B, Koller K, Nicolaides T.

Cureus. 2021 Aug 31;13(8):e17595. doi: 10.7759/cureus.17595. eCollection 2021 Aug.

PMID: 34646647

Prospective Prediction of Plasma Pharmacokinetics of a Novel Immune-modulating Agent in Cancer Patients after Intra-tumoral Administration: Translation from Non-clinical Species to Humans.

Vuppugalla R, Sane R, Wichroski M, Gavai AK, Boyanapalli S, Yang Z.

Xenobiotica. 2021 Aug 31:1-30. doi: 10.1080/00498254.2021.1934606. Online ahead of print.

PMID: 34461800

Fast and high-resolution purification of a PEGylated protein using a z2 laterally-fed membrane chromatography device.

Chen G, Pagano J, Yu D, Ghose S, Li Z, Ghosh R.

J Chromatogr A. 2021 Aug 30;1652:462375. doi: 10.1016/j.chroma.2021.462375. Epub 2021 Jun 29.

PMID: 34256267

Factors associated with opioid prescriptions among women proximal to pregnancy in the United States.

Chen G, Delcher C, Xiao H, Roussos-Ross D, Huo J, Chen X.

Res Social Adm Pharm. 2021 Aug;17(8):1483-1488. doi: 10.1016/j.sapharm.2020.11.008. Epub 2020 Nov 17.

PMID: 33234451

Sub/supercritical Fluid Chromatography Purification and Desalting of a Cyclic Dinucleotide STING Agonist.

Li P, Yip H, Sun D, Kempson J, Caceres-Cortes J, Mathur A, Wu DR.

J Chromatogr A. 2021 Aug 30;1652:462356. doi: 10.1016/j.chroma.2021.462356. Epub 2021 Jun 22.

PMID: 34218126

Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.

Gasparetto C, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Toomey K, Hardin JW, Wagner L, Ailawadhi S, Omel JL, Srinivasan S, Dhalla M, Catamero D, Kitali A, Agarwal A, Abonour R; Connect MM Registry Investigators.

Clin Lymphoma Myeloma Leuk. 2021 Aug 29:S2152-2650(21)00365-7. doi: 10.1016/j.clml.2021.08.007.

PMID: 34588149

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.

Ravandi F, Roboz GJ, Wei AH, Döhner H, Pocock C, Selleslag D, Montesinos P, Sayar H, Musso M, Figuera-Alvarez A, Safah H, Tse W, Sohn SK, Hiwase D, Chevassut T, Pierdomenico F, La Torre I, Skikne B, Bailey R, Zhong J, Beach CL, Dombret H.

J Hematol Oncol. 2021 Aug 28;14(1):133. doi: 10.1186/s13045-021-01142-x.

PMID: 34454540

Patient-Specific Cell Communication Networks Associate With Disease Progression in Cancer.

Gibbs DL, Aguilar B, Thorsson V, Ratushny AV, Shmulevich I.

Front Genet. 2021 Aug 27;12:667382. doi: 10.3389/fgene.2021.667382. eCollection 2021.

PMID: 34512714

Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.

Abbiati RA, Pourdehnad M, Carrancio S, Pierce DW, Kasibhatla S, McConnell M, Trotter MWB, Loos R, Santini CC, Ratushny AV.

AAPS J. 2021 Aug 27;23(5):103. doi: 10.1208/s12248-021-00623-8.

PMID: 34453265

No ordinary proteins: Adsorption and molecular orientation of monoclonal antibodies.

Kanthe A, Ilott A, Krause M, Zheng S, Li J, Bu W, Bera MK, Lin B, Maldarelli C, Tu RS.

Sci Adv. 2021 Aug 27;7(35):eabg2873. doi: 10.1126/sciadv.abg2873. Print 2021 Aug.

PMID: 34452912

Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005.

Papa P, Whitefield B, Mortensen DS, Cashion D, Huang D, Torres E, Parnes J, Sapienza J, Hansen J, Correa M, Delgado M, Harris R, Hegde S, Norris S, Bahmanyar S, Plantevin-Krenitsky V, Liu Z, Leftheris K, Kulkarni A, Bennett B, Hur EM, Ringheim G, Khambatta G, Chan H, Muir J, Blease K, Burnett K, LeBrun L, Morrison L, Celeridad M, Khattri R, Cathers BE.

J Med Chem. 2021 Aug 26;64(16):11886-11903. doi: 10.1021/acs.jmedchem.1c00388. Epub 2021 Aug 6.

PMID: 34355886

High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study.

Behrens F, Rech J, Thaçi D, Zinke S, Rothnie KJ, Oefner Daamen C, Leipe J.

Mod Rheumatol. 2021 Aug 26:1816597. doi: 10.1080/14397595.2020.1816597. Online ahead of print.

PMID: 34922390

Brief Synopsis: "Instruction Manual for Juvenile Clinical Pathology".

Provencher A, Katavolos P.

Toxicol Pathol. 2021 Aug 25:1926233211041338. doi: 10.1177/01926233211041338. Online ahead of print.

PMID: 34431401

The proliferation of belatacept-resistant T cells requires early IFNα pathway activation.

Herr F, Desterke C, Bargiel K, Vernochet A, Vanhove B, Vadanici R, Ye F, Dekeyser M, Durrbach A.

Am J Transplant. 2021 Aug 24. doi: 10.1111/ajt.16811. Online ahead of print.

PMID: 34431219

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.

Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones JA, Drew J, Wu C, Mulvey E, Revuelta MV, Cerchietti L, Leonard JP.

Blood. 2021 Aug 24:blood.2021011679. doi: 10.1182/blood.2021011679. Online ahead of print.

PMID: 34428285

Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic.

Leung D, Bonacorsi S, Smith RA, Weber W, Hayes W.

Front Oncol. 2021 Aug 23;11:698425. doi: 10.3389/fonc.2021.698425. eCollection 2021.

PMID: 34497758

Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction.

García RA, Lupisella JA, Ito BR, Hsu MY, Fernando G, Carson NL, Allocco JJ, Ryan CS, Zhang R, Wang Z, Heroux M, Carrier M, St-Onge S, Bouvier M, Dudhgaonkar S, Nagar J, Bustamante-Pozo MM, Garate-Carrillo A, Chen J, Ma X, Search DJ, Dierks EA, Kick EK, Wexler RR, Gordon DA, Ostrowski J, Wurtz NR, Villarreal F.

JACC Basic Transl Sci. 2021 Aug 23;6(8):676-689. doi: 10.1016/j.jacbts.2021.07.007. eCollection 2021 Aug.

PMID: 34466754

Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.

Forsberg PA, Rossi AC, Boyer A, Pearse RN, Pekle KA, Jayabalan D, Lakritz S, Flicker K, Ribadeneyra D, Liotta B, Ely S, Boussi L, Allan JN, Coleman M, Niesvizky R, Mark TM.

Am J Hematol. 2021 Aug 23. doi: 10.1002/ajh.26329. Online ahead of print.

PMID: 34424561

Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.

Tsutsué S, Makita S, Yi J, Crawford B.

Future Oncol. 2021 Aug 20:10.2217/fon-2021-0400. doi: 10.2217/fon-2021-0400. Online ahead of print.

PMID: 34414783

A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance.

Anisul M, Shilts J, Schwartzentruber J, Hayhurst J, Buniello A, Shaikho Elhaj Mohammed E, Zheng J, Holmes M, Ochoa D, Carmona M, Maranville J, Gaunt TR, Emilsson V, Gudnason V, McDonagh EM, Wright GJ, Ghoussaini M, Dunham I.

Elife. 2021 Aug 17;10:e69719. doi: 10.7554/eLife.69719.

PMID: 34402426

A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses.

Cimen Bozkus C, Blazquez AB, Enokida T, Bhardwaj N.

STAR Protoc. 2021 Aug 17;2(3):100758. doi: 10.1016/j.xpro.2021.100758. eCollection 2021 Sep 17.

PMID: 34458873

The effect of water on the large-scale supercritical fluid chromatography purification of two factor XIa active pharmaceutical ingredients.

Li P, Wu DR, Yip H, Sun D, Zhang H, Hou X, Kempson J, Mathur A.

J Chromatogr A. 2021 Aug 16;1651:462318. doi: 10.1016/j.chroma.2021.462318. Epub 2021 Jun 4.

PMID: 34161834

Large-scale supercritical fluid chromatography purification of unstable STING agonist intermediates.

Sun D, Wu DR, Li P, Yip H, Wang B, Hou X, Zhao R, Zhang H, Kempson J, Mathur A.

J Chromatogr A. 2021 Aug 16;1651:462309. doi: 10.1016/j.chroma.2021.462309. Epub 2021 Jun 6.

PMID: 34147835

A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia.

Oliva EN, Ronnebaum SM, Zaidi O, Patel DA, Nehme SA, Chen C, Almeida AM.

Am J Blood Res. 2021 Aug 15;11(4):325-360. eCollection 2021.

PMID: 34540343

Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis.

Okubo Y, Ohtsuki M, Komine M, Imafuku S, Kassir N, Petric R, Nemoto O.

J Dermatol. 2021 Aug 15. doi: 10.1111/1346-8138.16068. Online ahead of print.

PMID: 34396569

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.

Qi YA, Maity TK, Cultraro CM, Misra V, Zhang X, Ade C, Gao S, Milewski D, Nguyen KD, Ebrahimabadi MH, Hanada KI, Khan J, Sahinalp C, Yang JC, Guha U.

Mol Cell Proteomics. 2021 Aug 13;20:100136. doi: 10.1016/j.mcpro.2021.100136. Online ahead of print.

PMID: 34391887

Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study.

Tanaka Y, Matsubara T, Hashizume K, Amano N, Takeuchi T.

Mod Rheumatol. 2021 Aug 13:roab029. doi: 10.1093/mr/roab029. Online ahead of print.

PMID: 34897499

Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.

Takeno M, Dobashi H, Tanaka Y, Kono H, Sugii S, Kishimoto M, Cheng S, McCue S, Paris M, Chen M, Ishigatsubo Y.

Mod Rheumatol. 2021 Aug 12:roab008. doi: 10.1093/mr/roab008. Online ahead of print.

PMID: 34894266

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma.

Young MH, Pietz G, Whalen E, Copeland W, Thompson E, Fox BA, Newhall KJ.

Sci Rep. 2021 Aug 12;11(1):16460. doi: 10.1038/s41598-021-95902-x.

PMID: 34385543

Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.

Hartz RA, Ahuja VT, Nara SJ, Kumar CMV, Brown JM, Bristow LJ, Rajamani R, Muckelbauer JK, Camac D, Kiefer SE, Hunihan L, Gulianello M, Lewis M, Easton A, Lippy JS, Surti N, Pattipati SN, Dokania M, Elavazhagan S, Dandapani K, Hamman BD, Allen J, Kostich W, Bronson JJ, Macor JE, Dzierba CD.

J Med Chem. 2021 Aug 12;64(15):11090-11128. doi: 10.1021/acs.jmedchem.1c00472. Epub 2021 Jul 16.

PMID: 34270254

Effective anti-BCMA retreatment in multiple myeloma.

Gazeau N, Beauvais D, Yakoub-Agha I, Mitra S, Campbell TB, Facon T, Manier S.

Blood Adv. 2021 Aug 10;5(15):3016-3020. doi: 10.1182/bloodadvances.2021004176.

PMID: 34351389

A chemoproteomics approach to determine the mechanism of testicular toxicity for the Bruton's tyrosine kinase inhibitor CC-292.

Labenski M, Voortman L, Medikonda AP, Sherratt PJ, Corin AF.

J Pharmacol Exp Ther. 2021 Aug 9:JPET-AR-2021-000614. doi: 10.1124/jpet.121.000614. Online ahead of print.

PMID: 34373353

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment.

Frost CE, Ly V, Garonzik SM.

Drugs R D. 2021 Aug 7. doi: 10.1007/s40268-021-00359-y. Online ahead of print.

PMID: 34363188

Characteristics and outcomes of hospitalised adults with COVID-19 in a Global Health Research Network: a cohort study.

Zhu J, Wei Z, Suryavanshi M, Chen X, Xia Q, Jiang J, Ayodele O, Bradbury BD, Brooks C, Brown CA, Cheng A, Critchlow CW, Devercelli G, Gandhi V, Gondek K, Londhe AA, Ma J, Jonsson-Funk M, Keenan HA, Manne S, Ren K, Sanders L, Yu P, Zhang J, Zhou L, Bao Y.

BMJ Open. 2021 Aug 6;11(8):e051588. doi: 10.1136/bmjopen-2021-051588.

PMID: 34362806

Scalable Asymmetric Synthesis of the All Cis Triamino Cyclohexane Core of BMS-813160.

La Cruz TE, González-Bobes F, Eastgate MD, Sfouggatakis C, Zheng B, Kopp N, Xiao Y, Fan Y, Galindo KA, Pathirana C, Galella MA, Deerberg J.

J Org Chem. 2021 Aug 6. doi: 10.1021/acs.joc.1c01162. Online ahead of print.

PMID: 34355895

Radical Perfluoroalkylation of Arenes via Carbanion Intermediates.

Hernandez LW, Gallagher WP, Guerrero CA, Gonzalez-Bobes F, Coombs JR.

J Org Chem. 2021 Aug 6;86(15):10903-10913. doi: 10.1021/acs.joc.1c01296. Epub 2021 Jul 21.

PMID: 34286987

A Process Chemistry Benchmark for sp²-sp³ Cross Couplings.

Beutner GL, Simmons EM, Ayers S, Bemis CY, Goldfogel MJ, Joe CL, Marshall J, Wisniewski SR.

J Org Chem. 2021 Aug 6;86(15):10380-10396. doi: 10.1021/acs.joc.1c01073. Epub 2021 Jul 13.

PMID: 34255510

Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.

Carpenter J, Wu G, Wang Y, Cook EM, Wang T, Sitkoff D, Rossi KA, Mosure K, Zhuo X, Cao GG, Ziegler M, Azzara AV, Krupinski J, Soars MG, Ellsworth BA, Wacker DA.

ACS Med Chem Lett. 2021 Aug 5;12(9):1413-1420. doi: 10.1021/acsmedchemlett.1c00198. eCollection 2021 Sep 9.

PMID: 34531950

Quantification of azacitidine incorporation into human DNA/RNA by accelerator mass spectrometry as direct measure of target engagement.

Wang X, Vaes WHJ, van Duijn E, Nooijen I, Tong Z, de Menezes DL, Maxwell SE.

J Pharm Biomed Anal. 2021 Aug 5;202:114152. doi: 10.1016/j.jpba.2021.114152. Epub 2021 May 19.

PMID: 34051483

Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.

Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M.

Jpn J Clin Oncol. 2021 Aug 4:hyab114. doi: 10.1093/jjco/hyab114. Online ahead of print.

PMID: 34350454

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.

Lip GYH, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, Klem C, Ferri M, Jiang J, Yuce H, Deitelzweig S.

JAMA Netw Open. 2021 Aug 2;4(8):e2120064. doi: 10.1001/jamanetworkopen.2021.20064.

PMID: 34398204

Cost-effectiveness of nivolumab in patients with NSCLC in the United States.

Chaudhary MA, Lubinga SJ, Smare C, Hertel N, Penrod JR.

Am J Manag Care. 2021 Aug 1;27(8):e254-e260. doi: 10.37765/ajmc.2021.88726.

PMID: 34460179

Psoriatic Arthritis Diagnosis and Management in the Era of Telehealth.

Han G.

Cutis. 2021 Aug;108(2S):5-6. doi: 10.12788/cutis.0313.

PMID: 34662272

Discussion of talks from the symposium: Factor X: From thrombokinase to oral anti-coagulants and beyond.

Milstone LM, Jackson C, Becker RC, Camire R, Knabb R, Mann K, Ruf W, Wexler RR, Wood J.

J Thromb Thrombolysis. 2021 Aug;52(2):408-413. doi: 10.1007/s11239-021-02545-w. Epub 2021 Oct 12.

PMID: 34637116

Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.

Bhujbal SV, Mitra B, Jain U, Gong Y, Agrawal A, Karki S, Taylor LS, Kumar S, Tony Zhou Q.

Acta Pharm Sin B. 2021 Aug;11(8):2505-2536. doi: 10.1016/j.apsb.2021.05.014. Epub 2021 Jun 5.

PMID: 34522596

CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.

Schroeder BA, LaFranzo NA, LaFleur BJ, Gittelman RM, Vignali M, Zhang S, Flanagan KC, Rytlewski J, Riolobos L, Schulte BC, Kim TS, Chen E, Smythe KS, Wagner MJ, Mantilla JG, Campbell JS, Pierce RH, Jones RL, Cranmer LD, Pollack SM.

J Immunother Cancer. 2021 Aug;9(8):e002812. doi: 10.1136/jitc-2021-002812.

PMID: 34465597

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.

Mandala M, Larkin J, Ascierto PA, Del Vecchio M, Gogas H, Cowey CL, Arance A, Dalle S, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez I, Butler MO, Di Giacomo AM, Lutzky J, De La Cruz-Merino L, Atkinson V, Arenberger P, Hill A, Fecher L, Millward M, Khushalani NI, de Pril V, Lobo M, Weber J.

J Immunother Cancer. 2021 Aug;9(8):e003188. doi: 10.1136/jitc-2021-003188.

PMID: 34452930

Management of lung cancer patients' quality of life in clinical practice: a Delphi study.

Westeel V, Bourdon M, Cortot AB, Debieuvre D, Toffart AC, Acquadro M, Arnould B, Lambert J, Cotte FE, Gaudin AF, Lemasson H.

ESMO Open. 2021 Aug;6(4):100239. doi: 10.1016/j.esmoop.2021.100239. Epub 2021 Aug 10.

PMID: 34388690

Cycling cancer persister cells arise from lineages with distinct programs.

Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hütter JC, Hu B, Thakore PI, Tabaka M, Fulco CP, Colgan W, Cuevas BM, Hurvitz SA, Slamon DJ, Deik A, Pierce KA, Clish C, Hata AN, Zaganjor E, Lahav G, Politi K, Brugge JS, Regev A.

Nature. 2021 Aug;596(7873):576-582. doi: 10.1038/s41586-021-03796-6. Epub 2021 Aug 11.

PMID: 34381210

From basic science to life-saving therapy: the rationale, and drug discovery efforts that led to the direct factor Xa inhibitor eliquis.

Knabb RM, Wexler RR.

J Thromb Thrombolysis. 2021 Aug;52(2):403-407. doi: 10.1007/s11239-021-02529-w. Epub 2021 Aug 5.

PMID: 34351559

Snyder S, Albertson T, Garcia J, Gitlin M, Jun MP.

Adv Ther. 2021 Aug;38(8):4541-4555. doi: 10.1007/s12325-021-01839-y. Epub 2021 Jul 18.

PMID: 34279805

Dynamin-dependent vesicle twist at the final stage of clathrin-mediated endocytosis.

Cheng X, Chen K, Dong B, Yang M, Filbrun SL, Myoung Y, Huang TX, Gu Y, Wang G, Fang N.

Nat Cell Biol. 2021 Aug;23(8):859-869. doi: 10.1038/s41556-021-00713-x. Epub 2021 Jul 12.

PMID: 34253896

Concordance of 3 alternative teratogenicity assays with results from corresponding in vivo embryo-fetal development studies: Final report from the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) DruSafe working group 2.

McNerney M, Potter D, Augustine-Rauch K, Barrow P, Beyer B, Brannen K, Engel S, Enright BP, Nowland WS, Powles-Glover N, Powlin S, Schneidkraut MJ, Stanislaus D, Turner K, Graziano M.

Regul Toxicol Pharmacol. 2021 Aug;124:104984. doi: 10.1016/j.yrtph.2021.104984. Epub 2021 Jul 1.

PMID: 34216694

Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.

Kaplan DL, Ung BL, Pelletier C, Udeze C, Khilfeh I, Tian M.

J Comp Eff Res. 2021 Aug;10(12):989-998. doi: 10.2217/cer-2020-0285. Epub 2021 Jun 30.

PMID: 34187202

Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitor.

Chacko SA, Yang W, Wang Y, Tian Y, Hong Y, Wallace M, Wang B, Ewing WR, Luettgen JM, Shu YZ, Christopher LJ.

Xenobiotica. 2021 Aug;51(8):933-948. doi: 10.1080/00498254.2021.1943565. Epub 2021 Jul 5.

PMID: 34151691

Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.

Luan X, Yuan H, Song Y, Hu H, Wen B, He M, Zhang H, Li Y, Li F, Shu P, Burnett JP, Truchan N, Palmisano M, Pai MP, Zhou S, Gao W, Sun D.

Biomaterials. 2021 Aug;275:120910. doi: 10.1016/j.biomaterials.2021.120910. Epub 2021 Jun 3.

PMID: 34144373

Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme.

Soni M, Kiff C, Carroll R, Stein D, Saragoussi D, Nassar A, Maisey N, Tyas D.

Future Oncol. 2021 Aug;17(24):3163-3174. doi: 10.2217/fon-2021-0199. Epub 2021 Jun 8.

PMID: 34098737

TSPEAR variants are primarily associated with ectodermal dysplasia and tooth agenesis but not hearing loss: A novel cohort study.

Bowles B, Ferrer A, Nishimura CJ, Pinto E Vairo F, Rey T, Leheup B, Sullivan J, Schoch K, Stong N, Agolini E, Cocciadiferro D, Williams A, Cummings A, Loddo S, Genovese S, Roadhouse C, McWalter K; Undiagnosed Diseases Network, Wentzensen IM, Li C, Babovic-Vuksanovic D, Lanpher BC, Dentici ML, Ankala A, Hamm JA, Dallapiccola B, Radio FC, Shashi V, Gérard B, Bloch-Zupan A, Smith RJ, Klee EW.

Am J Med Genet A. 2021 Aug;185(8):2417-2433. doi: 10.1002/ajmg.a.62347. Epub 2021 May 27.

PMID: 34042254

Investigation into MAO B-Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (S)-Enantiomer of Indaneamine (RP101075) by MAO B.

Bai A, Shanmugasundaram V, Selkirk JV, Surapaneni S, Dalvie D.

Drug Metab Dispos. 2021 Aug;49(8):601-609. doi: 10.1124/dmd.121.000447. Epub 2021 May 19.

PMID: 34011531

CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.

De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S.

Clin Lung Cancer. 2021 Jul 19:S1525-7304(21)00186-8. doi: 10.1016/j.cllc.2021.07.005. Online ahead of print.

PMID: 34489161

Development of BET inhibitors as potential treatments for cancer: A search for structural diversity.

Hill MD, Fang H, Tokarski J, Fanslau C, Haarhoff Z, Huang C, Kramer M, Menard K, Monereau L, Morrison J, Ranasinghe A, Shields EE, Tye CK, Westhouse R, Everlof G, Sheriff S, Yan C, Marsilio F, Zhang L, Zvyaga T, Lee F, Gavai AV, Degnan AP.

Bioorg Med Chem Lett. 2021 Jul 15;44:128108. doi: 10.1016/j.bmcl.2021.128108. Epub 2021 May 13.

PMID: 33991625

Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis.

Erhardtsen E, Rasmussen DGK, Frederiksen P, Leeming DJ, Shevell D, Gluud LL, Karsdal MA, Aithal GP, Schattenberg JM.

JHEP Rep. 2021 Jul 10;3(4):100317. doi: 10.1016/j.jhepr.2021.100317. eCollection 2021 Aug.

PMID: 34466796

PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD.

Cohen CC, Castillo-Leon E, Farris AB, Caltharp SA, Cleeton RL, Sinclair EM, Shevell DE, Karsdal MA, Nielsen MJF, Leeming DJ, Vos MB.

Hepatol Commun. 2021 Jul 8. doi: 10.1002/hep4.1766. Online ahead of print.

PMID: 34558828

Apoptosis Marker Assays for HTS.

Riss TL, O’Brien MA, Moravec RA, Kupcho K, Niles AL.. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Hall MD, Haas JV, Hoare SRJ, Inglese J, Iversen PW, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Sittampalam GS, Tarselli M, Trask OJ Jr, Wang Y, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X, editors.

Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004–2021 Jul 1.

PMID: 34339159

A Novel Algorithm Using Within-leg Calibration for Enhanced Accuracy of Detection of Arthritis by Infrared Thermal Imaging in Children.

Zhao Y, Iyer RS, Thapa M, Biswas D, Bhide N, Scheck J, Cain K, Partridge SC, Wallace CA.

J Rheumatol. 2021 Jul 1:jrheum.210077. doi: 10.3899/jrheum.210077. Online ahead of print.

PMID: 34210832

Synthesis, structure-activity relationship studies and evaluation of a TLR 3/8/9 agonist and its analogues.

Sarkar A, Galasiti Kankanamalage AC, Zhang Q, Cheng H, Sivaprakasam P, Naglich J, Xie C, Gangwar S, Boger DL.

Med Chem Res. 2021 Jul;30(7):1377-1385. doi: 10.1007/s00044-021-02736-3. Epub 2021 May 18.

PMID: 34421287

Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative.

Ekman S, Horvat P, Rosenlund M, Kejs AM, Patel D, Juarez-Garcia A, Lacoin L, Daumont MJ, Penrod JR, Brustugun OT, Sørensen JB.

JTO Clin Res Rep. 2021 Mar 24;2(5):100165. doi: 10.1016/j.jtocrr.2021.100165. eCollection 2021 May.

PMID: 34590017

Atorvastatin and blood flow regulate expression of distinctive sets of genes in mouse carotid artery endothelium.

Kumar S, Sur S, Perez J, Demos C, Kang DW, Kim CW, Hu S, Xu K, Yang J, Jo H.

Curr Top Membr. 2021;87:97-130. doi: 10.1016/bs.ctm.2021.08.004. Epub 2021 Oct 6.

PMID: 34696890

Antibody blockade of CD96 by distinct molecular mechanisms.

Lee PS, Chau B, Barman I, Bee C, Jashnani A, Hogan JM, Aguilar B, Dollinger G, Rajpal A, Strop P.

MAbs. 2021 Jan-Dec;13(1):1979800. doi: 10.1080/19420862.2021.1979800.

PMID: 34595996

In Silico Meets In Vitro Techniques in ADMET Profiling of Drug Discovery (Part II).

Kar S, Chatterjee S.

Curr Drug Metab. 2021;22(7):502. doi: 10.2174/138920022207210812124757.

PMID: 34525918

Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.

Jain SS, Li SS, Xie J, Sutton MB, Fine JT, Edelberg JM, Gao W, Spertus JA, Cohen DJ.

J Med Econ. 2021 Jan-Dec;24(1):1115-1123. doi: 10.1080/13696998.2021.1978242.

PMID: 34493144

Characterizing and understanding the formation of cysteine conjugates and other by-products in a random, lysine-linked antibody drug conjugate.

Qiu D, Huang Y, Chennamsetty N, Miller SA, Hay M.

MAbs. 2021 Jan-Dec;13(1):1974150. doi: 10.1080/19420862.2021.1974150.

PMID: 34486490

Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer.

Smare C, Dave K, Juarez-Garcia A, Abraham P, Penrod JR, Camidge DR, Yuan Y.

J Med Econ. 2021 Jan-Dec;24(1):1124-1133. doi: 10.1080/13696998.2021.1974763.

PMID: 34465261

Profiling CELMoD-Mediated Degradation of Cereblon Neosubstrates.

Thompson JW, Clayton T, Khambatta G, Bateman LA, Carroll CW, Chamberlain PP, Matyskiela ME. Methods Mol Biol. 2021;2365:283-300. doi: 10.1007/978-1-0716-1665-9_15.

PMID: 34432250

Untargeted proteomics reveals upregulation of stress response pathways during CHO-based monoclonal antibody manufacturing process leading to disulfide bond reduction.

Park SY, Egan S, Cura AJ, Aron KL, Xu X, Zheng M, Borys M, Ghose S, Li Z, Lee K.

MAbs. 2021 Jan-Dec;13(1):1963094. doi: 10.1080/19420862.2021.1963094.

PMID: 34424810

The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model.

Sussman M, Di Fusco M, Tao CY, Guo JD, Gillespie JA, Ferri M, Adair N, Cato MS, Shirkhorshidian I, Barnes GD.

J Med Econ. 2021 Jan-Dec;24(1):1070-1082. doi: 10.1080/13696998.2021.1970954.

PMID: 34415229

Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.

Pardanani A, Tefferi A, Masszi T, Mishchenko E, Drummond M, Jourdan E, Vannucchi A, Jurgutis M, Ribrag V, Rambaldi A, Koh LP, Rose S, Zhang J, Harrison C.Br J Haematol. 2021 Jul 30. doi: 10.1111/bjh.17727. Online ahead of print.

PMID: 34331348

Antibody toolkit reveals N-terminally ubiquitinated substrates of UBE2W.

Davies CW, Vidal SE, Phu L, Sudhamsu J, Hinkle TB, Chan Rosenberg S, Schumacher FR, Zeng YJ, Schwerdtfeger C, Peterson AS, Lill JR, Rose CM, Shaw AS, Wertz IE, Kirkpatrick DS, Koerber JT, et al.

Nat Commun. 2021 Jul 29;12(1):4608. doi: 10.1038/s41467-021-24669-6.

PMID: 34326324

Self-reporting data assets and their representation in the pharmaceutical industry.

Della Corte D, Colsman W, Fessenmayr H, Sawczuk da Silva A, Vanderwall DE, et al.

Drug Discov Today. 2021 Jul 28:S1359-6446(21)00328-7. doi: 10.1016/j.drudis.2021.07.019. Online ahead of print.

PMID: 34332096

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.

Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, Ghobrial IM, Gormley NJ, Gupta I, Higley H, Hillengass J, Kanapuru B, Kazandjian D, Kelloff GJ, Kirsch IR, Kremer BE, Landgren O, Lightbody ED, Lomas OC, Lonial S, Mateos MV, Montes de Oca R, Mukundan L, Munshi NC, O'Donnell EK, Orfao A, Paiva B, Patel R, Pugh TJ, Ramasamy K, Ray J, Roshal M, Ross JA, Sigman CC, Thoren KL, Trudel S, Ulaner GA, Valente N, Weiss BM, Zamagni E, Kumar SK, et al.

Clin Cancer Res. 2021 Jul 28:clincanres.1059.2021. doi: 10.1158/1078-0432.CCR-21-1059. Online ahead of print.

PMID: 34321279

Real-World Treatment Patterns and Outcomes in Patients with Head and Neck Cancer: Point-in-Time Survey of Oncologists in Italy and Spain.

Singh P, Contente M, Bennett B, Hall J, Bailey H, Bailey A, Zarrelli L, Polanco Sanchez C, et al.

Adv Ther. 2021 Jul 28. doi: 10.1007/s12325-021-01851-2. Online ahead of print.

PMID: 34319551

Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.

Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F, et al.

Blood Adv. 2021 Jul 27;5(14):2901-2908. doi: 10.1182/bloodadvances.2020004144.

PMID: 34297046

Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without alzheimer's disease and related dementias (ADRD).

Zhang Y, Bian J, Huo J, Yang S, Guo Y, Shao H, et al.

Curr Med Res Opin. 2021 Jul 26:1-7. doi: 10.1080/03007995.2021.1953972. Online ahead of print.

PMID: 34252317

Heterogeneity of treatment effects in malignant pleural mesothelioma - Authors' reply.

Baas P, Scherpereel A, Nowak AK, Oukessou A, Zalcman G, et al.

Lancet. 2021 Jul 24;398(10297):302. doi: 10.1016/S0140-6736(21)00876-X.

PMID: 34303436

Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe.

Singh P, Bennett B, Bailey T, Taylor-Stokes G, Rajkovic I, Contente M, Curtis S, Curtis C, et al.

BMC Cancer. 2021 Jul 24;21(1):854. doi: 10.1186/s12885-021-08557-2.

PMID: 34303346

Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.

Snyder S, Chung KC, Jun MP, Gitlin M, et al.

Adv Ther. 2021 Jul 23. doi: 10.1007/s12325-021-01838-z. Online ahead of print.

PMID: 34302277

Inhibition of Cancer Cell Adhesion, Migration and Proliferation by a Bispecific Antibody that Targets two Distinct Epitopes on αv Integrins.

Gallo E, Kelil A, Haughey M, Cazares-Olivera M, Yates BP, Zhang M, Wang NY, Blazer L, Carderelli L, Adams JJ, Kossiakoff AA, Wells JA, Xie W, Sidhu SS, et al.

J Mol Biol. 2021 Jul 23;433(15):167090. doi: 10.1016/j.jmb.2021.167090. Epub 2021 Jun 4.

PMID: 34090922

Specific White Matter Tracts and Diffusion Properties Predict Conversion From Mild Cognitive Impairment to Alzheimer's Disease.

Stone DB, Ryman SG, Hartman AP, Wertz CJ, Vakhtin AA; Alzheimer’s Disease Neuroimaging Initiative.

Front Aging Neurosci. 2021 Jul 23;13:711579. doi: 10.3389/fnagi.2021.711579. eCollection 2021.

PMID: 34366830

DGKζ exerts greater control than DGKα over CD8⁺ T cell activity and tumor inhibition.

Gu J, Wang C, Cao C, Huang J, Holzhauer S, Desilva H, Wesley EM, Evans DB, Benci J, Wichroski M, Wee S, Riese MJ, et al.

Oncoimmunology. 2021 Jul 21;10(1):1941566. doi: 10.1080/2162402X.2021.1941566. eCollection 2021.

PMID: 34350062

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect^® MM Registry.

Lee HC, Ailawadhi S, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Toomey K, Hardin JW, Wagner L, Omel JL, Dhalla M, Liu L, Joshi P, Abonour R; Connect® MM Registry.

Blood Cancer J. 2021 Jul 23;11(7):134. doi: 10.1038/s41408-021-00524-1.

PMID: 34301916

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of phase 3 ozanimod trials.

Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA; ozanimod study investigators.

Eur J Neurol. 2021 Jul 22. doi: 10.1111/ene.15009. Online ahead of print.

PMID: 34292643

Transcriptome analysis reveals key genes modulated by ALK5 inhibition in a bleomycin model of systemic sclerosis.

Decato BE, Ammar R, Reinke-Breen L, Thompson JR, Azzara AV, et al.

Rheumatology (Oxford). 2021 Jul 21:keab580. doi: 10.1093/rheumatology/keab580. Online ahead of print.

PMID: 34289031

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma.

Thakurta A, Pierceall WE, Amatangelo MD, Flynt E, Agarwal A, et al.

Oncotarget. 2021 Jul 20;12(15):1555-1563. doi: 10.18632/oncotarget.27973. eCollection 2021 Jul 20.

PMID: 34316334

Chemoselective, Scalable Nickel-Electrocatalytic O-Arylation of Alcohols.

Baran PS, Zhang HJ, Chen L, Oderinde MS, Edwards JT, Kawamata Y, et al.

Angew Chem Int Ed Engl. 2021 Jul 20. doi: 10.1002/anie.202107820. Online ahead of print.

PMID: 34288303

Small cell lung cancer treatment and survival in Portugal: A retrospective analysis from the I-O Optimise initiative.

Soares M, Antunes L, Redondo P, Borges M, Grimson F, Hermans R, Chaib C, Lacoin L, Juarez-Garcia A, Daumont MJ, Penrod JR, Bento MJ, Gonçalves FR, et al.

Eur J Cancer Care (Engl). 2021 Jul 20:e13496. doi: 10.1111/ecc.13496. Online ahead of print.

PMID: 34288191

Equivalence testing of a newly developed interviewer-led telephone script for the EORTC QLQ-C30.

Piccinin C, Pe M, Kuliś D, Shaw JW, Wheelwright SJ, Bottomley A, et al.

Qual Life Res. 2021 Jul 20. doi: 10.1007/s11136-021-02955-6. Online ahead of print.

PMID: 34286416

The PROTACtable genome.

Schneider M, Radoux CJ, Hercules A, Ochoa D, Dunham I, Zalmas LP, Hessler G, Ruf S, Shanmugasundaram V, Hann MM, Thomas PJ, Queisser MA, Benowitz AB, Brown K, Leach AR, et al.

Nat Rev Drug Discov. 2021 Jul 20. doi: 10.1038/s41573-021-00245-x. Online ahead of print.

PMID: 34285415

Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review.

Anota A, Pozet A, Lemasson H, Cotté FE, Falcoz A, Eberst G, Mouillet G, Guerzider S, Charton É, Westeel V, et al.

Qual Life Res. 2021 Jul 20. doi: 10.1007/s11136-021-02945-8. Online ahead of print.

PMID: 34283382

Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014.

Chen Z, Babcock A, Sanogo V, Nelson DR, Xiao H, Diaby V, et al.

Expert Rev Pharmacoecon Outcomes Res. 2021 Jul 16:1-7. doi: 10.1080/14737167.2021.1927717. Online ahead of print.

PMID: 33985399

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).

Kalff A, Khong T, Ramachandran M, Walker P, Schwarer A, Roberts AW, Campbell P, Filshie R, Norton S, Reynolds J, Young M, Pierceall W, Thakurta A, Guo M, Oppermann U, Wang M, Ren Y, Kennedy N, Parekh S, Spencer A, et al.

Leuk Lymphoma. 2021 Jul 15:1-11. doi: 10.1080/10428194.2021.1948030. Online ahead of print.

PMID: 34263697

Investigation on hot melt extrusion and prediction on 3D printability of pharmaceutical grade polymers.

Tabriz AG, Scoutaris N, Gong Y, Hui HW, Kumar S, Douroumis D, et al.

Int J Pharm. 2021 Jul 15;604:120755. doi: 10.1016/j.ijpharm.2021.120755. Epub 2021 May 28.

PMID: 34052338

Stereoselective and Divergent Aza-Adenosine and Aza-Guanosine Syntheses from Xylofuranose, the Key Fragments of a STING Cyclic Dinucleotide Agonist.

Yuan C, Ortiz A, Xu Z, Zhu J, Schmidt MA, Rogers A, Eastgate M, et al.

J Org Chem. 2021 Jul 14. doi: 10.1021/acs.joc.1c00984. Online ahead of print.

PMID: 34259509

Effect of Baseline Disease Severity on Achievement of Treatment Target With Apremilast: Results From a Pooled Analysis.

Reich K, Mrowietz U, Menter A, Griffiths CEM, Bagel J, Strober B, Nunez Gomez N, Shi R, Guerette B, Lebwohl M, et al.

J Eur Acad Dermatol Venereol. 2021 Jul 13. doi: 10.1111/jdv.17520. Online ahead of print.

PMID: 34255891

The use of proxies and proxy-reported measures: a report of the international society for quality of life research (ISOQOL) proxy task force.

Roydhouse JK, Cohen ML, Eshoj HR, Corsini N, Yucel E, Rutherford C, Wac K, Berrocal A, Lanzi A, Nowinski C, Roberts N, Kassianos AP, Sebille V, King MT, Mercieca-Bebber R; ISOQOL Proxy Task Force and the ISOQOL Board of Directors.

Qual Life Res. 2021 Jul 12. doi: 10.1007/s11136-021-02937-8. Online ahead of print.

PMID: 34254262

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.

Narla RK, Modi H, Bauer D, Abbasian M, Leisten J, Piccotti JR, Kopytek S, Eckelman BP, Deveraux Q, Timmer J, Zhu D, Wong L, Escoubet L, Raymon HK, Hariharan K, et al.

Cancer Immunol Immunother. 2021 Jul 10. doi: 10.1007/s00262-021-03010-6. Online ahead of print.

PMID: 34247273

Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies.

Awosemo O, Neelakantan H, Watowich S, Ma J, Wu L, Chow DS, Liang D, et al.

J Pharm Biomed Anal. 2021 Jul 8;204:114255. doi: 10.1016/j.jpba.2021.114255. Online ahead of print.

PMID: 34304009

The importance of specific citrullinated clusterin and vimentin found in a multi-coloured bead-based citrulline-peptide array system in rheumatoid arthritis.

Yoshizawa Y, Nakao T, Tsuritani K, Yamada T, Watanabe N, Chiba A, Robinson WH, Miyake S, et al.

Clin Exp Rheumatol. 2021 Jul 8. Online ahead of print.

PMID: 34251306

The obesity paradox may not lead to functional gains in stroke patients undergoing acute inpatient rehabilitation.

Freeman C, Blough A, Rotich D, Curl A, Eickmeyer SM, et al.

PM R. 2021 Jul 8. doi: 10.1002/pmrj.12671. Online ahead of print.

PMID: 34240565

Synthesis and characterization of a series of N, N'-substituted urea derivatives by using electrospray ionization tandem mass spectrometry (ESI-MS/MS): Differentiation of positional isomers.

Singh DK, Chauthe SK, Anjanappa P, Kumar S, Arulraj RA, Gajjela R, Mohammed N, Kanthappa VT, Karmakar A, Gupta AK, Bajpai L, Bagadi M, Mathur A, et al.

Rapid Commun Mass Spectrom. 2021 Jul 8:e9161. doi: 10.1002/rcm.9161. Online ahead of print.

PMID: 34240514

Thymic lymphomas in a 6-Month rasH2-Tg mouse carcinogenicity study with the RORγt Inverse Agonist, BMS-986251.

Haggerty HG, Sathish JG, Gleason CR, Al-Haddawi M, Brodie TA, Bonnette KL, Lewis BS, Graziano MJ, et al.

Toxicol Sci. 2021 Jul 8:kfab086. doi: 10.1093/toxsci/kfab086. Online ahead of print.

PMID: 34240189

Author Correction: A one-step tRNA-CRISPR system for genome-wide genetic interaction mapping in mammalian cells.

Zhao Y, Tyrishkin K, Sjaarda C, Khanal P, Stafford J, Rauh M, Liu X, Babak T, Yang X, et al.

Sci Rep. 2021 Jul 8;11(1):14483. doi: 10.1038/s41598-021-92514-3.

PMID: 34238941

Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment.

Tencer T, Will O, Kumar J, Cambron-Mellott MJ, Mackie DS, Beusterien K, et al.

Curr Med Res Opin. 2021 Jul 8:1-10. doi: 10.1080/03007995.2021.1940911. Online ahead of print.

PMID: 34129418

Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment.

Kumar J, Cambron-Mellott MJ, Tencer T, Will O, Mackie DS, Beusterien K, et al.

Patient Prefer Adherence. 2021 Jul 8;15:1515-1527. doi: 10.2147/PPA.S306498. eCollection 2021.

PMID: 34267507

Covid-19 Knowledge and Perceptions Among Dental Specialists: A Cross-Sectional Online Questionnaire Survey.

Aldhuwayhi S, Mallineni SK, Sakhamuri S, Thakare AA, Mallineni S, Sajja R, Sethi M, Nettam V, Mohammad AM, et al.

Risk Manag Healthc Policy. 2021 Jul 7;14:2851-2861. doi: 10.2147/RMHP.S306880. eCollection 2021.

PMID: 34262372

P(III) vs P(V): A P(V) Reagent for Thiophosphoramidate Linkages and Application to an Asymmetric Synthesis of a Cyclic Dinucleotide STING Agonist.

Zheng B, Hang C, Zhu J, Purdum GE, Sezen-Edmonds M, Treitler DS, Yu M, Yuan C, Zhu Y, Freitag A, Guo S, Zhu G, Hritzko B, Paulson J, Shackman JG, He BL, Fu W, Tai HC, Ayers S, Park H, Eastgate MD, Cohen B, Rogers A, Wang Q, Schmidt MA, et al.

J Org Chem. 2021 Jul 7. doi: 10.1021/acs.joc.1c01055. Online ahead of print.

PMID: 34232659

Predictive immune checkpoint blockade classifiers identify tumors responding to inhibition of PD-1 and/or CTLA-4.

Krijgsman O, Kemper K, Boshuizen J, Vredevoogd DW, Rozeman EA, Ibanez Molero S, de Bruijn B, Cornelissen-Steijger P, Shahrabi A, Del Castillo Velasco-Herrera M, Song JY, Ligtenberg MA, Kluin RJC, Kuilman T, Ross-Macdonald P, Haanen J, Adams DJ, Blank C, Peeper DS, et al.

Clin Cancer Res. 2021 Jul 6:clincanres.CCR-20-4218-A.2020. doi: 10.1158/1078-0432.CCR-20-4218. Online ahead of print.

PMID: 34230026

Molecular mechanism of interspecies differences in the binding affinity of TD139 to Galectin-3.

Kumar A, Paul M, Panda M, Jayaram S, Kalidindi N, Sale H, Vetrichelvan M, Gupta A, Mathur A, Beno B, Regueiro-Ren A, Cheng D, Ramarao M, Ghosh K, et al.

Glycobiology. 2021 Jul 6:cwab072. doi: 10.1093/glycob/cwab072. Online ahead of print.

PMID: 34228782

Qualitative and psychometric approaches to evaluate the PROMIS pain interference and sleep disturbance item banks for use in patients with rheumatoid arthritis.

Becker B, Raymond K, Hawkes C, Foster AM, Lovley A, Saucier C, Rizio AA, Bjorner JB, Kosinski M, et al.

J Patient Rep Outcomes. 2021 Jul 6;5(1):52. doi: 10.1186/s41687-021-00318-w.

PMID: 34228217

The Transcriptome of Paired Major and Minor Salivary Gland Tissue in Patients With Primary Sjögren's Syndrome.

Verstappen GM, Gao L, Pringle S, Haacke EA, van der Vegt B, Liefers SC, Patel V, Hu Y, Mukherjee S, Carman J, Menard LC, Spijkervet FKL, Vissink A, Bootsma H, Kroese FGM, et al.

Front Immunol. 2021 Jul 6;12:681941. doi: 10.3389/fimmu.2021.681941. eCollection 2021.

PMID: 34295332

Acute Effects of Pimobendan on Cardiac Function in Dogs With Tachycardia Induced Dilated Cardiomyopathy: A Randomized, Placebo-Controlled, Crossover Study.

Abbott-Johnson K, Pierce KV, Roof S, Del Rio CL, Hamlin R, et al.

Front Vet Sci. 2021 Jul 1;8:646437. doi: 10.3389/fvets.2021.646437. eCollection 2021.

PMID: 34277749

High-Throughput Screening to Identify Small Molecules That Selectively Inhibit APOL1 Protein Level in Podocytes.

Choy J, Kan Y, Cifelli S, Johnson J, Chen M, Shiao LL, Zhou H, Previs S, Lei Y, Johnstone R, Liaw A, Saigal A, Hu L, Ramos R, Visconti R, McElroy WT, Kreamer A, Wildey MJ, Peier A, Shin MK, Imbriglio J, Ren Z, Hoek M, Weinglass A, Ai X, et al.

SLAS Discov. 2021 Jul 3:24725552211026245. doi: 10.1177/24725552211026245. Online ahead of print.

PMID: 34218698

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA, et al.

Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.

PMID: 34102137

Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.

Ogasawara K, Dodds M, Mack T, Lymp J, Dell'Aringa J, Smith J, et al.

Clin Pharmacokinet. 2021 Jul 3. doi: 10.1007/s40262-021-01055-5. Online ahead of print.

PMID: 34216384

Phylogenetic and Phylodynamic Analyses of HCV Strains Circulating among Patients Using Injectable Drugs in Central Italy.

Minosse C, Salichos L, Taibi C, Luzzitelli I, Nardozi D, Capobianchi MR, D'Offizi G, McPhee F, Garbuglia AR, et al.

Microorganisms. 2021 Jul 2;9(7):1432. doi: 10.3390/microorganisms9071432.

PMID: 34361868

Gordon J, Stainthorpe A, Jones B, Jacob I, Hertel N, Diaz J, Yuan Y, Borrill J, et al.

Pharmacoecon Open. 2021 Jul 2. doi: 10.1007/s41669-021-00279-2. Online ahead of print.

PMID: 34216002

Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform.

Xia Y, Ji X, Jang IS, Surka C, Hsu C, Wang K, Rolfe M, Bence N, Lu G, et al.

Commun Biol. 2021 Jul 2;4(1):834. doi: 10.1038/s42003-021-02352-2.

PMID: 34215850

Ni-Catalyzed 1,2-Diarylation of Alkenyl Ketones: A Comparative Study of Carbonyl-Directed Reaction Systems.

Kleinmans R, Apolinar O, Derosa J, Karunananda MK, Li ZQ, Tran VT, Wisniewski SR, Engle KM, et al.

Org Lett. 2021 Jul 16;23(14):5311-5316. doi: 10.1021/acs.orglett.1c01447. Epub 2021 Jul 2.

PMID: 34213351

Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.

Wu YJ, Meanwell NA, et al.

J Med Chem. 2021 Jul 22;64(14):9786-9874. doi: 10.1021/acs.jmedchem.1c00790. Epub 2021 Jul 2.

PMID: 34213340

Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.

Taube JM, Roman K, Engle EL, Wang C, Ballesteros-Merino C, Jensen SM, McGuire J, Jiang M, Coltharp C, Remeniuk B, Wistuba I, Locke D, Parra ER, Fox BA, Rimm DL, Hoyt C, et al.

J Immunother Cancer. 2021 Jul;9(7):e002197. doi: 10.1136/jitc-2020-002197.

PMID: 34266881

Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.

Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B, Wheeler ML, Bezman N, Wang F, Strop P, Leif Bergsagel P, Chesi M, et al.

Blood Cancer Discov. 2021 Jul;2(4):354-369. doi: 10.1158/2643-3230.bcd-21-0038.

PMID: 34258584

Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.

Rahme E, Godin R, Nedjar H, Dasgupta K, Tagalakis V, et al.

Thromb Res. 2021 Jul;203:121-130. doi: 10.1016/j.thromres.2021.05.005. Epub 2021 May 11.

PMID: 34000493

A Stereocontrolled Synthesis of a Phosphorothioate Cyclic Dinucleotide-Based STING Agonist.

Kempson J, Zhang H, Hou X, Cornelius L, Zhao R, Wang B, Hong Z, Oderinde MS, Pawluczyk J, Wu DR, Sun D, Li P, Yip S, Smith A, Caceres-Cortes J, Aulakh D, Sarjeant AA, Park PK, Harikrishnan LS, Qin LY, Dodd DS, Fink B, Vite G, Mathur A, et al.

J Org Chem. 2021 Jul 2;86(13):8851-8861. doi: 10.1021/acs.joc.1c00784. Epub 2021 Jun 14.

PMID: 34126006

Nanopore sequencing of single-cell transcriptomes with scCOLOR-seq.

Philpott M, Watson J, Thakurta A, Brown T Jr, Brown T Sr, Oppermann U, Cribbs AP, et al.

Nat Biotechnol. 2021 Jul 1. doi: 10.1038/s41587-021-00965-w. Online ahead of print.

PMID: 34211161

Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals.

Kosmicki JA, Horowitz JE, Banerjee N, Lanche R, Marcketta A, Maxwell E, Bai X, Sun D, Backman JD, Sharma D, Kury FSP, Kang HM, O'Dushlaine C, Yadav A, Mansfield AJ, Li AH, Watanabe K, Gurski L, McCarthy SE, Locke AE, Khalid S, O'Keeffe S, Mbatchou J, Chazara O, Huang Y, Kvikstad E, O'Neill A, Nioi P, Parker MM, Petrovski S, Runz H, Szustakowski JD, Wang Q, Wong E, Cordova-Palomera A, Smith EN, Szalma S, Zheng X, Esmaeeli S, Davis JW, Lai YP, Chen X, Justice AE, Leader JB, Mirshahi T, Carey DJ, Verma A, Sirugo G, Ritchie MD, Rader DJ, Povysil G, Goldstein DB, Kiryluk K, Pairo-Castineira E, Rawlik K, Pasko D, Walker S, Meynert A, Kousathanas A, Moutsianas L, Tenesa A, Caulfield M, Scott R, Wilson JF, Baillie JK, Butler-Laporte G, Nakanishi T, Lathrop M, Richards JB; Regeneron Genetics Center; UKB Exome Sequencing Consortium, Jones M, Balasubramanian S, Salerno W, Shuldiner AR, Marchini J, Overton JD, Habegger L, Cantor MN, Reid JG, Baras A, Abecasis GR, Ferreira MAR, et al.

Am J Hum Genet. 2021 Jul 1;108(7):1350-1355. doi: 10.1016/j.ajhg.2021.05.017. Epub 2021 Jun 3.

PMID: 34115965

Spectrum and Outcome of Noninfectious Aortitis.

Ferfar Y, Morinet S, Espitia O, Agard C, Vautier M, Comarmond C, Desbois AC, Domont F, Resche-Rigon M, Cacoub P, Biard L, Saadoun D; French Study Group for Large Vessel Vasculitis (GEFA), et al.

J Rheumatol. 2021 Jul 1:jrheum.201274. doi: 10.3899/jrheum.201274. Online ahead of print.

PMID: 34210830

The future of immune checkpoint combinations with tumor-targeted small molecule drugs.

Sceneay J, Sinclair C, et al.

Emerg Top Life Sci. 2021 Jul 1:ETLS20210064. doi: 10.1042/ETLS20210064. Online ahead of print.

PMID: 34196724

Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology.

Sanghavi K, Vuppala P, Ivaturi V, Hamuro L, Roy A, Suryawanshi S, et al.

CPT Pharmacometrics Syst Pharmacol. 2021 Jul;10(7):748-759. doi: 10.1002/psp4.12642. Epub 2021 Jun 11.

PMID: 33955714

Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.

Huh KY, Choi Y, Nissel J, Palmisano M, Wang X, Liu L, Ramirez-Valle F, Lee H, et al.

Clin Transl Sci. 2021 Jul;14(4):1505-1511. doi: 10.1111/cts.13013. Epub 2021 May 1.

PMID: 33932093

Process analytics 4.0: A paradigm shift in rapid analytics for biologics development.

Wasalathanthri DP, Shah R, Ding J, Leone A, Li ZJ, et al.

Biotechnol Prog. 2021 Jul;37(4):e3177. doi: 10.1002/btpr.3177. Epub 2021 May 31.

PMID: 34036755

Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis.

Ruperto N, Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Cimaz R, Dare J, Espada G, Faugier E, Ferrandiz M, Gerloni V, Quartier P, Silva CA, Wagner-Weiner L, Gandhi Y, Passarell J, Nys M, Wong R, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO).

J Rheumatol. 2021 Jul;48(7):1073-1081. doi: 10.3899/jrheum.200154. Epub 2021 Jan 15.

PMID: 33452173

Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank.

Szustakowski JD, Balasubramanian S, Kvikstad E, Khalid S, Bronson PG, Sasson A, Wong E, Liu D, Wade Davis J, Haefliger C, Katrina Loomis A, Mikkilineni R, Noh HJ, Wadhawan S, Bai X, Hawes A, Krasheninina O, Ulloa R, Lopez AE, Smith EN, Waring JF, Whelan CD, Tsai EA, Overton JD, Salerno WJ, Jacob H, Szalma S, Runz H, Hinkle G, Nioi P, Petrovski S, Miller MR, Baras A, Mitnaul LJ, Reid JG; UKB-ESC Research Team.

Nat Genet. 2021 Jul;53(7):942-948. doi: 10.1038/s41588-021-00885-0. Epub 2021 Jun 28.

PMID: 34183854

Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor Types.

Szabo PM, Pant S, Ely S, Desai K, Anguiano E, Wang L, Edwards R, Green G, Zhang N, et al.

J Mol Diagn. 2021 Jun 29:S1525-1578(21)00172-0. doi: 10.1016/j.jmoldx.2021.06.002. Online ahead of print.

PMID: 34197924

Micafungin-Induced Cell Wall Damage Stimulates Morphological Changes Consistent with Microcycle Conidiation in Aspergillus nidulans.

Reese S, Chelius C, Riekhof W, Marten MR, Harris SD, et al.

J Fungi (Basel). 2021 Jun 29;7(7):525. doi: 10.3390/jof7070525.

PMID: 34210108

Affinity precipitation of monoclonal antibodies using ELP-Z in the elution without resolubilization mode.

Bhat M, Mullerpatan A, Chen J, Holstein M, Ghose S, Li ZJ, Cramer S, et al.

J Biotechnol. 2021 Jun 29;338:1-4. doi: 10.1016/j.jbiotec.2021.06.020. Online ahead of print.

PMID: 34197822

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients.

Boucher Y, Kumar AS, Posada JM, Gjini E, Pfaff K, Lipschitz M, Lako A, Duda DG, Rodig SJ, Hodi FS, Jain RK, et al.

NPJ Precis Oncol. 2021 Jun 29;5(1):62. doi: 10.1038/s41698-021-00197-w.

PMID: 34188163

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.

Stegherr R, Schmoor C, Beyersmann J, Rufibach K, Jehl V, Brückner A, Eisele L, Künzel T, Kupas K, Langer F, Leverkus F, Loos A, Norenberg C, Voss F, Friede T, et al.

Trials. 2021 Jun 29;22(1):420. doi: 10.1186/s13063-021-05354-x.

PMID: 34187527

Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.

Etxeberria I, Bolaños E, Teijeira A, Garasa S, Yanguas A, Azpilikueta A, Kavanaugh WM, Vasiljeva O, Belvin M, Howng B, Irving B, Tipton K, West J, Mei L, Korman AJ, Sega E, Olivera I, Cirella A, Ochoa MC, Rodriguez ME, Melero A, Sanmamed MF, Engelhardt JJ, Melero I, et al.

Proc Natl Acad Sci U S A. 2021 Jun 29;118(26):e2025930118. doi: 10.1073/pnas.2025930118.

PMID: 34172583

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies.

Fazeli MS, Khaychuk V, Wittstock K, Breznen B, Crocket G, Pourrahmat MM, Ferri L, et al.

Clin Med Insights Arthritis Musculoskelet Disord. 2021 Jun 28;14:11795441211028751. doi: 10.1177/11795441211028751. eCollection 2021.

PMID: 34262386

Site-selective tyrosine bioconjugation via photoredox catalysis for native-to-bioorthogonal protein transformation.

Li BX, Kim DK, Bloom S, Huang RY, Qiao JX, Ewing WR, Oblinsky DG, Scholes GD, MacMillan DWC, et al.

Nat Chem. 2021 Jun 28. doi: 10.1038/s41557-021-00733-y. Online ahead of print.

PMID: 34183819

Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma.

Wall MA, Turkarslan S, Wu WJ, Danziger SA, Reiss DJ, Mason MJ, Dervan AP, Trotter MWB, Bassett D, Hershberg RM, Lomana ALG, Ratushny AV, Baliga NS, et al.

NPJ Precis Oncol. 2021 Jun 28;5(1):60. doi: 10.1038/s41698-021-00185-0.

PMID: 34183722

Flexible use of copula-type model for dose-finding in drug combination clinical trials.

Hashizume K, Tshuchida J, Sozu T, et al.

Biometrics. 2021 Jun 28. doi: 10.1111/biom.13510. Online ahead of print.

PMID: 34181760

A functional three-dimensional microphysiological human model of myeloma bone disease.

Visconti RJ, Kolaja K, Cottrell JA, et al.

J Bone Miner Res. 2021 Jun 25. doi: 10.1002/jbmr.4404. Online ahead of print.

PMID: 34173283

Optimized damping parameters for empirical dispersion corrections to symmetry-adapted perturbation theory.

Schriber JB, Sirianni DA, Smith DGA, Burns LA, Sitkoff D, Cheney DL, Sherrill CD, et al.

J Chem Phys. 2021 Jun 21;154(23):234107. doi: 10.1063/5.0049745.

PMID: 34241276

Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.

Hiramatsu K, Barrett A, Miyata Y; PhRMA Japan Medical Affairs Committee Working Group 1.

Drugs Real World Outcomes. 2021 Jun 19. doi: 10.1007/s40801-021-00266-3. Online ahead of print.

PMID: 34148219

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.

Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, Rodriguez-Otero P, Powles R, Matsue K, Shah N, Anderson LD Jr, Streetly M, Wilson K, Le HV, Swern AS, Agarwal A, Siegel DS, et al.

Blood Cancer J. 2021 Jun 18;11(6):116. doi: 10.1038/s41408-021-00507-2.

PMID: 34145225

Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms.

Shah KK, Bennett B, Lenny A, Longworth L, Brazier JE, Oppe M, Pickard AS, Shaw JW, et al.

Eur J Health Econ. 2021 Jun 17. doi: 10.1007/s10198-021-01337-6. Online ahead of print.

PMID: 34142266

Idecabtagene Vicleucel in Relapsed Myeloma. Reply.

Munshi NC, Hege K, San-Miguel J, et al.

N Engl J Med. 2021 Jun 17;384(24):2357-2358. doi: 10.1056/NEJMc2105069.

PMID: 34133871

Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors.

Cherney EC, Zhang L, Guo W, Huang A, Williams D, Seitz S, Shan W, Zhu X, Gullo-Brown J, Maley D, Lin TA, Hunt JT, Huang C, Yang Z, D'Arienzo CJ, Discenza LN, Ranasinghe A, Grubb MF, Traeger SC, Li X, Johnston KA, Kopcho L, Fereshteh M, Foster KA, Stefanski K, Delpy D, Dhar G, Anandam A, Mahankali S, Padmanabhan S, Rajanna P, Murali V, Mariappan TT, Pattasseri S, Nimje RY, Hong Z, Kempson J, Rampulla R, Mathur A, Gupta A, Borzilleri R, Vite G, Balog A, et al.

ACS Med Chem Lett. 2021 Jun 16;12(7):1143-1150. doi: 10.1021/acsmedchemlett.1c00236. eCollection 2021 Jul 8.

PMID: 34267885

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs.

Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D'Offizi G, McPhee F, Garbuglia AR, et al.

Viruses. 2021 Jun 16;13(6):1151. doi: 10.3390/v13061151.

PMID: 34208646

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.

Freeman L, Kee A, Tian M, Mehta R, et al.

Drugs Real World Outcomes. 2021 Jun 16. doi: 10.1007/s40801-021-00251-w. Online ahead of print.

PMID: 34136997

Effectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence risk.

Johnsen SP, Rasmussen TB, Falstie-Jensen AM, Harboe L, Stynes G, Dybro L, Hansen ML, Brandes A, Grove EL, Münster AM, et al.

Basic Clin Pharmacol Toxicol. 2021 Jun 15. doi: 10.1111/bcpt.13625. Online ahead of print.

PMID: 34128322

Advanced continuous-flow microfluidic device for parallel screening of crystal polymorphs, morphology, and kinetics at controlled supersaturation.

Coliaie P, Kelkar MS, Langston M, Liu C, Nazemifard N, Patience D, Skliar D, Nere NK, Singh MR, et al.

Lab Chip. 2021 Jun 15;21(12):2333-2342. doi: 10.1039/d1lc00218j.

PMID: 34096561

Cartesian message passing neural networks for directional properties: Fast and transferable atomic multipoles.

Glick ZL, Koutsoukas A, Cheney DL, Sherrill CD, et al.

J Chem Phys. 2021 Jun 14;154(22):224103. doi: 10.1063/5.0050444.

PMID: 34241239

Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.

Ogasawara K, Dodds M, Mack T, Lymp J, Dell'Aringa J, Smith J, et al.

Clin Pharmacokinet. 2021 Jun 14. doi: 10.1007/s40262-021-01039-5. Online ahead of print.

PMID: 34125421

Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens.

Zamagni E, Dhanasiri S, Ghale A, Moore A, Roussel M, et al.

Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1924369. Online ahead of print.

PMID: 34121589

Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer.

Cohen AT, Keshishian A, Lee T, Rosenblatt L, Hlavacek P, Sah J, Luo X, et al.

Curr Med Res Opin. 2021 Jun 14:1-16. doi: 10.1080/03007995.2021.1932448. Online ahead of print.

PMID: 34030541

General population normative data for the EQ-5D-3L in the five largest European economies.

Janssen MF, Pickard AS, Shaw JW, et al.

Eur J Health Econ. 2021 Jun 12. doi: 10.1007/s10198-021-01326-9. Online ahead of print.

PMID: 34117986

Pediatric soft tissue neoplasms with BRAF activating mutations.

Mochel MC, Wojcik JB, Gowda M, Tye GW, Patel RM, Smith SC, et al.

Mod Pathol. 2021 Jun 11. doi: 10.1038/s41379-021-00852-4. Online ahead of print.

PMID: 34117348

A practical response adaptive block randomization (RABR) design with analytic type I error protection.

Zhan T, Cui L, Geng Z, Zhang L, Gu Y, Chan ISF, et al.

Stat Med. 2021 Jun 10. doi: 10.1002/sim.9104. Online ahead of print.

PMID: 34111902

Telomerase Reverse Transcriptase Increases Proliferation and Lifespan of Human NK Cells without Immortalization.

Streltsova MA, Ustiuzhanina MO, Barsov EV, Kust SA, Velichinskii RA, Kovalenko EI, et al.

Biomedicines. 2021 Jun 9;9(6):662. doi: 10.3390/biomedicines9060662.

PMID: 34207853

Mouse IL-2/CD25 Fusion Protein Induces Regulatory T Cell Expansion and Immune Suppression in Preclinical Models of Systemic Lupus Erythematosus.

Xie JH, Zhang Y, Loubeau M, Mangan P, Heimrich E, Tovar C, Zhou X, Madia P, Doyle M, Dudhgaonkar S, Rudra A, Subramani S, Young J, Salter-Cid L, Malek TR, Struthers M, et al.

J Immunol. 2021 Jun 9:ji2100078. doi: 10.4049/jimmunol.2100078. Online ahead of print.

PMID: 34108258

Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naive patients.

Wells AF, Edwards CJ, Kivitz AJ, Bird P, Guerette B, Delev N, Paris M, Teng L, Aelion JA, et al.

Rheumatology (Oxford). 2021 Jun 8:keab449. doi: 10.1093/rheumatology/keab449. Online ahead of print.

PMID: 34100922

Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers.

Paczesny S, Pasquini MC, Pavletic SZ, Agarwal A, Spellman S, Kean L, Bernatchez C, Gust J, Staedtke V, Perales MA, et al.

Blood Adv. 2021 Jun 8;5(11):2519-2522. doi: 10.1182/bloodadvances.2021004604.

PMID: 34100901

Opalescence Measurements: Improvements in Fundamental Knowledge, Identifying Sources of Analytical Biases, and Advanced Applications for the Development of Therapeutic Proteins.

Barros M, Zhang X, Kenrick S, Valente JJ, et al.

J Pharm Sci. 2021 Jun 7:S0022-3549(21)00303-8. doi: 10.1016/j.xphs.2021.06.013. Online ahead of print.

PMID: 34111445

Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset.

Waterhouse D, Lam J, Betts KA, Yin L, Gao S, Yuan Y, Hartman J, Rao S, Lubinga S, Stenehjem D.

Data Brief. 2021 Jun 6;37:107195. doi: 10.1016/j.dib.2021.107195. eCollection 2021 Aug.

PMID: 34169127

Mimicking Low pH Virus Inactivation Used in Antibody Manufacturing Processes: Effect of Processing Conditions and Biophysical Properties on Antibody Aggregation and Particle Formation.

Kim NA, Kar S, Li Z, Das TK, Carpenter JF, et al.

J Pharm Sci. 2021 Jun 6:S0022-3549(21)00292-6. doi: 10.1016/j.xphs.2021.06.002. Online ahead of print.

PMID: 34090901

A Novel Use of Nanocrystalline Suspensions to Develop Sub-Microgram Dose Micro-Tablets.

Meruva S, Thool P, Gong Y, Agrawal A, Karki S, Bowen W, Mitra B, Kumar S, et al.

J Pharm Sci. 2021 Jun 5:S0022-3549(21)00290-2. doi: 10.1016/j.xphs.2021.05.025. Online ahead of print.

PMID: 34097976

Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG).

Bienfait K, Chhibber A, Marshall JC, Armstrong M, Cox C, Shaw PM, Paulding C, et al.

Hum Genet. 2021 Jun 3. doi: 10.1007/s00439-021-02282-3. Online ahead of print.

PMID: 34081195

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.

Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD, et al.

N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.

PMID: 34077643

Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review.

Prince EA, Sanzari JK, Pandya D, Huron D, Edwards R, et al.

JCO Precis Oncol. 2021 Jun 8;5:953-973. doi: 10.1200/PO.20.00412. eCollection 2021 Jun.

PMID: 34136742

Editorial overview: Hot targets and new modalities.

Ciulli A, Wertz IE, et al.

Curr Opin Chem Biol. 2021 Jun;62:A1-A3. doi: 10.1016/j.cbpa.2021.04.010. Epub 2021 Jun 8.

PMID: 34116929

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.

Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL, et al.

J Immunother Cancer. 2021 Jun;9(6):e002568. doi: 10.1136/jitc-2021-002568.

PMID: 34083421

Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.

Harrold LR, Bryson J, Lehman T, Zhuo J, Gao S, Han X, Schrader A, Rebello S, Pappas DA, Sommers T, Kremer JM, et al.

Rheumatol Ther. 2021 Jun;8(2):937-953. doi: 10.1007/s40744-021-00310-2. Epub 2021 May 28.

PMID: 34047953

The role of ligand-binding assay and LC-MS in the bioanalysis of complex protein and oligonucleotide therapeutics.

Kotapati S, Deshpande M, Jashnani A, Thakkar D, Xu H, Dollinger G, et al.

Bioanalysis. 2021 Jun;13(11):931-954. doi: 10.4155/bio-2021-0009. Epub 2021 May 17.

PMID: 33998268

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Spertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S, Li W, Dolan C, Reaney M, Sehnert AJ, Jacoby D, et al.

Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15.

PMID: 34004177

Critical review of oncology clinical trial design under non-proportional hazards.

Ananthakrishnan R, Green S, Previtali A, Liu R, Li D, LaValley M, et al.

Crit Rev Oncol Hematol. 2021 Jun;162:103350. doi: 10.1016/j.critrevonc.2021.103350. Epub 2021 May 12.

PMID: 33989767

Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1.

Salles G, Spin P, Liu FF, Garcia J, Kim Y, Hasskarl, et al.

J.Adv Ther. 2021 Jun;38(6):3266-3280. doi: 10.1007/s12325-021-01756-0. Epub 2021 May 10.

PMID: 33970454

Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity.

Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Klem C, Rosenblatt L, Mardekian J, Jiang J, Yuce H, Lip GYH, et al.

Adv Ther. 2021 Jun;38(6):3166-3184. doi: 10.1007/s12325-021-01724-8. Epub 2021 May 7.

PMID: 33963511

Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases: A Stated Preference Survey of Adults Diagnosed With and Without Lung Cancer.

Shafrin J, May SG, Zhao LM, Bognar K, Yuan Y, Penrod JR, Romley JA.

Value Health. 2021 Jun;24(6):855-861. doi: 10.1016/j.jval.2020.06.021. Epub 2021 Mar 31.

PMID: 34119084

Qualitative analysis of actual Standard for Exchange of Nonclinical Data (SEND) datasets for Data Domains: Proposition from Japan Pharmaceutical Manufacturers Association SEND Taskforce Team on standardization of nonclinical data.

Sato G, Matsumoto I, Watanabe M, Kinomoto T, Nakajima M, Yamamoto M, Inoue Y, Kobayashi K, Tanaharu T, Kiya A, Yamaguchi T, Hayashi H, Motoyama K, Suzuki M, Watanabe K.

Regul Toxicol Pharmacol. 2021 Jun;122:104919. doi: 10.1016/j.yrtph.2021.104919. Epub 2021 Mar 20.

PMID: 33753112

Role of surface molecular environment and amorphous content in moisture sorption behavior of milled Terbutaline Sulphate.

Bagwan NUS, Sheokand S, Kaur A, Dubey G, Puri V, Bharatam PV, Bansal AK.

Eur J Pharm Sci. 2021 Jun 1;161:105782. doi: 10.1016/j.ejps.2021.105782. Epub 2021 Mar 3.

PMID: 33675911

Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.

Lopes RD, Thomas L, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Friend K, Mardekian J, Pan X, Yuce H, Jones WS.

Am J Cardiol. 2021 Jun 1;148:69-77. doi: 10.1016/j.amjcard.2021.02.021. Epub 2021 Mar 3.

PMID: 33667438

Multimorbidity Accrual After Incident Rheumatoid Arthritis: A Wolf at the Door.

Sparks JA,

J Rheumatol. 2021 Jun 1:jrheum.210224. doi: 10.3899/jrheum.210224. Online ahead of print.

PMID: 34074680

Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers.

Ali S, & Esper P.

Clin J Oncol Nurs. 2021 Jun 1;25(3):321-328. doi: 10.1188/21.CJON.321-328.

PMID: 34019017

Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study.

Monestier S, Dalle S, Mortier L, Dutriaux C, Dalac-Rat S, Meyer N, Leccia MT, Mansard S, Montaudié H, Saiag P, Combemale P, Guillot B, Skowron F, Duval Modeste AB, Bénéton N, Hainaut E, Robert C, Arnault JP, Le Corre Y, Jouary T, Ameur N, Varey E, Khammari A, Dréno B; RIC-Mel network.

Int J Cancer. 2021 Jun 1;148(11):2789-2798. doi: 10.1002/ijc.33467. Epub 2021 Feb 19.

PMID: 33428772

Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors.

Fangusaro J, Cefalo MG, Garré ML, Marshall LV, Massimino M, Benettaib B, Biserna N, Poon J, Quan J, Conlin E, Lewandowski J, Simcock M, Jeste N, Hargrave DR, Doz F, Warren KE, et al.

Front Oncol. 2021 Jun 8;11:660892. doi: 10.3389/fonc.2021.660892. eCollection 2021.

PMID: 34168987

Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in Japan.

Chen L, Ionescu-Ittu R, Romdhani H, Guerin A, Kessler P, Borentain M, Friend K, DeSouza M, Sato N, et al.

Cardiol Ther. 2021 Jun;10(1):211-228. doi: 10.1007/s40119-021-00212-y. Epub 2021 Feb 20.

PMID: 33609268

An Industry Perspective on the Challenges of Using Closed System Transfer Devices with Biologics and Communication Guidance to Healthcare Professionals.

Gopalrathnam G, Christian TR, Jagannathan B, Petoskey F, Kühnle B, Weiser S, Kagdi R, Saluja S, Bhattacharyya A, Burton L, Zamiri C, Hanley K, et al.

J Pharm Sci. 2021 Jun;110(6):2329-2335. doi: 10.1016/j.xphs.2021.02.008. Epub 2021 Feb 19.

PMID: 33617871

Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey.

Mitra MS, Datta K, Hutchinson R, Nicolette JJ, Pettersen JC, Wegesser TC, Bercu JP, et al.

Regul Toxicol Pharmacol. 2021 Jun;122:104895. doi: 10.1016/j.yrtph.2021.104895. Epub 2021 Feb 19.

PMID: 33610610

A custom ÄKTA avant configuration enabling automated parallel protein purification over a range of process scales.

Hollander C, Walrond SC, Connelly C, Megson L, Bove E, McDonagh T, et al.

Protein Expr Purif. 2021 Jun;182:105842. doi: 10.1016/j.pep.2021.105842. Epub 2021 Feb 11.

PMID: 33582289

Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns.

Ghanima W, Schultze A, Donaldson R, Brodin E, Halvorsen S, Graham S, Carroll R, Ulvestad M, Lambrelli D, et al.

Clin Ther. 2021 May 31:S0149-2918(21)00212-5. doi: 10.1016/j.clinthera.2021.04.017. Online ahead of print.

PMID: 34083030

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.

Dalle S, Mortier L, Corrie P, Lotem M, Board R, Arance AM, Meiss F, Terheyden P, Gutzmer R, Buysse B, Oh K, Brokaw J, Le TK, Mathias SD, Scotto J, Lord-Bessen J, Moshyk A, Kotapati S, Middleton MR, et al.

BMC Cancer. 2021 May 29;21(1):642. doi: 10.1186/s12885-021-08032-y.

PMID: 34051732

Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.

Wang R, Ascanelli C, Abdelbaki A, Fung A, Rasmusson T, Michaelides I, Roberts K, Lindon C, et al.

Commun Biol. 2021 May 28;4(1):640. doi: 10.1038/s42003-021-02158-2.

PMID: 34050235

Identification of Novel, Immunogenic HLA-DR-Presented Prevotella copri Peptides in Patients with Rheumatoid Arthritis: Patients with Rheumatoid Arthritis.

Pianta A, Chiumento G, Ramsden K, Wang Q, Strle K, Arvikar S, Costello CE, Steere AC, et al.

Arthritis Rheumatol. 2021 May 27. doi: 10.1002/art.41807. Online ahead of print.

PMID: 34042327

Native mass spectrometry and gas-phase fragmentation provide rapid and in-depth topological characterization of a PROTAC ternary complex.

Song JH, Wagner ND, Yan J, Li J, Huang RY, Balog AJ, Newitt JA, Chen G, Gross ML, et al.

Cell Chem Biol. 2021 May 26:S2451-9456(21)00222-1. doi: 10.1016/j.chembiol.2021.05.005. Online ahead of print.

PMID: 34081921

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.

Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaika M, Wisniewski T, Sangro B, et al.

J Hepatol. 2021 May 26:S0168-8278(21)00313-5. doi: 10.1016/j.jhep.2021.04.047. Online ahead of print.

PMID: 34051329

Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.

Yang MG, Xiao Z, Zhao R, Tebben AJ, Wang B, Cherney RJ, Batt DG, Brown GD, Cvijic ME, Duncia JV, Gallela MA, Gardner DS, Khandelwal P, Malley MF, Pang J, Rose AV, Santella JB 3rd, Sarjeant AA, Xu S, Mathur A, Mandlekar S, Vuppugalla R, Zhao Q, Carter PH, et al.

ACS Med Chem Lett. 2021 May 25;12(6):969-975. doi: 10.1021/acsmedchemlett.1c00082. eCollection 2021 Jun 10.

PMID: 34141082

Detecting undiagnosed atrial fibrillation in UK primary care: Validation of a machine learning prediction algorithm in a retrospective cohort study.

Sekelj S, Sandler B, Johnston E, Pollock KG, Hill NR, Gordon J, Tsang C, Khan S, Ng FS, Farooqui U, et al.

Eur J Prev Cardiol. 2021 May 22;28(6):598-605. doi: 10.1177/2047487320942338.

PMID: 34021576

Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.

Palomba ML, Jun MP, Lymp J, Nguyen A, McGarvey N, Gitlin M, Pelletier C, Keating SJ, Godwin J, et al.

Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1910686. Online ahead of print.

PMID: 34018458

Myeloma NK cells are exhausted and have impaired regulation of activation.

D'Souza C, Keam SP, Yeang HXA, Neeson M, Richardson K, Hsu AK, Canfield R, Bezman N, Robbins M, Quach H, Ritchie DS, Harrison SJ, Trapani JA, Prince HM, Beavis PA, Darcy PK, Neeson PJ, et al.

Haematologica. 2021 May 20. doi: 10.3324/haematol.2020.277525. Online ahead of print.

PMID: 34011135

Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors.

Han X, Lobo F, Broder MS, Chang E, Gibbs SN, Ridley DJ, Yermilov I.

J Health Econ Outcomes Res. 2021 May 19;8(1):71-78. doi: 10.36469/jheor.2021.23684.

PMID: 34046511

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients.

Frerichs KA, Verkleij CPM, Dimopoulos MA, Marin Soto JA, Zweegman S, Young MH, Newhall KJ, Mutis T, van de Donk NWCJ, et al.

Cancers (Basel). 2021 May 18;13(10):2452. doi: 10.3390/cancers13102452.

PMID: 34070044

Exploring the Role of Surfactants in Enhancing Drug Release from Amorphous Solid Dispersions at Higher Drug Loadings.

Saboo S, Bapat P, Moseson DE, Kestur US, Taylor LS, et al.

Pharmaceutics. 2021 May 17;13(5):735. doi: 10.3390/pharmaceutics13050735.

PMID: 34067666

Toluidine blue staining of murine mast cells and quantitation by a novel, automated image analysis method using whole slide skin images.

Raja N, Naikodi S, Govindarajan A, Palanisamy K, et al.

J Histotechnol. 2021 May 17:1-6. doi: 10.1080/01478885.2021.1915934. Online ahead of print.

PMID: 33998401

Safety and Effectiveness of Apixaban in Japanese Patients With Venous Thromboembolism in Clinical Practice　- A Post-Marketing Surveillance.

Yamada N, Mo M, Ohsawa A, Sato M, Umeyama M, Shima D, Nakamura M, et al.

Circ J. 2021 May 15. doi: 10.1253/circj.CJ-20-0829. Online ahead of print.

PMID: 33994408

Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals.

van Lint JA, Jessurun NT, Tas SW, van den Bemt BJF, Nurmohamed MT, van Doorn MBA, Spuls PI, van Tubergen AM, Ten Klooster PM, van Puijenbroek EP, Hoentjen F, Vonkeman HE, et al.

J Rheumatol. 2021 May 15:jrheum.201373. doi: 10.3899/jrheum.201373. Online ahead of print.

PMID: 33993115

Canadian Rheumatologists' Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis.

Gladman DD, Starr M, Cividino A, Gaudreau AJ, Jelley J, Nicholson D, Karsh J, et al.

J Rheumatol. 2021 May 15:jrheum.201195. doi: 10.3899/jrheum.201195. Online ahead of print.

PMID: 33993114

SCLIFF: A component-based, machine-learned, intermolecular force field.

Schriber JB, Nascimento DR, Koutsoukas A, Spronk SA, Cheney DL, Sherrill CD, et al.

J Chem Phys. 2021 May 14;154(18):184110. doi: 10.1063/5.0042989.

PMID: 34241025

Synthesis, Structure-Activity Relationships, and In Vivo Evaluation of Novel Tetrahydropyran-Based Thiodisaccharide Mimics as Galectin-3 Inhibitors.

Xu L, Hartz RA, Beno BR, Ghosh K, Shukla JK, Kumar A, Patel D, Kalidindi N, Lemos N, Gautam SS, Kumar A, Ellsworth BA, Shah D, Sale H, Cheng D, Regueiro-Ren A, et al.

J Med Chem. 2021 May 27;64(10):6634-6655. doi: 10.1021/acs.jmedchem.0c02001. Epub 2021 May 14.

PMID: 33988358

Integrin αVβ1 regulates procollagen I production through a non-canonical transforming growth factor β signaling pathway in human hepatic stellate cells.

Han Z, Ma Y, Cao G, Ma Z, Chen R, Cvijic ME, Cheng D, et al.

Biochem J. 2021 May 14;478(9):1689-1703. doi: 10.1042/BCJ20200749.

PMID: 33876829

Clinical Relevance of Torque Teno Virus (TTV) in HIV/HCV Coinfected and HCV Monoinfected Patients Treated with Direct-Acting Antiviral Therapy.

Lapa D, Del Porto P, Minosse C, D'Offizi G, Antinori A, Capobianchi MR, Visco-Comandini U, McPhee F, Garbuglia AR, Zaccarelli M, et al.

J Clin Med. 2021 May 13;10(10):2092. doi: 10.3390/jcm10102092.

PMID: 34068071

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.

Selvaraj EA, Mózes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, Levick CK, Young LAJ, Palaniyappan N, Liu CH, Aithal GP, Romero-Gómez M, Brosnan MJ, Tuthill TA, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators.

J Hepatol. 2021 May 13:S0168-8278(21)00309-3. doi: 10.1016/j.jhep.2021.04.044. Online ahead of print.

PMID: 33991635

N-Ammonium Ylide Mediators for Electrochemical C-H Oxidation.

Saito M, Kawamata Y, Meanwell M, Navratil R, Chiodi D, Carlson E, Hu P, Chen L, Udyavara S, Kingston C, Tanwar M, Tyagi S, McKillican BP, Gichinga MG, Schmidt MA, Eastgate MD, Lamberto M, He C, Tang T, Malapit CA, Sigman MS, Minteer SD, Neurock M, Baran PS, et al.

J Am Chem Soc. 2021 May 26;143(20):7859-7867. doi: 10.1021/jacs.1c03780. Epub 2021 May 13.

PMID: 33983721

3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration.

Wang H, Brown PC, Chow ECY, Ewart L, Ferguson SS, Fitzpatrick S, Freedman BS, Guo GL, Hedrich W, Heyward S, Hickman J, Isoherranen N, Li AP, Liu Q, Mumenthaler SM, Polli J, Proctor WR, Ribeiro A, Wang JY, Wange RL, Huang SM, et al.

Clin Transl Sci. 2021 May 13. doi: 10.1111/cts.13066. Online ahead of print.

PMID: 33982436

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.

Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K, et al.

Nat Commun. 2021 May 10;12(1):2607. doi: 10.1038/s41467-021-22874-x.

PMID: 33972549

Evaluation of fully-functionalized diazirine tags for chemical proteomic applications.

Conway LP, Jadhav AM, Homan RA, Li W, Rubiano JS, Hawkins R, Lawrence RM, Parker CG, et al.

Chem Sci. 2021 May 7;12(22):7839-7847. doi: 10.1039/d1sc01360b.

PMID: 34168837

Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource.

Iwaki H, Leonard HL, Makarious MB, Bookman M, Landin B, Vismer D, Casey B, Gibbs JR, Hernandez DG, Blauwendraat C, Vitale D, Song Y, Kumar D, Dalgard CL, Sadeghi M, Dong X, Misquitta L, Scholz SW, Scherzer CR, Nalls MA, Biswas S, Singleton AB; Uniformed Services University of the Health Sciences Associates; AMP PD Whole Genome Sequencing Working Group; AMP PD consortium.

Mov Disord. 2021 May 7. doi: 10.1002/mds.28549. Online ahead of print.

PMID: 33960523

Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative.

Snee M, Cheeseman S, Thompson M, Riaz M, Sopwith W, Lacoin L, Chaib C, Manley Daumont M, Penrod JR, O'Donnell JC, Hall G, et al.

BMJ Open. 2021 May 3;11(5):e043442. doi: 10.1136/bmjopen-2020-043442.

PMID: 33941627

Dental nurse role in operatory during and post pandemic outbreak of COVID-19.

Sajja R.

J Family Med Prim Care. 2021 May;10(5):2047. doi: 10.4103/jfmpc.jfmpc_2229_20. Epub 2021 May 31.

PMID: 34195149

Evaluation of vanillin as a probe drug for aldehyde oxidase and phenotyping for its activity in a Western Indian Cohort.

Subash S, Gogtay NJ, Iyer KR, Gandhe P, Budania R, Thatte UM, et al.

Indian J Pharmacol. 2021 May-Jun;53(3):213-220. doi: 10.4103/ijp.IJP_463_18.

PMID: 34169906

Improved efficacy/safety profile of factor XIa inhibitor BMS-724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys.

Wong PC and Quan ML.

Res Pract Thromb Haemost. 2021 May 28;5(4):e12524. doi: 10.1002/rth2.12524. eCollection 2021 May.

PMID: 34095733

The impact of ligand binding based assays critical reagent characterization and storage.

Haulenbeek J and Beaver CJ.

Bioanalysis. 2021 May;13(10):797-805. doi: 10.4155/bio-2020-0288. Epub 2021 May 18.

PMID: 34002637

Context matters in CAR T cell tonic signaling.

Hege K.

Nat Med. 2021 May;27(5):763-764. doi: 10.1038/s41591-021-01340-7.

PMID: 33972792

Calibrator material selection: a key criteria during biomarker assay method development.

Thankamony SP, Liu R, Peterson JE, Santockyte R, Olah T, Zhang Y, et al.

Bioanalysis. 2021 May;13(10):787-796. doi: 10.4155/bio-2020-0208. Epub 2021 May 7.

PMID: 33960820

Pain in Axial Spondyloarthritis: More to It Than Just Inflammation.

Magrey MN, Mease PJ, et al.

J Rheumatol. 2021 May 1:jrheum.210137. doi: 10.3899/jrheum.210137. Online ahead of print.

PMID: 33934079

Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis.

Rahman P, Ritchlin CT, Helliwell PS, Boehncke WH, Mease PJ, Gottlieb AB, Kafka S, Kollmeier AP, Hsia EC, Xu XL, Shawi M, Sheng S, Agarwal P, Zhou B, Ramachandran P, Zhuang Y, McInnes IB, et al.

J Rheumatol. 2021 May 1:jrheum.201532. doi: 10.3899/jrheum.201532. Online ahead of print.

PMID: 33934076

Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-world Data Analysis Using Machine Learning.

Johansson FD, Collins JE, Yau V, Guan H, Kim SC, Losina E, Sontag D, Stratton J, Trinh H, Greenberg J, Solomon DH, et al.

J Rheumatol. 2021 May 1:jrheum.201626. doi: 10.3899/jrheum.201626. Online ahead of print.

PMID: 33934070

SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma.

Venugopalan A, Lynberg M, Cultraro CM, Nguyen KDP, Zhang X, Waris M, Dayal N, Abebe A, Maity TK, Guha U, et al.

Oncogene. 2021 May;40(18):3331-3346. doi: 10.1038/s41388-021-01764-y. Epub 2021 Apr 13.

PMID: 33850265

Genome-wide enhancer maps link risk variants to disease genes.

Nasser J, Bergman DT, Fulco CP, Guckelberger P, Doughty BR, Patwardhan TA, Jones TR, Nguyen TH, Ulirsch JC, Lekschas F, Mualim K, Natri HM, Weeks EM, Munson G, Kane M, Kang HY, Cui A, Ray JP, Eisenhaure TM, Collins RL, Dey K, Pfister H, Price AL, Epstein CB, Kundaje A, Xavier RJ, Daly MJ, Huang H, Finucane HK, Hacohen N, Lander ES, Engreitz JM, et al.

Nature. 2021 May;593(7858):238-243. doi: 10.1038/s41586-021-03446-x. Epub 2021 Apr 7.

PMID: 33828297

United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument.

Revicki DA, King MT, Viney R, Pickard AS, Mercieca-Bebber R, Shaw JW, Müller F, Norman R, et al.

Med Decis Making. 2021 May;41(4):485-501. doi: 10.1177/0272989X211003569. Epub 2021 Apr 5.

PMID: 33813946

Novel techniques and the new age of biomarkers: panel discussion report.

Pasas-Farmer S, James C, Fandozzi C, Warrino D, Durham R, Hayes R, Cape S, Olah T.

Bioanalysis. 2021 May;13(9):675-678. doi: 10.4155/bio-2021-0049. Epub 2021 Mar 26.

PMID: 33769091

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.

Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, Olíva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A.

J Clin Oncol. 2021 May 1;39(13):1426-1436. doi: 10.1200/JCO.20.02619. Epub 2021 Mar 25.

PMID: 33764805

Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab.

Desai NR, Wade RL, Xiang P, Pinto L, Nunna S, Wang X, Exter J, Mues KE, Habib M, Chen CC.

Clin Cardiol. 2021 May;44(5):715-722. doi: 10.1002/clc.23600. Epub 2021 Mar 24.

PMID: 33760276

Evaluation of a polysaccharide-based chiral reversed-phase liquid chromatography screen strategy in pharmaceutical analysis.

Lin Z, Tai HC, Zhu G, Fabiano A, Borges-Muñoz A, Ye YK, He BL.

J Chromatogr A. 2021 May 24;1645:462085. doi: 10.1016/j.chroma.2021.462085. Epub 2021 Mar 22.

PMID: 33848654

Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.

Renneville A, Gasser JA, Grinshpun DE, Jean Beltran PM, Udeshi ND, Matyskiela ME, Clayton T, McConkey M, Viswanathan K, Tepper A, Guirguis AA, Sellar RS, Cotteret S, Marzac C, Saada V, De Botton S, Kiladjian JJ, Cayuela JM, Rolfe M, Chamberlain PP, Carr SA, Ebert BL.

Blood Cancer Discov. 2021 May;2(3):250-265. doi: 10.1158/2643-3230.bcd-20-0105. Epub 2021 Mar 10.

PMID: 34027417

Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.

Surapaneni S, Yerramilli U, Bai A, Dalvie D, Brooks J, Wang X, Selkirk JV, Yan YG, Zhang P, Hargreaves R, Kumar G, Palmisano M, Tran JQ.

Drug Metab Dispos. 2021 May;49(5):405-419. doi: 10.1124/dmd.120.000220. Epub 2021 Mar 4.

PMID: 33674268

A Metal-Free Reductive N-Alkylation of Indoles with Aldehydes.

Clanton NA, Spiller TE, Ortiz E, Gao Z, Rodriguez-Poirier JM, DelMonte AJ, Frantz DE, et al.

Org Lett. 2021 May 7;23(9):3233-3236. doi: 10.1021/acs.orglett.1c00179. Epub 2021 Feb 25.

PMID: 33630601

FEATURED

FEATURED

FEATURED

FEATURED

FEATURED

FEATURED

FEATURED

NOTE: The links provided below redirect to third-party websites that may require a subscription to access publications.